96. クローン病 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 2,442 / 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209
薬物ごとの開発者(Primary Sponsor)、臨床試験情報(抜粋)です。
( L ) ASCORBATO DI CALCIO
ASTRAZENECA AB
2021 Phase 3 EUCTR2019-001866-14-IT Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
-aminosalicylic acid
University of Vermont
1995 - NCT00004423 -
0,25 mg RPC1063
Celgene International II Sarl (CISII) awholly owned subsidiary of Celgene Corporation
2015 Phase 2 EUCTR2015-002025-19-HU Canada;Hungary;Italy;Poland;Ukraine;United States;
00000
CELLTRION INC.
2019 Phase 3 EUCTR2019-001087-30-IT Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
0114-0006B
Novo Nordisk A/S
2013 - EUCTR2012-002432-93-SK Bulgaria;Czech Republic;Hungary;Poland;Russian Federation;Serbia;Slovakia;Spain;United States;
2013 - EUCTR2012-002432-93-PL Bulgaria;Czech Republic;Hungary;Poland;Russian Federation;Serbia;Slovakia;Spain;United States;
2013 - EUCTR2012-002432-93-CZ Bulgaria;Czech Republic;Hungary;Poland;Russian Federation;Serbia;Slovakia;Spain;United States;
2013 - EUCTR2012-002432-93-BG Bulgaria;Czech Republic;Hungary;Poland;Russian Federation;Serbia;Slovakia;Spain;United States;
2012 - EUCTR2012-002432-93-HU Bulgaria;Czech Republic;Hungary;Poland;Russian Federation;Serbia;Slovakia;Spain;United States;
2012 - EUCTR2012-002432-93-ES Bulgaria;Czech Republic;Hungary;Poland;Russian Federation;Serbia;Slovakia;Spain;United States;
1000 IU D3
Cedars-Sinai Medical Center
2018 Early Phase 1 NCT03615378 United States;
13-valent pneumococcal conjugated vaccine (PCV13)
Klara M. Pósfay Barbe
2014 Phase 4 NCT01908283 Switzerland;
14C]-RPC1063 Solution (0.1 mg/mL) for Oral Administration
Celgene International II Sàrl
2016 Phase 1 EUCTR2016-003073-18-GB United Kingdom;
18F-FDG
Peking Union Medical College Hospital
2020 Phase 2 NCT04502303 -
2'-Fucosyllactose
Children's Hospital Medical Center, Cincinnati
2019 Phase 1/Phase 2 NCT03847467 United States;
23-valent polysaccharide pneumococcal vaccine
Kyunghee University Medical Center
2011 Phase 4 NCT01505855 Korea, Republic of;
23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)
Cedars-Sinai Medical Center
2005 - NCT00829595 United States;
3-hydroxy-2-methyl-4H-pyrane-4-one iron (III) complex (3:1), Ferric (3-hydroxy-2-methyl-4-pyrone), Tris-maltol-iron (III), Tri=maltol-iron (III)
Iron Therapeutics (Switzerland) AG
2012 - EUCTR2010-023589-39-DE Austria;Germany;Hungary;United Kingdom;
2011 Phase 3 EUCTR2010-023589-39-GB Austria;Germany;Hungary;United Kingdom;
2011 - EUCTR2010-023589-39-AT Austria;Germany;Hungary;United Kingdom;
- - EUCTR2010-023589-39-HU Austria;Germany;Hungary;United Kingdom;
331731-18-1
AbbVie GK
- - EUCTR2015-004121-13-Outside-EU/EEA Japan;
Abbott Deutschland GmbH & Co. KG
- - EUCTR2014-004560-38-Outside-EU/EEA Japan;
- - EUCTR2014-004531-39-Outside-EU/EEA Japan;
4-Aminosalicylic acid
Jacobus Pharmaceutical
2007 Phase 2 NCT00417690 Israel;United States;
4-Aminosalicylic acid extended release granules
Jacobus Pharmaceutical
2007 Phase 2 NCT00495521 Israel;United States;
42942019
UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
2016 Phase 4 EUCTR2016-002061-54-IT Italy;
5-ASA
Alimentiv Inc.
2017 Phase 4 NCT03261206 Canada;Italy;Ukraine;United Kingdom;
5-Aminosalicyl acid
Dr. Falk Pharma GmbH
2007 - EUCTR2004-001213-34-GB Czech Republic;United Kingdom;
5-HTP
University Hospital, Ghent
2018 Phase 2 NCT03574948 Belgium;
5-aminolevulinic acid
University Hospital, Akershus
2019 Phase 1/Phase 2 NCT04164849 Norway;
5-aminosalicylate (Pentasa, Ferring)
VU University Medical Center
2005 Phase 4 NCT00167882 Netherlands;
5-aminosalicylic acid
Lower GI disease, Hyogo College of Medicine
2007 Phase 2,3 JPRN-UMIN000004427 Japan;
5000 IU D3
Cedars-Sinai Medical Center
2018 Early Phase 1 NCT03615378 United States;
549-0261/F02-01
F. Hoffmann-La Roche Ltd
2018 Phase 1 EUCTR2017-003649-10-GB Belgium;Germany;Poland;Spain;United Kingdom;
2018 Phase 1 EUCTR2017-003649-10-DE Belgium;Germany;Poland;Spain;United Kingdom;United States;
2018 Phase 1 EUCTR2017-003649-10-BE Belgium;Germany;Poland;Spain;United Kingdom;
- Phase 1 EUCTR2017-003649-10-PL Belgium;Germany;Poland;Spain;United Kingdom;United States;
6 Mercaptopurine
Tel-Aviv Sourasky Medical Center
2012 Phase 3 NCT01629628 Israel;
6 mercaptopurine
Indiana University
2015 - NCT02413047 United States;
6-Mercaptopurine
PIBD net
2018 Phase 4 EUCTR2016-000522-18-GB Belgium;Canada;Czech Republic;France;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
6-Mercaptopurine (Puri-Nethol)
University of Edinburgh
2007 Phase 4 EUCTR2006-005800-15-GB United Kingdom;
6-Mercaptopurine (Puri-nethol)
University of Edinburgh
2007 Phase 4 EUCTR2006-005800-15-GB United Kingdom;
6-[(methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-purine
Centocor B.V.
2005 Phase 3 EUCTR2004-002815-10-GB Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
2005 Phase 3 EUCTR2004-002815-10-ES Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-SE Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-DK Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-DE Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-AT Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
683699
GlaxoSmithKline
2004 Phase 2 NCT00101946 Canada;United States;
99mTc-S-HYNIC Certolizumab pegol
Ghent University Hospital
2012 Phase 3 EUCTR2009-017998-37-BE Belgium;
?-3 polyunsaturated fatty acid
Sir Run Run Shaw Hospital
2019 Phase 4 NCT03901937 China;
A fixed-dose combination of 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine
RedHill Biopharma Limited
2017 Phase 3 NCT03009396 Canada;Czechia;Israel;New Zealand;Poland;Serbia;United States;
A-1293543.74
ABBVIE DEUTSCHLAND GMBH & CO. KG
2015 Phase 2 EUCTR2014-003240-12-IT Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
AbbVie Deutschland GmbH & Co. KG
2015 Phase 2 EUCTR2014-003240-12-SK Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-PL Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-NO Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-NL Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-HU Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-ES Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-DK Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-DE Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-CZ Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-BE Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
AB1010
AB Science
2015 Phase 2;Phase 3 EUCTR2012-004222-25-GR Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;India;Italy;Morocco;Poland;Romania;Russian Federation;Slovakia;Spain;Tunisia;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-004222-25-SK Belgium;Czech Republic;France;Greece;India;Morocco;Slovakia;Spain;Tunisia;
2013 Phase 3 EUCTR2012-004222-25-BE Belgium;Canada;Central African Republic;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Romania;Slovakia;South Africa;Spain;Switzerland;Tunisia;United Kingdom;United States;
ABBV-066
ABBVIE DEUTSCHLAND GMBH & CO. KG
2020 Phase 3 EUCTR2020-002674-26-IT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003191-50-IT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003190-17-IT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003123-32-IT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
AbbVie Deutschland GmbH & Co. KG
2021 Phase 3 EUCTR2020-002674-26-SK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-002674-26-HU Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-002674-26-DE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-002674-26-CZ Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002674-26-SE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002674-26-NL Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002674-26-GB Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002674-26-AT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2016-003191-50-FR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2016-003190-17-FR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003191-50-SE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003191-50-NL Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003191-50-LT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003191-50-IE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003191-50-HR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003191-50-GR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003191-50-DE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003191-50-BE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003190-17-IE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003190-17-HR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003190-17-GR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003190-17-DE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003190-17-BE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003123-32-SE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003123-32-LT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003123-32-IE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003123-32-HR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003123-32-GR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003123-32-DE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003123-32-BE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003191-50-SK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003191-50-PT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003191-50-LV Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003191-50-GB Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003191-50-ES Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003191-50-EE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003191-50-DK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003191-50-CZ Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003191-50-BG Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003191-50-AT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003190-17-SK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003190-17-PT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003190-17-NL Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003190-17-LV Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003190-17-LT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003190-17-GB Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003190-17-ES Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003190-17-EE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003190-17-DK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003190-17-CZ Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003190-17-BG Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003190-17-AT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003123-32-SK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003123-32-PT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003123-32-LV Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003123-32-GB Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003123-32-ES Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003123-32-EE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003123-32-BG Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003123-32-AT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2016-003191-50-PL Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2016-003191-50-NO Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2016-003190-17-PL Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2016-003123-32-PL Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2016-003123-32-NO Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2016-003123-32-NL Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2016-003123-32-CZ Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
ABBV-154
AbbVie
2022 Phase 2 NCT05068284 Australia;Austria;Belgium;Bulgaria;Canada;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;United States;
AbbVie Deutschland GmbH & Co. KG
2022 Phase 2 EUCTR2021-002869-18-GR Australia;Austria;Belgium;Bulgaria;Canada;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;United States;
2022 Phase 2 EUCTR2021-002869-18-ES Australia;Austria;Belgium;Bulgaria;Canada;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;United Kingdom;United States;
2022 Phase 2 EUCTR2021-002869-18-CZ Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;United States;
2022 Phase 2 EUCTR2021-002869-18-BE Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;United Kingdom;United States;
ABR-215062 sodium salt
Teva Pharmaceutical Industries Ltd.
2008 Phase 2 EUCTR2008-004276-49-GB Belgium;France;Italy;Netherlands;Spain;United Kingdom;
2008 Phase 2 EUCTR2008-004276-49-FR Belgium;France;Italy;Netherlands;Spain;United Kingdom;
2008 Phase 2 EUCTR2008-004276-49-ES Belgium;France;Italy;Netherlands;Spain;United Kingdom;
2008 Phase 2 EUCTR2008-004276-49-BE Belgium;France;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2008-004276-49-NL Belgium;France;Italy;Netherlands;Spain;United Kingdom;
ABT 494
ABBVIE DEUTSCHLAND GMBH & CO. KG
2015 Phase 2 EUCTR2014-003240-12-IT Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
AbbVie Deutschland GmbH & Co. KG
2015 Phase 2 EUCTR2014-003240-12-SK Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-PL Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-NO Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-NL Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-HU Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-ES Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-DK Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-DE Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-CZ Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-BE Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
ABT Humira
Abbott GmbH & Co. KG
2007 - EUCTR2006-002078-23-SE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
ABT-494
ABBVIE DEUTSCHLAND GMBH & CO. KG
2018 Phase 3 EUCTR2017-001240-35-IT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-IT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001225-41-IT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
AbbVie
2016 Phase 2 NCT02782663 Belgium;Canada;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Romania;Slovakia;Spain;United Kingdom;United States;
2015 Phase 2 NCT02365649 Australia;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
AbbVie Deutschland GmbH & Co. KG
2020 Phase 3 EUCTR2017-001240-35-FR Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-001240-35-SI Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-001240-35-IE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-001226-18-SI Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-001226-18-IE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-001225-41-SI Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-001225-41-IE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001240-35-SK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001240-35-SE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001240-35-PT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001240-35-PL Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001240-35-NL Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001240-35-LV Argentina;Australia;Austria;Belarus;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Colombia;Egypt;Hong Kong;Hungary;Israel;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Russian Federation;Serbia;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-001240-35-LT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001240-35-HU Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001240-35-HR Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001240-35-GB Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001240-35-ES Argentina;Australia;Austria;Belarus;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Colombia;Egypt;Hong Kong;Israel;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Russian Federation;Serbia;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-001240-35-EE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001240-35-DK Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001240-35-DE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001240-35-BG Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001240-35-BE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001240-35-AT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-SK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-SE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-PT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-PL Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-LV Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-LT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-HU Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-HR Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-GB Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-ES Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-EE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-DK Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-DE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-CZ Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-BG Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-BE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-AT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001225-41-SK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001225-41-SE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001225-41-PT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001225-41-NL Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001225-41-LV Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001225-41-LT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001225-41-HU Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001225-41-HR Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001225-41-GB Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001225-41-ES Argentina;Australia;Austria;Belarus;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Colombia;Egypt;Hong Kong;Hungary;Israel;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Russian Federation;Serbia;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-001225-41-DK Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001225-41-DE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001225-41-CZ Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001225-41-BG Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001225-41-BE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001225-41-AT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2015-003759-23-NO Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Israel;Netherlands;New Zealand;Norway;Slovakia;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2015-003759-23-HU Australia;Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Israel;Netherlands;New Zealand;Puerto Rico;Slovakia;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2015-003759-23-CZ Australia;Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Israel;Netherlands;New Zealand;Puerto Rico;Slovakia;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-003759-23-SK Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Israel;Netherlands;New Zealand;Norway;Slovakia;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-003759-23-NL Australia;Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Israel;Netherlands;New Zealand;Norway;Slovakia;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-003759-23-GB Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Israel;Netherlands;New Zealand;Norway;Slovakia;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-003759-23-ES Australia;Canada;Israel;New Zealand;Puerto Rico;Spain;United States;
2016 Phase 2 EUCTR2015-003759-23-DK Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Israel;Netherlands;New Zealand;Norway;Slovakia;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-003759-23-DE Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Israel;Netherlands;New Zealand;Norway;Slovakia;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-003759-23-BE Australia;Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Israel;Netherlands;New Zealand;Puerto Rico;Slovakia;Spain;United Kingdom;United States;
ABT-874
Abbott
2009 - EUCTR2008-004919-36-SE Austria;Denmark;Sweden;
2009 - EUCTR2008-004919-36-DK Austria;Denmark;Sweden;
2009 - EUCTR2008-004919-36-BE Austria;Belgium;Denmark;Sweden;
2009 - EUCTR2008-004919-36-AT Austria;Denmark;Sweden;
2007 Phase 2 NCT00562887 Australia;Austria;Belgium;Canada;Denmark;Germany;Puerto Rico;United States;
ABX464
Abivax S.A.
2020 Phase 2 NCT03905109 Belgium;
ADSVF
ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE
2019 Phase 2 EUCTR2019-001948-21-FR France;
AIN457
Novartis Pharma Services AG
2010 - EUCTR2009-011621-14-DE Austria;Germany;
2009 - EUCTR2009-011621-14-AT Austria;Germany;
2009 - EUCTR2008-008359-40-PL Austria;Germany;Poland;
2009 - EUCTR2008-008359-40-DE Austria;Germany;Poland;
2009 - EUCTR2008-008359-40-AT Austria;Germany;Poland;
Novartis Pharmaceuticals
2009 Phase 2 NCT01009281 Austria;Canada;Germany;Poland;United States;
2008 Phase 2 NCT00584740 Canada;Germany;United States;
ALBUMINE HUMAINE
ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE
2019 Phase 2 EUCTR2019-001948-21-FR France;
ALLO-ASC
Anterogen Co., Ltd.
2015 Phase 1 NCT02580617 Korea, Republic of;
ALLO-ASC-CD
Anterogen Co., Ltd.
2016 - NCT03183661 -
ALLOPURINOL SODIUM
Marianne Kiszka-Kanowitz
2013 Phase 3 EUCTR2013-001503-37-DK Denmark;
ALX-0600
Shire
2003 Phase 2 NCT00072839 Canada;United States;
AMG 139
AstraZeneca
2011 Phase 1 NCT01258205 Australia;United States;
AMG 181
Amgen
2011 Phase 1 NCT01290042 Australia;United States;
Amgen Inc
2013 Phase 2 EUCTR2012-000529-31-NL Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Netherlands;United Kingdom;United States;
2012 Phase 2 EUCTR2012-000529-31-HU Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Netherlands;United Kingdom;United States;
2012 Phase 2 EUCTR2012-000529-31-GB Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Netherlands;United Kingdom;United States;
2012 Phase 2 EUCTR2012-000529-31-DK Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Netherlands;United Kingdom;United States;
2012 Phase 2 EUCTR2012-000529-31-DE Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Netherlands;United Kingdom;United States;
2012 Phase 2 EUCTR2012-000529-31-CZ Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Netherlands;United Kingdom;United States;
2012 Phase 2 EUCTR2012-000529-31-BE Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Netherlands;United Kingdom;United States;
2012 Phase 2 EUCTR2012-000529-31-AT Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Netherlands;United Kingdom;United States;
AMG 827
Amgen
2010 Phase 2 NCT01199302 Australia;Belgium;Canada;France;Netherlands;Poland;Spain;United States;
2010 Phase 2 NCT01150890 Australia;Belgium;Canada;France;Netherlands;Poland;Spain;United States;
Amgen Inc
2011 Phase 2 EUCTR2010-020881-53-BE Australia;Belgium;Canada;France;Netherlands;Poland;Spain;United States;
2011 - EUCTR2010-020881-53-NL Belgium;Netherlands;Spain;
2011 - EUCTR2010-020881-53-ES Belgium;Netherlands;Spain;
2011 - EUCTR2010-019544-39-NL Belgium;France;Netherlands;Spain;
2010 Phase 2 EUCTR2010-019544-39-BE Australia;Belgium;Canada;France;Netherlands;Poland;Spain;United States;
2010 - EUCTR2010-019544-39-FR Belgium;France;Netherlands;Spain;
2010 - EUCTR2010-019544-39-ES Belgium;France;Netherlands;Spain;
AMGEVITA (Adalimumab biosimilar )
Fundación Publica Andaluza para la Gestión de Salud en Sevilla (FISEVI)
2019 Phase 4 EUCTR2019-000717-37-ES Spain;
AMGEVITA®
Fundación Publica Andaluza para la Gestión de Salud en Sevilla (FISEVI)
2019 Phase 4 EUCTR2019-000717-37-ES Spain;
AN100226
Elan Pharma Ltd.
2005 - EUCTR2004-003839-31-DK Denmark;
APD334
ARENA PHARMACEUTICALS, INC.
2021 Phase 2;Phase 3 EUCTR2020-004775-40-IT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-IT Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Arena Pharmaceuticals Inc.
2021 Phase 2;Phase 3 EUCTR2020-004775-40-PT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-NL Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-LT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-HU Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-HR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-ES Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-DK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-DE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-CZ Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-BG Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-SK Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-PT Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-NO Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-NL Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-LT Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-HU Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-GR Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-GB Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-FR Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-ES Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-CZ Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-BG Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Arena Pharmaceuticals, Inc.
2017 Phase 2 EUCTR2016-003797-40-DE Belgium;Germany;United States;
2017 Phase 2 EUCTR2016-003797-40-BE Belgium;Germany;United States;
APD371
Arena Pharmaceuticals
2017 Phase 2 NCT03155945 United States;
AR401959 L-arginine
ARENA PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-002895-14-IT Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Arena Pharmaceuticals Inc.
2021 Phase 2;Phase 3 EUCTR2020-004775-40-PT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-NL Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-LT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-HU Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-HR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-ES Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-DK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-DE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-CZ Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-BG Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-SK Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-PT Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-NO Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-NL Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-LT Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-HU Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-GR Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-GB Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-FR Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-ES Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-CZ Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-BG Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
ASCs: Adipose derived Stem Cells
CELLERIX S.A.
2009 - EUCTR2008-004286-25-DE Austria;Belgium;Czech Republic;Germany;Netherlands;Spain;
2009 - EUCTR2008-004286-25-BE Austria;Belgium;Czech Republic;Germany;Netherlands;Spain;
AST-120
Ocera Therapeutics, Inc.
2007 - EUCTR2005-005363-28-HU Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
2007 - EUCTR2005-005363-28-AT Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
2006 Phase 3 EUCTR2005-005363-28-GB Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
2006 - EUCTR2005-005363-28-DE Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
2006 - EUCTR2005-005363-28-CZ Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
2006 - EUCTR2005-005363-28-BE Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
ATG
Paul Szabolcs
2012 Phase 1/Phase 2 NCT00692939 United States;
AVB-114
Avobis Bio, LLC
2021 Phase 2 NCT04847739 United States;
AZA
Merck Sharp & Dohme Corp.
2003 Phase 3 NCT00796250 -
AZA capsules
Centre Hospitalier Universitaire, Amiens
2021 Phase 3 NCT05040464 France;
AZATHIOPRINE or METHOTREXATE
Prof. Arie Levine
2013 Phase 4 NCT01802593 Israel;
AZATIOPRINA ASPEN - 50 COMPRESSE
UMBERTO I - POLICLINICO DI ROMA
2017 Phase 4 EUCTR2016-000522-18-IT Belgium;Czech Republic;Czechia;France;Germany;Hungary;Italy;Netherlands;Poland;United Kingdom;
AZD9056
AstraZeneca AB
2006 - EUCTR2005-002319-26-HU Austria;Belgium;Germany;Hungary;
2006 - EUCTR2005-002319-26-AT Austria;Belgium;Germany;Hungary;
2005 - EUCTR2005-002319-26-DE Austria;Belgium;Germany;Hungary;
2005 - EUCTR2005-002319-26-BE Austria;Belgium;Germany;Hungary;
Abatacept
Bristol-Myers Squibb
2006 Phase 3 NCT00406653 Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;India;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;South Africa;Spain;Switzerland;United Kingdom;United States;
Bristol-Myers Squibb International Corporation
2008 Phase 3 EUCTR2006-003371-13-IE Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2008 - EUCTR2006-003371-13-PL Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2008 - EUCTR2006-003371-13-CZ Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 Phase 3 EUCTR2006-003371-13-FR Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-NL Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-IT Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-GB Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-DK Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-DE Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-BE Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
Abrilumab
Amgen
2012 Phase 2 NCT01696396 Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Netherlands;Switzerland;United Kingdom;United States;
Accelerated 1 hour-infusion
Asan Medical Center
2011 Phase 4 NCT01346826 Korea, Republic of;
Accelerated 30 minutes-infusion
Asan Medical Center
2011 Phase 4 NCT01346826 Korea, Republic of;
Acetaminophen
Cedars-Sinai Medical Center
2020 Phase 1/Phase 2 NCT04224558 United States;
Adalimumab
AbbVie
2016 - NCT02750800 Hungary;
2015 Phase 3 NCT02499783 China;
2014 Phase 4 NCT02148718 Spain;
2014 Phase 3 NCT02185014 Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Puerto Rico;Romania;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
2014 Phase 3 NCT02065570 Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Puerto Rico;Romania;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
2013 Phase 3 NCT01958827 Japan;
2013 Phase 2 NCT02015793 China;
2013 - NCT01768858 Austria;
AbbVie (prior sponsor, Abbott)
2011 Phase 3 NCT01235689 Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;
2008 Phase 3 NCT00686374 Belgium;Canada;Czech Republic;Czechia;France;Netherlands;Poland;United Kingdom;United States;
AbbVie Deutschland GmbH & Co. KG
2015 Phase 3 EUCTR2013-004034-15-IT Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
2015 Phase 3 EUCTR2013-004034-15-GB Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
2015 Phase 3 EUCTR2013-004034-15-FR Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
2015 Phase 3 EUCTR2013-004034-15-DK Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
2015 Phase 3 EUCTR2013-004034-15-DE Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
2015 Phase 3 EUCTR2013-004034-15-BE Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
2015 Phase 3 EUCTR2013-001746-33-FR Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2015 Phase 3 EUCTR2013-001746-33-BE Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2014 Phase 3 EUCTR2013-004034-15-SK Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004034-15-HU Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
2014 Phase 3 EUCTR2013-004034-15-ES Austria;Canada;Czech Republic;Denmark;European Union;France;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
2014 Phase 3 EUCTR2013-004034-15-AT Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
2014 Phase 3 EUCTR2013-001746-33-SK Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2014 Phase 3 EUCTR2013-001746-33-NL Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2014 Phase 3 EUCTR2013-001746-33-IT Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2014 Phase 3 EUCTR2013-001746-33-ES Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2014 Phase 3 EUCTR2013-001746-33-DK Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2014 Phase 3 EUCTR2013-001746-33-DE Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2014 Phase 3 EUCTR2013-001746-33-CZ Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Hungary;Israel;Netherlands;Slovakia;Spain;Switzerland;United States;
2014 Phase 3 EUCTR2013-001746-33-AT Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2014 - EUCTR2013-001746-33-HU Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Hungary;Israel;Netherlands;Slovakia;Spain;Switzerland;United States;
2009 Phase 3 EUCTR2007-006494-90-CZ Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
AbbVie GK
2013 Phase 3 JPRN-JapicCTI-142426 -
Abbott
2007 Phase 3 NCT00427921 United States;
2007 Phase 3 NCT00409682 Belgium;Canada;Czech Republic;France;Italy;Netherlands;Poland;United Kingdom;United States;
2007 Phase 2/Phase 3 NCT00445939 Japan;
2007 Phase 2/Phase 3 NCT00445432 Japan;
2006 Phase 3 NCT00409617 Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Norway;Portugal;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States;
2006 Phase 3 NCT00348283 Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Sweden;United States;
2006 Phase 3 NCT00338650 United States;
2004 Phase 3 NCT00195715 Australia;Belgium;Canada;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;South Africa;Spain;Sweden;United Kingdom;United States;
2004 Phase 3 NCT00105300 Belgium;Canada;France;United States;
2003 Phase 3 NCT00077779 United States;
Abbott GmBH Co KG
2005 - EUCTR2004-002163-24-IT Denmark;Germany;Hungary;Italy;Spain;United Kingdom;
Abbott GmBH & Co. KG
2010 Phase 3 EUCTR2010-020137-10-IT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
Abbott GmbH Co.KG
2006 - EUCTR2005-005291-32-IT Austria;Belgium;Germany;Italy;Netherlands;Sweden;
Abbott GmbH & Co. K.G.
2009 Phase 3 EUCTR2007-006494-90-GB Belgium;Czech Republic;United Kingdom;
- - EUCTR2007-006494-90-Outside-EU/EEA Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
Abbott GmbH & Co. KG
2009 - EUCTR2006-004814-41-GB Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
2008 - EUCTR2006-004814-41-NL Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
2008 - EUCTR2006-004814-41-IT Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
2008 - EUCTR2006-004814-41-CZ Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
2008 - EUCTR2006-004814-41-BE Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
2008 - EUCTR2004-002163-24-GB Denmark;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-004814-41-FR Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
2006 - EUCTR2005-005291-32-SE Austria;Belgium;Germany;Italy;Netherlands;Sweden;
2006 - EUCTR2005-005291-32-NL Austria;Belgium;Germany;Italy;Netherlands;Sweden;
2006 - EUCTR2005-005291-32-DE Austria;Belgium;Germany;Italy;Netherlands;Sweden;
2006 - EUCTR2005-005291-32-BE Austria;Belgium;Germany;Italy;Netherlands;Sweden;
2006 - EUCTR2005-005291-32-AT Austria;Belgium;Germany;Italy;Netherlands;Sweden;
2005 - EUCTR2004-002934-20-BE Belgium;
2005 - EUCTR2004-002163-24-DE Denmark;Germany;Hungary;Italy;Spain;United Kingdom;
2004 - EUCTR2004-002163-24-SE Denmark;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
2004 - EUCTR2004-002163-24-ES Denmark;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
2004 - EUCTR2004-002163-24-DK Denmark;Germany;Hungary;Italy;Spain;United Kingdom;
- - EUCTR2006-004814-41-Outside-EU/EEA -
Abbott GmbH & Co. KG (Abbott)
2006 - EUCTR2006-002078-23-NL Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
Abbott GmbH & co. KG
2004 - EUCTR2004-002163-24-BE Belgium;Denmark;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
Abbott Japan Co., Ltd.
2007 Phase 2-3 JPRN-JapicCTI-070367 -
2007 Phase 2-3 JPRN-JapicCTI-070366 -
Abbott Laboratories
2004 - EUCTR2004-002163-24-HU Belgium;Denmark;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
Abbvie Deutschland GmbH & Co. K.G.
2008 Phase 3 EUCTR2007-006494-90-BE Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
Academic Medical Center
2019 Phase 4 EUCTR2018-002064-15-NL Netherlands;
2013 Phase 4 EUCTR2013-002932-25-NL Netherlands;
Biogen
2019 - NCT04089514 Belgium;Germany;Ireland;Italy;Spain;United Kingdom;
2018 - NCT03662919 France;
Children's Hospital Medical Center, Cincinnati
2019 - NCT04131504 United States;
Department of Internal Medicine, School of Medicine, Keio University
2013 - JPRN-UMIN000009596 Japan;
2011 Phase 4 JPRN-UMIN000005146 Japan;
Department of Lower Gastroenterology, Hyogo College of Medicine
2012 Phase 4 JPRN-UMIN000006882 Japan;
Foundation for Liver Research
2008 Phase 3 NCT00736983 Netherlands;
Fukuoka University Chikushi Hospital
2016 - JPRN-UMIN000023871 Japan;
GETAID - Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives
2015 Phase 4 EUCTR2013-003199-11-BE Belgium;France;
GETECCU
2011 - EUCTR2011-000885-36-ES Spain;
Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
2012 Phase 3 NCT01564823 Spain;
Hospital Universitari Vall d'Hebron Research Institute
2014 - NCT02539849 Spain;
ISTITUTO CLINICO HUMANITAS
2009 - EUCTR2009-011763-37-IT Italy;
Innovaderm Research Inc.
2012 Phase 4 NCT01556672 Canada;
Iwate Medical UniversityKochi Medical School HospitalKeio University School of Medicine
2016 - JPRN-UMIN000019958 Japan;
Janssen Research & Development, LLC
2021 Phase 2 NCT04655807 Canada;France;Germany;Italy;Japan;Spain;Sweden;United States;
Kenji Watanabe
2010 - JPRN-UMIN000005762 Japan;
2010 - JPRN-UMIN000005761 Japan;
Landos Biopharma Inc.
2021 Phase 2 NCT05057273 -
Maastricht University Medical Center
2019 Phase 4 NCT03917303 Netherlands;
McMaster University
2018 Phase 4 NCT03059849 -
Mikami Yohei
2019 - JPRN-jRCT1031190056 Japan;
Nagoya University Gradeate School of MedicineDepartment of Gastroenterology
2012 Phase 2 JPRN-UMIN000007514 Japan;
Numaguchi Hirotaka
2021 Phase 2 JPRN-jRCT2031200406 Canada;France;Germany;Italy;Japan;Spain;United States Of America;
PIBD-Net
2017 Phase 4 NCT02852694 France;
Radboud University
2017 Phase 4 NCT03172377 Netherlands;
Royal Liverpool University Hospital
2012 - EUCTR2011-006084-22-GB United Kingdom;
Saitama Medical Center
2016 - JPRN-UMIN000022270 Japan;
Saitama Medical Center, Saitama Medical University
2016 - JPRN-UMIN000023735 Japan;
Sakura Medical Center,Toho university
2012 Phase 2 JPRN-UMIN000009284 Japan;
Sakura medical center, Toho university
2015 - JPRN-UMIN000032485 Japan;
Sara Varea
2014 Phase 3 NCT01986127 Spain;
Schneider Children's Medical Center, Israel
2015 Phase 4 NCT02256462 Israel;
Takeda
2017 Phase 4 NCT02764762 Canada;United States;
Tel-Aviv Sourasky Medical Center
2012 Phase 3 NCT01629628 Israel;
Toho University Medical Center Sakura Hospital
2016 - JPRN-UMIN000024566 Japan;
Tohoku University Graduate School of Medicine (Tohoku University Hospital)
2012 - JPRN-UMIN000007343 Japan;
UCB Biopharma SRL
2021 Phase 3 NCT04643483 -
Universitaire Ziekenhuizen Leuven
2012 - NCT02450513 Belgium;
University Hospital Southampton NHS Foundation Trust
2019 Phase 4 EUCTR2018-004967-30-GB United Kingdom;
University Medical Center Groningen
2021 Phase 4 NCT04646187 Belgium;Netherlands;Spain;
University of Alberta
2009 Phase 4 NCT00972218 Canada;
University of Western Ontario, Canada
2014 Phase 4 NCT01960426 United States;
Vanderbilt University Medical Center
2008 Phase 4 NCT00517296 United States;
Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine
2021 Phase 4 ChiCTR2000036845 China;
Yamaguchi University Graduate School of Medicine Department of Gastroenterology and Hepatology
2011 - JPRN-UMIN000007047 Japan;
waqqas.afif
2017 - NCT03261102 Canada;
Adalimumab (40 mg)
Janssen Scientific Affairs, LLC
2018 Phase 3 NCT03464136 Australia;Belgium;Brazil;Bulgaria;Canada;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
Adalimumab (D2E7)
Abbott
2002 Phase 2 NCT00055523 United States;
Adalimumab 40 mg eow or ew
Abbott
2002 Phase 3 NCT01070303 United States;
Adalimumab Injection
St Vincent's Hospital Melbourne
2017 Phase 4 NCT03220841 Australia;
Adalimumab PRN
Peter Higgins
2013 Phase 3 NCT01674413 United States;
Adalimumab and Infliximab
University Hospital, Ghent
2011 - NCT01338740 Belgium;
Adult human mesenchymal stem cells
Mesoblast, Inc.
2010 Phase 3 NCT01233960 Australia;New Zealand;United States;
Agri-King Synbiotic (AKSB)
Mayo Clinic
2006 Phase 1/Phase 2 NCT00587041 United States;
Albendazole (Eskazole)
academic medical centre
2018 Phase 4 EUCTR2017-001737-85-NL Netherlands;
Alemtuzumab
Northwestern University
2019 Phase 2 NCT04154735 United States;
Paul Szabolcs
2012 Phase 1/Phase 2 NCT00692939 United States;
Alequel
Hadassah Medical Organization
2008 Phase 1/Phase 2 NCT02185183 -
Alfacalcidol
Nagoya University Hospital
2017 - JPRN-UMIN000025961 Japan;
Nakamura Masanao
2017 Phase 2 JPRN-jRCTs041180126 Japan;
Alicaforsen
Isis Pharmaceuticals
2002 Phase 3 NCT00048295 Belgium;Czech Republic;Germany;Italy;Poland;Spain;
2001 Phase 3 NCT00048113 Canada;United States;
Alicalm (polymeric liquid formula)
University Hospital Birmingham
2008 Phase 4 NCT00609752 United Kingdom;
Allogeneic Bone Marrow Transplantation
Fred Hutchinson Cancer Research Center
2012 Phase 2 NCT01570348 United States;
Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs)
Joshua M Hare
2019 Phase 1 NCT02677350 United States;
Allogeneic Stem Cell Therapy
Northwestern University
2010 Phase 1/Phase 2 NCT01288053 United States;
Allogenic eASCs 5 milion cells/ml suspension for injection. Cx601
CELLERIX S.A.
2012 Phase 3 EUCTR2011-006064-43-IT Austria;Belgium;Germany;Israel;Italy;Netherlands;Spain;
Allogenic eASCs 5 million cells/ml suspension for injection CX601
TIGENIX S.A.U
2018 Phase 3 EUCTR2017-000725-12-IT Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
TiGenix, S.A.U.
2021 Phase 3 EUCTR2017-000725-12-SE Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2017-000725-12-DK Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2017-000725-12-GB Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2017-000725-12-DE Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-PL Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-HU Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-FR Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-CZ Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-BE Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
Allogenic eASCs 5 million cells/ml suspension for injection. CX601
TiGenix S.A.U.
2012 Phase 3 EUCTR2011-006064-43-DE Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;
TiGenix, S.A.U.
2012 Phase 3 EUCTR2011-006064-43-AT Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;
Allogenic eASCs 5 million/ml suspension for injection.
TiGenix, S.A. Unipersonal
2012 Phase 3 EUCTR2011-006064-43-BE Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;
2012 - EUCTR2011-006064-43-NL Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;
Allopurinol
SOIBD (The Swedish Organisation for the study of Inflammatory Bowel Diseases)
2018 Phase 4 EUCTR2016-004112-35-SE Sweden;
Allopurinol Sandoz 100 mg, tabletten
Meander Medical Center
2016 Phase 4 EUCTR2016-001638-84-NL Netherlands;
Alofisel
MILLENNIUM PHARMACEUTICALS, INC.
2019 Phase 4 EUCTR2019-000333-39-IT Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
Millennium Pharmaceuticals, Inc (MPI)
2020 Phase 4 EUCTR2019-000333-39-FR Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2020 Phase 4 EUCTR2017-002491-10-FR Austria;Czech Republic;France;Germany;Spain;United Kingdom;
2020 Phase 4 EUCTR2017-002491-10-ES Austria;Czech Republic;France;Germany;Spain;United Kingdom;
2020 Phase 4 EUCTR2017-002491-10-CZ Austria;Czech Republic;Czechia;France;Germany;Spain;United Kingdom;
2019 Phase 4 EUCTR2019-000333-39-CZ Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
Takeda Development Center Americas, Inc
2020 Phase 4 EUCTR2019-000333-39-BE Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
Takeda Development Center Americas, Inc.
2021 Phase 3 EUCTR2020-003193-48-NL Israel;Italy;Japan;Netherlands;Poland;Spain;
2020 Phase 4 EUCTR2017-002491-10-DE Austria;Czech Republic;Czechia;France;Germany;Israel;Spain;
2020 Phase 4 EUCTR2017-002491-10-AT Austria;Czech Republic;Czechia;France;Germany;Israel;Spain;
- Phase 3 EUCTR2020-003193-48-PL Israel;Japan;Netherlands;Poland;
TiGenix, S.A.U.
2021 Phase 3 EUCTR2017-000725-12-SE Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2017-000725-12-DK Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2017-000725-12-GB Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2017-000725-12-DE Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-PL Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-HU Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-CZ Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-BE Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
Also referred to as 'MEDI2070'
AstraZeneca AB
2021 Phase 2;Phase 3 EUCTR2018-004346-42-HU Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-004346-42-DE Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Also referred to as MED2070
ASTRAZENECA AB
2021 Phase 3 EUCTR2019-001866-14-IT Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
AstraZeneca AB
2021 Phase 3 EUCTR2019-001866-14-PL Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2019-001866-14-HU Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2019-001866-14-DE Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Also referred to as MEDI2070
ASTRAZENECA AB
2021 Phase 3 EUCTR2019-001866-14-IT Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
AstraZeneca AB
2021 Phase 3 EUCTR2019-001866-14-PL Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2019-001866-14-HU Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2019-001866-14-DE Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Amgevita
University Medical Center Groningen
2021 Phase 4 EUCTR2020-001811-26-BE Belgium;Netherlands;
2020 Phase 4 EUCTR2020-001811-26-NL Netherlands;
Amgevita 40 mg Injektionslösung im Fertigpen
Universitätsklinikum Erlangen
2019 Phase 4 EUCTR2019-003662-40-DE Germany;
Amgevita 40 mg Injektionslösung in einer Fertigspritze
Universitätsklinikum Erlangen
2019 Phase 4 EUCTR2019-003662-40-DE Germany;
Amgevita 40Mg Solution for Injection
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
2019 Phase 4 NCT04131322 Spain;
Amoxicillin
Ishikawa Dai
2017 - JPRN-jRCTs031180415 Japan;
Juntendo university school of medicineDepartment of gastroenterology
2017 - JPRN-UMIN000025846 Japan;
Andecaliximab
Gilead Sciences
2015 Phase 2 NCT02405442 Australia;Canada;Czech Republic;Czechia;France;Germany;Hungary;Iceland;Italy;New Zealand;Poland;South Africa;Spain;United Kingdom;United States;
AndoSan
Oslo University Hospital
2011 Phase 2/Phase 3 NCT01496053 Norway;
Anti TNF
University Hospital, Lille
2017 - NCT02872506 -
Anti TNF Alfa.
Carmel Medical Center
2014 - NCT01881464 Israel;
Anti TNF humanized antibody Fab fragment-PEG conjugate
UCB PHARMA S.A.
2008 - EUCTR2007-003239-21-FR France;
Anti TNF therapy including infliximab
Janssen Biotech, Inc.
2007 - NCT00606346 Canada;United States;
Anti-CD3 Monoclonal antibody
PDL BioPharma, Inc
2005 - EUCTR2004-004388-31-DE Germany;
PDL BioPharma, Inc.
2005 - EUCTR2004-004387-72-DE Germany;
Protein Design Labs, Inc.
2005 - EUCTR2004-004387-72-AT Austria;Germany;
Anti-IL-23 monoclonal antibody
Allergan Limited
2017 Phase 2 EUCTR2015-000609-38-GB Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2015-000609-38-HU Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2015-000609-38-DE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2015-000609-38-BG Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
AstraZeneca AB
2013 Phase 2 EUCTR2012-004098-26-HU Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United States;
2013 Phase 2 EUCTR2012-004098-26-FR Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United States;
2013 Phase 2 EUCTR2012-004098-26-ES Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United States;
2013 Phase 2 EUCTR2012-004098-26-DE Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United States;
2013 Phase 2 EUCTR2012-004098-26-CZ Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United States;
MedImmune Limited
2016 Phase 2 EUCTR2015-000609-38-CZ Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
MedImmune, Ltd, a wholly owned subsidiary of AstraZeneca UK
2016 Phase 2 EUCTR2015-000609-38-NL Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2015-000609-38-ES Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2015-000609-38-BE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
Anti-IL-6 mAb
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2012 - EUCTR2011-004763-72-IT Australia;Austria;Brazil;Canada;Czech Republic;European Union;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
Bristol-Myers Squibb International Corporation
2012 - EUCTR2011-004763-72-NL Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-004763-72-HU Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-004763-72-GB Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-004763-72-DE Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-004763-72-CZ Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-004763-72-AT Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
Anti-Interferon-gamma monoclonal antibody
Facet Biotech
2002 Phase 2 NCT00072943 Canada;United States;
Anti-Interleukin-23 Immunoglobulin G2 (IgG2) Huma
ALLERGAN LIMITED
2020 Phase 2;Phase 3 EUCTR2018-004346-42-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Anti-Interleukin-23 Immunoglobulin G2 (IgG2) Human Monoclonal Antibody
ALLERGAN LIMITED
2020 Phase 2;Phase 3 EUCTR2018-004346-42-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
ASTRAZENECA AB
2021 Phase 3 EUCTR2019-001866-14-IT Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Allergan Limited
2021 Phase 3 EUCTR2019-001866-14-ES Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Allergan Ltd.
2020 Phase 2;Phase 3 EUCTR2018-004346-42-RO Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2;Phase 3 EUCTR2018-004346-42-BG Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2;Phase 3 EUCTR2018-004346-42-BE Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-004346-42-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-004346-42-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
AstraZeneca AB
2021 Phase 3 EUCTR2019-001866-14-PL Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2019-001866-14-HU Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2019-001866-14-DE Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2018-004346-42-HU Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-004346-42-GB Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-004346-42-DE Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2019-001866-14-GB Australia;Austria;Belgium;Bulgaria;Canada;China;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2018-004346-42-PL Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Astrazeneca AB
2020 Phase 2;Phase 3 EUCTR2018-004346-42-AT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Anti-Interleukin-6 Monoclonal Antibody
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2012 - EUCTR2011-004763-72-IT Australia;Austria;Brazil;Canada;Czech Republic;European Union;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
Bristol-Myers Squibb International Corporation
2012 - EUCTR2011-004763-72-NL Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-004763-72-HU Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-004763-72-GB Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-004763-72-DE Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-004763-72-CZ Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-004763-72-AT Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
Anti-MAdCAM antibody
Pfizer Inc.
2013 - EUCTR2012-002030-37-BE Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Norway;Poland;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;United Kingdom;
SHIRE HUMAN GENETIC THERAPIES, INC
2019 Phase 3 EUCTR2017-000617-23-IT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
Shire Human Genetic Therapies, Inc.
2019 Phase 3 EUCTR2017-000617-23-GR Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-000576-29-GR Argentina;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Estonia;Greece;Hungary;Ireland;Japan;Korea, Republic of;Mexico;Portugal;Slovakia;Spain;Switzerland;Ukraine;United States;
2019 Phase 3 EUCTR2017-000574-11-GR Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000617-23-ES Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000576-29-HU Argentina;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Estonia;Greece;Hungary;Ireland;Japan;Korea, Republic of;Mexico;Portugal;Slovakia;Spain;Switzerland;Ukraine;United States;
2018 Phase 3 EUCTR2017-000576-29-ES Argentina;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Estonia;France;Greece;Hungary;Ireland;Japan;Korea, Republic of;Mexico;Portugal;Slovakia;Spain;Switzerland;Ukraine;United States;
2018 Phase 3 EUCTR2017-000576-29-BE Argentina;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Estonia;Greece;Hungary;Ireland;Japan;Korea, Republic of;Mexico;Portugal;Slovakia;Spain;Switzerland;Ukraine;United States;
- Phase 3 EUCTR2017-000617-23-CZ Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2017-000575-88-CZ Australia;Austria;Brazil;Croatia;Czech Republic;Germany;Israel;Italy;Japan;Lithuania;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;South Africa;United Kingdom;United States;
Anti-TNF
University of Maryland, Baltimore
2011 - NCT02619552 United States;
Anti-TNF Drug
Hospices Civils de Lyon
2021 - NCT03712826 France;
Schneider Children's Medical Center, Israel
2019 - NCT03681652 Israel;
Anti-TNF Therapy
Takeda
2017 - NCT03090139 Argentina;China;Colombia;Korea, Republic of;Mexico;Russian Federation;Saudi Arabia;Singapore;Taiwan;Turkey;
Anti-TNF discontinuation: Physiological saline solution
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
2017 Phase 4 NCT02994836 Spain;
Anti-TNF: Infliximab (Infusion)
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
2017 Phase 4 NCT02994836 Spain;
Anti-TNF:Adalimumab (Subcutaneus)
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
2017 Phase 4 NCT02994836 Spain;
Anti-thymocyte globulin (rabbit)
Cedars-Sinai Medical Center
2020 Phase 1/Phase 2 NCT04224558 United States;
Antibiotics
St Vincent's Hospital Melbourne
2021 Phase 2/Phase 3 NCT04970446 -
Anticorpo monoclonale anti IL-23
ASTRAZENECA
2013 Phase 2 EUCTR2012-004098-26-IT Canada;Czech Republic;France;Germany;Hungary;Italy;Spain;United States;
Anticorpo monoclonale anti-IL-23
MEDIMMUNE, LLC
2016 Phase 2 EUCTR2015-000609-38-IT Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
Anticorpo monoclonale umano anti-Interleuchina-23 Immunoglobulina G2 (IgG2)
ALLERGAN LIMITED
2020 Phase 2;Phase 3 EUCTR2018-004346-42-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Antithymocyte immunoglobulin (rabbit)
WOLFSON DIGESTIVE DISEASES CENTRE
2007 - EUCTR2005-003337-40-IT Italy;United Kingdom;
Apheresis catheter placement
Cedars-Sinai Medical Center
2020 Phase 1/Phase 2 NCT04224558 United States;
Apixaban 2.5 milligram
McMaster University
2021 Early Phase 1 NCT03935451 Canada;
Application of Adalimumab
Gerhard Rogler
2009 - NCT01012570 Switzerland;
Artesunate
Sanjay Gandhi Postgraduate Institute of Medical Sciences
2021 Phase 2 NCT04713631 India;
Atorvastatin
Region Skåne
2006 - EUCTR2005-000496-17-SE Sweden;
Skane University Hospital
2006 Phase 2 NCT00454545 Sweden;
Autologous ADIpose derived stromal vascular fraction
ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE
2019 Phase 2 EUCTR2019-001948-21-FR France;
Autologous CD34-selected peripheral blood stem cells transplant
Paul Szabolcs
2012 Phase 1/Phase 2 NCT00692939 United States;
Autologous Stem Cell Transplantation
Northwestern University
2005 Phase 2 NCT00271947 United States;
Autologous mesenchymal stromal cell
Emory University
2012 Phase 1 NCT01659762 United States;
Autologous ovalbumin-specific type 1 regulatory T lymphocytes expanded population
TxCell
2014 Phase 2 EUCTR2014-001295-65-IT Austria;Belgium;Germany;Italy;
2014 Phase 2 EUCTR2014-001295-65-DE Austria;Belgium;Germany;Italy;
2014 Phase 2 EUCTR2014-001295-65-BE Austria;Belgium;Germany;Italy;
2014 Phase 2 EUCTR2014-001295-65-AT Austria;Belgium;Germany;Italy;
Autologous stem cell transplant
Icahn School of Medicine at Mount Sinai
2017 Phase 2 NCT03219359 United States;
Azathioprin
PIBD-Net
2017 Phase 3 EUCTR2016-000522-18-DE Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
PIBDNet
2018 Phase 4 EUCTR2016-000522-18-CZ Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
Azathioprin-ratiopharm
Abbott GmBH & Co. KG
2010 Phase 3 EUCTR2010-020137-10-IT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
Azathioprin-ratiopharm 25mg Filmtabletten
AbbVie Deutschland GmbH & Co. KG
2015 Phase 3 EUCTR2010-020137-10-LT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2010-020137-10-HU Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2010-020137-10-BE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-SE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-NL Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2010-020137-10-GB Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-DE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-CZ Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-AT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
Abbott GmbH & Co. KG
2010 Phase 3 EUCTR2010-020137-10-FR Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2010-020137-10-ES Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
Azathioprin-ratiopharm 50 mg Filmtabletten
AbbVie Deutschland GmbH & Co. KG
2015 Phase 3 EUCTR2010-020137-10-LT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2010-020137-10-HU Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2010-020137-10-BE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-SE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-NL Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2010-020137-10-GB Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-DE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-CZ Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-AT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
Abbott GmbH & Co. KG
2010 Phase 3 EUCTR2010-020137-10-FR Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2010-020137-10-ES Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
Azathioprine
Dental University Gastroenterology
AbbVie (prior sponsor, Abbott)
2011 Phase 3 NCT01235689 Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;
Academic Medical Center, department of Gastroenterology and hepatology
2008 - EUCTR2008-001131-35-NL Netherlands;
Centocor B.V.
2005 Phase 3 EUCTR2004-002815-10-GB Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
2005 Phase 3 EUCTR2004-002815-10-ES Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-SE Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-DK Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-DE Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-AT Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
Department of Gastroenterology and Hepatology, Kyoto University Hospital
2011 - JPRN-UMIN000005689 Japan;
Department of Gastroenterology, Nanfang Hospital, Southern Medical University
2016 - ChiCTR1800020305 China;
Department of Internal Medicine, School of Medicine, Keio University
2013 - JPRN-UMIN000009596 Japan;
2011 Phase 4 JPRN-UMIN000005146 Japan;
Dr. Falk Pharma GmbH
2002 Phase 3 NCT00946946 Austria;Germany;
Erasmus Medical Center
2015 Phase 4 NCT02517684 Belgium;Denmark;Finland;Italy;Netherlands;Poland;
2013 Phase 4 NCT01880307 Italy;Netherlands;
GETAID
2018 Phase 4 EUCTR2014-002311-41-NL Belgium;France;Germany;Netherlands;Sweden;United Kingdom;
2015 Phase 4 EUCTR2014-002311-41-DE Australia;France;Germany;Netherlands;Sweden;United Kingdom;
2014 - EUCTR2014-002311-41-FR France;Sweden;United Kingdom;
Gastroenterology Research of America
2013 Phase 3 NCT01817972 United States;
Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
2012 Phase 3 NCT01564823 Spain;
Indiana University
2015 - NCT02413047 United States;
Jinling Hospital, China
2009 - NCT01015391 China;
Lower GI disease, Hyogo College of Medicine
2007 Phase 2,3 JPRN-UMIN000004427 Japan;
Massachusetts General Hospital
2005 Phase 3 NCT00098111 United States;
Novartis Pharma Services AG
2005 Phase 2 EUCTR2005-001148-22-SK Slovakia;
PIBD net
2018 Phase 4 EUCTR2016-000522-18-GB Belgium;Canada;Czech Republic;France;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
PIBDnet (Pediatric Inflammatory Bowel Disease Network)
- Phase 4 EUCTR2016-000522-18-PL Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
Region Örebro län
2021 Phase 4 EUCTR2019-002942-19-DK Denmark;
SOIBD (The Swedish Organisation for the study of Inflammatory Bowel Diseases)
2018 Phase 4 EUCTR2016-004112-35-SE Sweden;
Schneider Children's Medical Center, Israel
2019 - NCT03681652 Israel;
Shanghai Research Institute of Acupuncture and Meridian
2016 Phase 1 study ChiCTR-IIR-16007751 China;
Sixth Affiliated Hospital, Sun Yat-sen University
2021 - NCT04761952 -
2017 Phase 3 NCT03185611 China;
Tokyo Medical &
University of Edinburgh
2015 - EUCTR2014-002311-41-GB Belgium;France;Germany;Sweden;United Kingdom;
Zhu Weiming
2018 - NCT04160325 China;
Azathioprine (AZA) caps
Centocor Ortho Biotech Services, L.L.C.
2005 Phase 3 NCT00094458 Austria;Belgium;Canada;Denmark;France;Germany;Greece;Israel;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States;
Azathioprine (AZA) or 6-mercaptopurine (6-MP)
ZonMw: The Netherlands Organisation for Health Research and Development
2007 - NCT00521950 Netherlands;
Azathioprine - ratiopharm
Abbott GmBH & Co. KG
2010 Phase 3 EUCTR2010-020137-10-IT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
Azathioprine / 6 Mercaptopurine
PIBD-Net
2017 Phase 4 NCT02852694 France;
Azathioprine OR Mesalazine
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
2002 Phase 3 NCT00976690 France;
Azathioprine in case of endoscopic recurrence
Universitaire Ziekenhuizen Leuven
2005 Phase 2 NCT02247258 Belgium;Czech Republic;Greece;
Azathioprine individualised dose
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2005 Phase 2 NCT00113503 Canada;United States;
Azathioprine or 6-mercaptopurine
ZonMw: The Netherlands Organisation for Health Research and Development
2007 - NCT00521950 Netherlands;
Azathioprine or adalimumab and infliximab
Tokyo Medical and Dental University
2014 Phase 3 NCT02332356 Japan;
Azathioprine weight-based dose
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2005 Phase 2 NCT00113503 Canada;United States;
Azathioprine+enteral nutrition
Jinling Hospital, China
2012 - NCT01823042 China;
Azatioprina
GETECCU
2011 - EUCTR2011-000885-36-ES Spain;
Azithromycin
Erasmus MC
2014 - EUCTR2012-005226-29-PL Belgium;Canada;Israel;Netherlands;Poland;Portugal;United States;
University of North Carolina, Chapel Hill
2021 Phase 2 NCT04186247 Canada;Israel;Netherlands;United States;
Wolfson Medical Center
2013 - EUCTR2012-005226-29-BE Belgium;Canada;Israel;Netherlands;Poland;Portugal;United States;
- - EUCTR2012-005226-29-NL Canada;Israel;Netherlands;United States;
Azithromycin + Metronidazole
Prof. Arie Levine
2012 Phase 4 NCT01596894 Israel;
B. theta
4D Pharma
2015 Phase 1 EUCTR2014-005666-29-GB United Kingdom;
BFAHF-2
Icahn School of Medicine at Mount Sinai
2021 Phase 1 NCT03992469 United States;
BI 655066 10 mg/ml
AbbVie Deutschland GmbH & Co. KG
2015 Phase 2 EUCTR2015-001834-15-NL Belgium;Canada;Germany;Korea, Republic of;Netherlands;Spain;United States;
2015 Phase 2 EUCTR2015-001834-15-DE Belgium;Canada;Germany;Ireland;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 2 EUCTR2015-001834-15-BE Belgium;Canada;Germany;Korea, Republic of;Netherlands;Spain;United States;
Boehringer Ingelheim España, S.A.
2015 Phase 2 EUCTR2015-001834-15-ES Belgium;Canada;Germany;Korea, Republic of;Netherlands;Spain;United States;
2014 Phase 2 EUCTR2013-002902-29-ES Belgium;Canada;France;Ireland;Korea, Republic of;Netherlands;Spain;United Kingdom;United States;
Boehringer Ingelheim bv
2015 Phase 2 EUCTR2013-002902-29-NL Belgium;Canada;Germany;Ireland;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
SCS Boehringer Ingelheim Comm.V
2014 Phase 2 EUCTR2013-002902-29-BE Belgium;Canada;Germany;Ireland;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
BI 655066 90 mg/ml
AbbVie Deutschland GmbH & Co. KG
2015 Phase 2 EUCTR2015-001834-15-NL Belgium;Canada;Germany;Korea, Republic of;Netherlands;Spain;United States;
2015 Phase 2 EUCTR2015-001834-15-DE Belgium;Canada;Germany;Ireland;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 2 EUCTR2015-001834-15-BE Belgium;Canada;Germany;Korea, Republic of;Netherlands;Spain;United States;
Boehringer Ingelheim España, S.A.
2015 Phase 2 EUCTR2015-001834-15-ES Belgium;Canada;Germany;Korea, Republic of;Netherlands;Spain;United States;
2014 Phase 2 EUCTR2013-002902-29-ES Belgium;Canada;France;Ireland;Korea, Republic of;Netherlands;Spain;United Kingdom;United States;
Boehringer Ingelheim bv
2015 Phase 2 EUCTR2013-002902-29-NL Belgium;Canada;Germany;Ireland;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
SCS Boehringer Ingelheim Comm.V
2014 Phase 2 EUCTR2013-002902-29-BE Belgium;Canada;Germany;Ireland;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
BI 655130
BOEHRINGER-INGELHEIM ITALIA S.P.A.
2021 Phase 2 EUCTR2020-005770-99-IT Aruba;Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Serbia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Boehringer Ingelheim
2021 Phase 2 EUCTR2020-005770-99-NL Australia;Austria;Belgium;Brazil;Canada;China;Denmark;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Serbia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2021 Phase 2 EUCTR2019-001673-93-BE Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
2020 Phase 2 EUCTR2019-001673-93-AT Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
Boehringer Ingelheim AB
2021 Phase 2 EUCTR2020-005770-99-SE Australia;Austria;Belgium;Brazil;Canada;China;Denmark;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Serbia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Boehringer Ingelheim B.V
2021 Phase 2 EUCTR2020-005770-99-DK Australia;Austria;Belgium;Brazil;Canada;China;Denmark;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Serbia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Boehringer Ingelheim BV
2020 Phase 2 EUCTR2017-003090-34-DK Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
Boehringer Ingelheim Ltd
2021 Phase 2 EUCTR2020-005770-99-IE Australia;Austria;Belgium;Brazil;Canada;China;Denmark;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Serbia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Boehringer Ingelheim Netherlands BV
2019 Phase 2 EUCTR2017-003090-34-NL Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
Boehringer Ingelheim Norway KS
2022 Phase 2 EUCTR2020-005770-99-NO Australia;Austria;Belgium;Brazil;Canada;China;Denmark;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Serbia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Boehringer Ingelheim Pharma GmbH & Co. KG
2020 Phase 2 EUCTR2019-001673-93-DE Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
2019 Phase 2 EUCTR2017-003090-34-DE Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
Boehringer Ingelheim RCV GmbH & Co KG
2020 Phase 2 EUCTR2019-001673-93-HU Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
2019 Phase 2 EUCTR2017-003090-34-HU Austria;Belgium;Germany;Hungary;Netherlands;
2019 Phase 2 EUCTR2017-003090-34-AT Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
Boehringer Ingelheim S.A.
2021 Phase 2 EUCTR2019-001673-93-ES Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
SCS Boehringer Ingelheim Comm.V
2018 Phase 2 EUCTR2017-003090-34-BE Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
BI 695501
Boehringer Ingelheim
2016 Phase 3 NCT02871635 Belarus;Bosnia and Herzegovina;Croatia;Czechia;Germany;Greece;Israel;Poland;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
Boehringer Ingelheim International GmbH
2017 Phase 3 EUCTR2016-000612-14-HR Belarus;Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000612-14-GR Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000612-14-GB Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000612-14-DE Belarus;Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000612-14-CZ Belarus;Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
BI 706321
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
2021 Phase 2 EUCTR2020-004527-16-IT Belgium;Czechia;France;Italy;Poland;Spain;United States;
Boehringer Ingelheim
2021 Phase 2 NCT04978493 Poland;United States;
BIBR 796 BS,
Boehringer Ingelheim
2001 Phase 2 NCT02209792 -
BLI-1300 high dose
Braintree Laboratories
2011 Phase 2 NCT01442363 United States;
BLI-1300 low dose
Braintree Laboratories
2011 Phase 2 NCT01442363 United States;
BMS-188667
Bristol-Myers Squibb International Corporation
2008 Phase 3 EUCTR2006-003371-13-IE Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2008 - EUCTR2006-003371-13-PL Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2008 - EUCTR2006-003371-13-CZ Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 Phase 3 EUCTR2006-003371-13-FR Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-NL Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-GB Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-DK Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-DE Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-BE Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
BMS-936557
Bristol-Myers Squibb International Corporation
2012 - EUCTR2011-002981-19-PL Belgium;France;Hungary;Poland;South Africa;United States;
2012 - EUCTR2011-002981-19-HU Belgium;France;Hungary;Poland;South Africa;United States;
2012 - EUCTR2011-002981-19-BE Belgium;France;Hungary;Poland;South Africa;United States;
BMS-936557 (Anti-IP-10 Antibody)
Bristol-Myers Squibb
2011 Phase 2 NCT01466374 Belgium;France;Hungary;Israel;Poland;Puerto Rico;South Africa;United States;
BMS-945429
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2012 - EUCTR2011-004763-72-IT Australia;Austria;Brazil;Canada;Czech Republic;European Union;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
Bristol-Myers Squibb International Corporation
2012 - EUCTR2011-004763-72-NL Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-004763-72-HU Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-004763-72-GB Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-004763-72-DE Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-004763-72-CZ Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-004763-72-AT Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
CSL Behring
2012 Phase 2 NCT01545050 Australia;Austria;Brazil;Canada;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
BMS-986165
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2021 Phase 2 EUCTR2020-004461-40-IT Australia;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 2 EUCTR2017-001976-48-IT Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Poland;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
Bristol-Myers Squibb
2021 Phase 2 NCT04877990 Australia;Brazil;China;Germany;Hungary;Italy;Japan;Poland;Romania;Russian Federation;United Kingdom;United States;
2018 Phase 2 NCT03599622 Australia;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
Bristol-Myers Squibb International Corporation
2021 Phase 2 EUCTR2020-004461-40-DE Australia;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
2021 Phase 2 EUCTR2017-001976-48-NL Australia;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
2021 Phase 2 EUCTR2017-001976-48-BE Australia;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 2 EUCTR2017-001976-48-DK Australia;Belgium;Bouvet Island;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Slovakia;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2017-001976-48-GB Australia;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
Bristol-Myers Squibb international Corporation
2020 Phase 2 EUCTR2017-001976-48-FR Australia;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 2 EUCTR2017-001976-48-PT Australia;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 2 EUCTR2017-001976-48-PL Australia;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 2 EUCTR2017-001976-48-HU Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Poland;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 2 EUCTR2017-001976-48-ES Australia;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States;
2018 Phase 2 EUCTR2017-001976-48-DE Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
BMS986165
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2018 Phase 2 EUCTR2017-001976-48-IT Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Poland;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
Bristol-Myers Squibb International Corporation
2021 Phase 2 EUCTR2020-004461-40-DE Australia;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
2021 Phase 2 EUCTR2017-001976-48-NL Australia;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 2 EUCTR2017-001976-48-DK Australia;Belgium;Bouvet Island;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Slovakia;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2017-001976-48-GB Australia;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
Bristol-Myers Squibb international Corporation
2020 Phase 2 EUCTR2017-001976-48-FR Australia;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 2 EUCTR2017-001976-48-PT Australia;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 2 EUCTR2017-001976-48-PL Australia;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 2 EUCTR2017-001976-48-HU Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Poland;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 2 EUCTR2017-001976-48-ES Australia;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States;
2018 Phase 2 EUCTR2017-001976-48-DE Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
BT-11
Landos Biopharma Inc.
2021 Phase 2 EUCTR2019-000824-17-SK Albania;Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Georgia;North Macedonia;Poland;Serbia;Slovakia;Spain;Turkey;Ukraine;United States;
2021 Phase 2 EUCTR2019-000824-17-HR Albania;Austria;Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Czechia;Georgia;Moldova, Republic of;Netherlands;North Macedonia;Poland;Serbia;Slovakia;Spain;Turkey;Ukraine;United States;
2021 Phase 2 EUCTR2019-000824-17-BG Albania;Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Georgia;North Macedonia;Poland;Serbia;Slovakia;Spain;Turkey;Ukraine;United States;
2020 Phase 2 EUCTR2018-005086-39-BG Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Georgia;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
2019 Phase 2 EUCTR2018-005086-39-PL Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Georgia;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
2019 Phase 2 EUCTR2018-005086-39-HU Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Georgia;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
2019 Phase 2 EUCTR2018-005086-39-HR Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Georgia;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
BT-11 (Omilancor)
Landos Biopharma Inc.
2021 Phase 2 NCT05057273 -
BT-11 1,
Landos Biopharma Inc.
2021 Phase 2 NCT03870334 Bulgaria;Poland;United States;
BT-11 Active
Landos Biopharma Inc.
2018 Phase 1 NCT03860571 United States;
Bacteriophage preparation
Intralytix, Inc.
2019 Phase 1/Phase 2 NCT03808103 United States;
Bacteriotherapy
David Suskind
2012 Phase 1 NCT01757964 United States;
Beta carotene from Dunaliella algae
Bnai Zion Medical Center
2002 Phase 3 NCT00275418 Israel;
Betamethasone
The Sixth Affiliated Hospital of Sun Yat-sen University
2019 - ChiCTR1900023696 China;
Bezlotoxumab
David Binion, MD
2021 Phase 4 NCT04626947 United States;
Bif195 capsules
Hvidovre University Hospital
2021 - NCT04842149 Denmark;
Bifidobacterium infantis 35624
University College Cork
2002 Phase 2/Phase 3 NCT00510978 Ireland;
Biological samplings
Hospices Civils de Lyon
2011 - NCT02504255 France;
Biosimilar
McGill University Health Centre/Research Institute of the McGill University Health Centre
2018 - NCT03729674 Canada;
Biosimilar infliximab
Diakonhjemmet Hospital
2014 Phase 4 NCT02148640 Norway;
Bleomycin
The Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine
2020 Phase 0 ChiCTR2000031344 China;
Blood and stools samples
University Hospital, Lille
2015 - NCT02851134 France;
Blood sample
Centre Hospitalier Universitaire, Amiens
2021 Phase 3 NCT05040464 France;
Blood sampling
Centre Hospitalier Universitaire Dijon
2013 - NCT02859675 France;
Blood sampling from infant
UCB BIOSCIENCES, Inc.
2014 Phase 1 NCT02019602 France;Netherlands;Switzerland;United States;
Blood sampling from mother
UCB BIOSCIENCES, Inc.
2014 Phase 1 NCT02019602 France;Netherlands;Switzerland;United States;
Blood sampling from umbilical cord
UCB BIOSCIENCES, Inc.
2014 Phase 1 NCT02019602 France;Netherlands;Switzerland;United States;
Blue light photopheresis
University Hospital, Akershus
2019 Phase 1/Phase 2 NCT04164849 Norway;
Bone Marrow Derived Mesenchymal Stem cells (MSCs)
Leiden University Medical Center
2010 - EUCTR2009-015680-14-NL Netherlands;
Bone Marrow MSC Derived Extracellular Vesicle Isolate
Direct Biologics, LLC
2022 Phase 1 NCT05130983 -
Boulardii
University Clinic Dr Dragisa Misovic-Dedinje
2019 - NCT03941418 -
Brazikumab
ASTRAZENECA AB
2021 Phase 3 EUCTR2019-001866-14-IT Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Brazikumab IV Infusion
Allergan
2016 Phase 2 NCT02574637 Australia;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
Brazikumab Induction Dose
AstraZeneca
2020 Phase 3 NCT03961815 Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Brazikumab Maintenance Dose
AstraZeneca
2020 Phase 3 NCT03961815 Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Brazikumab SC Injection
Allergan
2016 Phase 2 NCT02574637 Australia;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
Brazikumab high dose
AstraZeneca
2018 Phase 2/Phase 3 NCT03759288 Australia;Austria;Bulgaria;Canada;China;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Brazikumab low dose
AstraZeneca
2018 Phase 2/Phase 3 NCT03759288 Australia;Austria;Bulgaria;Canada;China;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Breast milk sampling
UCB BIOSCIENCES, Inc.
2014 Phase 1 NCT02154425 France;Netherlands;Switzerland;United States;
Brepocitinib
Pfizer Inc.
2018 Phase 2 EUCTR2017-003359-43-SK Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-CZ Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017
2018 Phase 2 EUCTR2017-003359-43-PL Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-HU Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-DE Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-BE Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-AT Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
Budenofalk
Dr. Falk Pharma GmbH
2007 - EUCTR2004-001213-34-GB Czech Republic;United Kingdom;
University Medical Center Utrecht
2009 - EUCTR2007-005455-42-NL Netherlands;
Budenofalk 3mg gastro-resistant capsules
Dr. Falk Pharma GmbH
2009 - EUCTR2008-006957-42-SK Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Slovakia;
2009 - EUCTR2008-006957-42-LV Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Slovakia;
2009 - EUCTR2008-006957-42-LT Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Romania;Russian Federation;Slovakia;Ukraine;
2009 - EUCTR2008-006957-42-HU Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Slovakia;
2009 - EUCTR2008-006957-42-DE Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Romania;Russian Federation;Slovakia;Ukraine;
2009 - EUCTR2008-006957-42-CZ Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Slovakia;
2009 - EUCTR2008-006957-42-BG Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Slovakia;
Budenofalk 9mg gastro-resistant granules
Dr. Falk Pharma GmbH
2009 - EUCTR2008-006957-42-SK Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Slovakia;
2009 - EUCTR2008-006957-42-LV Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Slovakia;
2009 - EUCTR2008-006957-42-LT Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Romania;Russian Federation;Slovakia;Ukraine;
2009 - EUCTR2008-006957-42-HU Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Slovakia;
2009 - EUCTR2008-006957-42-DE Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Romania;Russian Federation;Slovakia;Ukraine;
2009 - EUCTR2008-006957-42-CZ Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Slovakia;
2009 - EUCTR2008-006957-42-BG Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Slovakia;
Budesonide
AstraZeneca
- Phase 2 JPRN-JapicCTI-080566 -
AstraZeneca AB
- - EUCTR2011-003743-22-DE Canada;Germany;Italy;Poland;United States;
AstraZeneca K.K.
- Phase 3 EUCTR2014-004132-20-Outside-EU/EEA Japan;
Dr. Falk Pharma GmbH
2009 Phase 3 NCT01086553 Germany;
2007 - EUCTR2004-001213-34-GB Czech Republic;United Kingdom;
2004 Phase 3 NCT00300118 Germany;
2004 Phase 3 EUCTR2004-001213-34-SK Czech Republic;Slovakia;United Kingdom;
2004 - EUCTR2004-001213-34-CZ Czech Republic;United Kingdom;
Hillel Yaffe Medical Center
2020 - NCT04233463 Israel;
Osaka University Graduate School of MedicineDepartment of Gastroenterology and Hepatology
2018 - JPRN-UMIN000031839 Japan;
Royal Liverpool & Broadgreen University Hospitals Trust
2009 Phase 2 EUCTR2008-001137-99-GB United Kingdom;
Royal Liverpool University Hospital
2014 Phase 2 NCT01783106 United Kingdom;
Takehara Tetsuo
2018 Phase 2 JPRN-jRCT1051190043 Japan;
Tohoku University Hospital, Division of Gastroenterology
2018 - JPRN-UMIN000030884 Japan;
Budesonide ( Zentacort Capsules 3mg )
ZERIA Pharmaceutical Co., Ltd.
2017 - JPRN-JapicCTI-184152 -
Bupivacaine/epinephrine/dexamethasone
Cedars-Sinai Medical Center
2018 Phase 4 NCT03723447 United States;
By demand
Hospital Galdakao-Usansolo
2020 - NCT04188990 Spain;
C326, IL-6 Inhibitory Avimer protein
Avidia
2006 Phase 1 NCT00353756 Australia;
CC-5013
Celgene Corporation
2002 Phase 2 NCT00446433 France;Israel;United Kingdom;United States;
CCX282-B
ChemoCentryx
2006 Phase 2 NCT00306215 Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Netherlands;Poland;South Africa;Sweden;United Kingdom;
2004 Phase 2 NCT00102921 United States;
ChemoCentryx, Inc
2007 - EUCTR2005-003827-38-SE Austria;Belgium;Bulgaria;Czech Republic;Denmark;France;Hungary;Sweden;United Kingdom;
2007 - EUCTR2005-003827-38-HU Austria;Belgium;Bulgaria;Czech Republic;Denmark;France;Hungary;Sweden;United Kingdom;
2007 - EUCTR2005-003827-38-FR Austria;Belgium;Bulgaria;Czech Republic;Denmark;France;Hungary;Sweden;United Kingdom;
2007 - EUCTR2005-003827-38-DE Austria;Belgium;Bulgaria;Czech Republic;Denmark;France;Germany;Hungary;Sweden;United Kingdom;
2007 - EUCTR2005-003827-38-BG Austria;Belgium;Bulgaria;Czech Republic;Denmark;France;Hungary;Sweden;United Kingdom;
2007 - EUCTR2005-003827-38-BE Austria;Belgium;Bulgaria;Czech Republic;Denmark;France;Hungary;Sweden;United Kingdom;
2007 - EUCTR2005-003827-38-AT Austria;Belgium;Bulgaria;Czech Republic;Denmark;France;Hungary;Sweden;United Kingdom;
2006 Phase 2 EUCTR2005-003827-38-GB Austria;Belgium;Bulgaria;Czech Republic;Denmark;France;Germany;Hungary;Sweden;United Kingdom;
2006 - EUCTR2005-003827-38-DK Austria;Belgium;Bulgaria;Czech Republic;Denmark;France;Hungary;Sweden;United Kingdom;
2006 - EUCTR2005-003827-38-CZ Austria;Belgium;Bulgaria;Czech Republic;Denmark;France;Hungary;Sweden;United Kingdom;
CD
Fukuoka University Chikushi Hospital
2011 - JPRN-UMIN000005946 Japan;
Hyogo College of Medicine, Department of Inflammatory Bowel Disease, Division of Internal Medicine
2012 - JPRN-UMIN000013534 Japan;
Icahn School of Medicine at Mount Sinai
2019 - NCT03850600 United States;
NHS Greater Glasgow and Clyde
2020 - NCT04225689 United Kingdom;
Nanfang Hospital, Southern Medical University
2019 - ChiCTR1900027370 China;
Shikamura Mitsuhiro
2022 Phase 3 JPRN-jRCT2071210031 Australia;Belgium;Bosnia;China;Croatia;Czech Republic;Germany;Hungary;Israel;Italy;Japan;Lithuania;New Zealand;Poland;Romania;Russia;Slovakia;Spain;Ukraine;United Kingdom;United States;
The 7th Medical Center of the PLA General Hospital (Army general hospital)
2019 Phase 0 ChiCTR1900022728 China;
The First Hospital Affiliated to Sun Yat sen University
2020 - ChiCTR2000029543 China;
University of Glasgow
2014 - NCT02426567 United Kingdom;
University of Miami
2019 - NCT04213729 United States;
CD-C-Food
Second Affiliated Hospital, School of Medicine, Zhejiang University
2020 - NCT04976491 China;
CD7 CAR T-cells
Zhejiang University
2022 Early Phase 1 NCT05239702 China;
CDP6038
UCB BIOSCIENCES GmbH
2012 Phase 2 EUCTR2011-002517-11-BG Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Netherlands;Poland;Romania;Serbia;
2012 - EUCTR2011-002517-11-HU Czech Republic;Germany;Hungary;Serbia;
2012 - EUCTR2011-002517-11-DE Czech Republic;Germany;Hungary;Serbia;
2012 - EUCTR2011-002517-11-CZ Czech Republic;Germany;Hungary;Serbia;
CDP870
UCB AE
2006 - EUCTR2006-002027-16-GR Greece;
UCB Celletech
2008 - EUCTR2007-001913-41-IT Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
UCB Celltech
2008 - EUCTR2007-002716-26-IT Austria;Belgium;Czech Republic;Estonia;Finland;Hungary;Italy;Latvia;
2008 - EUCTR2007-002716-26-EE Austria;Belgium;Czech Republic;Estonia;Finland;Hungary;Italy;Latvia;
2008 - EUCTR2007-002716-26-CZ Austria;Belgium;Czech Republic;Estonia;Finland;Hungary;Italy;Latvia;
2008 - EUCTR2007-002716-26-BE Australia;Austria;Belgium;Brazil;Canada;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;New Zealand;Poland;Romania;Russian Federation;Ukraine;United States;
2008 - EUCTR2007-002716-26-AT Australia;Austria;Belgium;Brazil;Canada;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;New Zealand;Poland;Romania;Russian Federation;Ukraine;United States;
2008 - EUCTR2007-001913-41-EE Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
2008 - EUCTR2007-001913-41-DE Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
2008 - EUCTR2007-001913-41-CZ Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
2008 - EUCTR2007-001913-41-BE Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
2008 - EUCTR2007-001913-41-AT Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
2007 - EUCTR2007-002716-26-LV Austria;Belgium;Czech Republic;Estonia;Finland;Hungary;Italy;Latvia;
2007 - EUCTR2007-002716-26-HU Australia;Austria;Belgium;Brazil;Canada;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;New Zealand;Poland;Romania;Russian Federation;Ukraine;United States;
2007 - EUCTR2007-002716-26-FI Austria;Belgium;Czech Republic;Estonia;Finland;Hungary;Italy;Latvia;
2007 - EUCTR2007-001913-41-LV Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
2007 - EUCTR2007-001913-41-HU Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
2007 - EUCTR2007-001913-41-FI Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
- - EUCTR2014-004381-24-Outside-EU/EEA Australia;Canada;New Zealand;United States;
UCB Japan Co., Ltd.
- - EUCTR2014-004400-30-Outside-EU/EEA Japan;
- - EUCTR2014-004399-42-Outside-EU/EEA Japan;
- - EUCTR2014-004354-34-Outside-EU/EEA Japan;
UCB PHARMA
2007 - EUCTR2006-001729-24-IT Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
UCB PHARMA S.A.
2008 - EUCTR2007-003239-21-FR France;
UCB Pharma S.A
2007 - EUCTR2005-003977-25-DE Belgium;Germany;
UCB Pharma S.A.
2007 - EUCTR2006-003871-11-DE Germany;
2007 - EUCTR2006-001729-24-SE Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-003870-88-DE Germany;
2006 - EUCTR2005-004104-37-DE Austria;Belgium;Germany;Italy;Spain;Sweden;United Kingdom;
UCB Pharma SA
2007 - EUCTR2006-001729-24-DE Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
UCB S.A
2007 Phase 3 EUCTR2006-001729-24-GB Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-001729-24-AT Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2005-003977-25-BE Belgium;Germany;
UCB S.A.
2007 Phase 3 EUCTR2006-001729-24-FR Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-001729-24-NL Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-001729-24-ES Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2005-004104-37-GB Austria;Belgium;Denmark;Germany;Italy;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2005-004104-37-ES Austria;Belgium;Denmark;Germany;Italy;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-001729-24-BE Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004104-37-SE Austria;Belgium;Germany;Italy;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004104-37-DK Austria;Belgium;Denmark;Germany;Italy;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004104-37-BE Austria;Belgium;Germany;Italy;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004104-37-AT Austria;Belgium;Germany;Italy;Spain;Sweden;United Kingdom;
CHOLECALCIFEROL CONCENTRATE
Academic Medical Center
2013 Phase 3 EUCTR2013-002838-20-NL Belgium;Netherlands;
CHOLECALCIFEROL CONCENTRATE (WATER-DISPERSIBLE FORM)
Academic Medical Center
2014 Phase 3 EUCTR2013-002838-20-BE Belgium;Netherlands;
CNTO1275
JANSSEN CILAG INTERNATIONAL NV
2019 Phase 3 EUCTR2018-002629-51-IT Austria;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004209-41-IT Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-IT Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002918-43-IT Belgium;Denmark;France;Germany;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2016 Phase 2 EUCTR2016-000634-21-IT Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
JANSSEN-CILAG INTERNATIONAL N.V.
2011 - EUCTR2010-022759-42-IT Australia;Brazil;Bulgaria;Canada;Croatia;Germany;Hungary;Iceland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-022758-18-IT Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;New Zealand;South Africa;Spain;United Kingdom;United States;
Janssen-Cilag International N.V.
2020 Phase 3 EUCTR2018-002629-51-GB Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002629-51-SE Austria;Czech Republic;Czechia;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002629-51-FR France;Germany;Netherlands;Spain;Sweden;United States;
2019 Phase 3 EUCTR2018-002629-51-AT Austria;France;Germany;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-002629-51-ES France;Germany;Netherlands;Spain;Sweden;United States;
2018 Phase 3 EUCTR2017-004209-41-PL Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004209-41-FR Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004209-41-ES Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004209-41-BG Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004209-41-BE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2016-002918-43-SK Belgium;Denmark;France;Germany;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2018 Phase 3 EUCTR2016-002918-43-DK Belgium;Denmark;France;Germany;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2017 Phase 3 EUCTR2016-002918-43-SE Belgium;Denmark;France;Germany;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2017 Phase 3 EUCTR2016-002918-43-PT Belgium;Denmark;France;Germany;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2017 Phase 3 EUCTR2016-002918-43-NL Belgium;Denmark;France;Germany;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2017 Phase 3 EUCTR2016-002918-43-GB Belgium;Germany;Netherlands;Portugal;Spain;United Kingdom;
2017 Phase 3 EUCTR2016-002918-43-FR Belgium;Denmark;France;Germany;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2017 Phase 3 EUCTR2016-002918-43-ES Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2017 Phase 3 EUCTR2016-002918-43-DE Belgium;Denmark;France;Germany;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2017 Phase 3 EUCTR2016-002918-43-BE Belgium;Denmark;France;Germany;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2017 Phase 1 EUCTR2016-001956-22-PL Belgium;Canada;France;Germany;Poland;United States;
2017 Phase 1 EUCTR2016-001956-22-DE Belgium;Canada;France;Germany;Poland;United States;
2017 Phase 1 EUCTR2016-001956-22-BE Belgium;Canada;France;Germany;Poland;United States;
2012 Phase 3 EUCTR2010-022760-12-NL Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
2012 Phase 3 EUCTR2010-022760-12-BE Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
2012 Phase 3 EUCTR2010-022758-18-BE Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;European Union;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;New Zealand;Serbia;South Africa;Spain;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022760-12-IT Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022760-12-IS Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022760-12-IE Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022760-12-HU Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022760-12-GB Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022760-12-FR Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022760-12-ES Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022760-12-DK Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022760-12-DE Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022760-12-CZ Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022760-12-BG Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022760-12-AT Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022759-42-GB Australia;Brazil;Bulgaria;Canada;Croatia;Germany;Hungary;Iceland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;South Africa;Spain;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022758-18-GB Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;New Zealand;Serbia;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-022759-42-NL Australia;Brazil;Bulgaria;Canada;Croatia;European Union;Germany;Hungary;Iceland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-022759-42-IS Australia;Brazil;Bulgaria;Canada;Croatia;European Union;Germany;Hungary;Iceland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-022759-42-HU Australia;Brazil;Bulgaria;Canada;Croatia;European Union;Germany;Hungary;Iceland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-022759-42-ES Australia;Brazil;Bulgaria;Canada;Croatia;European Union;Germany;Hungary;Iceland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-022759-42-DE Australia;Brazil;Bulgaria;Canada;Croatia;European Union;Germany;Hungary;Iceland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-022759-42-BG Australia;Brazil;Bulgaria;Canada;Croatia;European Union;Germany;Hungary;Iceland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-022758-18-IS Austria;Belgium;Czech Republic;Denmark;Germany;Hungary;Iceland;Ireland;Italy;Spain;United Kingdom;
2011 - EUCTR2010-022758-18-IE Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;New Zealand;Serbia;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-022758-18-HU Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;European Union;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;New Zealand;Serbia;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-022758-18-ES Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;European Union;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;New Zealand;Serbia;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-022758-18-DK Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;European Union;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;New Zealand;Serbia;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-022758-18-DE Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;European Union;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;New Zealand;Serbia;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-022758-18-CZ Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;European Union;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;New Zealand;Serbia;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-022758-18-AT Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;New Zealand;Serbia;South Africa;Spain;United Kingdom;United States;
- Phase 1 EUCTR2016-001956-22-FR Belgium;Canada;France;Germany;Poland;United States;
Janssen-Cilag International NV
2021 Phase 3 EUCTR2020-004457-76-PL Argentina;France;Japan;Poland;Russian Federation;Turkey;United States;
2021 Phase 3 EUCTR2019-004225-24-HU Belgium;Germany;Hungary;Japan;Poland;Russian Federation;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004225-24-DE Belgium;Germany;Hungary;Japan;Poland;Russian Federation;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004225-24-BE Belgium;Germany;Hungary;Japan;Poland;Russian Federation;United Kingdom;United States;
2021 Phase 3 EUCTR2018-002629-51-CZ Austria;Czech Republic;Czechia;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002629-51-NL Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2017-002195-13-PT Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2017-002195-13-GB Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2016-000634-21-FR Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004209-41-NL Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004209-41-GB Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004209-41-DE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004209-41-CZ Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-PL Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-NL Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-LV Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-LT Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-HR Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-GR Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-ES Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-DE Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-CZ Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-BE Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-AT Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000634-21-PL Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2016-000634-21-HU Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2016-000634-21-GB Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2016-000634-21-DE Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2020-004457-76-FR Argentina;Belgium;France;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2019-004225-24-PL Belgium;Germany;Hungary;Japan;Poland;Russian Federation;United Kingdom;United States;
- Phase 3 EUCTR2019-004225-24-Outside-EU/EEA Belgium;Germany;Hungary;Japan;Poland;Russian Federation;United Kingdom;United States;
- Phase 3 EUCTR2019-004225-24-GB Belgium;Germany;Hungary;Japan;Poland;Russian Federation;United Kingdom;United States;
CNTO1959
JANSSEN CILAG INTERNATIONAL NV
2018 Phase 2;Phase 3 EUCTR2017-002195-13-IT Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
Janssen-Cilag International NV
2019 Phase 2;Phase 3 EUCTR2017-002195-13-PT Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2017-002195-13-GB Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-SK Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-PL Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-NL Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-LV Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-LT Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-HR Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-GR Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-ES Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-DE Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-CZ Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-BE Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-AT Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
CP-461
Astellas Pharma Inc
2002 Phase 2 NCT00042055 United States;
CP-690,550
PFIZER
2008 - EUCTR2008-003571-45-IT Belgium;Czech Republic;France;Hungary;Italy;Netherlands;Spain;United Kingdom;
Pfizer
2012 Phase 2 NCT01470599 Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Ukraine;United States;
2012 Phase 2 NCT01393899 Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Ukraine;United States;
2011 Phase 2 NCT01393626 Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Romania;South Africa;Spain;Sweden;Ukraine;United States;
2008 Phase 2 NCT00615199 Belgium;Czech Republic;France;Hungary;Italy;Netherlands;Poland;Slovakia;South Africa;Spain;United Kingdom;United States;
Pfizer Limited, Ramsgate Road,Sandwich,Kent CT13 9NJ
2009 - EUCTR2008-003571-45-GB Belgium;Czech Republic;France;Hungary;Italy;Netherlands;Spain;United Kingdom;
Pfizer Ltd, Ramsgate Road,Sandwich,Kent CT13 9NJ
2009 - EUCTR2008-003571-45-CZ Belgium;Czech Republic;France;Hungary;Italy;Netherlands;Spain;United Kingdom;
2008 Phase 2 EUCTR2008-003571-45-SK Belgium;Czech Republic;France;Hungary;Italy;Netherlands;Slovakia;Spain;United Kingdom;
2008 Phase 2 EUCTR2008-003571-45-FR Belgium;Czech Republic;France;Hungary;Italy;Netherlands;Slovakia;Spain;United Kingdom;
2008 - EUCTR2008-003571-45-NL Belgium;Czech Republic;France;Hungary;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2008-003571-45-HU Belgium;Czech Republic;France;Hungary;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2008-003571-45-BE Belgium;Czech Republic;France;Hungary;Italy;Netherlands;Spain;United Kingdom;
Pfizer S.A
2008 Phase 2 EUCTR2008-003571-45-ES Belgium;Czech Republic;France;Hungary;Italy;Netherlands;Slovakia;Spain;United Kingdom;
CP-690,550-10
Pfizer Inc
2012 Phase 2 EUCTR2011-003622-27-CZ Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
Pfizer Inc, 235 East 42nd Street, New York, New York 10017
2013 Phase 2 EUCTR2011-003622-27-NL Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
2013 Phase 2 EUCTR2011-003622-27-HR Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Romania;South Africa;Spain;Sweden;Ukraine;United States;
2013 Phase 2 EUCTR2011-003622-27-AT Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Romania;South Africa;Spain;Sweden;Ukraine;United States;
2012 Phase 2 EUCTR2011-003622-27-HU Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
2012 Phase 2 EUCTR2011-003622-27-GR Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Netherlands;Norway;Romania;Slovakia;South Africa;Spain;Sweden;Ukraine;United States;
2012 Phase 2 EUCTR2011-003622-27-ES Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Netherlands;Norway;Romania;Slovakia;South Africa;Spain;Sweden;Ukraine;United States;
2012 Phase 2 EUCTR2011-003622-27-BG Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
2012 - EUCTR2011-003622-27-SE Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Netherlands;Norway;Romania;Slovakia;South Africa;Spain;Sweden;Ukraine;United States;
Pfizer Inc, 235 East 42nd Street, New York, New York 10017, USA
2012 Phase 2 EUCTR2011-003622-27-DE Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;Netherlands Antilles;South Africa;Spain;Sweden;Ukraine;United States;
Pfizer Inc.
2012 Phase 2 EUCTR2011-001754-28-CZ Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
2012 - EUCTR2011-001733-16-CZ Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
Pfizer Inc.235 East 42nd Street, New York, NY 10017
2013 Phase 2 EUCTR2011-001754-28-HR Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Romania;South Africa;Spain;Sweden;Ukraine;United States;
2013 - EUCTR2011-001733-16-HR Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Romania;South Africa;Spain;Sweden;Ukraine;United States;
2012 Phase 2 EUCTR2011-001754-28-BG Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
2012 - EUCTR2011-001754-28-NL Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
2012 - EUCTR2011-001754-28-HU Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
2012 - EUCTR2011-001754-28-GR Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Norway;Romania;Slovakia;South Africa;Spain;Sweden;Ukraine;United States;
2012 - EUCTR2011-001754-28-ES Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Norway;Romania;Slovakia;South Africa;Spain;Sweden;Ukraine;United States;
2012 - EUCTR2011-001754-28-AT Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Romania;South Africa;Spain;Sweden;Ukraine;United States;
2012 - EUCTR2011-001733-16-NL Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
2012 - EUCTR2011-001733-16-HU Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;Norway;Slovakia;South Africa;Spain;Sweden;Ukraine;United States;
2012 - EUCTR2011-001733-16-GR Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Norway;Romania;Slovakia;South Africa;Spain;Sweden;Ukraine;United States;
2012 - EUCTR2011-001733-16-BG Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
2012 - EUCTR2011-001733-16-AT Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Romania;South Africa;Spain;Sweden;Ukraine;United States;
2011 - EUCTR2011-001754-28-SE Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Norway;Romania;Slovakia;South Africa;Spain;Sweden;Ukraine;United States;
2011 - EUCTR2011-001733-16-SE Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Norway;Romania;Slovakia;South Africa;Spain;Sweden;Ukraine;United States;
2011 - EUCTR2011-001733-16-ES Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Norway;Romania;Slovakia;South Africa;Spain;Sweden;Ukraine;United States;
Pfizer Inc.235 East 42nd Street, New York, NY 10017, USA
2012 Phase 2 EUCTR2011-001754-28-DE Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
2012 - EUCTR2011-001733-16-DE Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
CPSI-2364
Ferring Pharmaceuticals
2009 Phase 1 NCT00950105 United States;
CROWN
Prometheus Laboratories
2016 Phase 2 NCT02793778 United States;
CT-P13
CELLTRION INC.
2019 Phase 3 EUCTR2019-001087-30-IT Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
Celltrion
2016 Phase 1 NCT02883452 Korea, Republic of;
2014 Phase 3 NCT02096861 United States;
Celltrion, Inc
2019 Phase 3 EUCTR2019-001087-30-PL Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Czechia;Estonia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-LV Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-HU Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-HR Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-GR Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-FR Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-ES Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-DE Austria;Belarus;Bulgaria;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-CZ Austria;Belarus;Bulgaria;Chile;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-BG Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Czechia;Estonia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-AT Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
Celltrion, Inc.
2014 Phase 3 EUCTR2013-004497-10-RO Belgium;Brazil;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004497-10-NL Belgium;Brazil;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004497-10-IT Belgium;Brazil;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004497-10-HU Belgium;Brazil;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004497-10-GB Belgium;Brazil;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004497-10-ES Belgium;Brazil;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004497-10-DK Belgium;Brazil;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004497-10-BE Belgium;Brazil;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Pfizer
2015 - NCT02539368 Belgium;Czech Republic;Czechia;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
CT-P13 SC (Infliximab)
Celltrion
2019 Phase 3 NCT03945019 Poland;United States;
CTLA4Ig
Bristol-Myers Squibb International Corporation
2008 Phase 3 EUCTR2006-003371-13-IE Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2008 - EUCTR2006-003371-13-PL Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2008 - EUCTR2006-003371-13-CZ Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 Phase 3 EUCTR2006-003371-13-FR Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-NL Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-GB Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-DK Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-DE Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-BE Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
CURCUMA LONGA RHIZOMA
CHU de Clermont-Ferrand
2014 Phase 3 EUCTR2014-000261-51-FR France;
Caffeine
Janssen Research & Development, LLC
2018 Phase 1 NCT03358706 Austria;Belgium;Denmark;Germany;Sweden;United Kingdom;United States;
Takeda
2016 Phase 4 NCT02760615 United States;
Calcitonin nasal spray (salmon)
Children's Hospital Boston
2004 - NCT00114803 United States;
Calcitriol
Atlanta VA Medical Center
2007 - NCT00427804 United States;
Caltrate Pill
Second Affiliated Hospital of Wenzhou Medical University
2020 Early Phase 1 NCT04276636 China;
2014 - NCT04606017 China;
Cannabidiol
Meir Medical Center
2010 Phase 1/Phase 2 NCT01037322 Israel;
University of Illinois at Chicago
2018 Phase 2/Phase 3 NCT03467620 -
Cannabidiol , synthetic form
Stero Biotechs Ltd.
2019 Phase 2 NCT04056442 Israel;
Cannabis, Medical
OMNI Medical Services, LLC
2018 Phase 2 NCT03944447 United States;
Capsule endoscopy
Innovaderm Research Inc.
2012 Phase 4 NCT01556672 Canada;
Capsule fecal microbiota material (cap-FMT)
University of Minnesota
2022 Phase 1 NCT05248191 United States;
Celebrex
University of Pittsburgh
2003 Phase 4 NCT00177866 United States;
Cellulose
Ciim Plus, d.o.o.
2018 - NCT04370535 Slovenia;
Certican
Novartis Pharma Services AG
2005 Phase 2 EUCTR2005-001148-22-SK Slovakia;
Certolizumab
Baylor College of Medicine
2011 - NCT01582568 United States;
Certolizumab Pegol (CDP870)
UCB Pharma
2004 Phase 3 NCT00152425 -
2003 Phase 3 NCT00152490 -
UCB Pharma SA
2004 Phase 3 NCT00160706 Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;New Zealand;Norway;Poland;Russian Federation;Serbia;Singapore;Slovenia;South Africa;Spain;Ukraine;United States;
2004 Phase 3 NCT00160524 Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Estonia;Georgia;Germany;Hong Kong;Hungary;Israel;Italy;Latvia;Lithuania;New Zealand;Norway;Poland;Russian Federation;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Tunisia;Ukraine;United States;
Certolizumab Pegol /Cimzia
UCB Celltech
- - EUCTR2014-004381-24-Outside-EU/EEA Australia;Canada;New Zealand;United States;
UCB Japan Co., Ltd.
- - EUCTR2014-004400-30-Outside-EU/EEA Japan;
- - EUCTR2014-004399-42-Outside-EU/EEA Japan;
- - EUCTR2014-004354-34-Outside-EU/EEA Japan;
Certolizumab pegol
Atlanta Gastroenterology Associates
2009 Phase 4 NCT01024647 United States;
Gastroenterology Research of America
2013 Phase 3 NCT01817972 United States;
Shafran Gastroenterology Center
2010 - NCT01053559 United States;
UCB AE
2006 - EUCTR2006-002027-16-GR Greece;
UCB Biopharma SRL
2021 Phase 3 NCT04643483 -
UCB Celletech
2008 - EUCTR2007-001913-41-IT Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
UCB Celltech
2008 - EUCTR2007-002716-26-IT Austria;Belgium;Czech Republic;Estonia;Finland;Hungary;Italy;Latvia;
2008 - EUCTR2007-002716-26-EE Austria;Belgium;Czech Republic;Estonia;Finland;Hungary;Italy;Latvia;
2008 - EUCTR2007-002716-26-CZ Austria;Belgium;Czech Republic;Estonia;Finland;Hungary;Italy;Latvia;
2008 - EUCTR2007-002716-26-BE Australia;Austria;Belgium;Brazil;Canada;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;New Zealand;Poland;Romania;Russian Federation;Ukraine;United States;
2008 - EUCTR2007-002716-26-AT Australia;Austria;Belgium;Brazil;Canada;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;New Zealand;Poland;Romania;Russian Federation;Ukraine;United States;
2008 - EUCTR2007-001913-41-EE Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
2008 - EUCTR2007-001913-41-DE Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
2008 - EUCTR2007-001913-41-CZ Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
2008 - EUCTR2007-001913-41-BE Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
2008 - EUCTR2007-001913-41-AT Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
2007 - EUCTR2007-002716-26-LV Austria;Belgium;Czech Republic;Estonia;Finland;Hungary;Italy;Latvia;
2007 - EUCTR2007-002716-26-HU Australia;Austria;Belgium;Brazil;Canada;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;New Zealand;Poland;Romania;Russian Federation;Ukraine;United States;
2007 - EUCTR2007-002716-26-FI Austria;Belgium;Czech Republic;Estonia;Finland;Hungary;Italy;Latvia;
2007 - EUCTR2007-001913-41-LV Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
2007 - EUCTR2007-001913-41-HU Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
2007 - EUCTR2007-001913-41-FI Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
UCB PHARMA
2007 - EUCTR2006-001729-24-IT Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
UCB Pharma
2010 Phase 2 NCT01190410 Australia;Canada;United States;
2007 Phase 3 NCT00358683 -
2007 Phase 3 NCT00356408 Canada;Germany;United States;
2007 Phase 3 NCT00354367 -
2007 Phase 3 NCT00307931 Greece;
2006 Phase 3 NCT00349752 Belgium;Canada;Germany;United States;
2006 Phase 3 NCT00308581 Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2006 Phase 3 NCT00297648 Belgium;France;Germany;
2006 Phase 2 NCT00329420 Japan;
UCB Pharma S.A
2007 - EUCTR2005-003977-25-DE Belgium;Germany;
UCB Pharma S.A.
2007 - EUCTR2006-003871-11-DE Germany;
2007 - EUCTR2006-001729-24-SE Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-003870-88-DE Germany;
2006 - EUCTR2005-004104-37-DE Austria;Belgium;Germany;Italy;Spain;Sweden;United Kingdom;
UCB Pharma SA
2007 - EUCTR2006-001729-24-DE Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
UCB S.A
2007 Phase 3 EUCTR2006-001729-24-GB Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-001729-24-AT Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2005-003977-25-BE Belgium;Germany;
UCB S.A.
2007 Phase 3 EUCTR2006-001729-24-FR Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-001729-24-NL Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-001729-24-ES Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2005-004104-37-GB Austria;Belgium;Denmark;Germany;Italy;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2005-004104-37-ES Austria;Belgium;Denmark;Germany;Italy;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-001729-24-BE Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004104-37-SE Austria;Belgium;Germany;Italy;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004104-37-DK Austria;Belgium;Denmark;Germany;Italy;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004104-37-BE Austria;Belgium;Germany;Italy;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004104-37-AT Austria;Belgium;Germany;Italy;Spain;Sweden;United Kingdom;
Certolizumab pegol (CDP870)
UCB Pharma
2006 Phase 3 NCT00333788 Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
Certolizumab pegol (CDP870, CZP)
UCB Pharma
2008 Phase 3 NCT00552058 Australia;Austria;Belgium;Brazil;Canada;Chile;Czech Republic;Czechia;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;New Zealand;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
Certolizumab pegol (CZP)
UCB Japan Co. Ltd.
2006 Phase 2 NCT00329550 Japan;
Certolizumab pegol (rINN)
UCB PHARMA S.A.
2008 - EUCTR2007-003239-21-FR France;
ChAdOx2 HAV
University of Oxford
2017 Phase 1 NCT03027193 United Kingdom;
Chenodiol
University Medical Center Utrecht
2009 - EUCTR2009-013348-35-NL Netherlands;
Chenofalk
University Medical Center Utrecht
2009 - EUCTR2009-013348-35-NL Netherlands;
Chimeric IgG1 monoclonal antibody
Centocor B.V.
2005 Phase 3 EUCTR2004-002815-10-GB Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-SE Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-DK Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-DE Denmark;Germany;Spain;Sweden;United Kingdom;
Cholecalciferol
Boston Children’s Hospital
2008 - NCT00621257 United States;
University Hospital Birmingham NHS Foundation Trust
2019 Phase 4 NCT03718182 United Kingdom;
University of California, Los Angeles
2010 Phase 1 NCT01046773 United States;
Cholecalciferol 10,000 IU
University of Michigan
2015 Phase 4 NCT02208310 United States;
Cholecalciferol 400 IU
University of Michigan
2015 Phase 4 NCT02208310 United States;
Cholestagel
LMU München, Campus Großhadern
2011 - EUCTR2009-010727-91-DE Germany;
University College London
2009 Phase 2 EUCTR2009-010163-16-GB United Kingdom;
Chondroitin sulfate
University Hospital Case Medical Center
2011 Phase 1/Phase 2 NCT01245088 United States;
Cimzia
Milton S. Hershey Medical Center
2013 Phase 4 NCT01696942 United States;
UCB BIOSCIENCES GmbH
2008 Phase 3 NCT00552344 Australia;Austria;Belgium;Brazil;Canada;Chile;Czech Republic;Czechia;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;New Zealand;Poland;Romania;Russian Federation;Ukraine;United States;
UCB Pharma
2009 - NCT00844285 United States;
Cimzia 200 mg solution for injection
Ghent University Hospital
2012 Phase 3 EUCTR2009-017998-37-BE Belgium;
Ciprofloxacin
Assistance Publique - Hôpitaux de Paris
2015 Phase 2 NCT02620007 France;
Children's Hospital of Philadelphia
2018 Phase 2 NCT03476317 United States;
European Group for Blood and Marrow Transplantation (EMBT)
2006 - EUCTR2005-003337-40-GB United Kingdom;
Foundation for Liver Research
2008 Phase 3 NCT00736983 Netherlands;
Mount Sinai Hospital, Canada
2006 Phase 2 NCT00257699 Canada;
Royal Liverpool University Hospital
2014 Phase 2 NCT01783106 United Kingdom;
University of North Carolina, Chapel Hill
2008 Phase 2 NCT00609973 United States;
University of Pennsylvania
2016 Phase 2 NCT02765256 United States;
Ciprofloxacin hydrochloride
Royal Liverpool & Broadgreen University Hospitals Trust
2009 Phase 2 EUCTR2008-001137-99-GB United Kingdom;
Clarithromycin
Royal Liverpool University Hospital
2000 Phase 3 NCT00269386 United Kingdom;
Clofarabine
Jonsson Comprehensive Cancer Center
2016 Early Phase 1 NCT02925351 United States;
Coffee
University Hospital Heidelberg
2010 - NCT01231217 Germany;
Colecalciferol
Academic Medical Center
2013 Phase 3 EUCTR2013-002838-20-NL Belgium;Netherlands;
Colecalciferol D3 (Vigantol Oil)
Imperial College London
2008 Phase 4 NCT00672763 United Kingdom;
Colesevelam
Florian Beigel
2010 Phase 4 NCT01203254 Germany;
LMU München, Campus Großhadern
2011 - EUCTR2009-010727-91-DE Germany;
ColoVit capsule
University Medical Center Groningen
2021 - NCT04913467 Netherlands;
Colonoscopic fecal microbiota material (colo-FMT)
University of Minnesota
2022 Phase 1 NCT05248191 United States;
Colony-purified Bacteroides thetaiotaomicron (B.theta)
4D Pharma
2015 Phase 1 EUCTR2014-005666-29-GB United Kingdom;
Companion diagnostic (CDx)
Prometheus Biosciences, Inc.
2021 Phase 2 NCT05013905 United States;
Computed Tomography
Jonsson Comprehensive Cancer Center
2016 Early Phase 1 NCT02925351 United States;
Continuous Mononuclear Cell Collection (CMNC)
University Hospital, Akershus
2019 Phase 1/Phase 2 NCT04164849 Norway;
Contrast Enhanced Ultrasound
University of Michigan
2015 Phase 1/Phase 2 NCT02061163 United States;
Contrast enhanced ultrasound
Yonsei University
2020 Phase 4 NCT04660136 Korea, Republic of;
Cortecosteroid
Children's Hospital Medical Center, Cincinnati
2005 Phase 2 NCT00109473 United States;
Corticosteroid
Jinling Hospital, China
2014 Phase 4 NCT02056418 China;
Yale University
2015 Phase 4 NCT02392286 United States;
CosmoFer 50mg/ml solution for infusion or injection
Barts Health NHS Trust
2011 Phase 4 EUCTR2010-023797-39-GB United Kingdom;
Crohn's Disease
Ferring Pharmaceuticals
2005 Phase 4 NCT00225810 Czech Republic;
Crohn's disease exclusion diet
Hospital Italiano de Buenos Aires
2021 - NCT05034458 Argentina;
Crohn's disease exclusion diet (CDED)
Assistance Publique - Hôpitaux de Paris
2022 Phase 2/Phase 3 NCT05284136 France;Netherlands;
Crohns Disease Exclusion Diet + PEN
Prof. Arie Levine
2016 - NCT02231814 Israel;
Curcumin
Hamamatsu South Hospital, Centre for Gastroenterology and Inflammatory Bowel Disease Research
2014 - JPRN-UMIN000015770 Japan;
Sanjay Gandhi Postgraduate Institute of Medical Sciences
2021 Phase 2 NCT04713631 India;
Seattle Children's Hospital
2009 Phase 1 NCT00889161 United States;
University Hospital, Clermont-Ferrand
2014 Phase 3 NCT02255370 France;
Cx401
CELLERIX S.A.
2009 - EUCTR2008-004286-25-DE Austria;Belgium;Czech Republic;Germany;Netherlands;Spain;
2009 - EUCTR2008-004286-25-BE Austria;Belgium;Czech Republic;Germany;Netherlands;Spain;
Cx601
MILLENNIUM PHARMACEUTICALS, INC.
2019 Phase 4 EUCTR2019-000333-39-IT Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
Millennium Pharmaceuticals, Inc (MPI)
2020 Phase 4 EUCTR2019-000333-39-FR Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2020 Phase 4 EUCTR2017-002491-10-FR Austria;Czech Republic;France;Germany;Spain;United Kingdom;
2020 Phase 4 EUCTR2017-002491-10-ES Austria;Czech Republic;France;Germany;Spain;United Kingdom;
2020 Phase 4 EUCTR2017-002491-10-CZ Austria;Czech Republic;Czechia;France;Germany;Spain;United Kingdom;
2019 Phase 4 EUCTR2019-000333-39-CZ Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
Takeda Development Center Americas, Inc
2020 Phase 4 EUCTR2019-000333-39-BE Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
Takeda Development Center Americas, Inc.
2021 Phase 3 EUCTR2020-003193-48-NL Israel;Italy;Japan;Netherlands;Poland;Spain;
2020 Phase 4 EUCTR2017-002491-10-DE Austria;Czech Republic;Czechia;France;Germany;Israel;Spain;
2020 Phase 4 EUCTR2017-002491-10-AT Austria;Czech Republic;Czechia;France;Germany;Israel;Spain;
- Phase 3 EUCTR2020-003193-48-PL Israel;Japan;Netherlands;Poland;
TiGenix, S.A. Unipersonal
2012 Phase 3 EUCTR2011-006064-43-BE Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;
2012 - EUCTR2011-006064-43-NL Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;
TiGenix, S.A.U.
2017 Phase 3 EUCTR2017-000725-12-ES Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
Tigenix S.A.U.
2017 Phase 3 NCT03279081 Belgium;Canada;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Puerto Rico;Spain;Sweden;United Kingdom;United States;
2009 Phase 1/Phase 2 NCT01372969 Spain;
Cyclophosphamide
Cedars-Sinai Medical Center
2020 Phase 1/Phase 2 NCT04224558 United States;
European Group for Blood and Marrow Transplantation (EMBT)
2006 - EUCTR2005-003337-40-GB United Kingdom;
Fred Hutchinson Cancer Research Center
2012 Phase 2 NCT01570348 United States;
Icahn School of Medicine at Mount Sinai
2017 Phase 2 NCT03219359 United States;
Northwestern University
2019 Phase 2 NCT04154735 United States;
Paul Szabolcs
2012 Phase 1/Phase 2 NCT00692939 United States;
WOLFSON DIGESTIVE DISEASES CENTRE
2007 - EUCTR2005-003337-40-IT Italy;United Kingdom;
Cyclophosphamide monohydrate
Barts Health NHS Trust
2017 Phase 3 EUCTR2017-002545-30-GB United Kingdom;
Cyltezo
Boehringer Ingelheim International GmbH
2017 Phase 3 EUCTR2016-000612-14-HR Belarus;Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000612-14-DE Belarus;Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000612-14-CZ Belarus;Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
Cytochrome P450 (CYP) Substrates
AbbVie
2020 Phase 1 NCT04254783 Germany;Israel;United States;
Cytoxan
Cedars-Sinai Medical Center
2020 Phase 1/Phase 2 NCT04224558 United States;
D9421-C
AstraZeneca
- Phase 3 JPRN-JapicCTI-121765 -
AstraZeneca K.K.
- Phase 3 EUCTR2014-004132-20-Outside-EU/EEA Japan;
D9421-C capsule
AstraZeneca
2012 Phase 3 NCT01514240 Japan;
D9421-C,
AstraZeneca
2006 Phase 2 NCT00573469 Japan;
DB adalimumab 40 mg eow
Abbott
2002 Phase 3 NCT00055497 United States;
DB adalimumab 40 mg ew
Abbott
2002 Phase 3 NCT00055497 United States;
DEXA scan
University of Texas Southwestern Medical Center
2006 - NCT00286689 United States;
DLX105
Delenex Therapeutics AG
2012 Phase 2 NCT01624376 Switzerland;
DOXYCYCLINE HYCLATE
Royal Liverpool & Broadgreen University Hospitals Trust
2009 Phase 2 EUCTR2008-001137-99-GB United Kingdom;
DR-6MP
Teva GTC
2011 Phase 2 NCT01433432 Israel;
Darvadstrocel
MILLENNIUM PHARMACEUTICALS, INC.
2019 Phase 4 EUCTR2019-000333-39-IT Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
Millennium Pharmaceuticals, Inc (MPI)
2020 Phase 4 EUCTR2017-002491-10-FR Austria;Czech Republic;France;Germany;Spain;United Kingdom;
2020 Phase 4 EUCTR2017-002491-10-ES Austria;Czech Republic;France;Germany;Spain;United Kingdom;
2020 Phase 4 EUCTR2017-002491-10-CZ Austria;Czech Republic;Czechia;France;Germany;Spain;United Kingdom;
Millennium Pharmaceuticals, Inc.
2019 Phase 3 NCT04075825 Belgium;Czechia;France;Hungary;Israel;Italy;Poland;Spain;United States;
Shikamura Mitsuhiro
2021 Phase 3 JPRN-jRCT2033200314 Israel;Italy;Japan;Netherlands;Poland;Spain;
Takeda
2021 Phase 3 NCT04701411 Israel;Japan;Netherlands;Poland;Spain;
2021 - NCT05113095 Japan;
2020 Phase 4 NCT04118088 Austria;Czechia;France;Germany;Israel;Spain;
2019 Phase 3 NCT03706456 Japan;
Takeda Development Center Americas, Inc.
2021 Phase 3 EUCTR2020-003193-48-NL Israel;Italy;Japan;Netherlands;Poland;Spain;
2020 Phase 4 EUCTR2017-002491-10-DE Austria;Czech Republic;Czechia;France;Germany;Israel;Spain;
2020 Phase 4 EUCTR2017-002491-10-AT Austria;Czech Republic;Czechia;France;Germany;Israel;Spain;
- Phase 3 EUCTR2020-003193-48-PL Israel;Japan;Netherlands;Poland;
Takeda Pharmaceutical Company Limited
2019 Phase 3 JPRN-JapicCTI-184145 Japan;
TiGenix, S.A.U.
2021 Phase 3 EUCTR2017-000725-12-DK Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
Decortin
AbbVie Deutschland GmbH & Co. KG
2015 Phase 3 EUCTR2010-020137-10-LT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2010-020137-10-HU Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2010-020137-10-BE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-SE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-NL Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2010-020137-10-GB Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-DE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-CZ Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-AT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
Abbott GmBH & Co. KG
2010 Phase 3 EUCTR2010-020137-10-IT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
Abbott GmbH & Co. KG
2010 Phase 3 EUCTR2010-020137-10-FR Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2010-020137-10-ES Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
Dehydroepiandrosterone [DHEA]
Inflabloc Pharmaceuticals
2005 Phase 2 NCT00106314 Canada;United States;
Dekristol 20.000 ie
Jørgen Agnholt
2013 Phase 3 EUCTR2013-000971-34-DK Denmark;
Delayed Release 6 mercaptopurine
Teva GTC
2010 Phase 1/Phase 2 NCT01094613 Israel;
2008 Phase 1 NCT00774982 Israel;
Delayed Release 6MP or Calcitriol vs. Purinethol
Teva GTC
2006 Phase 1/Phase 2 NCT00287170 Israel;
Denosumab
University of Manitoba
2015 Phase 1/Phase 2 NCT02321280 Canada;
Deucravacitinib
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2021 Phase 2 EUCTR2020-004461-40-IT Australia;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
Bristol-Myers Squibb International Corporation
2021 Phase 2 EUCTR2020-004461-40-DE Australia;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
Dexamethasone
Erydel
2009 Phase 3 NCT01277289 Italy;Romania;Spain;
Dexamethasone sodium phosphate 250 mg/ 10 ml
ERYDEL S.P.A.
2009 - EUCTR2008-007329-38-IT Italy;Spain;
2009 - EUCTR2008-007329-38-ES Italy;Spain;
Dextromethorphan
Janssen Research & Development, LLC
2018 Phase 1 NCT03358706 Austria;Belgium;Denmark;Germany;Sweden;United Kingdom;United States;
Takeda
2016 Phase 4 NCT02760615 United States;
Diet 1
University of Washington
2017 - NCT03012542 United States;
Diet 2
University of Washington
2017 - NCT03012542 United States;
Dietary therapy
Rush University Medical Center
2006 Phase 1/Phase 2 NCT00343642 United States;
Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphtalen-2-ylmethyl]-ammonium chloride mon
Italfarmaco S.p.A.
2005 Phase 2 EUCTR2004-004854-19-SK Slovakia;
Dietician designed diet
St Vincent's Hospital Melbourne
2021 Phase 2/Phase 3 NCT04970446 -
Diflucan
Cliniques Universitaires Saint Luc
2008 - EUCTR2008-003167-39-BE Belgium;
Diphenhydramine
Cedars-Sinai Medical Center
2020 Phase 1/Phase 2 NCT04224558 United States;
Dipyridamole
Guangzhou Women and Children's Medical Center
2021 Phase 0 ChiCTR2100048717 China;
Doxycycline
Royal Liverpool University Hospital
2014 Phase 2 NCT01783106 United Kingdom;
E-Device
UCB Biopharma S.P.R.L.
2017 Phase 3 NCT03357471 United States;
E6011
EA Pharma Co., Ltd.
2019 Phase 2 NCT03733314 Czechia;Hungary;Japan;Poland;Russian Federation;
2019 Phase 2 EUCTR2018-002109-70-HU Czech Republic;Hungary;Japan;Poland;
2019 Phase 2 EUCTR2018-002109-70-CZ Czech Republic;Czechia;Hungary;Japan;Poland;Russian Federation;
2014 Phase 1/Phase 2 NCT02039063 Japan;
Eisai Inc.
2014 Phase 1 NCT02249078 -
EB8018
Millennium Pharmaceuticals, Inc (a wholly owned subsidiary
2020 Phase 2 EUCTR2019-000886-19-FR France;Germany;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000886-19-GB Austria;France;Germany;Netherlands;United Kingdom;United States;
Millennium Pharmaceuticals, Inc (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited)
2020 Phase 2 EUCTR2019-000886-19-NL Austria;France;Germany;Netherlands;United Kingdom;United States;
2020 Phase 2 EUCTR2019-000886-19-AT Austria;France;Germany;Netherlands;United Kingdom;United States;
Takeda Development Center Americas,Inc.
2019 Phase 2 EUCTR2019-000886-19-DE Austria;France;Germany;Netherlands;United Kingdom;United States;
EB8018 (First-in-class FimH blocker)
Enterome
2018 Phase 1 NCT03709628 Austria;France;Germany;Italy;
EEN
Sun Yat-sen University
2013 - NCT02887287 China;
The Second Hospital of Nanjing Medical University
2016 - NCT02897661 China;
EEN (Nestle Modulen®)
Duzce University
2021 Phase 3 NCT04921033 Turkey;
EEN intervention group
Shaare Zedek Medical Center
2020 - NCT04239248 Israel;
EGG WHITE PROTEIN
Lument AB
2019 Phase 2 EUCTR2019-002093-32-SE Sweden;
EMEA/H/C/000240
Santeon
2015 Phase 4 EUCTR2015-001954-14-NL Netherlands;
EMEA/H/C/002576
Amsterdam UMC location AMC
2021 Phase 3;Phase 4 EUCTR2021-000469-33-NL Netherlands;
EMEA/H/C/002778
Department of medical gastroenterology, Herlev Hospital
2016 Phase 4 EUCTR2012-002702-51-NO Denmark;Finland;Norway;Sweden;
ENDOXAN BAXTER
WOLFSON DIGESTIVE DISEASES CENTRE
2007 - EUCTR2005-003337-40-IT Italy;United Kingdom;
ENTYVIO - 300 MG - POLVERE PE RCONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) (20ML) - 1 FLACONCINO
FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
2016 Phase 4 EUCTR2015-003270-32-IT Italy;
TAKEDA DEVELOPMENT CENTER AMERICAS INC.
2021 Phase 3 EUCTR2020-004301-31-IT Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;China;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Lithuania;New Zealand;Poland;Romania;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
ERB-041
Wyeth is now a wholly owned subsidiary of Pfizer
2004 Phase 1 NCT00245947 -
ERY-DEX
ERYDEL S.P.A.
2009 - EUCTR2008-007329-38-IT Italy;Spain;
2009 - EUCTR2008-007329-38-ES Italy;Spain;
EU/1/03/268/002
LMU München, Campus Großhadern
2011 - EUCTR2009-010727-91-DE Germany;
EU/1/99/116/003
Academic Medical Center, department of Gastroenterology and hepatology
2008 - EUCTR2008-001131-35-NL Netherlands;
EUA with seton placement if necessary
Vanderbilt University Medical Center
2008 Phase 4 NCT00517296 United States;
EUS
Vanderbilt University Medical Center
2008 Phase 4 NCT00517296 United States;
Early immunosuppressants (azathioprine, methotrexate)
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
2005 Phase 4 NCT00546546 France;
Ebetrex 15 mg = 0,75 ml, oplossing voor injectie in voorgevulde injectiespuit 20 mg/ml
Amsterdam UMC location AMC
2021 Phase 3;Phase 4 EUCTR2021-000469-33-NL Netherlands;
Efmarodocokin alfa
Genentech, Inc.
2018 Phase 2 EUCTR2017-004997-32-IE Bulgaria;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
Egg Albumen Powder
Lument AB
2019 Phase 2 EUCTR2019-002093-32-SE Sweden;
Eicosapentaenoic acid
Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi
2014 - NCT02179372 Italy;
Empagliflozin
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 1 NCT05078879 United States;
Endopath from Itamar medical - FDA approved device.
Carmel Medical Center
2014 - NCT01881464 Israel;
Endoscopic balloon dilatation
St Vincent's Hospital Melbourne
2017 Phase 4 NCT03220841 Australia;
Entecavir
Saitama Medical University
2016 - JPRN-UMIN000020029 Japan;
Enteral nutrition
Jinling Hospital, China
2014 Phase 4 NCT02056418 China;
Zhu Weiming
2012 - NCT01820247 China;
Enteral nutrition.
Jinling Hospital, China
2012 - NCT01823029 China;
Entocort
ASTRAZENECA
2011 Phase 3 EUCTR2011-003743-22-IT Canada;Germany;Italy;United States;
AstraZeneca K.K.
- Phase 3 EUCTR2014-004132-20-Outside-EU/EEA Japan;
Padagis LLC
2011 Phase 3 NCT01453946 Canada;Germany;Italy;Poland;United States;
2011 Phase 3 NCT01444092 Canada;Germany;Italy;Poland;United States;
Entocort CR
Royal Liverpool & Broadgreen University Hospitals Trust
2009 Phase 2 EUCTR2008-001137-99-GB United Kingdom;
Entocort® Kapseln
AstraZeneca AB
- - EUCTR2011-003743-22-DE Canada;Germany;Italy;Poland;United States;
- - EUCTR2011-003742-40-DE Canada;Germany;Italy;Poland;United States;
Entyvio
AMC MEDICAL RESEARCH B.V.
2017 Phase 3 EUCTR2015-000555-24-IT France;Italy;Netherlands;Spain;
Academic Medical Center Amsterdam
2016 Phase 4 EUCTR2015-000555-24-NL Netherlands;
2016 Phase 4 EUCTR2015-000555-24-FR France;Netherlands;Spain;
2016 Phase 4 EUCTR2015-000555-24-ES Netherlands;Spain;
Academic Medical Center, Gastroenterology
2017 Phase 4 EUCTR2014-005376-29-HU Belgium;Hungary;Netherlands;
2015 Phase 4 EUCTR2014-005376-29-BE Belgium;Netherlands;
2015 - EUCTR2014-005376-29-NL Netherlands;
TAKEDA DEVELOPMENT CENTRE EUROPE LTD
2016 Phase 3 EUCTR2015-000481-58-IT Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Takeda Development Centre Europe Limited
2017 Phase 4 EUCTR2016-000678-40-BG Australia;Bulgaria;Czech Republic;Estonia;Hungary;India;Italy;Korea, Republic of;Latvia;Malaysia;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Turkey;Ukraine;
2016 Phase 4 EUCTR2016-000678-40-LV Australia;Bulgaria;Czech Republic;Estonia;Hungary;India;Italy;Korea, Republic of;Latvia;Malaysia;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Turkey;Ukraine;
2016 Phase 4 EUCTR2016-000678-40-HU Australia;Bulgaria;Czech Republic;Czechia;Estonia;Hungary;India;Italy;Korea, Republic of;Latvia;Malaysia;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Turkey;Ukraine;
2016 Phase 4 EUCTR2016-000678-40-EE Australia;Bulgaria;Czech Republic;Estonia;Hungary;India;Italy;Korea, Republic of;Latvia;Malaysia;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Turkey;Ukraine;
2016 Phase 4 EUCTR2016-000678-40-CZ Australia;Bulgaria;Czech Republic;Estonia;Hungary;India;Italy;Korea, Republic of;Latvia;Malaysia;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Turkey;Ukraine;
Takeda Development Centre Europe, Ltd.
2018 Phase 2 EUCTR2017-002231-41-PL Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002231-41-NL Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002231-41-BE Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002182-21-PL Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002182-21-NL Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002182-21-BE Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2017 Phase 4 EUCTR2015-000852-12-BE Belgium;Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2017-002231-41-HU Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2017-002231-41-GB Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2017-002231-41-DE Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2017-002182-21-HU Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2017-002182-21-GB Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2017-002182-21-FR Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2017-002182-21-DE Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2016 Phase 4 EUCTR2015-000852-12-NL Belgium;Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
2016 Phase 4 EUCTR2015-000852-12-GB Belgium;Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
2016 Phase 4 EUCTR2015-000852-12-FR Belgium;Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
2016 Phase 4 EUCTR2015-000852-12-ES Belgium;Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000482-31-NL Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000482-31-HR Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-SK Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-SE Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-NL Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-LT Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-HU Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-GB Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-ES Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-DK Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-DE Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-CZ Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-BG Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-BE Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
- Phase 2 EUCTR2017-002231-41-FR Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
Epanova
Tillotts Pharma AG
2003 Phase 3 NCT00613197 Belgium;
Epanova™ (Omega-3 Free Fatty Acids)
Tillotts Pharma AG
2002 Phase 3 NCT00074542 Canada;United States;
Epaxal Berna (virosomal hepatitis A vaccine)
Asan Medical Center
2011 Phase 4 NCT01341808 Korea, Republic of;
Ergocalciferol
Boston Children’s Hospital
2008 - NCT00621257 United States;
Erythropoietin
Jinling Hospital, China
2012 - NCT01823029 China;
Etiprednol dicloacetate
Teva Branded Pharmaceutical Products R&D, Inc.
2002 Phase 2 NCT00035503 Canada;United States;
Etrasimod
Arena Pharmaceuticals
2020 Phase 2/Phase 3 NCT04173273 Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United States;
Samia Hassan El-Shishtawy
2021 Phase 2/Phase 3 NCT05033340 -
Etrasimod L-arginine
ARENA PHARMACEUTICALS, INC.
2021 Phase 2;Phase 3 EUCTR2020-004775-40-IT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-IT Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Arena Pharmaceuticals Inc.
2021 Phase 2;Phase 3 EUCTR2020-004775-40-PT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-NL Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-LT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-HU Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-HR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-ES Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-DK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-DE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-CZ Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-BG Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-SK Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-PT Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-NO Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-NL Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-LT Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-HU Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-GR Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-GB Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-FR Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-ES Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-CZ Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-BG Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Etrolizumab
F. HOFFMANN - LA ROCHE LTD.
2016 Phase 3 EUCTR2014-003855-76-IT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003824-36-IT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;Italy;Korea, Democratic People's Republic of;Latvia;Lithuania;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
Hoffmann-La Roche
2018 Phase 1 NCT03478956 Belgium;Germany;Poland;Spain;United Kingdom;United States;
2015 Phase 3 NCT02403323 Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Luxembourg;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2015 Phase 3 NCT02394028 Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Luxembourg;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
Evaluation of biological predictive factors of clinical response to ustekinumab
Hospices Civils de Lyon
2018 - NCT03351647 France;
Everolimus
Novartis Pharma Services AG
2005 Phase 2 EUCTR2005-001148-22-SK Slovakia;
Exclusive Enteral Nutrition
Children's Hospital of Fudan University
2022 Phase 4 NCT04530877 -
2017 - NCT03755583 China;
McMaster University
2018 Phase 4 NCT03833596 Canada;
Tel-Aviv Sourasky Medical Center
2020 Phase 3 NCT04398836 Israel;
Exclusive Enteral Nutrition Therapy
Jinling Hospital, China
2013 - NCT02233062 China;
Expanded allogenic adipose-derived adult stem cells
Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz
2009 Phase 1/Phase 2 NCT00999115 Spain;
Expanded autologous adipose-derived adult stem cells (eASCs)
Tigenix S.A.U.
2008 Phase 3 NCT01378390 Austria;Netherlands;Spain;
Expanded human allogenic mesemchymal adult stem cells extracted from adipose tissue (eASCs)
TiGenix, S.A. Unipersonal
2012 - EUCTR2011-006064-43-NL Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;
Expanded human allogenic mesenchymal adult stem cells extractd from adipose tissue (eASCs)
CELLERIX S.A.
2012 Phase 3 EUCTR2011-006064-43-IT Austria;Belgium;Germany;Israel;Italy;Netherlands;Spain;
Expanded human allogenic mesenchymal adult stem cells extracted from adipose
MILLENNIUM PHARMACEUTICALS, INC.
2019 Phase 4 EUCTR2019-000333-39-IT Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
Expanded human allogenic mesenchymal adult stem cells extracted from adipose tissue (eASCs
Millennium Pharmaceuticals, Inc (MPI)
2020 Phase 4 EUCTR2017-002491-10-FR Austria;Czech Republic;France;Germany;Spain;United Kingdom;
2020 Phase 4 EUCTR2017-002491-10-ES Austria;Czech Republic;France;Germany;Spain;United Kingdom;
2020 Phase 4 EUCTR2017-002491-10-CZ Austria;Czech Republic;Czechia;France;Germany;Spain;United Kingdom;
Takeda Development Center Americas, Inc.
2020 Phase 4 EUCTR2017-002491-10-DE Austria;Czech Republic;Czechia;France;Germany;Israel;Spain;
2020 Phase 4 EUCTR2017-002491-10-AT Austria;Czech Republic;Czechia;France;Germany;Israel;Spain;
Expanded human allogenic mesenchymal adult stem cells extracted from adipose tissue (eASCs)
Millennium Pharmaceuticals, Inc (MPI)
2020 Phase 4 EUCTR2019-000333-39-FR Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 4 EUCTR2019-000333-39-CZ Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
Takeda Development Center Americas, Inc
2020 Phase 4 EUCTR2019-000333-39-BE Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
Takeda Development Center Americas, Inc.
2021 Phase 3 EUCTR2020-003193-48-NL Israel;Italy;Japan;Netherlands;Poland;Spain;
- Phase 3 EUCTR2020-003193-48-PL Israel;Japan;Netherlands;Poland;
TiGenix S.A.U.
2012 Phase 3 EUCTR2011-006064-43-DE Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;
TiGenix, S.A. Unipersonal
2012 Phase 3 EUCTR2011-006064-43-BE Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;
TiGenix, S.A.U.
2021 Phase 3 EUCTR2017-000725-12-SE Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2017-000725-12-DK Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2017-000725-12-GB Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2017-000725-12-DE Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-PL Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-HU Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-FR Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-ES Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-CZ Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-BE Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-006064-43-AT Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;
Extracorporeal Photopheresis
Mallinckrodt
2004 Phase 2 NCT00221026 Austria;Belgium;Germany;United States;
FE 999301
University Hospital Schleswig-Holstein (UKSH)
2016 Phase 2 EUCTR2016-000205-36-DE Germany;
FFP104
Fast Forward Pharmaceuticals
2016 Phase 1/Phase 2 NCT02465944 Belgium;Netherlands;
Fast Forward Pharmaceuticals, B.V.
2016 Phase 2 EUCTR2015-001678-17-NL Belgium;Netherlands;
2015 Phase 2 EUCTR2015-001678-17-BE Belgium;Netherlands;
FITC-Adalimumab
University of Erlangen-Nürnberg Medical School
2011 Phase 1/Phase 2 NCT01275508 Germany;
FMT
Children's Hospital Los Angeles
2017 Phase 1/Phase 2 NCT03194529 United States;
St Vincent's Hospital Melbourne
2021 Phase 2/Phase 3 NCT04970446 -
Yanling Wei
2015 Phase 2 NCT02335281 China;
FOS
Hospital Universitari Vall d'Hebron Research Institute
2014 - NCT02539849 Spain;
Faecal Microbiota Transplantation
St Vincent's Hospital Melbourne
2018 - NCT03477032 Australia;
Faecal microbiota transplantation
Torkell Ellingsen
2022 Phase 2 NCT04924270 -
Fecal Microbial Transplantation
Beth Israel Deaconess Medical Center
2013 Phase 1 NCT01847170 United States;
Stony Brook University
2017 Early Phase 1 NCT03267238 United States;
Fecal Microbial transplant
Seattle Children's Hospital
2015 Phase 1/Phase 2 NCT02272868 United States;
Fecal Microbiota Transplant
Children's Hospital of Philadelphia
2015 - NCT02636517 United States;
Stacy A. Kahn
2017 Phase 1/Phase 2 NCT02330211 United States;
University of Alberta
2014 Phase 1/Phase 2 NCT02199561 Canada;
Fecal Microbiota Transplant (FMT)
Boston Medical Center
2015 Phase 2 NCT02417974 United States;
Stacy A. Kahn
2015 Phase 1/Phase 2 NCT02330653 United States;
University of Alberta
2017 Phase 2 NCT03078803 Canada;
Fecal Microbiota Transplantation
Stanford University
2022 Phase 1 NCT03747718 United States;
Fecal Microbiota Transplantation (FMT)
Assistance Publique - Hôpitaux de Paris
2021 Phase 3 NCT04997733 France;
Children's Mercy Hospital Kansas City
2014 Phase 1 NCT02108821 United States;
Fecal microbiota
ASSISTANCE PUBLIQUE -HOPITAUX DE PARIS (AP-HP)
2019 Phase 3 EUCTR2019-003816-29-FR France;
Fecal microbiota transplantation
Gulhane Military Medical Academy
2015 Phase 3 NCT02575040 Turkey;
Ferric Carboxy Maltose
Shield Therapeutics
2016 Phase 3 NCT02680756 Belgium;France;Germany;Hungary;Spain;United States;
Ferric carboxymaltose
Vifor Inc.
2008 Phase 3 NCT00810030 Austria;Russian Federation;
Ferrous sulphate
Barts Health NHS Trust
2011 Phase 4 EUCTR2010-023797-39-GB United Kingdom;
Queen Mary University of London
2011 Phase 4 NCT01991314 United Kingdom;
Fibrin glue injection in fistula
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
2003 Phase 3 NCT00723047 Belgium;France;
Filgotinib
GILEAD SCIENCES INCORPORATED
2018 Phase 3 EUCTR2016-002763-34-IT Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001367-36-IT Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
Gilead Sciences
2018 Phase 1 NCT03417778 Germany;New Zealand;United States;
2017 Phase 3 NCT02914600 Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 2 NCT03077412 Austria;Belgium;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 2 NCT03046056 Austria;Belgium;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 NCT02914561 Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
Filgrastim
Barts Health NHS Trust
2017 Phase 3 EUCTR2017-002545-30-GB United Kingdom;
Cedars-Sinai Medical Center
2020 Phase 1/Phase 2 NCT04224558 United States;
European Group for Blood and Marrow Transplantation (EMBT)
2006 - EUCTR2005-003337-40-GB United Kingdom;
Fish oil
The First Affiliated Hospital of Sun Yat-sen University
2011 - ChiCTR-TRC-11001321 China;
Flagyl
GETECCU
2011 - EUCTR2011-000885-36-ES Spain;
Flixabi
University Medical Center Groningen
2021 Phase 4 EUCTR2020-001811-26-BE Belgium;Netherlands;
2020 Phase 4 EUCTR2020-001811-26-NL Netherlands;
University Southampton Hospital NHS Foundation Trust
2018 Phase 4 EUCTR2018-001546-33-GB United Kingdom;
Fluconazole
Children's Hospital of Philadelphia
2018 Phase 2 NCT03476317 United States;
University Hospital, Lille
2008 Phase 2 NCT02997059 France;
University of Pennsylvania
2016 Phase 2 NCT02765256 United States;
Fludarabine
Cedars-Sinai Medical Center
2020 Phase 1/Phase 2 NCT04224558 United States;
Northwestern University
2019 Phase 2 NCT04154735 United States;
Fludarabine Phosphate
Fred Hutchinson Cancer Research Center
2012 Phase 2 NCT01570348 United States;
Fludarabine phosphate
Barts Health NHS Trust
2017 Phase 3 EUCTR2017-002545-30-GB United Kingdom;
Fluorescence endoscopy and spectroscopy
University Medical Center Groningen
2020 Phase 1 NCT04112212 Netherlands;
FolateScan (Technetium Tc 99mEC20)
Mayo Clinic
2006 Phase 2 NCT00588393 United States;
Foralumab
Tiziana Life Sciences, PLC
2021 Phase 1 NCT05028946 -
Fosfato sodico de dexametasona
ERYDEL S.P.A.
2009 - EUCTR2008-007329-38-ES Italy;Spain;
Fosfomycin
Ishikawa Dai
2017 - JPRN-jRCTs031180415 Japan;
Fully humanised, recombinant monoclonal antibody (IgG1)
University of Birmingham
2018 Phase 1 EUCTR2018-002001-65-GB United Kingdom;
G-CSF
National Institute of Allergy and Infectious Diseases (NIAID)
2001 Phase 1 NCT00025805 United States;
Northwestern University
2019 Phase 2 NCT04154735 United States;
Paul Szabolcs
2012 Phase 1/Phase 2 NCT00692939 United States;
G321605
Galapagos NV
2014 - EUCTR2014-001892-30-HU Belgium;Czech Republic;France;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;United Kingdom;
2014 - EUCTR2014-001892-30-BE Belgium;Czech Republic;France;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;United Kingdom;
GED-0301
CELGENE CORPORATION
2017 Phase 3 EUCTR2015-001924-40-IT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-IT Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2015-001693-18-IT Italy;
Celgene
2017 Phase 3 NCT02974322 Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 NCT02641392 Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 2 NCT02685683 Italy;
2015 Phase 3 NCT02596893 Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;Former Serbia and Montenegro;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2015 Phase 1 NCT02367183 Australia;Canada;Hungary;Slovakia;United States;
Celgene Corporation
2017 Phase 3 EUCTR2015-001963-37-FI Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001925-18-FI Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-SK Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-PT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-NL Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-LV Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-HU Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-HR Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-GR Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-GB Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-FR Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-FI Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-ES Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-DK Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-DE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-CZ Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-BE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-AT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-SK Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-SE Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-PT Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-LV Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-HU Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-HR Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-GR Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-GB Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Oman;Pakistan;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-ES Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-DK Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-DE Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-CZ Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-BG Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-BE Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-AT Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-SK Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-SE Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-PT Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-LV Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-HU Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-HR Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-GR Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-GB Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-ES Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-DK Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-DE Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-CZ Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-BG Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-BE Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-AT Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2015 Phase 3 EUCTR2015-001963-37-EE Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2015 Phase 3 EUCTR2015-001925-18-EE Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2015-001925-18-NO Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2015-001924-40-PL Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
GIULIANI
2013 - EUCTR2011-002640-27-DE Germany;Italy;
2012 - EUCTR2011-005678-47-IT Italy;
2011 - EUCTR2011-002640-27-IT Germany;Italy;
GLPG0634
Galapagos NV
2014 Phase 2 NCT02048618 Belgium;Czech Republic;France;Germany;Hungary;Poland;Romania;Russian Federation;United Kingdom;
2014 Phase 2 EUCTR2013-002857-32-GB Belgium;Czech Republic;France;Germany;Hungary;Poland;Romania;Russian Federation;United Kingdom;
2014 Phase 2 EUCTR2013-002857-32-DE Belgium;Czech Republic;France;Germany;Hungary;Poland;Romania;Russian Federation;United Kingdom;
2014 Phase 2 EUCTR2013-002857-32-CZ Belgium;Czech Republic;France;Germany;Hungary;Poland;Romania;Russian Federation;United Kingdom;
2014 - EUCTR2013-002857-32-PL Belgium;Czech Republic;France;Germany;Hungary;Poland;Romania;Russian Federation;United Kingdom;
2014 - EUCTR2013-002857-32-HU Belgium;Czech Republic;France;Germany;Hungary;Poland;Romania;Russian Federation;United Kingdom;
2014 - EUCTR2013-002857-32-BE Belgium;Czech Republic;France;Germany;Hungary;Poland;Romania;Russian Federation;United Kingdom;
GLPG1205
Galapagos NV
2014 - EUCTR2014-001892-30-HU Belgium;Czech Republic;France;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;United Kingdom;
2014 - EUCTR2014-001892-30-BE Belgium;Czech Republic;France;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;United Kingdom;
GS-5745
GILEAD SCIENCES INCORPORATED
2015 Phase 2 EUCTR2015-001249-10-IT Australia;Canada;Czech Republic;Germany;Hungary;Iceland;Italy;South Africa;Spain;United Kingdom;United States;
Gilead Sciences, Inc
2016 Phase 2 EUCTR2015-001249-10-IS Australia;Canada;Czech Republic;Germany;Hungary;Iceland;New Zealand;South Africa;Spain;United Kingdom;United States;
2015 Phase 2 EUCTR2015-001249-10-HU Australia;Canada;Czech Republic;Germany;Hungary;Iceland;New Zealand;South Africa;Spain;United Kingdom;United States;
2015 Phase 2 EUCTR2015-001249-10-GB Australia;Canada;Czech Republic;Germany;Hungary;Iceland;Italy;New Zealand;South Africa;Spain;United Kingdom;United States;
2015 Phase 2 EUCTR2015-001249-10-ES Australia;Canada;Czech Republic;Germany;Hungary;Iceland;New Zealand;South Africa;Spain;United Kingdom;United States;
2015 Phase 2 EUCTR2015-001249-10-DE Australia;Canada;Czech Republic;Germany;Hungary;Iceland;New Zealand;South Africa;Spain;United Kingdom;United States;
2015 Phase 2 EUCTR2015-001249-10-CZ Australia;Canada;Czech Republic;Germany;Hungary;Iceland;New Zealand;South Africa;Spain;United Kingdom;United States;
GS-6034
GILEAD SCIENCES INCORPORATED
2018 Phase 3 EUCTR2016-002763-34-IT Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001367-36-IT Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003179-23-IT Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003153-15-IT Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States;
Galapagos NV
2017 Phase 3 EUCTR2016-002763-34-SK Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002763-34-SE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002763-34-HU Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002763-34-DE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002763-34-BG Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001367-36-SK Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001367-36-DE Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001367-36-BG Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
Gilead Sciences, Inc.
2018 Phase 2 EUCTR2016-003179-23-BE Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2016-003179-23-AT Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2016-003153-15-BE Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2018 Phase 2 EUCTR2016-003153-15-AT Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002763-34-PT Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002763-34-NL Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002763-34-IS Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002763-34-HR Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002763-34-GR Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002763-34-GB Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002763-34-ES Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002763-34-CZ Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002763-34-BE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002763-34-AT Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001367-36-SE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001367-36-PT Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001367-36-NO Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001367-36-NL Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001367-36-IS Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001367-36-HU Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001367-36-HR Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001367-36-GR Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001367-36-GB Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001367-36-ES Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001367-36-CZ Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001367-36-BE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001367-36-AT Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003179-23-PL Austria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003179-23-HU Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003179-23-GB Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003179-23-FR Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003179-23-ES Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003179-23-DE Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003179-23-CZ Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003153-15-PL Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003153-15-HU Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003153-15-GB Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003153-15-ES Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003153-15-DE Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003153-15-CZ Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States;
GSK1070806
University of Birmingham
2019 Phase 1/Phase 2 NCT03681067 United Kingdom;
2018 Phase 1 EUCTR2018-002001-65-GB United Kingdom;
GSK1605786
GlaxoSmithKline
2011 Phase 1 NCT01489943 United States;
2010 Phase 1 NCT01611805 Australia;
GSK1605786 ChemoCentryx: formulation A
GlaxoSmithKline
2010 Phase 1 NCT01114607 United States;
GSK1605786 GSK direct-fill: formulation C
GlaxoSmithKline
2010 Phase 1 NCT01114607 United States;
GSK1605786 GSK modified-process: formulation D
GlaxoSmithKline
2010 Phase 1 NCT01114607 United States;
GSK1605786 GSK tablet: formulation E
GlaxoSmithKline
2010 Phase 1 NCT01114607 United States;
GSK1605786 GSK: formulation B
GlaxoSmithKline
2010 Phase 1 NCT01114607 United States;
GSK1605786 capsule
GlaxoSmithKline
2013 Phase 1 NCT01827631 China;
GSK1605786A
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
2012 - EUCTR2010-022384-35-IT Argentina;Australia;Austria;Brazil;Bulgaria;Canada;China;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;New Zealand;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2010-022383-12-IT Argentina;Australia;Austria;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Estonia;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2010-022382-10-IT Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;South Africa;Spain;Sweden;United Kingdom;United States;
GlaxoSmithKline
2011 Phase 3 NCT01536418 Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 NCT01318993 Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;New Zealand;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 NCT01316939 Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2010 Phase 3 NCT01277666 Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
GlaxoSmithKline Research & Development Limited
2013 - EUCTR2010-022383-12-BG Argentina;Austria;Brazil;Bulgaria;Chile;Czech Republic;Denmark;Estonia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2012 Phase 3 EUCTR2010-022382-10-ES Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2010-022383-12-SK Argentina;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Denmark;Estonia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022383-12-PT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2010-022383-12-GR Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2010-022383-12-ES Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2010-022383-12-EE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022383-12-AT Argentina;Australia;Austria;Brazil;Bulgaria;Chile;Czech Republic;Denmark;Estonia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022382-10-SK Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2010-022382-10-AT Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022383-12-SE Argentina;Austria;Brazil;Bulgaria;Chile;Czech Republic;Denmark;Estonia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-022383-12-NL Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2011 - EUCTR2010-022383-12-DK Argentina;Austria;Brazil;Bulgaria;Chile;Czech Republic;Denmark;Estonia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
GlaxoSmithKline Research & Development Ltd
2013 - EUCTR2010-022384-35-BG Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2012 Phase 3 EUCTR2010-022384-35-EE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022384-35-SK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022384-35-PT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2010-022384-35-PL Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2010-022384-35-GR Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2010-022384-35-ES Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2010-022384-35-AT Argentina;Austria;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022383-12-PL Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022384-35-GB Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022384-35-DK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022384-35-BE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022383-12-NO Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;Germany;Greece;Hungary;Italy;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2011 Phase 3 EUCTR2010-022383-12-GB Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;Germany;Greece;Hungary;Italy;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2011 Phase 3 EUCTR2010-022383-12-BE Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022382-10-GB Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022382-10-BE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022384-35-SE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-022384-35-HU Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022384-35-DE Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022384-35-CZ Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022383-12-HU Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022383-12-CZ Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022382-10-SE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022382-10-NL Austria;Belgium;Czech Republic;Denmark;Germany;Hungary;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
2011 - EUCTR2010-022382-10-HU Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022382-10-DK Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022382-10-DE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
2010 - EUCTR2010-022382-10-CZ Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2010-022382-10-NO Austria;Belgium;Czech Republic;Denmark;Germany;Hungary;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
- - EUCTR2010-022383-12-DE Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
GlaxoSmithKline Research and Development Limited
2013 - EUCTR2011-002817-12-NL Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2013 - EUCTR2011-002817-12-DE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2013 - EUCTR2011-002817-12-CZ Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2013 - EUCTR2011-002817-12-BG Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2012 Phase 3 EUCTR2011-002817-12-DK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-002817-12-SK Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-002817-12-PT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-002817-12-HU Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-002817-12-GR Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-002817-12-ES Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-002817-12-EE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-002817-12-AT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
GSK2330811
GlaxoSmithKline
2021 Phase 2 NCT04151225 -
Glatiramer acetate
Tel-Aviv Sourasky Medical Center
2008 Phase 2 NCT00731172 Israel;
Glucose
The First Affiliated Hospital of Sun Yat-sen University
2011 - ChiCTR-TRC-11001321 China;
Glutamine
All India Institute of Medical Sciences, New Delhi
2005 Phase 1 NCT00838149 India;
Gold
The 7th Medical Center of the PLA General Hospital (Army general hospital)
2019 Phase 0 ChiCTR1900022728 China;
The First Affiliated Hospital of Anhui Medical University
2020 Phase 0 ChiCTR2000037094 China;
The First Hospital Affiliated to Sun Yat sen University
2020 - ChiCTR2000029543 China;
West China Hospital, Sichuan University
2013 - ChiCTR-DDT-14004999 China;
Golimumab
Janssen Research & Development, LLC
2022 Phase 2 NCT05242471 Italy;
Janssen Scientific Affairs, LLC
2013 Phase 4 NCT01804166 United States;
Green Tea
University Hospital Heidelberg
2010 - NCT01231217 Germany;
Group 2 ustekinumab
Janssen Research & Development, LLC
2011 Phase 3 NCT01369342 Australia;Belgium;Brazil;Bulgaria;Canada;Croatia;France;Germany;Hungary;Iceland;Ireland;Israel;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
2011 Phase 3 NCT01369329 Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Hungary;Iceland;Ireland;Israel;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Serbia;South Africa;Spain;United Kingdom;United States;
Group 3: ustekinumab approximately
Janssen Research & Development, LLC
2011 Phase 3 NCT01369342 Australia;Belgium;Brazil;Bulgaria;Canada;Croatia;France;Germany;Hungary;Iceland;Ireland;Israel;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
2011 Phase 3 NCT01369329 Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Hungary;Iceland;Ireland;Israel;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Serbia;South Africa;Spain;United Kingdom;United States;
Growth hormone
Children's Hospital Medical Center, Cincinnati
2005 Phase 2 NCT00109473 United States;
Guselkumab
Janssen Pharmaceutical K.K.
2020 Phase 3 NCT04397263 Japan;
2020 Phase 3 JPRN-JapicCTI-205298 Japan;
2018 Phase 2-3 JPRN-JapicCTI-183950 Japan, North America;
Janssen Research & Development, LLC
2022 Phase 2 NCT05242471 Italy;
University of California, San Diego
2013 - NCT02103361 United States;
Guselkumab Dose 1
Janssen Research & Development, LLC
2022 Phase 3 NCT05197049 Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;China;Croatia;Czechia;France;Germany;Hungary;Italy;Japan;Jordan;Korea, Republic of;Lithuania;Netherlands;New Zealand;Poland;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2/Phase 3 NCT03466411 Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Colombia;Croatia;Czechia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, The Former Yugoslav Republic of;Malaysia;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Puerto Rico;Russian Federation;Saudi Arabia;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
Guselkumab Dose 2
Janssen Research & Development, LLC
2022 Phase 3 NCT05197049 Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;China;Croatia;Czechia;France;Germany;Hungary;Italy;Japan;Jordan;Korea, Republic of;Lithuania;Netherlands;New Zealand;Poland;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2/Phase 3 NCT03466411 Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Colombia;Croatia;Czechia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, The Former Yugoslav Republic of;Malaysia;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Puerto Rico;Russian Federation;Saudi Arabia;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
Guselkumab Dose 3
Janssen Research & Development, LLC
2022 Phase 3 NCT05197049 Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;China;Croatia;Czechia;France;Germany;Hungary;Italy;Japan;Jordan;Korea, Republic of;Lithuania;Netherlands;New Zealand;Poland;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2/Phase 3 NCT03466411 Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Colombia;Croatia;Czechia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, The Former Yugoslav Republic of;Malaysia;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Puerto Rico;Russian Federation;Saudi Arabia;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
Guselkumab Dose 4
Janssen Research & Development, LLC
2018 Phase 2/Phase 3 NCT03466411 Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Colombia;Croatia;Czechia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, The Former Yugoslav Republic of;Malaysia;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Puerto Rico;Russian Federation;Saudi Arabia;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
Guselkumab Dose 5
Janssen Research & Development, LLC
2018 Phase 2/Phase 3 NCT03466411 Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Colombia;Croatia;Czechia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, The Former Yugoslav Republic of;Malaysia;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Puerto Rico;Russian Federation;Saudi Arabia;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
HM201
Syneos Health
2021 Early Phase 1 NCT05088369 -
HMPL-004
Hutchison Medipharma Limited
2006 Phase 2 NCT00655733 United States;
HMPL004-6599
Nutrition Science Partners Limited
2018 Phase 1 NCT03597971 Australia;
HUMAN ALBUMIN AS MACROAGGREGATES
ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE
2019 Phase 2 EUCTR2019-001948-21-FR France;
HUMAN PLASMA FOR FRACTIONATION
Fundación FISEVI
2012 - EUCTR2011-006127-38-ES Spain;
2012 - EUCTR2011-004820-37-ES Spain;
HUMIRA
Abbott GmbH & Co. KG
2008 - EUCTR2006-004814-41-IT Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
Abbott GmbH & Co. KG (Abbott)
- Phase 3 EUCTR2006-002078-23-SK Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
Boehringer Ingelheim
2016 Phase 3 NCT02871635 Belarus;Bosnia and Herzegovina;Croatia;Czechia;Germany;Greece;Israel;Poland;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
GETAID
2014 Phase 4 EUCTR2013-003199-11-FR Belgium;France;
University of Leuven, Division of Gastroenterology
2007 Phase 4 EUCTR2006-006632-22-BE Belgium;
HUMIRA (adalimumab)
Boehringer Ingelheim International GmbH
2017 Phase 3 EUCTR2016-000612-14-HR Belarus;Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000612-14-GR Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000612-14-GB Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000612-14-DE Belarus;Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000612-14-CZ Belarus;Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
HUMIRA - 40MG/0.8ML SOLUZ. INIETTABILE- USO SOTTOCUTANEO-FLACONCINO(VETRO) 0.8ML 2 ASTUCCI:1 FLACONCINO+1SIRINGA+1AGO+1ADATT.STERILE-2TAMPONI IMBEVUTI ALCOOL
UMBERTO I - POLICLINICO DI ROMA
2017 Phase 4 EUCTR2016-000522-18-IT Belgium;Czech Republic;Czechia;France;Germany;Hungary;Italy;Netherlands;Poland;United Kingdom;
HUMIRA 40 mg solución inyectable en jeringa precargada
Abbott GmbH & Co. KG
2010 Phase 3 EUCTR2010-020137-10-ES Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
HUMIRA 40Mg Solution for Injection
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
2019 Phase 4 NCT04131322 Spain;
HUMIRA ®
Fundación Publica Andaluza para la Gestión de Salud en Sevilla (FISEVI)
2019 Phase 4 EUCTR2019-000717-37-ES Spain;
HUMIRA*SC 2SIR+F 40MG 0,8ML+2T
Abbott GmBH Co KG
2005 - EUCTR2004-002163-24-IT Denmark;Germany;Hungary;Italy;Spain;United Kingdom;
Abbott GmBH & Co. KG
2010 Phase 3 EUCTR2010-020137-10-IT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
Abbott GmbH Co.KG
2006 - EUCTR2005-005291-32-IT Austria;Belgium;Germany;Italy;Netherlands;Sweden;
HYDROXYCHLOROQUINE SULPHATE
Royal Liverpool & Broadgreen University Hospitals Trust
2009 Phase 2 EUCTR2008-001137-99-GB United Kingdom;
Hematopoietic stem cell transplantation
University of California, Los Angeles
2014 Phase 0 NCT01932658 United States;
Herpes Zoster Vaccine
University of Alabama at Birmingham
2016 Phase 2 NCT02538341 United States;
2013 Phase 2 NCT02538757 United States;
Hextend
Spectrum Health Hospitals
2007 Phase 3 NCT00467922 United States;
High Oligosaccharide Group
University of British Columbia
2015 - NCT02193750 Australia;Canada;
High dose TSO
Dr. Falk Pharma GmbH
2010 Phase 2 NCT01279577 Germany;
High serine diet
University of Michigan
2021 - NCT04795960 United States;
High-dose Cyclophosphamide
Johns Hopkins University
2015 Phase 1/Phase 2 NCT01836289 United States;
HuM291
PDL BioPharma, Inc
2005 - EUCTR2004-004388-31-DE Germany;
PDL BioPharma, Inc.
2005 - EUCTR2004-004387-72-DE Germany;
Protein Design Labs, Inc.
2005 - EUCTR2004-004387-72-AT Austria;Germany;
Hulio
University Medical Center Groningen
2021 Phase 4 EUCTR2020-001811-26-BE Belgium;Netherlands;
2020 Phase 4 EUCTR2020-001811-26-NL Netherlands;
Human Anti-IL-12 Antibody
Centocor BV
2009 Phase 2 EUCTR2008-000649-77-FR Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
2009 Phase 2 EUCTR2008-000649-77-ES Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-000649-77-NL Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-000649-77-GB Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-000649-77-DE Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-000649-77-BE Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
2008 - EUCTR2008-000649-77-AT Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
Human Monoclonal Antibody (CNTO 1275) to Interleukin 12p-40
Centocor BV
2009 Phase 2 EUCTR2008-000649-77-FR Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
2009 Phase 2 EUCTR2008-000649-77-ES Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-000649-77-NL Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-000649-77-GB Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-000649-77-DE Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-000649-77-BE Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
2008 - EUCTR2008-000649-77-AT Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
Human Placenta-Derived Cells PDA001 Intravenous Infusion
Celularity Incorporated
2010 Phase 2 NCT01155362 United States;
Human Umbilical Cord Mesenchymal Stem Cells
Shanghai East Hospital
2022 - NCT05262829 China;
Human anti-IP10 monoclonal antibody
Bristol-Myers Squibb International Corporation
2012 - EUCTR2011-002981-19-PL Belgium;France;Hungary;Poland;South Africa;United States;
2012 - EUCTR2011-002981-19-HU Belgium;France;Hungary;Poland;South Africa;United States;
2012 - EUCTR2011-002981-19-BE Belgium;France;Hungary;Poland;South Africa;United States;
Human umbilical cord mesenchymal stem cells (UC-MSCs)
CryoCord Sdn Bhd
2022 Phase 1 NCT05039411 Malaysia;
Humira
Abbott GmbH & Co. KG
2008 - EUCTR2006-004814-41-NL Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
2008 - EUCTR2006-004814-41-CZ Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
2008 - EUCTR2006-004814-41-BE Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
2008 - EUCTR2004-002163-24-GB Denmark;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-004814-41-FR Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
2006 - EUCTR2005-005291-32-SE Austria;Belgium;Germany;Italy;Netherlands;Sweden;
2006 - EUCTR2005-005291-32-NL Austria;Belgium;Germany;Italy;Netherlands;Sweden;
2006 - EUCTR2005-005291-32-DE Austria;Belgium;Germany;Italy;Netherlands;Sweden;
2006 - EUCTR2005-005291-32-BE Austria;Belgium;Germany;Italy;Netherlands;Sweden;
2006 - EUCTR2005-005291-32-AT Austria;Belgium;Germany;Italy;Netherlands;Sweden;
2005 - EUCTR2004-002934-20-BE Belgium;
2005 - EUCTR2004-002163-24-DE Denmark;Germany;Hungary;Italy;Spain;United Kingdom;
2004 - EUCTR2004-002163-24-SE Denmark;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
2004 - EUCTR2004-002163-24-ES Denmark;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
2004 - EUCTR2004-002163-24-DK Denmark;Germany;Hungary;Italy;Spain;United Kingdom;
- - EUCTR2006-004814-41-Outside-EU/EEA -
Abbott GmbH & co. KG
2004 - EUCTR2004-002163-24-BE Belgium;Denmark;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
Abbott Laboratories
2004 - EUCTR2004-002163-24-HU Belgium;Denmark;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
Academic Medical Center
2019 Phase 4 EUCTR2018-002064-15-NL Netherlands;
2013 Phase 4 EUCTR2013-002932-25-NL Netherlands;
Department of medical gastroenterology, Herlev Hospital
2009 Phase 4 EUCTR2009-009926-94-DK Denmark;
Fundació Clínic per a la Recerca Biomèdica
2013 Phase 3 EUCTR2012-001723-12-ES Spain;
GETAID - Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives
2015 Phase 4 EUCTR2013-003199-11-BE Belgium;France;
GETECCU
2011 - EUCTR2011-000885-36-ES Spain;
Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU)
2012 - EUCTR2011-003966-34-ES Spain;
2011 Phase 3 EUCTR2011-003966-34-BE Belgium;Spain;
IBD Center LMU Munich
2008 - EUCTR2008-004926-18-DE Germany;
PIBD-Net
2017 Phase 3 EUCTR2016-000522-18-DE Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
PIBDNet
2018 Phase 4 EUCTR2016-000522-18-BE Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
2017 Phase 4 EUCTR2016-000522-18-NL Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
- Phase 4 EUCTR2016-000522-18-FR Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
Region Örebro län
2021 Phase 4 EUCTR2019-002942-19-DK Denmark;
Robarts Clinical Trials
2015 Phase 4 EUCTR2014-001050-41-DE Canada;Germany;United Kingdom;United States;
Royal Liverpool University Hospital
2012 - EUCTR2011-006084-22-GB United Kingdom;
University Hospital Southampton NHS Foundation Trust
2019 Phase 4 EUCTR2018-004967-30-GB United Kingdom;
University Maastricht
2019 Phase 4 EUCTR2017-004588-11-NL Netherlands;
University Medical Center Groningen
2021 Phase 4 EUCTR2020-001811-26-BE Belgium;Netherlands;
2020 Phase 4 EUCTR2020-001811-26-NL Netherlands;
Humira (adalimumab original)
Fundación Publica Andaluza para la Gestión de Salud en Sevilla (FISEVI)
2019 Phase 4 EUCTR2019-000717-37-ES Spain;
Humira (adalimumab)
Radboud University Medical Centre
2017 Phase 4 EUCTR2016-003321-42-NL Netherlands;
Humira 20 mg solution for injection in pre-filled syringe
AbbVie Deutschland GmbH & Co. KG
2009 Phase 3 EUCTR2007-006494-90-CZ Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
Abbott GmbH & Co. K.G.
- - EUCTR2007-006494-90-Outside-EU/EEA Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
Abbvie Deutschland GmbH & Co. K.G.
2008 Phase 3 EUCTR2007-006494-90-BE Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
Humira 40 mg injekcní roztok v predplnené injekcní stríkacce
PIBDNet
2018 Phase 4 EUCTR2016-000522-18-CZ Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
Humira 40 mg solution for injection in pre-filled pen
Abbott GmbH & Co. KG
2009 - EUCTR2006-004814-41-GB Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
Humira 40 mg solution for injection in pre-filled syringe
AbbVie Deutschland GmbH & Co. KG
2015 Phase 3 EUCTR2013-004034-15-IT Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
2015 Phase 3 EUCTR2013-004034-15-GB Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
2015 Phase 3 EUCTR2013-004034-15-FR Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
2015 Phase 3 EUCTR2013-004034-15-DK Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
2015 Phase 3 EUCTR2013-004034-15-DE Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
2015 Phase 3 EUCTR2013-004034-15-BE Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
2015 Phase 3 EUCTR2013-001746-33-FR Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2015 Phase 3 EUCTR2013-001746-33-BE Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2015 Phase 3 EUCTR2010-020137-10-LT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004034-15-SK Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004034-15-HU Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
2014 Phase 3 EUCTR2013-004034-15-ES Austria;Canada;Czech Republic;Denmark;European Union;France;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
2014 Phase 3 EUCTR2013-004034-15-AT Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
2014 Phase 3 EUCTR2013-001746-33-SK Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2014 Phase 3 EUCTR2013-001746-33-NL Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2014 Phase 3 EUCTR2013-001746-33-IT Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2014 Phase 3 EUCTR2013-001746-33-ES Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2014 Phase 3 EUCTR2013-001746-33-DK Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2014 Phase 3 EUCTR2013-001746-33-DE Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2014 Phase 3 EUCTR2013-001746-33-CZ Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Hungary;Israel;Netherlands;Slovakia;Spain;Switzerland;United States;
2014 Phase 3 EUCTR2013-001746-33-AT Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2014 - EUCTR2013-001746-33-HU Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Hungary;Israel;Netherlands;Slovakia;Spain;Switzerland;United States;
2012 Phase 3 EUCTR2010-020137-10-HU Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2010-020137-10-BE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-SE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-NL Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2010-020137-10-GB Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-DE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-CZ Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-AT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2009 Phase 3 EUCTR2007-006494-90-CZ Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
AbbVie Farmacéutica S.L.U.
2014 Phase 4 EUCTR2013-004781-34-ES Spain;
Abbott GmbH & Co. K.G.
2009 Phase 3 EUCTR2007-006494-90-GB Belgium;Czech Republic;United Kingdom;
- - EUCTR2007-006494-90-Outside-EU/EEA Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
Abbott GmbH & Co. KG
2010 Phase 3 EUCTR2010-020137-10-FR Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2006-004814-41-GB Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
Abbvie Deutschland GmbH & Co. K.G.
2008 Phase 3 EUCTR2007-006494-90-BE Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
Humira 40 mg/0.8 ml solution for injection
AbbVie GK
- - EUCTR2015-004121-13-Outside-EU/EEA Japan;
Abbott Deutschland GmbH & Co. KG
- - EUCTR2014-004560-38-Outside-EU/EEA Japan;
- - EUCTR2014-004531-39-Outside-EU/EEA Japan;
Humira 40mg/0.4ml pre-filled syringe
PIBD net
2018 Phase 4 EUCTR2016-000522-18-GB Belgium;Canada;Czech Republic;France;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
Humira 40mg/0.8ml solution for injection for paediatric use
AbbVie Deutschland GmbH & Co. KG
2009 Phase 3 EUCTR2007-006494-90-CZ Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
Abbott GmbH & Co. K.G.
- - EUCTR2007-006494-90-Outside-EU/EEA Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
Abbvie Deutschland GmbH & Co. K.G.
2008 Phase 3 EUCTR2007-006494-90-BE Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
Humira pre-filled PEN
Abbott GmbH & Co. KG
2007 - EUCTR2006-002078-23-SE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
2007 - EUCTR2006-002078-23-PT Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
2007 - EUCTR2006-002078-23-GR Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-002078-23-FI Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
2006 - EUCTR2006-002078-23-ES Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002078-23-DK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
Abbott GmbH & Co. KG (Abbott)
2010 - EUCTR2006-002078-23-IE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
2007 - EUCTR2006-002078-23-GB Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Slovakia;Sweden;United Kingdom;
2006 Phase 3 EUCTR2006-002078-23-FR Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002078-23-NO Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002078-23-NL Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002078-23-DE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
2006 - EUCTR2006-002078-23-CZ Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
2006 - EUCTR2006-002078-23-BE Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002078-23-AT Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
Humira®
ALLERGAN LIMITED
2020 Phase 2;Phase 3 EUCTR2018-004346-42-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Allergan Ltd.
2020 Phase 2;Phase 3 EUCTR2018-004346-42-RO Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2;Phase 3 EUCTR2018-004346-42-BG Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2;Phase 3 EUCTR2018-004346-42-BE Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-004346-42-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-004346-42-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
AstraZeneca
2018 Phase 2/Phase 3 NCT03759288 Australia;Austria;Bulgaria;Canada;China;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
AstraZeneca AB
2021 Phase 2;Phase 3 EUCTR2018-004346-42-HU Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 2;Phase 3 EUCTR2018-004346-42-CZ Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-004346-42-GB Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-004346-42-DE Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2018-004346-42-PL Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Astrazeneca AB
2020 Phase 2;Phase 3 EUCTR2018-004346-42-AT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
JANSSEN CILAG INTERNATIONAL NV
2018 Phase 3 EUCTR2017-004209-41-IT Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
Janssen-Cilag International N.V.
2018 Phase 3 EUCTR2017-004209-41-PL Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004209-41-FR Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004209-41-ES Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004209-41-BG Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004209-41-BE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
Janssen-Cilag International NV
2018 Phase 3 EUCTR2017-004209-41-NL Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004209-41-GB Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004209-41-DE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004209-41-CZ Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
Samsung Bioepis Co., Ltd.
2014 Phase 3 EUCTR2013-005013-13-BG Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
2014 - EUCTR2013-005013-13-PL Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
2014 - EUCTR2013-005013-13-LT Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
2014 - EUCTR2013-005013-13-CZ Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
Hydroxychloroquine
Royal Liverpool University Hospital
2014 Phase 2 NCT01783106 United Kingdom;
ICG-guided bowel perfusion assessment
Leiden University Medical Center
2020 Phase 3 NCT04712032 Netherlands;
IGG2 ANTIBODIES
EA Pharma Co., Ltd.
2019 Phase 2 EUCTR2018-002109-70-HU Czech Republic;Hungary;Japan;Poland;
2019 Phase 2 EUCTR2018-002109-70-CZ Czech Republic;Czechia;Hungary;Japan;Poland;Russian Federation;
IM90838
Immunic AG
2019 Phase 2 EUCTR2018-001895-39-NL Bulgaria;Croatia;Czech Republic;Germany;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001895-39-HR Bulgaria;Croatia;Czech Republic;Germany;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001895-39-CZ Bulgaria;Croatia;Czech Republic;Germany;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001895-39-BG Bulgaria;Croatia;Czech Republic;Germany;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Ukraine;United Kingdom;United States;
IMP will be labeled as ''PF-04236921 106mg/vial, Clonal SC lyophilized form''.
PFIZER INC.
2011 - EUCTR2010-023034-23-IT Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Hungary;Israel;Italy;New Zealand;Sweden;Switzerland;United Kingdom;United States;
IMP will be labeled as PF-04236921 106mg/vial, Clonal SC lyophilized form
PFIZER INC.
2012 - EUCTR2011-000722-30-IT Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Greece;Hungary;Ireland;Israel;Italy;New Zealand;Sweden;Switzerland;United Kingdom;United States;
IMU-838
Immunic AG
2019 Phase 2 EUCTR2018-001895-39-NL Bulgaria;Croatia;Czech Republic;Germany;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001895-39-HR Bulgaria;Croatia;Czech Republic;Germany;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001895-39-CZ Bulgaria;Croatia;Czech Republic;Germany;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001895-39-BG Bulgaria;Croatia;Czech Republic;Germany;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Ukraine;United Kingdom;United States;
ITF 2357
ITALFARMACO
2008 - EUCTR2007-000189-19-IT Belgium;Italy;Netherlands;
ITF2357
Italfarmaco
2007 Phase 1/Phase 2 NCT00792740 Belgium;
Italfarmaco S.p.A.
2007 - EUCTR2007-000189-19-NL Belgium;Italy;Netherlands;
2007 - EUCTR2007-000189-19-BE Belgium;Italy;Netherlands;
2005 Phase 2 EUCTR2004-004854-19-SK Slovakia;
Ileocecal resection
University Hospital, Lille
2017 - NCT02872506 -
Ileocolonoscopy
Universitaire Ziekenhuizen Leuven
2005 Phase 2 NCT02247258 Belgium;Czech Republic;Greece;
Immune Ablation and Hematopoietic Stem Cell Support
Richard Burt, MD
2001 Phase 1 NCT00278577 United States;
Immunonutrition
Istituto Clinico Humanitas
2020 - NCT04014517 -
Immunosuppressor/TNFalpha
University Hospital, Grenoble
2018 - NCT03623932 France;
Immunosuppressors (Thiopurines or Methotrexate)
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
2021 Phase 4 NCT05072782 -
Impact
Lawson Health Research Institute
2016 - NCT02742597 Canada;
NHS Greater Glasgow and Clyde
2020 - NCT04273399 United Kingdom;
Imraldi
University Hospital Southampton NHS Foundation Trust
2019 Phase 4 EUCTR2018-004967-30-GB United Kingdom;
Imuran
Academic Medical Center, department of Gastroenterology and hepatology
2008 - EUCTR2008-001131-35-NL Netherlands;
Amsterdam UMC location AMC
2021 Phase 3;Phase 4 EUCTR2021-000469-33-NL Netherlands;
Centocor B.V.
2005 Phase 3 EUCTR2004-002815-10-GB Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
2005 Phase 3 EUCTR2004-002815-10-ES Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-SE Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-DK Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-DE Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-AT Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
Novartis Pharma Services AG
2005 Phase 2 EUCTR2005-001148-22-SK Slovakia;
PIBDNet
2017 Phase 4 EUCTR2016-000522-18-NL Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
University of Edinburgh
2015 - EUCTR2014-002311-41-GB Belgium;France;Germany;Sweden;United Kingdom;
Imurel
GETAID
2015 Phase 4 EUCTR2014-002311-41-SE France;Germany;Netherlands;Sweden;United Kingdom;
GETECCU
2011 - EUCTR2011-000885-36-ES Spain;
Marianne Kiszka-Kanowitz
2013 Phase 3 EUCTR2013-001503-37-DK Denmark;
PIBDNet
2018 Phase 4 EUCTR2016-000522-18-BE Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
- Phase 4 EUCTR2016-000522-18-FR Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
Region Örebro län
2021 Phase 4 EUCTR2019-002942-19-DK Denmark;
SOIBD (The Swedish Organisation for the study of Inflammatory Bowel Diseases)
2018 Phase 4 EUCTR2016-004112-35-SE Sweden;
InVita D3
Academic Medical Center
2013 Phase 3 EUCTR2013-002838-20-NL Belgium;Netherlands;
Increlex 10mg/ml solution for injection
Greater Glasgow & Clyde NHS
2011 Phase 2 EUCTR2010-022215-19-GB United Kingdom;
Queen Mary, University of London
2008 - EUCTR2007-004269-16-GB United Kingdom;
Indocyanine green
Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
2017 - ChiCTR-INR-17012532 China;
Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine
2020 Phase 0 ChiCTR2000035737 China;
Inflectra
CELLTRION INC.
2019 Phase 3 EUCTR2019-001087-30-IT Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
CUB- Hopital Erasme
2016 Phase 4 EUCTR2015-004618-10-BE Belgium;
Celltrion, Inc
2019 Phase 3 EUCTR2019-001087-30-PL Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Czechia;Estonia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-LV Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-HU Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-HR Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-GR Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-FR Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-ES Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-DE Austria;Belarus;Bulgaria;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-CZ Austria;Belarus;Bulgaria;Chile;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-BG Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Czechia;Estonia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-AT Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
Department of medical gastroenterology, Herlev Hospital
2016 Phase 4 EUCTR2012-002702-51-NO Denmark;Finland;Norway;Sweden;
Erasmus Medical Center
2015 Phase 4 EUCTR2014-005702-37-NL Netherlands;
Pfizer
2018 - NCT03801928 Canada;United States;
University Medical Center Groningen
2021 Phase 4 EUCTR2020-001811-26-BE Belgium;Netherlands;
2020 Phase 4 EUCTR2020-001811-26-NL Netherlands;
Inflectra 100 mg powder for concentrate for solution for infusion
Santeon
2015 Phase 4 EUCTR2015-001954-14-NL Netherlands;
Infliximab
Academic Medical Center
2019 Phase 4 EUCTR2018-002064-15-NL Netherlands;
2014 - EUCTR2013-001029-17-NL Netherlands;
2013 Phase 4 EUCTR2013-002932-25-NL Netherlands;
Academic Medical Center, department of Gastroenterology and hepatology
2008 - EUCTR2008-001131-35-NL Netherlands;
Beth Israel Deaconess Medical Center
2021 Phase 4 NCT04835506 United States;
Biogen
2018 - NCT03662919 France;
CHRU de Lille
2008 - EUCTR2006-004784-58-FR Belgium;France;Germany;United Kingdom;
Centocor B.V.
2005 Phase 3 EUCTR2004-002815-10-GB Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
2005 Phase 3 EUCTR2004-002815-10-ES Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-SE Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-DK Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-DE Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-AT Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
Centocor, Inc.
2003 Phase 3 NCT00207675 -
2000 Phase 3 NCT00207766 -
2000 Phase 3 NCT00207662 -
1996 Phase 3 NCT00269841 -
1995 Phase 2/Phase 3 NCT00269854 -
Chiba University Hospital
2012 Phase 2 JPRN-UMIN000015297 Japan;
2012 Phase 2 JPRN-UMIN000007806 Japan;
Children's Hospital Medical Center, Cincinnati
2019 - NCT04131504 United States;
Children's Hospital of Fudan University
2022 Phase 4 NCT04530877 -
Clinical Research Group of inflammatory bowel disease in Japan
2009 Phase 4 JPRN-UMIN000002604 Japan;
Copenhagen University Hospital at Herlev
2013 Phase 4 NCT01817426 Denmark;Finland;Norway;Sweden;
Daping Hospital, Army Medical University (Third Military Medical University)
2018 - ChiCTR1800019958 China;
Department of Gastroenterology and Hepatology, Kyoto University Hospital
2011 - JPRN-UMIN000005689 Japan;
Department of Gastroenterology, Nanfang Hospital, Southern Medical University
2016 - ChiCTR1800020305 China;
Department of Lower Gastroenterology, Hyogo College of Medicine
2012 Phase 4 JPRN-UMIN000006889 Japan;
Erasmus Medical Center
2015 Phase 4 NCT02517684 Belgium;Denmark;Finland;Italy;Netherlands;Poland;
2013 Phase 4 NCT01880307 Italy;Netherlands;
Ernest Seidman
2014 - NCT02453607 Canada;
Fukuoka University Chikushi Hospital
2021 - JPRN-UMIN000043165 Japan;
Graduate School of Medical Sciences, Kyushu University
2009 - JPRN-UMIN000010293 Japan;
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
2012 Phase 4 NCT01442025 France;
2005 Phase 3 NCT00571337 Belgium;France;
Hikma Pharmaceuticals LLC
2018 - NCT03452501 Saudi Arabia;
Hvidovre University Hospital
2014 - NCT02060318 Denmark;
IBD Center, Sapporo Kosei General Hospital
2014 - JPRN-UMIN000014006 Japan;
IRCCS Burlo Garofolo
2018 Phase 3 NCT03221166 Italy;
Ishida Tetsuya
2020 Phase 3 JPRN-jRCT2031200117 Austria;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Japan;Latvia;Poland;Spain;US;
Janssen Biotech, Inc.
2010 Phase 3 NCT01190839 Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Netherlands;New Zealand;Poland;Spain;United Kingdom;United States;
Janssen Korea, Ltd., Korea
2007 - NCT00724529 Korea, Republic of;
Janssen Scientific Affairs, LLC
2013 Phase 4 NCT01804166 United States;
Johnson & Johnson (China) Investment Ltd.
2020 - NCT04312659 China;
Klinikum Westbrandenburg GmbH
2015 - NCT02522169 -
Lower GI disease, Hyogo College of Medicine
2007 Phase 2,3 JPRN-UMIN000004427 Japan;
Massachusetts General Hospital
2019 - NCT04655729 United States;
Merck Sharp & Dohme Corp.
2012 - NCT01349920 Moldova, Republic of;United Kingdom;
2010 - NCT00988832 United Kingdom;
2006 - NCT00727298 Germany;
2005 - NCT00705471 -
2004 - NCT00724958 Austria;
2003 Phase 3 NCT00796250 -
Mikami Yohei
2019 - JPRN-jRCT1031190056 Japan;
Nanfang Hospital of Southern Medical University
2014 - NCT02088944 -
Novartis Pharmaceuticals
2011 Phase 2 NCT01355614 Germany;Switzerland;
Oregon Health and Science University
2010 - NCT01266785 United States;
Renji Hospital, School of Medicine, Shanghai Jiaotong University
2020 Phase 0 ChiCTR2000029323 China;
Royal Liverpool University Hospital
2012 - EUCTR2011-006084-22-GB United Kingdom;
Saitama Medical University
2011 - JPRN-UMIN000006232 Japan;
Saitama Medical center
2014 - JPRN-UMIN000012790 Japan;
Samsung Medical Center
2009 Phase 3 NCT01661257 Korea, Republic of;
Second Affiliated Hospital of Wenzhou Medical University
2017 - NCT04272788 China;
Sheba Medical Center
2005 - NCT00252369 Israel;
Sixth Affiliated Hospital, Sun Yat-sen University
2021 - NCT04761952 -
The First Affiliated Hospital of Sun Yat-sen University
2019 - ChiCTR1900026091 China;
The Jikei University School of MedicineDivision of Gastroenterology and Hepatology
2012 Phase 4 JPRN-UMIN000008043 Japan;
Tohoku University Graduate School of Medicine (Tohoku University Hospital)
2012 - JPRN-UMIN000007343 Japan;
University Hospitals Cleveland Medical Center
2008 - NCT00791557 United States;
University Medical Center Groningen
2021 Phase 4 NCT04646187 Belgium;Netherlands;Spain;
University Southampton Hospital NHS Foundation Trust
2018 Phase 4 EUCTR2018-001546-33-GB United Kingdom;
University of Alberta
2015 - NCT02847884 Canada;
University of Leuven Hospitals
2009 Phase 4 EUCTR2006-004784-58-GB Belgium;France;Germany;United Kingdom;
University of Pittsburgh
2005 Phase 4 NCT00688636 United States;
University of Rochester
2007 Phase 4 NCT00462072 United States;
University of Toyama
2017 - JPRN-UMIN000026330 Japan;
University of Western Ontario, Canada
2014 Phase 4 NCT01960426 United States;
Vanderbilt-Ingram Cancer Center
2006 - NCT00897312 -
Infliximab (IFX alone)
Children's Memorial Health Institute, Poland
2008 Phase 3 NCT01559142 Poland;
Infliximab (Remicade)
Centocor, Inc.
2002 - NCT00261976 Argentina;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Hungary;Ireland;Israel;Netherlands;Norway;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
Infliximab (Remicade): 100 mg of lyophilized infliximab
First Department of Medicine, University of Szeged
2014 - EUCTR2013-005629-21-HU Hungary;
Infliximab 5 mg/kg body weight infused over 2 hours
Janssen Inc.
2012 Phase 4 NCT01181765 Canada;
Infliximab 5 mg/kg every 6 weeks
Merck Sharp & Dohme Corp.
2008 Phase 4 NCT00752622 Canada;
Infliximab 7 mg/kg every 8 weeks
Merck Sharp & Dohme Corp.
2008 Phase 4 NCT00752622 Canada;
Infliximab CT-P13
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
2021 Phase 4 NCT05072782 -
Infliximab [infliximab biosimilar 3]
Pfizer
2019 - NCT03884439 Japan;
Infliximab and adalimumab
Regionshospitalet Viborg, Skive
2009 - NCT02322008 -
Infliximab and azathioprine combination at week 0
Sixth Affiliated Hospital, Sun Yat-sen University
2017 - NCT03393247 China;
Infliximab and azathioprine combination at week 14
Sixth Affiliated Hospital, Sun Yat-sen University
2017 - NCT03393247 China;
Infliximab and immunosuppressives
Children's Hospital of Fudan University
2022 Phase 4 NCT05043870 -
Infliximab infusion
Centocor Ortho Biotech Services, L.L.C.
2005 Phase 3 NCT00094458 Austria;Belgium;Canada;Denmark;France;Germany;Greece;Israel;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States;
Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
2019 Phase 4 NCT03885713 Spain;
Infliximab therapeutic drug monitoring
Imelda GI Clinical Research Center
2018 Phase 4 NCT04775732 Belgium;
Infliximab with azathioprine (IIFX + AZA)
Children's Memorial Health Institute, Poland
2008 Phase 3 NCT01559142 Poland;
Infliximab+azathioprine
Belgian IBD Research Group
2001 Phase 4 NCT00554710 Belgium;
Infliximab, adalimumab, certolizumab pegol
Oslo University Hospital
2013 - NCT02073526 Norway;
Infliximab, azathioprine
Sixth Affiliated Hospital, Sun Yat-sen University
2016 - NCT02998827 -
Infliximab-Biosimilar
Onze Lieve Vrouwe Gasthuis
2015 Phase 4 NCT02452151 -
Infliximab-Innovator
Onze Lieve Vrouwe Gasthuis
2015 Phase 4 NCT02452151 -
Injection of iron
Jinling Hospital, China
2012 - NCT01823029 China;
Innovator infliximab
Diakonhjemmet Hospital
2014 Phase 4 NCT02148640 Norway;
Inositol
National Cancer Institute (NCI)
2010 Phase 1/Phase 2 NCT01111292 United States;
Instillation of fibrin glue
Sheba Medical Center
2005 - NCT00252369 Israel;
Interferon beta-1a
EMD Serono
2001 Phase 2 NCT00304252 Germany;Italy;Sweden;Switzerland;United Kingdom;
Interleukin-2 (aldesleukin).
Boston Children's Hospital
2021 Phase 1/Phase 2 NCT04263831 United States;
Intestinal surgery for Crohn's Disease
Sir Run Run Shaw Hospital
2019 Phase 4 NCT03901937 China;
Intralipid
Mayo Clinic
2018 - NCT03773237 United States;
Radboud University
2014 Phase 4 NCT02349594 Netherlands;
Iron sulphate 200mg coated tablets
Barts Health NHS Trust
2011 Phase 4 EUCTR2010-023797-39-GB United Kingdom;
Iron supplement 300-600 mg/day
University Health Network, Toronto
2002 Phase 2 NCT00152841 Canada;
Iron(III)- hydroxide dextran complex
Barts Health NHS Trust
2011 Phase 4 EUCTR2010-023797-39-GB United Kingdom;
Itraconazole 400 mg/day and terbinafine 500 mg/day administered orally.
Montreal Heart Institute
2022 Phase 2 NCT05049525 -
J695
National Institute of Allergy and Infectious Diseases (NIAID)
2000 Phase 1 NCT00007163 United States;
J695, BSF 415977 (formerly LU415977), WAY-165772, A-796874.0
Abbott
2009 - EUCTR2008-004919-36-SE Austria;Denmark;Sweden;
2009 - EUCTR2008-004919-36-DK Austria;Denmark;Sweden;
2009 - EUCTR2008-004919-36-BE Austria;Belgium;Denmark;Sweden;
2009 - EUCTR2008-004919-36-AT Austria;Denmark;Sweden;
JNJ-40346527-AAC
Provention Bio, Inc.
2018 Phase 2 EUCTR2017-003017-25-PL Austria;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
2018 Phase 2 EUCTR2017-003017-25-HU Austria;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
2018 Phase 2 EUCTR2017-003017-25-ES Austria;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
2018 Phase 2 EUCTR2017-003017-25-DE Austria;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
2018 Phase 2 EUCTR2017-003017-25-AT Austria;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
JNJ-64304500
JANSSEN CILAG INTERNATIONAL NV
2021 Phase 2 EUCTR2020-002701-26-IT Canada;France;Germany;Italy;Japan;Spain;Sweden;United States;
Janssen Research & Development, LLC
2021 Phase 2 NCT04655807 Canada;France;Germany;Italy;Japan;Spain;Sweden;United States;
2016 Phase 2 NCT02877134 Belgium;Bulgaria;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Serbia;Ukraine;United Kingdom;United States;
JNJ-64304500-AAA
JANSSEN CILAG INTERNATIONAL NV
2016 Phase 2 EUCTR2016-000634-21-IT Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
Janssen-Cilag International NV
2019 Phase 2 EUCTR2016-000634-21-FR Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000634-21-PL Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2016-000634-21-HU Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2016-000634-21-GB Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2016-000634-21-DE Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
JNJ-67864238
JANSSEN CILAG INTERNATIONAL NV
2019 Phase 2 EUCTR2019-003335-37-IT Argentina;Germany;Italy;Poland;Russian Federation;United States;
Janssen Research & Development, LLC
2019 Phase 2 NCT04102111 Argentina;France;Germany;Italy;Poland;Russian Federation;Ukraine;United States;
Janssen-Cilag International NV
2020 Phase 2 EUCTR2019-003335-37-DE Argentina;Germany;Italy;Poland;Russian Federation;United States;
JNJ-78934804
Janssen Research & Development, LLC
2022 Phase 2 NCT05242471 Italy;
Kanamycin
Hyogo college of medicine
2014 Phase 2 JPRN-UMIN000013369 Japan;
Kenacort
University Medical Center Utrecht
2009 - EUCTR2007-005455-42-NL Netherlands;
Kremezin®, Spherical Adsorptive Carbon
Ocera Therapeutics, Inc.
2007 - EUCTR2005-005363-28-HU Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
2007 - EUCTR2005-005363-28-AT Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
2006 Phase 3 EUCTR2005-005363-28-GB Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
2006 - EUCTR2005-005363-28-DE Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
2006 - EUCTR2005-005363-28-CZ Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
2006 - EUCTR2005-005363-28-BE Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
L 44
Lument AB
2019 Phase 2 EUCTR2019-002093-32-SE Sweden;
L01BA
PIBDNet
2017 Phase 4 EUCTR2016-000522-18-NL Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
LDP-02
Millennium Pharmaceuticals, Inc.
2000 Phase 2 NCT00655135 -
LY3074828
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2021 Phase 3 EUCTR2019-002687-27-IT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004614-18-IT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Eli Lilly and Company
2022 Phase 3 EUCTR2019-002687-27-HR Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2019-002687-27-SK Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2019-002687-27-LV Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2019-002687-27-LT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2019-002687-27-FR Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2019-002687-27-DE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002687-27-NL Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002687-27-HU Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004614-18-LV Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004614-18-LT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004614-18-HR Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004614-18-DK Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004614-18-PL Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004614-18-NL Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004614-18-HU Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004614-18-GB Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004614-18-FR Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004614-18-DE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004614-18-AT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-002204-84-PL Australia;Austria;Belgium;Canada;Czech Republic;France;Hungary;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Switzerland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-002204-84-NL Australia;Austria;Belgium;Canada;Czech Republic;France;Hungary;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Switzerland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-002204-84-HU Australia;Austria;Belgium;Canada;Czech Republic;France;Hungary;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Switzerland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-002204-84-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Hungary;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Switzerland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-002204-84-CZ Australia;Austria;Belgium;Canada;Czech Republic;France;Hungary;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Switzerland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-002204-84-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Hungary;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Switzerland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-002204-84-AT Australia;Austria;Belgium;Canada;Czech Republic;France;Hungary;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Switzerland;Ukraine;United Kingdom;United States;
Lilly S.A.
2019 Phase 3 EUCTR2018-004614-18-ES Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Lactated Ringers
Spectrum Health Hospitals
2007 Phase 3 NCT00467922 United States;
Lactobacillus salivarius UCC118
University College Cork
2002 Phase 2/Phase 3 NCT00510978 Ireland;
Lactulose/Rhamnose solution
MediBeacon
2019 Early Phase 1 NCT03962998 United States;
Lap TAP Bupivacaine/Epinephrine
Cedars-Sinai Medical Center
2015 - NCT02538679 -
Laquinimod
Teva Pharmaceutical Industries
2010 Phase 2 NCT00737932 Belgium;France;Israel;Italy;Netherlands;Poland;South Africa;Spain;United Kingdom;
Teva Pharmaceutical Industries Ltd.
2008 - EUCTR2008-004276-49-IT Belgium;France;Italy;Netherlands;Spain;United Kingdom;
Laquinimod Capsules
Teva Pharmaceutical Industries Ltd.
2008 Phase 2 EUCTR2008-004276-49-GB Belgium;France;Italy;Netherlands;Spain;United Kingdom;
2008 Phase 2 EUCTR2008-004276-49-FR Belgium;France;Italy;Netherlands;Spain;United Kingdom;
2008 Phase 2 EUCTR2008-004276-49-BE Belgium;France;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2008-004276-49-NL Belgium;France;Italy;Netherlands;Spain;United Kingdom;
Laquinimod Cápsulas
Teva Pharmaceutical Industries Ltd.
2008 Phase 2 EUCTR2008-004276-49-ES Belgium;France;Italy;Netherlands;Spain;United Kingdom;
Leucine
Showa Inan General Hospital
2020 - NCT04535882 Japan;
Leukapheresis
Cedars-Sinai Medical Center
2020 Phase 1/Phase 2 NCT04224558 United States;
Lipitor
University College London
2009 Phase 2 EUCTR2009-010163-16-GB United Kingdom;
Liposomal bupivacaine
Cedars-Sinai Medical Center
2018 Phase 4 NCT03723447 United States;
Losartan
Takeda
2016 Phase 4 NCT02760615 United States;
Low dose TSO
Dr. Falk Pharma GmbH
2010 Phase 2 NCT01279577 Germany;
Low dose naltrexone
Santa Barbara Cottage Hospital
2013 Phase 2 NCT01810185 United States;
Low serine diet
University of Michigan
2021 - NCT04795960 United States;
Low-dose IL-2 administration
Nationwide Children's Hospital
2013 Phase 2 NCT02676622 -
Lumbar puncture
Shire
2012 Phase 1 NCT01387594 Austria;Belgium;France;Germany;Netherlands;
Lumentin 44
Lument AB
2019 Phase 2 EUCTR2019-002093-32-SE Sweden;
Lymphocyte immune globulin
Cedars-Sinai Medical Center
2020 Phase 1/Phase 2 NCT04224558 United States;
MB-102
MediBeacon
2019 Early Phase 1 NCT03962998 United States;
MDGN-002
Aevi Genomic Medicine, LLC, a Cerecor company
2017 Phase 1 NCT03169894 United States;
MDX-1100
Bristol-Myers Squibb International Corporation
2012 - EUCTR2011-002981-19-PL Belgium;France;Hungary;Poland;South Africa;United States;
2012 - EUCTR2011-002981-19-HU Belgium;France;Hungary;Poland;South Africa;United States;
2012 - EUCTR2011-002981-19-BE Belgium;France;Hungary;Poland;South Africa;United States;
MEDI2070
ASTRAZENECA
2013 Phase 2 EUCTR2012-004098-26-IT Canada;Czech Republic;France;Germany;Hungary;Italy;Spain;United States;
Allergan
2013 Phase 2 NCT01714726 Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United States;
Allergan Limited
2017 Phase 2 EUCTR2015-000609-38-GB Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2015-000609-38-HU Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2015-000609-38-DE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2015-000609-38-BG Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
AstraZeneca AB
2020 Phase 2;Phase 3 EUCTR2018-004346-42-CZ Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2013 Phase 2 EUCTR2012-004098-26-HU Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United States;
2013 Phase 2 EUCTR2012-004098-26-FR Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United States;
2013 Phase 2 EUCTR2012-004098-26-ES Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United States;
2013 Phase 2 EUCTR2012-004098-26-DE Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United States;
2013 Phase 2 EUCTR2012-004098-26-CZ Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United States;
MEDIMMUNE, LLC
2016 Phase 2 EUCTR2015-000609-38-IT Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
MedImmune Limited
2016 Phase 2 EUCTR2015-000609-38-CZ Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
MedImmune, Ltd, a wholly owned subsidiary of AstraZeneca UK
2016 Phase 2 EUCTR2015-000609-38-NL Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2015-000609-38-ES Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2015-000609-38-BE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
METHOTREXATE - 20 MG/0.8 ML SOLUZIONE INIETTABILE 4 SIRINGHE PRERIEMPITE MONOUSO DA 1.25 ML
UMBERTO I - POLICLINICO DI ROMA
2017 Phase 4 EUCTR2016-000522-18-IT Belgium;Czech Republic;Czechia;France;Germany;Hungary;Italy;Netherlands;Poland;United Kingdom;
METHOTREXATE DISODIUM
GETAID
2015 Phase 4 EUCTR2014-002311-41-SE France;Germany;Netherlands;Sweden;United Kingdom;
MICROBIOTA
McMaster Children's Hospital
2018 Phase 1 NCT03378167 Canada;
MLN0002
AMC MEDICAL RESEARCH B.V.
2017 Phase 3 EUCTR2015-000555-24-IT France;Italy;Netherlands;Spain;
Academic Medical Center Amsterdam
2016 Phase 4 EUCTR2015-000555-24-NL Netherlands;
2016 Phase 4 EUCTR2015-000555-24-FR France;Netherlands;Spain;
2016 Phase 4 EUCTR2015-000555-24-ES Netherlands;Spain;
Academic Medical Center, Gastroenterology
2015 Phase 4 EUCTR2014-005376-29-BE Belgium;Netherlands;
MILLENNIUM PHARMACEUTICALS, INC.
2011 - EUCTR2009-016488-12-IT Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Netherlands;
2009 - EUCTR2008-002783-33-IT Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
Millennium Pharmaceuticals, Inc.
2011 Phase 3 EUCTR2009-016488-12-SK Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Netherlands;Slovakia;
2011 Phase 3 EUCTR2009-016488-12-BE Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Netherlands;Slovakia;
2011 - EUCTR2009-016488-12-NL Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Netherlands;
2011 - EUCTR2009-016488-12-DE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Poland;Slovakia;South Africa;Turkey;United States;
2011 - EUCTR2009-016488-12-CZ Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Netherlands;Slovakia;
2011 - EUCTR2009-016488-12-AT Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Poland;Slovakia;South Africa;Turkey;United States;
2010 - EUCTR2009-016488-12-HU Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Netherlands;
2009 Phase 3 EUCTR2008-002784-14-PT Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-002784-14-IE Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2009 Phase 3 EUCTR2008-002784-14-GR Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-002784-14-FR Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-002784-14-EE Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2009 Phase 3 EUCTR2008-002783-33-IS Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-002783-33-GB Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-002783-33-FR Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-002783-33-BE Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-002784-14-MT Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-002783-33-SK Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-002783-33-SE Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-002783-33-PT Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-002783-33-NL Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-002783-33-MT Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-002783-33-IE Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-002783-33-HU Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-002783-33-GR Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-002783-33-EE Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-002783-33-DE Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;
2009 - EUCTR2008-002783-33-CZ Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-002783-33-BG Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-002783-33-AT Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;
2008 - EUCTR2008-002783-33-LV Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2008 - EUCTR2008-002783-33-DK Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
TAKEDA DEVELOPMENT CENTER AMERICAS INC.
2021 Phase 3 EUCTR2020-004301-31-IT Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;China;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Lithuania;New Zealand;Poland;Romania;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
Takeda Development Center Americas, Inc.
2021 Phase 3 EUCTR2020-004301-31-SK Australia;Belgium;Canada;China;Croatia;Czech Republic;Czechia;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004301-31-LT Australia;Belgium;Canada;China;Croatia;Czech Republic;Czechia;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004301-31-HU Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;China;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Lithuania;New Zealand;Poland;Romania;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004301-31-HR Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;China;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Lithuania;New Zealand;Poland;Romania;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004301-31-ES Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;China;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Lithuania;New Zealand;Poland;Romania;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2020-004301-31-PL Australia;Belgium;Canada;China;Croatia;Czech Republic;Czechia;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2020-004301-31-CZ Australia;Belgium;Canada;China;Croatia;Czech Republic;Czechia;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2020-004301-31-BE Australia;Belgium;Canada;China;Croatia;Czech Republic;Czechia;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
Takeda Development Centre Europe Ltd
2015 Phase 3 EUCTR2014-003509-13-PL Belgium;Canada;Czech Republic;Hungary;Poland;United States;
2015 Phase 3 EUCTR2014-003509-13-HU Belgium;Canada;Czech Republic;Hungary;Poland;United States;
2015 Phase 3 EUCTR2014-003509-13-CZ Belgium;Canada;Czech Republic;Hungary;Poland;United States;
2015 Phase 3 EUCTR2014-003509-13-BE Belgium;Canada;Czech Republic;Hungary;Poland;United States;
2009 Phase 3 EUCTR2008-002784-14-IS Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
Takeda Development Centre Europe Ltd.
2010 Phase 3 EUCTR2008-002784-14-SE Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2010 Phase 3 EUCTR2008-002784-14-GB Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-002784-14-SK Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2009 Phase 3 EUCTR2008-002784-14-NL Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2009 Phase 3 EUCTR2008-002784-14-DE Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2009 Phase 3 EUCTR2008-002784-14-CZ Australia;Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;
2009 Phase 3 EUCTR2008-002784-14-BG Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2009 Phase 3 EUCTR2008-002784-14-BE Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2009 Phase 3 EUCTR2008-002784-14-AT Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2008 Phase 3 EUCTR2008-002784-14-LV Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Takeda Development Centre Europe ltd.
2009 Phase 3 EUCTR2008-002784-14-HU Australia;Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Takeda Development Centre Europe, Ltd.
2018 Phase 2 EUCTR2017-002231-41-PL Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002231-41-NL Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002231-41-BE Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002182-21-PL Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002182-21-NL Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002182-21-BE Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2017-002231-41-HU Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2017-002231-41-GB Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2017-002231-41-DE Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2017-002182-21-HU Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2017-002182-21-GB Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2017-002182-21-FR Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2017-002182-21-DE Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
- Phase 2 EUCTR2017-002231-41-FR Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
MLN0002 (Vedolizumab)
Takeda Pharmaceutical Company Limited
2014 Phase 3 JPRN-JapicCTI-142402 Japan;
MLN0002 SC
TAKEDA DEVELOPMENT CENTRE EUROPE LTD
2016 Phase 3 EUCTR2015-000482-31-IT Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Montenegro;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-IT Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Takeda Development Centre Europe, Ltd.
2016 Phase 3 EUCTR2015-000482-31-SK Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000482-31-SE Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000482-31-NL Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000482-31-LT Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000482-31-HU Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000482-31-HR Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000482-31-GB Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000482-31-ES Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000482-31-DK Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000482-31-DE Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000482-31-CZ Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000482-31-BG Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000482-31-BE Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-SK Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-SE Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-NL Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-LT Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-HU Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-GB Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-ES Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-DK Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-DE Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-CZ Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-BG Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-BE Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
MLN002
Takeda Development Centre Europe Limited
2016 Phase 4 EUCTR2016-000678-40-CZ Australia;Bulgaria;Czech Republic;Estonia;Hungary;India;Italy;Korea, Republic of;Latvia;Malaysia;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Turkey;Ukraine;
MODULEN IBD
Assistance Publique - Hôpitaux de Paris
2014 - NCT02201693 France;
MODULEN IBD (R) (specific Enteral Nutrition)
Hôpital Necker-Enfants Malades
2005 Phase 4 NCT00265772 France;
MONOCLONAL ANTIBODY ANTI-IGG1
Boehringer Ingelheim
2021 Phase 2 EUCTR2019-001673-93-BE Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
2020 Phase 2 EUCTR2019-001673-93-AT Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
Boehringer Ingelheim BV
2020 Phase 2 EUCTR2017-003090-34-DK Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
Boehringer Ingelheim Netherlands BV
2019 Phase 2 EUCTR2017-003090-34-NL Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
Boehringer Ingelheim Pharma GmbH & Co. KG
2020 Phase 2 EUCTR2019-001673-93-DE Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
2019 Phase 2 EUCTR2017-003090-34-DE Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
Boehringer Ingelheim RCV GmbH & Co KG
2020 Phase 2 EUCTR2019-001673-93-HU Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
2019 Phase 2 EUCTR2017-003090-34-HU Austria;Belgium;Germany;Hungary;Netherlands;
2019 Phase 2 EUCTR2017-003090-34-AT Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
Boehringer Ingelheim S.A.
2021 Phase 2 EUCTR2019-001673-93-ES Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
SCS Boehringer Ingelheim Comm.V
2018 Phase 2 EUCTR2017-003090-34-BE Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
MSB11022
Fresenius Kabi SwissBioSim GmbH
2019 Phase 1 NCT04018599 United States;
MSC
CHU-ULg
2012 - EUCTR2011-005966-39-BE Belgium;
MSC injection 01
Sixth Affiliated Hospital, Sun Yat-sen University
2017 Phase 2/Phase 3 NCT03056664 -
MSC injection 02
Sixth Affiliated Hospital, Sun Yat-sen University
2017 Phase 2/Phase 3 NCT03056664 -
MSC treatment 01
Sixth Affiliated Hospital, Sun Yat-sen University
2016 Phase 2/Phase 3 NCT02532738 -
MSC treatment 02
Sixth Affiliated Hospital, Sun Yat-sen University
2016 Phase 2/Phase 3 NCT02532738 -
MSC-AFP
Mayo Clinic
2018 Phase 1 NCT03449069 United States;
2017 Phase 1 NCT03220243 United States;
William A. Faubion, M.D.
2013 Phase 1 NCT01915927 United States;
MT-1303
Mitsubishi Tanabe Pharma Corporation
2015 Phase 2 NCT02389790 Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;Ukraine;
2015 Phase 2 NCT02378688 Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;Ukraine;
2014 Phase 1 NCT02148185 Japan;
Mitsubishi Tanabe Pharma Corporation (MTPC)
2015 Phase 2 EUCTR2014-002557-19-SK Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;
2015 Phase 2 EUCTR2014-002557-19-PL Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;Ukraine;
2015 Phase 2 EUCTR2014-002557-19-NL Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;Ukraine;
2015 Phase 2 EUCTR2014-002557-19-IT Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;
2015 Phase 2 EUCTR2014-002556-77-SK Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;Ukraine;
2015 Phase 2 EUCTR2014-002556-77-PL Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;Ukraine;
2015 Phase 2 EUCTR2014-002556-77-NL Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;Ukraine;
2015 Phase 2 EUCTR2014-002556-77-IT Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;
2014 Phase 2 EUCTR2014-002557-19-HU Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;
2014 Phase 2 EUCTR2014-002557-19-CZ Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;Ukraine;
2014 Phase 2 EUCTR2014-002556-77-HU Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;
2014 Phase 2 EUCTR2014-002556-77-CZ Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;Ukraine;
MTX
Centre Hospitalier Universitaire, Amiens
2021 Phase 3 NCT05040464 France;
Peking Union Medical College Hospital
2016 - ChiCTR-OPC-16008655 China;
MVA HAV
University of Oxford
2017 Phase 1 NCT03027193 United Kingdom;
Magnetic Resonance Enterography (MRE)
Mayo Clinic
2017 Phase 4 NCT03235180 United States;
Maltodextrin
Katholieke Universiteit Leuven
2008 - NCT01487759 Belgium;
University of Alberta
2021 - NCT04804046 Canada;
2020 - NCT03950336 Canada;
Mango polyphenolics
Texas A&M University
2014 - NCT02227602 United States;
Mannitol
Sanming First Affiliated Hospital of Fujian Medical University
2014 Phase 4 study ChiCTR-DDT-14004402 China;
Mare´s milk
University of Jena
2000 - NCT00940576 Germany;
Masitinib mesylate
AB Science
2015 Phase 2;Phase 3 EUCTR2012-004222-25-GR Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;India;Italy;Morocco;Poland;Romania;Russian Federation;Slovakia;Spain;Tunisia;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-004222-25-SK Belgium;Czech Republic;France;Greece;India;Morocco;Slovakia;Spain;Tunisia;
2013 Phase 3 EUCTR2012-004222-25-BE Belgium;Canada;Central African Republic;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Romania;Slovakia;South Africa;Spain;Switzerland;Tunisia;United Kingdom;United States;
Measurement of serum infliximab and anti-infliximab antibodies
Copenhagen University Hospital at Herlev
2009 Phase 4 NCT00851565 Denmark;
Mecasermin [rDNA Origin] 10mg/ml solution
Greater Glasgow & Clyde NHS
2011 Phase 2 EUCTR2010-022215-19-GB United Kingdom;
Medium chain triglycerides
Imperial College London
2008 Phase 4 NCT00672763 United Kingdom;
Medium dose TSO
Dr. Falk Pharma GmbH
2010 Phase 2 NCT01279577 Germany;
Melphalan
Paul Szabolcs
2012 Phase 1/Phase 2 NCT00692939 United States;
Mensa
European Group for Blood and Marrow Transplantation (EMBT)
2006 - EUCTR2005-003337-40-GB United Kingdom;
Mercaptopurine
Lower GI disease, Hyogo College of Medicine
2007 Phase 2,3 JPRN-UMIN000004427 Japan;
University of Edinburgh
2015 - EUCTR2014-002311-41-GB Belgium;France;Germany;Sweden;United Kingdom;
Mesalamine
Milton S. Hershey Medical Center
2013 Phase 4 NCT01696942 United States;
Mesalamine, 5-aminosalicylic acid
Ferring Pharmaceuticals A/S
2009 Phase 3 EUCTR2008-002100-26-FR Belgium;Denmark;France;Germany;Sweden;United Kingdom;
2009 - EUCTR2008-002100-26-GB Belgium;Denmark;France;Germany;Sweden;United Kingdom;
2009 - EUCTR2008-002100-26-BE Belgium;Denmark;France;Germany;Sweden;United Kingdom;
2008 - EUCTR2008-002100-26-SE Belgium;Denmark;France;Germany;Sweden;United Kingdom;
2008 - EUCTR2008-002100-26-DK Belgium;Denmark;France;Germany;Sweden;United Kingdom;
2008 - EUCTR2008-002100-26-DE Belgium;Denmark;France;Germany;Sweden;United Kingdom;
Mesalazine
AstraZeneca
- Phase 3 JPRN-JapicCTI-121765 -
AstraZeneca K.K.
- Phase 3 EUCTR2014-004132-20-Outside-EU/EEA Japan;
Dr. Falk Pharma GmbH
2007 - EUCTR2004-001213-34-GB Czech Republic;United Kingdom;
2004 Phase 3 NCT00300118 Germany;
2004 Phase 3 EUCTR2004-001213-34-SK Czech Republic;Slovakia;United Kingdom;
2004 - EUCTR2004-001213-34-CZ Czech Republic;United Kingdom;
2002 Phase 3 NCT00946946 Austria;Germany;
Ferring Laegemidler A/S
2005 - EUCTR2005-002472-15-SE Sweden;
University Medical Center Utrecht
2009 - EUCTR2009-011220-62-NL Netherlands;
Yanling Wei
2015 Phase 2 NCT02335281 China;
Zeria Pharmaceutical Co., Ltd.
- Phase 2 JPRN-JapicCTI-111460 -
Zeria Pharmaceutical Co.,LTD
2005 Phase 3 JPRN-C000000300 Japan;
Zeria Pharmaceutical Co.,LTD.
2005 Phase 2,3 JPRN-C000000301 Japan;
Mesalazine (Mesalamine)
Ferring Pharmaceuticals
2009 Phase 3 NCT00245505 Sweden;
Mesalazine EC
Disphar International B.V.
2005 Phase 3 EUCTR2004-004083-77-SK Czech Republic;Slovakia;
2004 - EUCTR2004-004083-77-CZ Czech Republic;
Mesalazine Sustained-Release Tablets
Xijing Hospital of Digestive Diseases
2016 Phase 3 NCT02769494 China;
Mesalazine tablets
AstraZeneca
2012 Phase 3 NCT01514240 Japan;
Mesalazine, Tripterygium glycosides
Zhu Weiming
2014 Phase 2/Phase 3 NCT02044952 China;
Mesenchymal Stem Cells
Amy Lightner
2020 Phase 1/Phase 2 NCT04519697 United States;
2020 Phase 1/Phase 2 NCT04519671 United States;
Mesenchymal Stem Cells (MSC)
University of Liege
2013 Phase 1/Phase 2 NCT01540292 Belgium;
Mesenchymal Stromal Cells
University of Liege
2018 Phase 1/Phase 2 NCT03901235 Belgium;
Mesenchymal cell and fibroblast injection
Royan Institute
2013 Phase 1 NCT01874015 Iran, Islamic Republic of;
Mesenchymal cell transplantation
Royan Institute
2013 Phase 1 NCT01874015 Iran, Islamic Republic of;
Mesenchymal stem cells
Amy Lightner
2021 Phase 1 NCT04791878 United States;
2020 Phase 1/Phase 2 NCT04519684 United States;
CHU-ULg
2012 - EUCTR2011-005966-39-BE Belgium;
Mesenchymal stem cells (MSCs)
The Cleveland Clinic
2021 Phase 1 NCT04073472 United States;
Mesenchymal stromal cells (MSC) for infusion
R.P.Herrmann
2010 Phase 2 NCT01090817 Australia;
Mesna
Cedars-Sinai Medical Center
2020 Phase 1/Phase 2 NCT04224558 United States;
European Group for Blood and Marrow Transplantation (EMBT)
2006 - EUCTR2005-003337-40-GB United Kingdom;
Northwestern University
2019 Phase 2 NCT04154735 United States;
Paul Szabolcs
2012 Phase 1/Phase 2 NCT00692939 United States;
Methacholine
Rambam Health Care Campus
2008 - NCT01297907 Israel;
Methotrexat
PIBD-Net
2017 Phase 3 EUCTR2016-000522-18-DE Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
Methotrexate
Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University
2011 - JPRN-UMIN000005251 Japan;
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
2015 Phase 4 NCT02177071 Australia;Belgium;France;
Indiana University
2015 - NCT02413047 United States;
PIBD net
2018 Phase 4 EUCTR2016-000522-18-GB Belgium;Canada;Czech Republic;France;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
PIBD-Net
2017 Phase 4 NCT02852694 France;
PIBDNet
2018 Phase 4 EUCTR2016-000522-18-BE Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
- Phase 4 EUCTR2016-000522-18-FR Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
Takeda
2017 Phase 4 NCT02764762 Canada;United States;
University of Edinburgh
2015 - EUCTR2014-002311-41-GB Belgium;France;Germany;Sweden;United Kingdom;
University of North Carolina, Chapel Hill
2016 Phase 3 NCT02772965 United States;
University of Western Ontario, Canada
2005 Phase 3 NCT00132899 Canada;
Methotrexate injection
Amsterdam UMC location AMC
2019 Phase 4 EUCTR2018-003594-95-NL Netherlands;
Methoxsalen
Therakos
2005 - EUCTR2004-002693-37-DE Germany;
2004 - EUCTR2004-002693-37-AT Austria;Germany;
Methoxsalen +ECP
Mallinckrodt
2004 Phase 2 NCT00221026 Austria;Belgium;Germany;United States;
Methyl prednisolone
European Group for Blood and Marrow Transplantation (EMBT)
2006 - EUCTR2005-003337-40-GB United Kingdom;
Methylprednisolone
Cedars-Sinai Medical Center
2020 Phase 1/Phase 2 NCT04224558 United States;
Icahn School of Medicine at Mount Sinai
2017 Phase 2 NCT03219359 United States;
Methylprednisolone or budesonide
Belgian IBD Research Group
2001 Phase 4 NCT00554710 Belgium;
Metoject
GETAID
2015 Phase 4 EUCTR2014-002311-41-SE France;Germany;Netherlands;Sweden;United Kingdom;
Metotrexat
GETAID
2015 Phase 4 EUCTR2014-002311-41-SE France;Germany;Netherlands;Sweden;United Kingdom;
Metronidazol
GETECCU
2011 - EUCTR2011-000885-36-ES Spain;
Metronidazole
Erasmus MC
2014 - EUCTR2012-005226-29-PL Belgium;Canada;Israel;Netherlands;Poland;Portugal;United States;
Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
2012 Phase 3 NCT01564823 Spain;
Hyogo college of medicine
2014 Phase 2 JPRN-UMIN000013369 Japan;
Ishikawa Dai
2017 - JPRN-jRCTs031180415 Japan;
Juntendo university school of medicineDepartment of gastroenterology
2017 - JPRN-UMIN000025846 Japan;
Mount Sinai Hospital, Canada
2006 Phase 2 NCT00257699 Canada;
S.L.A. Pharma AG
2007 Phase 1 NCT00774969 United Kingdom;
University of North Carolina, Chapel Hill
2021 Phase 2 NCT04186247 Canada;Israel;Netherlands;United States;
Wolfson Medical Center
2013 - EUCTR2012-005226-29-BE Belgium;Canada;Israel;Netherlands;Poland;Portugal;United States;
- - EUCTR2012-005226-29-NL Canada;Israel;Netherlands;United States;
Metronidazole Ointment
S.L.A. Pharma AG
2005 Phase 3 NCT00509639 United Kingdom;United States;
Metronidazole Oral
University of Louisville
2021 Phase 4 NCT04682522 United States;
Midazolam
GlaxoSmithKline
2011 Phase 1 NCT01489943 United States;
Janssen Research & Development, LLC
2018 Phase 1 NCT03358706 Austria;Belgium;Denmark;Germany;Sweden;United Kingdom;United States;
Takeda
2016 Phase 4 NCT02760615 United States;
Mirikizumab
Eli Lilly and Company
2021 Phase 3 NCT04844606 Israel;Japan;Korea, Republic of;United States;
2020 Phase 3 NCT04232553 Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 NCT03926130 Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 2 NCT02891226 Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Hungary;Japan;Netherlands;Poland;Romania;Russian Federation;Switzerland;Ukraine;United Kingdom;United States;
Yoshimoto Yusuke
2021 Phase 3 JPRN-jRCT2031210210 Japan;United States;
Mobilization of stem cells to prepare for Leukapheresis
Nationwide Children's Hospital
2013 Phase 2 NCT02676622 -
Moderate Oligosaccharide Group
University of British Columbia
2015 - NCT02193750 Australia;Canada;
Modulen
Hillel Yaffe Medical Center
2020 - NCT04233463 Israel;
Mongersen
CELGENE CORPORATION
2017 Phase 3 EUCTR2015-001924-40-IT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-IT Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2015-001693-18-IT Italy;
Celgene Corporation
2017 Phase 3 EUCTR2015-001963-37-FI Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001925-18-FI Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-SK Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-PT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-NL Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-LV Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-HU Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-HR Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-GR Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-GB Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-FR Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-FI Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-ES Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-DK Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-DE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-CZ Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-BE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-AT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-SK Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-SE Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-PT Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-LV Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-HU Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-HR Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-GR Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-GB Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Oman;Pakistan;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-ES Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-DK Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-DE Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-CZ Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-BG Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-BE Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-AT Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-SK Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-SE Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-PT Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-LV Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-HU Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-HR Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-GR Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-GB Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-ES Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-DK Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-DE Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-CZ Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-BG Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-BE Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-AT Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2015 Phase 3 EUCTR2015-001963-37-EE Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2015 Phase 3 EUCTR2015-001925-18-EE Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2015-001925-18-NO Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2015-001924-40-PL Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Monoclonal antibodies
MILLENNIUM PHARMACEUTICALS, INC.
2011 - EUCTR2009-016488-12-IT Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Netherlands;
Monoclonal antibody cA2
FDA Office of Orphan Products Development
1996 Phase 3 NCT00004941 -
Mosapride
Department of Gastroenterology, Graduate School of Medicine, Osaka City University
2012 - JPRN-UMIN000008199 Japan;
Movprep
Lument AB
2019 Phase 2 EUCTR2019-002093-32-SE Sweden;
Mycodigest supplement
Tel-Aviv Sourasky Medical Center
2018 - NCT04329481 Israel;
N-3 Polyunsaturated Fatty Acids
Sixth Affiliated Hospital, Sun Yat-sen University
2021 - NCT04761952 -
N-{4-Chloro-2-[(1-oxido-4-pyridinyl)carbonyl]phenyl}-4-(1,1-dimethylethyl)benzenesulfonamide, sodium
GlaxoSmithKline Research & Development Ltd
2011 - EUCTR2010-022382-10-NL Austria;Belgium;Czech Republic;Denmark;Germany;Hungary;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
- Phase 3 EUCTR2010-022382-10-NO Austria;Belgium;Czech Republic;Denmark;Germany;Hungary;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
N-{4-Chloro-2-[(1-oxido-4-pyridinyl)carbonyl]phenyl}-4-(1,1-dimethylethyl)benzenesulfonamidesodium
GlaxoSmithKline Research & Development Ltd
2011 Phase 3 EUCTR2010-022383-12-NO Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;Germany;Greece;Hungary;Italy;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2011 Phase 3 EUCTR2010-022383-12-GB Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;Germany;Greece;Hungary;Italy;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;
NI-0401 (anti-CD3 mAB)
NovImmune SA
2006 Phase 1/Phase 2 NCT00630643 -
NNC 0142-0000-0002
Janssen Research & Development, LLC
2011 Phase 2 NCT01203631 Belgium;Canada;France;Hungary;Israel;Poland;Russian Federation;United States;
NNC0114-0006
Novo Nordisk A/S
2013 Phase 2 NCT01751152 Bulgaria;Czech Republic;Poland;Russian Federation;Serbia;Slovakia;Spain;United States;
NNC0142-0000-0002
Novo Nordisk A/S
2011 Phase 2 EUCTR2010-020836-21-BE Belgium;Canada;European Union;Hungary;Israel;Poland;Russian Federation;United States;
2011 - EUCTR2010-020836-21-PL Belgium;Canada;European Union;Hungary;Israel;Poland;Russian Federation;United States;
2010 - EUCTR2010-020836-21-HU Belgium;Hungary;Poland;
NNC142-0002
Novo Nordisk A/S
2011 Phase 2 EUCTR2010-020836-21-BE Belgium;Canada;European Union;Hungary;Israel;Poland;Russian Federation;United States;
2011 - EUCTR2010-020836-21-PL Belgium;Canada;European Union;Hungary;Israel;Poland;Russian Federation;United States;
2010 - EUCTR2010-020836-21-HU Belgium;Hungary;Poland;
NO
Rambam Health Care Campus
2008 - NCT01297907 Israel;
University of Texas at Austin
2021 - NCT04898530 United States;
2021 - NCT04617184 United States;
NORMIX*AD 12CPR RIV
ALFA WASSERMANN
2007 - EUCTR2007-001014-17-IT France;Germany;Hungary;Italy;
NSP001
Provexis Plc
2009 Phase 2 EUCTR2006-005526-23-GB United Kingdom;
Naltrexone
Milton S. Hershey Medical Center
2008 Phase 2 NCT00715117 United States;
Naltrexone hydrochloride
ErasmusMC
2020 Phase 2 EUCTR2019-000852-32-NL Netherlands;
Naltrexone-HCl
Milton S. Hershey Medical Center
2006 Phase 2 NCT00663117 United States;
Nap
TiGenix, S.A.U.
2021 Phase 3 EUCTR2017-000725-12-SE Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2017-000725-12-GB Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2017-000725-12-DE Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-PL Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-HU Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-FR Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-CZ Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-BE Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
Natalizumab
Biogen
2008 Phase 4 NCT00801125 -
2008 - NCT00707512 Puerto Rico;United States;
2004 Phase 3 NCT00078611 Canada;United States;
2002 Phase 4 NCT00280956 United States;
2002 Phase 3 NCT00032786 -
2002 Phase 2 NCT00055536 United States;
2002 Phase 2 NCT00055367 United Kingdom;United States;
2001 Phase 3 NCT00032799 United States;
Elan Pharma Ltd.
2005 - EUCTR2004-003839-31-DK Denmark;
Neomycin
Children's Hospital of Philadelphia
2018 Phase 2 NCT03476317 United States;
University of Pennsylvania
2016 Phase 2 NCT02765256 United States;
Nessuno
GILEAD SCIENCES INCORPORATED
2015 Phase 2 EUCTR2015-001249-10-IT Australia;Canada;Czech Republic;Germany;Hungary;Iceland;Italy;South Africa;Spain;United Kingdom;United States;
Nitazoxanide
Romark Laboratories L.C.
2005 Phase 2 NCT00130390 United States;
Nivolumab
Alliance Foundation Trials, LLC.
2019 Phase 1 NCT03656627 United States;
National Cancer Institute (NCI)
2019 Phase 1 NCT03816345 Canada;United States;
None
Abbott
2009 - EUCTR2008-004919-36-SE Austria;Denmark;Sweden;
2009 - EUCTR2008-004919-36-DK Austria;Denmark;Sweden;
2009 - EUCTR2008-004919-36-BE Austria;Belgium;Denmark;Sweden;
Novartis Pharma Services AG
2009 - EUCTR2009-011621-14-AT Austria;Germany;
None at this time
Millennium Pharmaceuticals, Inc (a wholly owned subsidiary
2020 Phase 2 EUCTR2019-000886-19-FR France;Germany;United Kingdom;United States;
Normal Saline
Seattle Children's Hospital
2015 Phase 1/Phase 2 NCT02272868 United States;
Nutraceutical Combination
Columbia University
2012 Phase 2 NCT01647412 United States;
Nutrition treat
Jinling Hospital, China
2011 - NCT01540942 China;
Nutritional dietary intervention
Hospital Galdakao-Usansolo
2020 - NCT04188990 Spain;
NutropinAq 10mg/2ml solution for injection
Greater Glasgow & Clyde NHS
2011 Phase 2 EUCTR2010-022215-19-GB United Kingdom;
NutropinAq®
Greater Glasgow & Clyde NHS
2011 Phase 2 EUCTR2010-022215-19-GB United Kingdom;
OL adalimumab
Abbott
2002 Phase 3 NCT00055497 United States;
OPC-6535
Otsuka Pharmaceutical Co., Ltd.
2009 Phase 2/Phase 3 NCT00989573 Japan;Korea, Republic of;
OPC-6535(Tetomilast)
Otsuka Pharmaceutical Co., Ltd.
2006 Phase 2 NCT00317369 Japan;
OPS-2071
Otsuka Pharmaceutical Development & Commercialization, Inc.
2020 Phase 2 NCT03850509 Poland;United States;
2020 Phase 2 EUCTR2019-000176-41-PL Belgium;Canada;Germany;Italy;Poland;United States;
2020 Phase 2 EUCTR2019-000176-41-HU Canada;Germany;Hungary;Italy;Poland;Russian Federation;Ukraine;United States;
- Phase 2 EUCTR2019-000176-41-DE Canada;Germany;Hungary;Italy;Poland;Russian Federation;Ukraine;United States;
Otsuka Pharmaceutical Development and Commercialization, Inc
2020 Phase 2 EUCTR2019-000176-41-IT Belgium;Canada;Germany;Hungary;Italy;Poland;United States;
Oligofructose enriched inulin
Katholieke Universiteit Leuven
2008 - NCT01487759 Belgium;
Olokizumab
UCB BIOSCIENCES GmbH
2012 Phase 2 EUCTR2011-002517-11-BG Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Netherlands;Poland;Romania;Serbia;
2012 - EUCTR2011-002517-11-HU Czech Republic;Germany;Hungary;Serbia;
2012 - EUCTR2011-002517-11-DE Czech Republic;Germany;Hungary;Serbia;
2012 - EUCTR2011-002517-11-CZ Czech Republic;Germany;Hungary;Serbia;
Olokizumab (OKZ)
UCB BIOSCIENCES GmbH
2012 Phase 2 NCT01635621 Bulgaria;Czech Republic;Germany;Hungary;Poland;
Omegaven
Radboud University
2014 Phase 4 NCT02349594 Netherlands;
Omeprazole
GlaxoSmithKline
2011 Phase 1 NCT01489943 United States;
Janssen Research & Development, LLC
2018 Phase 1 NCT03358706 Austria;Belgium;Denmark;Germany;Sweden;United Kingdom;United States;
Takeda
2016 Phase 4 NCT02760615 United States;
Only 1 arm: treatment with MSC-AFP
William A. Faubion, M.D.
2017 Phase 1 NCT03014219 United States;
Ontamalimab
SHIRE HUMAN GENETIC THERAPIES, INC
2018 Phase 3 EUCTR2017-000574-11-IT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
Shire
2019 Phase 3 NCT03627091 Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 NCT03566823 Argentina;Belgium;Bosnia and Herzegovina;Bulgaria;Colombia;Estonia;Greece;Hungary;Ireland;Japan;Korea, Republic of;Lebanon;Mexico;New Zealand;Portugal;Slovakia;Spain;Turkey;Ukraine;United States;
2018 Phase 3 NCT03559517 Australia;Austria;Croatia;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;South Africa;United Kingdom;United States;
2018 Phase 3 NCT03283085 Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Croatia;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
Shire Human Genetic Therapies, Inc.
2019 Phase 3 EUCTR2017-000617-23-HR Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-000617-23-GB Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-000575-88-HR Australia;Austria;Brazil;Croatia;Czech Republic;Czechia;Germany;Israel;Italy;Japan;Lithuania;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;South Africa;United Kingdom;United States;
2019 Phase 3 EUCTR2017-000575-88-GB Australia;Austria;Brazil;Croatia;Czech Republic;Germany;Israel;Italy;Japan;Lithuania;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;South Africa;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000617-23-SK Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000617-23-PT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000617-23-NL Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000617-23-LT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000617-23-HU Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000617-23-EE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000617-23-DE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000617-23-BG Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000617-23-BE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000617-23-AT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000576-29-SK Argentina;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Estonia;Greece;Hungary;Ireland;Japan;Korea, Republic of;Lebanon;Mexico;Portugal;Slovakia;Spain;Switzerland;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-000576-29-PT Argentina;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Estonia;Greece;Hungary;Ireland;Japan;Korea, Republic of;Lebanon;Mexico;Portugal;Slovakia;Spain;Switzerland;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-000576-29-EE Argentina;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Estonia;Greece;Hungary;Ireland;Japan;Korea, Republic of;Mexico;Portugal;Slovakia;Spain;Switzerland;Ukraine;United States;
2018 Phase 3 EUCTR2017-000576-29-BG Argentina;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Estonia;Greece;Hungary;Ireland;Japan;Korea, Republic of;Lebanon;Mexico;Portugal;Slovakia;Spain;Switzerland;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-000575-88-NL Australia;Austria;Brazil;Croatia;Czech Republic;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;South Africa;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000575-88-LT Australia;Austria;Brazil;Croatia;Czech Republic;Czechia;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;South Africa;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000575-88-DE Australia;Austria;Brazil;Croatia;Czech Republic;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;South Africa;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000575-88-AT Australia;Austria;Brazil;Croatia;Czech Republic;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;South Africa;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000574-11-PT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000574-11-NL Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000574-11-LT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000574-11-IE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000574-11-HU Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000574-11-HR Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000574-11-GB Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000574-11-EE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000574-11-DE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000574-11-BG Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000574-11-BE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000574-11-SK Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000574-11-AT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2017-000617-23-PL Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2017-000617-23-IE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2017-000576-29-IE Argentina;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Estonia;Greece;Hungary;Ireland;Japan;Korea, Republic of;Lebanon;Mexico;Portugal;Slovakia;Spain;Switzerland;Turkey;Ukraine;United States;
- Phase 3 EUCTR2017-000575-88-PL Australia;Austria;Brazil;Croatia;Czech Republic;Czechia;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;South Africa;United Kingdom;United States;
- Phase 3 EUCTR2017-000574-11-PL Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2017-000574-11-CZ Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
Optison
University of Michigan
2015 Phase 1/Phase 2 NCT02061163 United States;
Oral prednisolone
Assistance Publique - Hôpitaux de Paris
2022 Phase 2/Phase 3 NCT05284136 France;Netherlands;
Orencia
Bristol-Myers Squibb International Corporation
2008 - EUCTR2006-003371-13-PL Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2008 - EUCTR2006-003371-13-CZ Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-DK Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-DE Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-BE Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
Originator (legacy) drug
McGill University Health Centre/Research Institute of the McGill University Health Centre
2018 - NCT03729674 Canada;
Ossium vBM-MSC
Amy Lightner
2022 Phase 1/Phase 2 NCT05075811 United States;
Other Biologic Therapies
Janssen Scientific Affairs, LLC
2021 - NCT04372108 United States;
Other Biological Agent
Takeda
2015 - NCT02678052 Canada;United States;
Ova-Treg
TxCell
2014 Phase 2 EUCTR2014-001295-65-IT Austria;Belgium;Germany;Italy;
2014 Phase 2 EUCTR2014-001295-65-DE Austria;Belgium;Germany;Italy;
2014 Phase 2 EUCTR2014-001295-65-BE Austria;Belgium;Germany;Italy;
2014 Phase 2 EUCTR2014-001295-65-AT Austria;Belgium;Germany;Italy;
Ovasave
TxCell
2014 Phase 2 NCT02327221 Austria;Belgium;France;Germany;Italy;United Kingdom;
2014 Phase 2 EUCTR2014-001295-65-IT Austria;Belgium;Germany;Italy;
2014 Phase 2 EUCTR2014-001295-65-DE Austria;Belgium;Germany;Italy;
2014 Phase 2 EUCTR2014-001295-65-BE Austria;Belgium;Germany;Italy;
2014 Phase 2 EUCTR2014-001295-65-AT Austria;Belgium;Germany;Italy;
Oxadrop
Mayo Clinic
2006 Phase 1/Phase 2 NCT00587041 United States;
Oxygen
Assaf-Harofeh Medical Center
2013 - NCT01828190 Israel;
Daping Hospital, Army Medical University (Third Military Medical University)
2018 - ChiCTR1800019958 China;
Ozanimod
CELGENE INTERNATIONAL II SàRL
2018 Phase 3 EUCTR2017-004292-31-IT Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2015-002025-19-IT Canada;Hungary;Italy;Poland;Ukraine;United States;
Celgene
2018 Phase 3 NCT03467958 Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 NCT03464097 Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 NCT03440385 Australia;Austria;Brazil;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Korea, Republic of;Lithuania;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
2018 Phase 3 NCT03440372 Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;Moldova, Republic of;Norway;Poland;Romania;Russian Federation;Saudi Arabia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Celgene International II Sarl (CISII) awholly owned subsidiary of Celgene Corporation
2015 Phase 2 EUCTR2015-002025-19-HU Canada;Hungary;Italy;Poland;Ukraine;United States;
Celgene International II Sàrl (CIS II), a wholly owned subsidiary of Celgene Corporation
2016 Phase 2 EUCTR2015-002025-19-PL Canada;Hungary;Poland;Ukraine;United States;
Ozanimod hydrochloride
CELGENE INTERNATIONAL II SàRL
2018 Phase 3 EUCTR2017-004294-14-IT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Celgene International II Sàrl
2016 Phase 1 EUCTR2016-003073-18-GB United Kingdom;
P28GST
University Hospital, Lille
2014 Phase 2 NCT02281916 France;
PDA001
Celularity Incorporated
2013 Phase 1 NCT01769755 United States;
PENTASA Sachet
Ferring Pharmaceuticals A/S
2009 Phase 3 EUCTR2008-002100-26-FR Belgium;Denmark;France;Germany;Sweden;United Kingdom;
2009 - EUCTR2008-002100-26-GB Belgium;Denmark;France;Germany;Sweden;United Kingdom;
2009 - EUCTR2008-002100-26-BE Belgium;Denmark;France;Germany;Sweden;United Kingdom;
2008 - EUCTR2008-002100-26-SE Belgium;Denmark;France;Germany;Sweden;United Kingdom;
2008 - EUCTR2008-002100-26-DK Belgium;Denmark;France;Germany;Sweden;United Kingdom;
2008 - EUCTR2008-002100-26-DE Belgium;Denmark;France;Germany;Sweden;United Kingdom;
PF-00547659
PFIZER SLU
2011 - EUCTR2010-023437-30-ES Austria;Belgium;Bulgaria;Germany;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;
PFIZER, S.L.U.
2011 - EUCTR2010-024638-48-ES Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
Pfizer Inc.
2013 - EUCTR2012-002030-37-BE Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Norway;Poland;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;United Kingdom;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017
2012 Phase 2 EUCTR2010-024638-48-NO Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;United States;
2012 Phase 2 EUCTR2010-024638-48-DE Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
2012 Phase 2 EUCTR2010-024638-48-BG Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
2012 Phase 2 EUCTR2010-024638-48-BE Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
2012 Phase 2 EUCTR2010-023437-30-BG Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;South Africa;Spain;Sweden;United States;
2012 - EUCTR2010-023437-30-PL Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;South Africa;Spain;Sweden;United States;
2011 Phase 2 EUCTR2010-024638-48-SK Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
2011 Phase 2 EUCTR2010-024638-48-SE Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
2011 Phase 2 EUCTR2010-024638-48-NL Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Romania;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
2011 Phase 2 EUCTR2010-024638-48-AT Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
2011 Phase 2 EUCTR2010-023437-30-SE Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
2011 Phase 2 EUCTR2010-023437-30-PT Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;South Africa;Spain;Sweden;United States;
2011 Phase 2 EUCTR2010-023437-30-NO Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
2011 - EUCTR2010-024638-48-PT Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
2011 - EUCTR2010-023437-30-SK Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;South Africa;Spain;Sweden;United States;
2011 - EUCTR2010-023437-30-NL Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;South Africa;Spain;Sweden;United States;
2011 - EUCTR2010-023437-30-DE Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;South Africa;Spain;Sweden;United States;
2011 - EUCTR2010-023437-30-BE Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;South Africa;Spain;Sweden;United States;
2011 - EUCTR2010-023437-30-AT Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;South Africa;Spain;Sweden;United States;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017, United States
2012 Phase 2 EUCTR2010-024638-48-PL Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;United States;
Shire
2011 Phase 2 NCT01298492 Austria;Belgium;Bulgaria;Canada;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
PF-00547659 SC injection
Shire
2011 Phase 2 NCT01276509 Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
PF-04236921
Pfizer
2011 Phase 2 NCT01345318 Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;New Zealand;Switzerland;United Kingdom;United States;
PF-04236921 SC injection
Pfizer
2011 Phase 2 NCT01287897 Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;New Zealand;Romania;Sweden;Switzerland;United Kingdom;United States;
PF-06651600
Pfizer
2018 Phase 2 NCT03395184 Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
PF-06651600-15
PFIZER INC
2018 Phase 2 EUCTR2017-003359-43-IT Austria;Belgium;Croatia;Czech Republic;Germany;Hungary;Italy;Lithuania;Poland;Slovakia;Spain;United States;
Pfizer Inc.
2018 Phase 2 EUCTR2017-003359-43-SK Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-CZ Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017
2018 Phase 2 EUCTR2017-003359-43-PL Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-LT Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-HU Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-HR Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-ES Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Georgia;Germany;Hungary;Israel;Italy;Korea, Republic of;Lebanon;Lithuania;New Zealand;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-DE Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-BE Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-AT Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
PF-06700841
Pfizer
2018 Phase 2 NCT03395184 Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
PF-06700841-15
PFIZER INC
2018 Phase 2 EUCTR2017-003359-43-IT Austria;Belgium;Croatia;Czech Republic;Germany;Hungary;Italy;Lithuania;Poland;Slovakia;Spain;United States;
Pfizer Inc.
2018 Phase 2 EUCTR2017-003359-43-SK Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-CZ Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017
2018 Phase 2 EUCTR2017-003359-43-PL Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-LT Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-HU Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-HR Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-ES Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Georgia;Germany;Hungary;Israel;Italy;Korea, Republic of;Lebanon;Lithuania;New Zealand;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-DE Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-BE Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-AT Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
PL 17901/0122
Royal Liverpool & Broadgreen University Hospitals Trust
2009 Phase 2 EUCTR2008-001137-99-GB United Kingdom;
PL 20532/0012
Royal Liverpool & Broadgreen University Hospitals Trust
2009 Phase 2 EUCTR2008-001137-99-GB United Kingdom;
PLAQUENIL
Royal Liverpool & Broadgreen University Hospitals Trust
2009 Phase 2 EUCTR2008-001137-99-GB United Kingdom;
PMA-zeolite
Ciim Plus, d.o.o.
2018 - NCT04370535 Slovenia;
PRA023
Prometheus Biosciences, Inc.
2021 Phase 2 EUCTR2021-000092-37-PL Australia;Belarus;Belgium;Canada;Czech Republic;Czechia;France;Georgia;Israel;Poland;Russian Federation;Ukraine;United States;
2021 Phase 2 EUCTR2021-000092-37-CZ Australia;Belgium;Canada;Czech Republic;Czechia;France;Georgia;Poland;Russian Federation;Ukraine;United States;
PRA023 IV
Prometheus Biosciences, Inc.
2021 Phase 2 NCT05013905 United States;
PROCHYMAL (remestemcel-L)
Mesoblast, Inc.
2010 - NCT01510431 United States;
PROCHYMAL adult human mesenchymal stem cells
Mesoblast, Inc.
2007 Phase 3 NCT00543374 Canada;United States;
PRV-6527
Provention Bio, Inc.
2018 Phase 2 NCT03854305 Austria;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
PRV-6527 (JNJ-40346527)
Provention Bio, Inc.
2018 Phase 2 EUCTR2017-003017-25-PL Austria;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
2018 Phase 2 EUCTR2017-003017-25-ES Austria;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
2018 Phase 2 EUCTR2017-003017-25-DE Austria;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
2018 Phase 2 EUCTR2017-003017-25-AT Austria;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
PRV-6527(JNJ-40346527)
Provention Bio, Inc.
2018 Phase 2 EUCTR2017-003017-25-HU Austria;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
PTG-200
Janssen-Cilag International NV
2020 Phase 2 EUCTR2019-003335-37-DE Argentina;Germany;Italy;Poland;Russian Federation;United States;
PURINETHOL - 50 MG COMPRESSE25 COMPRESSE
UMBERTO I - POLICLINICO DI ROMA
2017 Phase 4 EUCTR2016-000522-18-IT Belgium;Czech Republic;Czechia;France;Germany;Hungary;Italy;Netherlands;Poland;United Kingdom;
Partial Enteral Nutrition
NHS Greater Glasgow and Clyde
2021 - NCT04859088 United Kingdom;
Pectin
Jinling Hospital, China
2014 Phase 2 NCT02164877 China;
Pegylated interferon alfa
Vanderbilt-Ingram Cancer Center
2006 - NCT00897312 -
Pending
Reistone Biopharma Company Limited
2019 Phase 2 EUCTR2018-003303-19-PL China;Poland;Ukraine;United States;
Pentasa
AstraZeneca K.K.
- Phase 3 EUCTR2014-004132-20-Outside-EU/EEA Japan;
Ferring Pharmaceuticals
2009 Phase 3 NCT00862121 Belgium;Denmark;France;Germany;Spain;Sweden;United Kingdom;United States;
Pentasa Sachet 1 g prolonged release granules
Ferring Laegemidler A/S
2005 - EUCTR2005-002472-15-SE Sweden;
Pentoxifylline
University of Miami
2017 Early Phase 1 NCT02953275 United States;
Peptidic+Probiotic
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
2020 - NCT04305535 Spain;
Peripheral Blood Stem Cell Infusion
Cedars-Sinai Medical Center
2020 Phase 1/Phase 2 NCT04224558 United States;
Pharmacokinetics of certolizumab pegol
UCB Biopharma S.P.R.L.
2020 Phase 1 NCT04163016 Canada;France;Germany;Netherlands;Spain;Switzerland;United States;
Phase1 : CDED/Modulen™IBD® + Maintenance therapy
Assistance Publique - Hôpitaux de Paris
2022 Phase 3 NCT04777656 France;
Phase2 and 3 :
Assistance Publique - Hôpitaux de Paris
2022 Phase 3 NCT04777656 France;
Phylloquinone (vitamin K1)
University College Cork
2008 Phase 4 NCT01235325 Ireland;
Physician standard-of-care
Merck Sharp & Dohme Corp.
2011 - NCT01218360 Greece;
Pioglitazone
GlaxoSmithKline
2011 Phase 1 NCT01489943 United States;
Placebo
Abbott Japan Co., Ltd.
2007 Phase 2-3 JPRN-JapicCTI-070367 -
2007 Phase 2-3 JPRN-JapicCTI-070366 -
Janssen Pharmaceutical K.K.
2018 Phase 2-3 JPRN-JapicCTI-183950 Japan, North America;
Takeda Pharmaceutical Company Limited
2016 Phase 3 JPRN-JapicCTI-163386 Japan, Refer to Othersection;
2014 Phase 3 JPRN-JapicCTI-142402 Japan;
Plantain NSP
Provexis Plc
2009 Phase 2 EUCTR2006-005526-23-GB United Kingdom;
Plasma rico en plaquetas y coagulo de fibrina procesados mediante la tecnología PRGF-System (BTI)
Fundación FISEVI
2012 - EUCTR2011-006127-38-ES Spain;
2012 - EUCTR2011-004820-37-ES Spain;
Pnemovax
Statens Serum Institut
2013 - EUCTR2012-002867-86-DK Denmark;
Pneumovax
Statens Serum Institut
2013 Phase 4 NCT01947010 Denmark;
2013 - EUCTR2012-002867-86-DK Denmark;
Polaprezinc
Kawasaki Medical School
2011 - JPRN-UMIN000005970 Japan;
Polyethylene Glycol 3350
Children's Hospital of Philadelphia
2018 Phase 2 NCT03476317 United States;
University of Pennsylvania
2016 Phase 2 NCT02765256 United States;
Pomegranate
IRCCS Azienda Ospedaliero-Universitaria di Bologna
2017 - NCT03000101 Italy;
Posaconazole Delayed Release Oral Tablet
Cedars-Sinai Medical Center
2022 Phase 4 NCT04966585 United States;
Positron Emission Tomography
Jonsson Comprehensive Cancer Center
2016 Early Phase 1 NCT02925351 United States;
Postoperative 3-month exclusive enteral nutrition
Zhu Weiming
2018 - NCT04160325 China;
Pravastatin
University of Virginia
2004 - NCT00599625 United States;
Prebiotics
University of Alberta
2020 - NCT03950336 Canada;
Precedentemente denominato MEDI2070 e AMG 139
ALLERGAN LIMITED
2020 Phase 2;Phase 3 EUCTR2018-004346-42-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Prednisolon
Erasmus Medical Center
2013 Phase 4 NCT01880307 Italy;Netherlands;
Hôpital Necker-Enfants Malades
2005 Phase 4 NCT00265772 France;
Prednisolon Jenapharm
4SC AG
2010 - EUCTR2008-005903-25-BG Bulgaria;Germany;
2009 - EUCTR2008-005903-25-DE Bulgaria;Germany;
Prednisolone
Central Manchester University Hospitals Foundation Trust
2011 Phase 2 EUCTR2010-022017-26-GB United Kingdom;
Erasmus Medical Center
2015 Phase 4 NCT02517684 Belgium;Denmark;Finland;Italy;Netherlands;Poland;
Merck Sharp & Dohme Corp.
2003 Phase 3 NCT00796250 -
University Hospital Birmingham
2008 Phase 4 NCT00609752 United Kingdom;
Prednisone
AbbVie (prior sponsor, Abbott)
2011 Phase 3 NCT01235689 Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;
Abbott GmBH & Co. KG
2010 Phase 3 EUCTR2010-020137-10-IT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
Icahn School of Medicine at Mount Sinai
2016 Phase 4 NCT02324699 United States;
McMaster University
2018 Phase 4 NCT03833596 Canada;
Shanghai Research Institute of Acupuncture and Meridian
2016 Phase 1 study ChiCTR-IIR-16007751 China;
Preparative regimen 4-6 weeks after Leukapheresis
Nationwide Children's Hospital
2013 Phase 2 NCT02676622 -
Prevenar 13
Statens Serum Institut
2013 Phase 4 NCT01947010 Denmark;
2013 - EUCTR2012-002867-86-DK Denmark;
Previously referred to as MEDI2070 and AMG 139, AGN-151-598
ALLERGAN LIMITED
2020 Phase 2;Phase 3 EUCTR2018-004346-42-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Allergan Limited
2021 Phase 3 EUCTR2019-001866-14-ES Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Allergan Ltd.
2020 Phase 2;Phase 3 EUCTR2018-004346-42-RO Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2;Phase 3 EUCTR2018-004346-42-BG Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2;Phase 3 EUCTR2018-004346-42-BE Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-004346-42-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-004346-42-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
AstraZeneca AB
2019 Phase 2;Phase 3 EUCTR2018-004346-42-GB Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2019-001866-14-GB Australia;Austria;Belgium;Bulgaria;Canada;China;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2018-004346-42-PL Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Astrazeneca AB
2020 Phase 2;Phase 3 EUCTR2018-004346-42-AT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Probiotic
The Baruch Padeh Medical Center, Poriya
2013 Phase 4 NCT01765998 Israel;
Probiotic - VSL#3
University of Alberta
2003 Phase 3 NCT00175292 Canada;
Probiotic Mixture
Massachusetts General Hospital
2017 - NCT03266484 United States;
Probiotics
The Baruch Padeh Medical Center, Poriya
2012 Phase 4 NCT01078935 -
Prochymal®
Mesoblast, Inc.
2007 Phase 3 NCT00482092 Australia;Canada;New Zealand;United States;
Prochymal™ adult human mesenchymal stem cells
Mesoblast, Inc.
2006 Phase 2 NCT00294112 United States;
Promethazine
University of Pennsylvania
2016 Phase 2 NCT02765256 United States;
Prucalopride
University of British Columbia
2016 Phase 4 NCT02806206 Canada;
Puri Nethol
Amsterdam UMC location AMC
2021 Phase 3;Phase 4 EUCTR2021-000469-33-NL Netherlands;
Puri-Nethol
GETAID
2015 Phase 4 EUCTR2014-002311-41-SE France;Germany;Netherlands;Sweden;United Kingdom;
Puri-nethol
Region Örebro län
2021 Phase 4 EUCTR2019-002942-19-DK Denmark;
QAX567
Gerhard Rogler
2011 Phase 2 NCT01316601 Switzerland;
QAX576
Novartis Pharma AG
2011 - EUCTR2010-019973-13-DE Germany;Switzerland;
Novartis Pharmaceuticals
2011 Phase 2 NCT01355614 Germany;Switzerland;
QBECO
Qu Biologics Inc.
2013 Phase 1/Phase 2 NCT01809275 Canada;
QBECO-SSI
Qu Biologics Inc.
2018 Phase 2 NCT03472690 Canada;
RAD001
Novartis Pharma Services AG
2005 Phase 2 EUCTR2005-001148-22-SK Slovakia;
RCTB-401
SBL Vaccin AB
2005 - EUCTR2005-002048-25-SE Sweden;
REMSIMA - 100 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLANCONCINO (VETRO) - 1 FLACONCINO
UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
2016 Phase 4 EUCTR2016-002061-54-IT Italy;
REMSINA
Celltrion, Inc
2019 Phase 3 EUCTR2019-001087-30-CZ Austria;Belarus;Bulgaria;Chile;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
RHB-104
RedHill Biopharma Limited
2017 Phase 3 NCT03009396 Canada;Czechia;Israel;New Zealand;Poland;Serbia;United States;
2013 Phase 3 NCT01951326 Australia;Bulgaria;Canada;Czech Republic;Czechia;Israel;New Zealand;Poland;Serbia;Slovakia;United States;
RedHill Biopharma Ltd.
2019 Phase 3 EUCTR2016-005199-90-SK Australia;Canada;Czech Republic;Israel;New Zealand;Poland;Serbia;Slovakia;United States;
2017 Phase 3 EUCTR2015-001179-36-SK Australia;Bulgaria;Canada;Czech Republic;Israel;New Zealand;Poland;Romania;Serbia;Slovakia;United States;
2017 Phase 3 EUCTR2015-001179-36-CZ Australia;Bulgaria;Canada;Czech Republic;Israel;New Zealand;Poland;Romania;Serbia;Slovakia;United States;
2017 Phase 3 EUCTR2015-001179-36-BG Australia;Bulgaria;Canada;Czech Republic;Israel;New Zealand;Poland;Romania;Serbia;Slovakia;United States;
2015 Phase 3 EUCTR2015-001179-36-PL Australia;Bulgaria;Canada;Czech Republic;Israel;New Zealand;Poland;Romania;Serbia;Slovakia;United States;
2015 Phase 3 EUCTR2014-004108-31-HU Belgium;Czech Republic;Germany;Hungary;Ireland;Netherlands;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;
2015 Phase 3 EUCTR2014-004108-31-CZ Czech Republic;Hungary;Ireland;Russian Federation;Ukraine;United Kingdom;
RPC0163
CELGENE INTERNATIONAL II SàRL
2016 Phase 2 EUCTR2015-002025-19-IT Canada;Hungary;Italy;Poland;Ukraine;United States;
RPC1063
CELGENE INTERNATIONAL II SàRL
2018 Phase 3 EUCTR2017-004292-31-IT Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2015-002025-19-IT Canada;Hungary;Italy;Poland;Ukraine;United States;
Celgene
2015 Phase 2 NCT02531113 Canada;Hungary;Italy;Poland;Ukraine;United States;
Celgene International II Sàrl (CIS II), a wholly owned subsidiary of Celgene Corporation
2016 Phase 2 EUCTR2015-002025-19-PL Canada;Hungary;Poland;Ukraine;United States;
RPC1063 (equivalent to ozanimod HCl)
Celgene International II Sàrl
2019 Phase 3 EUCTR2017-004295-55-PT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-004295-55-FR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-004294-14-FR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-004293-33-FR Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2017-004292-31-FR Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-SK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-SI Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-SE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-PL Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-NL Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-LV Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-LT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-IE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-HU Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-HR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-GR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-GB Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-FI Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-ES Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-DK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-DE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-BG Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-BE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-AT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-SK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-SI Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-SE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-PT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-PL Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-NL Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-LV Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-LT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-IE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-HU Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-HR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-GR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-GB Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-FI Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-ES Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-DK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-DE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-CZ Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-BG Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-BE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-AT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004293-33-SK Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-004293-33-SI Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-004293-33-SE Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-004293-33-PT Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-004293-33-PL Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-004293-33-NL Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-004293-33-LT Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-004293-33-HU Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-004293-33-GR Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-004293-33-FI Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-004293-33-ES Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-004293-33-BG Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-004293-33-AT Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-004292-31-PL Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004292-31-LV Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004292-31-IE Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004292-31-HR Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004292-31-GB Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004292-31-ES Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004292-31-DK Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004292-31-DE Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004292-31-CZ Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004292-31-BG Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004292-31-BE Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2017-004295-55-CZ Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2017-004293-33-DE Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
RPC1063 equiv to ozanimod HCI
CELGENE INTERNATIONAL II SàRL
2018 Phase 3 EUCTR2017-004295-55-IT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
RPC1063 equiv. to ozanimod HCI
CELGENE INTERNATIONAL II SàRL
2018 Phase 3 EUCTR2017-004294-14-IT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
RR110 (Tamibarotene)
R&R Inc.
2006 Phase 2 NCT00417391 Japan;
RVG 05565
Academic Medical Center, department of Gastroenterology and hepatology
2008 - EUCTR2008-001131-35-NL Netherlands;
RVG 07151
University Medical Center Utrecht
2009 - EUCTR2009-013348-35-NL Netherlands;
RVG 114681
Amsterdam UMC location AMC
2021 Phase 3;Phase 4 EUCTR2021-000469-33-NL Netherlands;
RVG 116648
Amsterdam UMC location AMC
2021 Phase 3;Phase 4 EUCTR2021-000469-33-NL Netherlands;
RVG00859
Amsterdam UMC location AMC
2021 Phase 3;Phase 4 EUCTR2021-000469-33-NL Netherlands;
RYAH-Medtech Inhaler
OMNI Medical Services, LLC
2018 Phase 2 NCT03944447 United States;
Rabbit anti-human thymocyte immunoglobulin
Barts Health NHS Trust
2017 Phase 3 EUCTR2017-002545-30-GB United Kingdom;
Rabbit antithymocyte globulin
European Group for Blood and Marrow Transplantation (EMBT)
2006 - EUCTR2005-003337-40-GB United Kingdom;
Racol
Graduate School of Medical Sciences, Kyushu University
2009 - JPRN-UMIN000010293 Japan;
Ranolazine
Vanderbilt University Medical Center
2022 Phase 2 NCT04456517 United States;
Rapamycin
The Second Hospital of Nanjing Medical University
2015 - NCT02675153 China;
Raptiva 100 mg/ml powder and solvent for solution for injection
Merck Serono International S.A.
2009 - EUCTR2007-001377-28-PT Austria;France;Germany;Netherlands;Portugal;
2008 - EUCTR2007-001377-28-NL Austria;France;Germany;Netherlands;Portugal;
2008 - EUCTR2007-001377-28-FR Austria;France;Germany;Netherlands;Portugal;
2008 - EUCTR2007-001377-28-DE Austria;France;Germany;Netherlands;Portugal;
2008 - EUCTR2007-001377-28-AT Austria;France;Germany;Netherlands;Portugal;
RbATG
European Group for Blood and Marrow Transplantation (EMBT)
2006 - EUCTR2005-003337-40-GB United Kingdom;
Received hormone maintenance therapy
Fuzhou General Hospital
2012 Phase 1/Phase 2 NCT02445547 China;
Recombinant Human Interleukin-11 (rhIL-11)
Wyeth is now a wholly owned subsidiary of Pfizer
2002 Phase 2 NCT00040521 United States;
Recombinant growth hormone
Greater Glasgow & Clyde NHS
2011 Phase 2 EUCTR2010-022215-19-GB United Kingdom;
Recombinant human Insulin-like Growth Factor
Greater Glasgow & Clyde NHS
2011 Phase 2 EUCTR2010-022215-19-GB United Kingdom;
Red light photopheresis
University Hospital, Akershus
2019 Phase 1/Phase 2 NCT04164849 Norway;
Remicade
Academic Medical Center
2019 Phase 4 EUCTR2018-002064-15-NL Netherlands;
2014 - EUCTR2013-001029-17-NL Netherlands;
2013 Phase 4 EUCTR2013-002932-25-NL Netherlands;
Academic Medical Center, department of Gastroenterology and hepatology
2008 - EUCTR2008-001131-35-NL Netherlands;
CHRU de Lille
2008 - EUCTR2006-004784-58-FR Belgium;France;Germany;United Kingdom;
CUB- Hopital Erasme
2016 Phase 4 EUCTR2015-004618-10-BE Belgium;
Celltrion
2014 Phase 3 NCT02096861 United States;
Centocor B.V.
2005 Phase 3 EUCTR2004-002815-10-GB Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
2005 Phase 3 EUCTR2004-002815-10-ES Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-SE Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-DK Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-DE Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-AT Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
Department of medical gastroenterology S, Odense University Hospital
2015 Phase 4 EUCTR2012-002702-51-SE Denmark;Finland;Norway;Sweden;
2012 Phase 4 EUCTR2012-002702-51-DK Denmark;Finland;Norway;Sweden;
Department of medical gastroenterology, Herlev Hospital
2016 Phase 4 EUCTR2012-002702-51-NO Denmark;Finland;Norway;Sweden;
2015 Phase 4 EUCTR2012-002702-51-FI Denmark;Finland;Norway;Sweden;
2009 Phase 4 EUCTR2009-009926-94-DK Denmark;
ErasmusMC
2013 - EUCTR2012-000645-13-BE Belgium;Netherlands;
2012 - EUCTR2012-000645-13-NL Belgium;Italy;Netherlands;
GETAID
2015 Phase 4 EUCTR2014-002311-41-SE France;Germany;Netherlands;Sweden;United Kingdom;
IBD Center LMU Munich
2008 - EUCTR2008-004926-18-DE Germany;
Janssen Biologics B.V.
2009 - EUCTR2008-005237-30-NL Canada;Netherlands;Sweden;United States;
Janssen Biologics BV
2011 - EUCTR2008-005237-30-SE Belgium;France;Germany;Hungary;Italy;Netherlands;Sweden;United Kingdom;United States;
Jørgen Agnholt
2013 Phase 3 EUCTR2013-000971-34-DK Denmark;
Katholieke Universiteit Leuven
2011 Phase 4 EUCTR2011-002061-38-BE Belgium;
Merck Sharp & Dohme Corp.
2003 - NCT00705614 -
Novartis Pharma AG
2011 - EUCTR2010-019973-13-DE Germany;Switzerland;
Pfizer
2015 - NCT02539368 Belgium;Czech Republic;Czechia;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
Region Örebro län
2021 Phase 4 EUCTR2019-002942-19-DK Denmark;
Royal Liverpool University Hospital
2012 - EUCTR2011-006084-22-GB United Kingdom;
Shradha Agarwal
2011 - NCT01438151 United States;
Univeristy Hospital Na Bulovce
2009 Phase 3 EUCTR2008-005688-32-CZ Czech Republic;
University Medical Center Groningen
2021 Phase 4 EUCTR2020-001811-26-BE Belgium;Netherlands;
2020 Phase 4 EUCTR2020-001811-26-NL Netherlands;
University of Edinburgh
2015 - EUCTR2014-002311-41-GB Belgium;France;Germany;Sweden;United Kingdom;
University of Leuven
2008 - EUCTR2006-004784-58-DE Belgium;France;Germany;United Kingdom;
2007 - EUCTR2006-004784-58-BE Belgium;France;Germany;United Kingdom;
University of Leuven Hospitals
2009 Phase 4 EUCTR2006-004784-58-GB Belgium;France;Germany;United Kingdom;
University of Leuven Hospitals, Division of Gastroenterology
2009 - EUCTR2008-007519-34-SE Sweden;
Universitätsklinik für Innere Medizin III, Klinische Abteilung für Gastroenterologie und Hepatologie
2013 - EUCTR2011-001332-29-AT Austria;
Remicade (infliximab)
Merck Sharp & Dohme Corp.
2002 - NCT00818272 Germany;
Zon MW
2014 Phase 4 EUCTR2013-002651-15-NL Netherlands;
Remicade 100 mg powder for concentrate for solution for infusion.
Santeon
2015 Phase 4 EUCTR2015-001954-14-NL Netherlands;
Remicade 100 mg pulver til konsentrat til infusjonsvæske, oppløsning
Diakonhjemmet Hospital AS
2014 - EUCTR2014-002056-40-NO Norway;
Remisma
CELLTRION INC.
2019 Phase 3 EUCTR2019-001087-30-IT Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
Remsima
Amsterdam UMC location AMC
2021 Phase 3;Phase 4 EUCTR2021-000469-33-NL Netherlands;
CUB- Hopital Erasme
2016 Phase 4 EUCTR2015-004618-10-BE Belgium;
Celltrion, Inc
2019 Phase 3 EUCTR2019-001087-30-PL Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Czechia;Estonia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-DE Austria;Belarus;Bulgaria;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-BG Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Czechia;Estonia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
Department of medical gastroenterology S, Odense University Hospital
2015 Phase 4 EUCTR2012-002702-51-SE Denmark;Finland;Norway;Sweden;
2012 Phase 4 EUCTR2012-002702-51-DK Denmark;Finland;Norway;Sweden;
Department of medical gastroenterology, Herlev Hospital
2016 Phase 4 EUCTR2012-002702-51-NO Denmark;Finland;Norway;Sweden;
2015 Phase 4 EUCTR2012-002702-51-FI Denmark;Finland;Norway;Sweden;
GETAID
2015 Phase 4 EUCTR2014-002311-41-SE France;Germany;Netherlands;Sweden;United Kingdom;
Jørgen Agnholt
2013 Phase 3 EUCTR2013-000971-34-DK Denmark;
Taina Sipponen
2016 Phase 4 EUCTR2016-001278-13-FI Finland;
University Medical Center Groningen
2021 Phase 4 EUCTR2020-001811-26-BE Belgium;Netherlands;
2020 Phase 4 EUCTR2020-001811-26-NL Netherlands;
Remsima (infliximab)
Mundipharma Pharmaceuticals B.V.
2016 Phase 4 EUCTR2014-004904-31-BE Belgium;Netherlands;
2015 Phase 4 EUCTR2014-004904-31-NL Netherlands;
Remsima 100 mg pulver til konsentrat til infusjonsvæske, oppløsning
Diakonhjemmet Hospital AS
2014 - EUCTR2014-002056-40-NO Norway;
Remsima and Inflectra
Janssen Biologics B.V.
2009 - EUCTR2008-005237-30-NL Canada;Netherlands;Sweden;United States;
RhIGF (Increlex)
Nationwide Children's Hospital
2008 Phase 2/Phase 3 NCT00764699 United States;
RhumAb to Il-17A (IgG1-k-class)
Novartis Pharma Services AG
2009 - EUCTR2008-008359-40-DE Austria;Germany;Poland;
RhumAb to Il-17A (IgG1-k-class) rhumAb to Il-17A (IgG1-k-class)
Novartis Pharma Services AG
2009 - EUCTR2008-008359-40-PL Austria;Germany;Poland;
Ribavirin
Vanderbilt-Ingram Cancer Center
2006 - NCT00897312 -
Riboflavin Sodium Phosphate Injection
Xijing Hospital of Digestive Diseases
2016 Phase 3 NCT02769494 China;
Riboflavin supplementation
University Medical Center Groningen
2016 - NCT02538354 Netherlands;
Rifabutin, Clarithromycin, and Clofazimine
Medstar Health Research Institute
2007 Phase 4 NCT00513552 United States;
Rifaximin
ALFA WASSERMANN
2007 - EUCTR2007-001014-17-IT France;Germany;Hungary;Italy;
Assistance Publique - Hôpitaux de Paris
2015 Phase 2 NCT02620007 France;
Mayo Clinic
2019 Phase 2 NCT04254549 United States;
Northwestern University
2019 Phase 2 NCT04154735 United States;
Scott Lee
2008 Phase 2 NCT00603616 United States;
Sixth Affiliated Hospital, Sun Yat-sen University
2017 Phase 3 NCT03185624 China;
2017 Phase 3 NCT03185611 China;
Rifaximin Delayed Release (DR)
Salix Pharmaceuticals, Inc subsidiary of Valeant Pharmaceuticals International Inc
2015 Phase 3 EUCTR2014-001645-24-CZ Canada;Czech Republic;France;Germany;Hungary;Israel;Poland;Russian Federation;United States;
Salix Pharmaceuticals, Inc.
2015 Phase 3 EUCTR2014-001645-24-PL Canada;Czech Republic;France;Germany;Hungary;Israel;Poland;Russian Federation;United States;
2015 Phase 3 EUCTR2014-001645-24-DE Canada;Czech Republic;France;Germany;Hungary;Israel;Poland;Russian Federation;United States;
2015 Phase 3 EUCTR2014-001644-38-PL Canada;Czech Republic;France;Germany;Hungary;Israel;Poland;Russian Federation;United States;
2015 Phase 3 EUCTR2014-001644-38-DE Canada;Czech Republic;France;Germany;Hungary;Israel;Poland;Russian Federation;United States;
2014 Phase 3 EUCTR2014-001645-24-HU Canada;Czech Republic;France;Germany;Hungary;Israel;Poland;Russian Federation;United States;
2014 Phase 3 EUCTR2014-001645-24-FR Canada;Czech Republic;France;Germany;Hungary;Israel;Poland;Russian Federation;United States;
2014 Phase 3 EUCTR2014-001644-38-HU Canada;Czech Republic;France;Germany;Hungary;Israel;Poland;Russian Federation;United States;
2014 Phase 3 EUCTR2014-001644-38-FR Canada;Czech Republic;France;Germany;Hungary;Israel;Poland;Russian Federation;United States;
Salix Pharmaceuticals, Inc. subsidiary of Valeant Pharmaceuticals International In
2015 Phase 3 EUCTR2014-001644-38-CZ Canada;Czech Republic;France;Germany;Hungary;Israel;Poland;Russian Federation;United States;
Rifaximin EIR
Bausch Health Americas, Inc.
2014 Phase 3 NCT02240121 United States;
2014 Phase 3 NCT02240108 United States;
Rifaximin delayed release 400 mg film coated tablet
ALFASIGMA S.P.A.
2018 Phase 2 EUCTR2017-002258-36-NL Belgium;Germany;Italy;Netherlands;Spain;
2018 Phase 2 EUCTR2017-002258-36-BE Belgium;Germany;Netherlands;Spain;
2017 Phase 2 EUCTR2017-002258-36-ES Germany;Spain;
2017 Phase 2 EUCTR2017-002258-36-DE Belgium;Germany;Netherlands;Spain;
Rifaximin delayed release tablets
Alfasigma S.p.A.
2017 Phase 2 NCT03537157 Italy;
Rifaximin+omeprazole+miralax
Seattle Children's Hospital
2015 Phase 1/Phase 2 NCT02272868 United States;
Rifaximin-EIR
ALFA WASSERMANN
2011 - EUCTR2011-002821-24-IT Italy;
ALFASIGMA S.P.A.
2018 Phase 2 EUCTR2017-002258-36-NL Belgium;Germany;Italy;Netherlands;Spain;
2018 Phase 2 EUCTR2017-002258-36-BE Belgium;Germany;Netherlands;Spain;
2017 Phase 2 EUCTR2017-002258-36-ES Germany;Spain;
2017 Phase 2 EUCTR2017-002258-36-DE Belgium;Germany;Netherlands;Spain;
Alfa Wassermann S.p.A.
2008 - EUCTR2007-001014-17-DE France;Germany;Hungary;Italy;
2007 Phase 2 NCT00528073 France;Germany;Hungary;Israel;Italy;Poland;Russian Federation;
2007 Phase 2 EUCTR2007-001014-17-HU France;Germany;Hungary;Italy;
2007 Phase 2 EUCTR2007-001014-17-FR France;Germany;Hungary;Italy;
Risankizumab
AbbVie
2020 Phase 3 NCT04524611 Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 1 NCT04254783 Germany;Israel;United States;
2019 - NCT03914261 Belgium;Israel;Spain;Switzerland;United States;
AbbVie Deutschland GmbH & Co. KG
2015 Phase 2 EUCTR2015-001834-15-DE Belgium;Canada;Germany;Ireland;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
Risankizumab 10 mg/ml
Boehringer Ingelheim Pharma GmbH & Co. KG
2014 Phase 2 EUCTR2013-002902-29-DE Belgium;Canada;Germany;Ireland;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
Risankizumab 180 mg SC
AbbVie
2015 Phase 2 NCT02513459 Belgium;Canada;Germany;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
Risankizumab 600 mg IV
AbbVie
2015 Phase 2 NCT02513459 Belgium;Canada;Germany;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
Risankizumab 90 mg/ml
Boehringer Ingelheim Pharma GmbH & Co. KG
2014 Phase 2 EUCTR2013-002902-29-DE Belgium;Canada;Germany;Ireland;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
Risankizumab IV
AbbVie
2018 Phase 3 NCT03105102 American Samoa;Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 NCT03105128 Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 NCT03104413 American Samoa;Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2014 Phase 2 NCT02031276 Belgium;Canada;France;Germany;Ireland;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
Risankizumab On-Body Injector (OBI)
AbbVie
2018 Phase 3 NCT03105102 American Samoa;Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Risankizumab SC
AbbVie
2018 Phase 3 NCT03105102 American Samoa;Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 NCT03105128 Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 NCT03104413 American Samoa;Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2014 Phase 2 NCT02031276 Belgium;Canada;France;Germany;Ireland;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
Risedronate
University of Alberta
2010 Phase 4 NCT01215890 Canada;
Ritlecitinib
Pfizer Inc.
2018 Phase 2 EUCTR2017-003359-43-SK Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-CZ Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017
2018 Phase 2 EUCTR2017-003359-43-PL Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-HU Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-DE Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-BE Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-AT Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
Rituximab
Paul Szabolcs
2012 Phase 1/Phase 2 NCT00692939 United States;
Rizankisumab
AbbVie Deutschland GmbH & Co. KG
2017 Phase 3 EUCTR2016-003190-17-SK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;It
ASTRAZENECA AB
2021 Phase 3 EUCTR2019-001866-14-IT Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
-aminosalicylic acid
University of Vermont
1995 - NCT00004423 -
0,25 mg RPC1063
Celgene International II Sarl (CISII) awholly owned subsidiary of Celgene Corporation
2015 Phase 2 EUCTR2015-002025-19-HU Canada;Hungary;Italy;Poland;Ukraine;United States;
00000
CELLTRION INC.
2019 Phase 3 EUCTR2019-001087-30-IT Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
0114-0006B
Novo Nordisk A/S
2013 - EUCTR2012-002432-93-SK Bulgaria;Czech Republic;Hungary;Poland;Russian Federation;Serbia;Slovakia;Spain;United States;
2013 - EUCTR2012-002432-93-PL Bulgaria;Czech Republic;Hungary;Poland;Russian Federation;Serbia;Slovakia;Spain;United States;
2013 - EUCTR2012-002432-93-CZ Bulgaria;Czech Republic;Hungary;Poland;Russian Federation;Serbia;Slovakia;Spain;United States;
2013 - EUCTR2012-002432-93-BG Bulgaria;Czech Republic;Hungary;Poland;Russian Federation;Serbia;Slovakia;Spain;United States;
2012 - EUCTR2012-002432-93-HU Bulgaria;Czech Republic;Hungary;Poland;Russian Federation;Serbia;Slovakia;Spain;United States;
2012 - EUCTR2012-002432-93-ES Bulgaria;Czech Republic;Hungary;Poland;Russian Federation;Serbia;Slovakia;Spain;United States;
1000 IU D3
Cedars-Sinai Medical Center
2018 Early Phase 1 NCT03615378 United States;
13-valent pneumococcal conjugated vaccine (PCV13)
Klara M. Pósfay Barbe
2014 Phase 4 NCT01908283 Switzerland;
14C]-RPC1063 Solution (0.1 mg/mL) for Oral Administration
Celgene International II Sàrl
2016 Phase 1 EUCTR2016-003073-18-GB United Kingdom;
18F-FDG
Peking Union Medical College Hospital
2020 Phase 2 NCT04502303 -
2'-Fucosyllactose
Children's Hospital Medical Center, Cincinnati
2019 Phase 1/Phase 2 NCT03847467 United States;
23-valent polysaccharide pneumococcal vaccine
Kyunghee University Medical Center
2011 Phase 4 NCT01505855 Korea, Republic of;
23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)
Cedars-Sinai Medical Center
2005 - NCT00829595 United States;
3-hydroxy-2-methyl-4H-pyrane-4-one iron (III) complex (3:1), Ferric (3-hydroxy-2-methyl-4-pyrone), Tris-maltol-iron (III), Tri=maltol-iron (III)
Iron Therapeutics (Switzerland) AG
2012 - EUCTR2010-023589-39-DE Austria;Germany;Hungary;United Kingdom;
2011 Phase 3 EUCTR2010-023589-39-GB Austria;Germany;Hungary;United Kingdom;
2011 - EUCTR2010-023589-39-AT Austria;Germany;Hungary;United Kingdom;
- - EUCTR2010-023589-39-HU Austria;Germany;Hungary;United Kingdom;
331731-18-1
AbbVie GK
- - EUCTR2015-004121-13-Outside-EU/EEA Japan;
Abbott Deutschland GmbH & Co. KG
- - EUCTR2014-004560-38-Outside-EU/EEA Japan;
- - EUCTR2014-004531-39-Outside-EU/EEA Japan;
4-Aminosalicylic acid
Jacobus Pharmaceutical
2007 Phase 2 NCT00417690 Israel;United States;
4-Aminosalicylic acid extended release granules
Jacobus Pharmaceutical
2007 Phase 2 NCT00495521 Israel;United States;
42942019
UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
2016 Phase 4 EUCTR2016-002061-54-IT Italy;
5-ASA
Alimentiv Inc.
2017 Phase 4 NCT03261206 Canada;Italy;Ukraine;United Kingdom;
5-Aminosalicyl acid
Dr. Falk Pharma GmbH
2007 - EUCTR2004-001213-34-GB Czech Republic;United Kingdom;
5-HTP
University Hospital, Ghent
2018 Phase 2 NCT03574948 Belgium;
5-aminolevulinic acid
University Hospital, Akershus
2019 Phase 1/Phase 2 NCT04164849 Norway;
5-aminosalicylate (Pentasa, Ferring)
VU University Medical Center
2005 Phase 4 NCT00167882 Netherlands;
5-aminosalicylic acid
Lower GI disease, Hyogo College of Medicine
2007 Phase 2,3 JPRN-UMIN000004427 Japan;
5000 IU D3
Cedars-Sinai Medical Center
2018 Early Phase 1 NCT03615378 United States;
549-0261/F02-01
F. Hoffmann-La Roche Ltd
2018 Phase 1 EUCTR2017-003649-10-GB Belgium;Germany;Poland;Spain;United Kingdom;
2018 Phase 1 EUCTR2017-003649-10-DE Belgium;Germany;Poland;Spain;United Kingdom;United States;
2018 Phase 1 EUCTR2017-003649-10-BE Belgium;Germany;Poland;Spain;United Kingdom;
- Phase 1 EUCTR2017-003649-10-PL Belgium;Germany;Poland;Spain;United Kingdom;United States;
6 Mercaptopurine
Tel-Aviv Sourasky Medical Center
2012 Phase 3 NCT01629628 Israel;
6 mercaptopurine
Indiana University
2015 - NCT02413047 United States;
6-Mercaptopurine
PIBD net
2018 Phase 4 EUCTR2016-000522-18-GB Belgium;Canada;Czech Republic;France;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
6-Mercaptopurine (Puri-Nethol)
University of Edinburgh
2007 Phase 4 EUCTR2006-005800-15-GB United Kingdom;
6-Mercaptopurine (Puri-nethol)
University of Edinburgh
2007 Phase 4 EUCTR2006-005800-15-GB United Kingdom;
6-[(methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-purine
Centocor B.V.
2005 Phase 3 EUCTR2004-002815-10-GB Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
2005 Phase 3 EUCTR2004-002815-10-ES Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-SE Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-DK Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-DE Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-AT Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
683699
GlaxoSmithKline
2004 Phase 2 NCT00101946 Canada;United States;
99mTc-S-HYNIC Certolizumab pegol
Ghent University Hospital
2012 Phase 3 EUCTR2009-017998-37-BE Belgium;
?-3 polyunsaturated fatty acid
Sir Run Run Shaw Hospital
2019 Phase 4 NCT03901937 China;
A fixed-dose combination of 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine
RedHill Biopharma Limited
2017 Phase 3 NCT03009396 Canada;Czechia;Israel;New Zealand;Poland;Serbia;United States;
A-1293543.74
ABBVIE DEUTSCHLAND GMBH & CO. KG
2015 Phase 2 EUCTR2014-003240-12-IT Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
AbbVie Deutschland GmbH & Co. KG
2015 Phase 2 EUCTR2014-003240-12-SK Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-PL Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-NO Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-NL Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-HU Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-ES Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-DK Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-DE Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-CZ Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-BE Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
AB1010
AB Science
2015 Phase 2;Phase 3 EUCTR2012-004222-25-GR Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;India;Italy;Morocco;Poland;Romania;Russian Federation;Slovakia;Spain;Tunisia;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-004222-25-SK Belgium;Czech Republic;France;Greece;India;Morocco;Slovakia;Spain;Tunisia;
2013 Phase 3 EUCTR2012-004222-25-BE Belgium;Canada;Central African Republic;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Romania;Slovakia;South Africa;Spain;Switzerland;Tunisia;United Kingdom;United States;
ABBV-066
ABBVIE DEUTSCHLAND GMBH & CO. KG
2020 Phase 3 EUCTR2020-002674-26-IT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003191-50-IT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003190-17-IT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003123-32-IT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
AbbVie Deutschland GmbH & Co. KG
2021 Phase 3 EUCTR2020-002674-26-SK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-002674-26-HU Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-002674-26-DE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-002674-26-CZ Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002674-26-SE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002674-26-NL Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002674-26-GB Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2020-002674-26-AT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2016-003191-50-FR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2016-003190-17-FR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003191-50-SE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003191-50-NL Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003191-50-LT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003191-50-IE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003191-50-HR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003191-50-GR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003191-50-DE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003191-50-BE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003190-17-IE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003190-17-HR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003190-17-GR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003190-17-DE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003190-17-BE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003123-32-SE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003123-32-LT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003123-32-IE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003123-32-HR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003123-32-GR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003123-32-DE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003123-32-BE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003191-50-SK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003191-50-PT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003191-50-LV Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003191-50-GB Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003191-50-ES Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003191-50-EE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003191-50-DK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003191-50-CZ Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003191-50-BG Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003191-50-AT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003190-17-SK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003190-17-PT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003190-17-NL Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003190-17-LV Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003190-17-LT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003190-17-GB Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003190-17-ES Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003190-17-EE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003190-17-DK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003190-17-CZ Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003190-17-BG Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003190-17-AT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003123-32-SK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003123-32-PT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003123-32-LV Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003123-32-GB Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003123-32-ES Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003123-32-EE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003123-32-BG Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003123-32-AT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2016-003191-50-PL Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2016-003191-50-NO Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2016-003190-17-PL Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2016-003123-32-PL Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2016-003123-32-NO Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2016-003123-32-NL Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2016-003123-32-CZ Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
ABBV-154
AbbVie
2022 Phase 2 NCT05068284 Australia;Austria;Belgium;Bulgaria;Canada;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;United States;
AbbVie Deutschland GmbH & Co. KG
2022 Phase 2 EUCTR2021-002869-18-GR Australia;Austria;Belgium;Bulgaria;Canada;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;United States;
2022 Phase 2 EUCTR2021-002869-18-ES Australia;Austria;Belgium;Bulgaria;Canada;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;United Kingdom;United States;
2022 Phase 2 EUCTR2021-002869-18-CZ Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;United States;
2022 Phase 2 EUCTR2021-002869-18-BE Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;United Kingdom;United States;
ABR-215062 sodium salt
Teva Pharmaceutical Industries Ltd.
2008 Phase 2 EUCTR2008-004276-49-GB Belgium;France;Italy;Netherlands;Spain;United Kingdom;
2008 Phase 2 EUCTR2008-004276-49-FR Belgium;France;Italy;Netherlands;Spain;United Kingdom;
2008 Phase 2 EUCTR2008-004276-49-ES Belgium;France;Italy;Netherlands;Spain;United Kingdom;
2008 Phase 2 EUCTR2008-004276-49-BE Belgium;France;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2008-004276-49-NL Belgium;France;Italy;Netherlands;Spain;United Kingdom;
ABT 494
ABBVIE DEUTSCHLAND GMBH & CO. KG
2015 Phase 2 EUCTR2014-003240-12-IT Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
AbbVie Deutschland GmbH & Co. KG
2015 Phase 2 EUCTR2014-003240-12-SK Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-PL Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-NO Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-NL Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-HU Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-ES Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-DK Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-DE Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-CZ Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003240-12-BE Australia;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
ABT Humira
Abbott GmbH & Co. KG
2007 - EUCTR2006-002078-23-SE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
ABT-494
ABBVIE DEUTSCHLAND GMBH & CO. KG
2018 Phase 3 EUCTR2017-001240-35-IT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-IT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001225-41-IT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
AbbVie
2016 Phase 2 NCT02782663 Belgium;Canada;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Romania;Slovakia;Spain;United Kingdom;United States;
2015 Phase 2 NCT02365649 Australia;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
AbbVie Deutschland GmbH & Co. KG
2020 Phase 3 EUCTR2017-001240-35-FR Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-001240-35-SI Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-001240-35-IE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-001226-18-SI Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-001226-18-IE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-001225-41-SI Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-001225-41-IE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001240-35-SK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001240-35-SE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001240-35-PT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001240-35-PL Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001240-35-NL Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001240-35-LV Argentina;Australia;Austria;Belarus;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Colombia;Egypt;Hong Kong;Hungary;Israel;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Russian Federation;Serbia;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-001240-35-LT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001240-35-HU Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001240-35-HR Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001240-35-GB Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001240-35-ES Argentina;Australia;Austria;Belarus;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Colombia;Egypt;Hong Kong;Israel;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Russian Federation;Serbia;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-001240-35-EE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001240-35-DK Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001240-35-DE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001240-35-BG Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001240-35-BE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001240-35-AT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Denmark;Egypt;Estonia;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-SK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-SE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-PT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-PL Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-LV Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-LT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-HU Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-HR Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-GB Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-ES Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-EE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-DK Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-DE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-CZ Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-BG Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-BE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001226-18-AT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001225-41-SK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001225-41-SE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001225-41-PT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001225-41-NL Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001225-41-LV Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001225-41-LT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001225-41-HU Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001225-41-HR Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001225-41-GB Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001225-41-ES Argentina;Australia;Austria;Belarus;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Colombia;Egypt;Hong Kong;Hungary;Israel;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Russian Federation;Serbia;Singapore;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-001225-41-DK Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001225-41-DE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001225-41-CZ Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001225-41-BG Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001225-41-BE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-001225-41-AT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;Germany;Hong Kong;Hungary;Ireland;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2015-003759-23-NO Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Israel;Netherlands;New Zealand;Norway;Slovakia;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2015-003759-23-HU Australia;Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Israel;Netherlands;New Zealand;Puerto Rico;Slovakia;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2015-003759-23-CZ Australia;Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Israel;Netherlands;New Zealand;Puerto Rico;Slovakia;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-003759-23-SK Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Israel;Netherlands;New Zealand;Norway;Slovakia;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-003759-23-NL Australia;Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Israel;Netherlands;New Zealand;Norway;Slovakia;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-003759-23-GB Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Israel;Netherlands;New Zealand;Norway;Slovakia;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-003759-23-ES Australia;Canada;Israel;New Zealand;Puerto Rico;Spain;United States;
2016 Phase 2 EUCTR2015-003759-23-DK Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Israel;Netherlands;New Zealand;Norway;Slovakia;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-003759-23-DE Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Israel;Netherlands;New Zealand;Norway;Slovakia;Spain;United Kingdom;United States;
2016 Phase 2 EUCTR2015-003759-23-BE Australia;Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Israel;Netherlands;New Zealand;Puerto Rico;Slovakia;Spain;United Kingdom;United States;
ABT-874
Abbott
2009 - EUCTR2008-004919-36-SE Austria;Denmark;Sweden;
2009 - EUCTR2008-004919-36-DK Austria;Denmark;Sweden;
2009 - EUCTR2008-004919-36-BE Austria;Belgium;Denmark;Sweden;
2009 - EUCTR2008-004919-36-AT Austria;Denmark;Sweden;
2007 Phase 2 NCT00562887 Australia;Austria;Belgium;Canada;Denmark;Germany;Puerto Rico;United States;
ABX464
Abivax S.A.
2020 Phase 2 NCT03905109 Belgium;
ADSVF
ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE
2019 Phase 2 EUCTR2019-001948-21-FR France;
AIN457
Novartis Pharma Services AG
2010 - EUCTR2009-011621-14-DE Austria;Germany;
2009 - EUCTR2009-011621-14-AT Austria;Germany;
2009 - EUCTR2008-008359-40-PL Austria;Germany;Poland;
2009 - EUCTR2008-008359-40-DE Austria;Germany;Poland;
2009 - EUCTR2008-008359-40-AT Austria;Germany;Poland;
Novartis Pharmaceuticals
2009 Phase 2 NCT01009281 Austria;Canada;Germany;Poland;United States;
2008 Phase 2 NCT00584740 Canada;Germany;United States;
ALBUMINE HUMAINE
ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE
2019 Phase 2 EUCTR2019-001948-21-FR France;
ALLO-ASC
Anterogen Co., Ltd.
2015 Phase 1 NCT02580617 Korea, Republic of;
ALLO-ASC-CD
Anterogen Co., Ltd.
2016 - NCT03183661 -
ALLOPURINOL SODIUM
Marianne Kiszka-Kanowitz
2013 Phase 3 EUCTR2013-001503-37-DK Denmark;
ALX-0600
Shire
2003 Phase 2 NCT00072839 Canada;United States;
AMG 139
AstraZeneca
2011 Phase 1 NCT01258205 Australia;United States;
AMG 181
Amgen
2011 Phase 1 NCT01290042 Australia;United States;
Amgen Inc
2013 Phase 2 EUCTR2012-000529-31-NL Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Netherlands;United Kingdom;United States;
2012 Phase 2 EUCTR2012-000529-31-HU Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Netherlands;United Kingdom;United States;
2012 Phase 2 EUCTR2012-000529-31-GB Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Netherlands;United Kingdom;United States;
2012 Phase 2 EUCTR2012-000529-31-DK Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Netherlands;United Kingdom;United States;
2012 Phase 2 EUCTR2012-000529-31-DE Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Netherlands;United Kingdom;United States;
2012 Phase 2 EUCTR2012-000529-31-CZ Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Netherlands;United Kingdom;United States;
2012 Phase 2 EUCTR2012-000529-31-BE Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Netherlands;United Kingdom;United States;
2012 Phase 2 EUCTR2012-000529-31-AT Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Netherlands;United Kingdom;United States;
AMG 827
Amgen
2010 Phase 2 NCT01199302 Australia;Belgium;Canada;France;Netherlands;Poland;Spain;United States;
2010 Phase 2 NCT01150890 Australia;Belgium;Canada;France;Netherlands;Poland;Spain;United States;
Amgen Inc
2011 Phase 2 EUCTR2010-020881-53-BE Australia;Belgium;Canada;France;Netherlands;Poland;Spain;United States;
2011 - EUCTR2010-020881-53-NL Belgium;Netherlands;Spain;
2011 - EUCTR2010-020881-53-ES Belgium;Netherlands;Spain;
2011 - EUCTR2010-019544-39-NL Belgium;France;Netherlands;Spain;
2010 Phase 2 EUCTR2010-019544-39-BE Australia;Belgium;Canada;France;Netherlands;Poland;Spain;United States;
2010 - EUCTR2010-019544-39-FR Belgium;France;Netherlands;Spain;
2010 - EUCTR2010-019544-39-ES Belgium;France;Netherlands;Spain;
AMGEVITA (Adalimumab biosimilar )
Fundación Publica Andaluza para la Gestión de Salud en Sevilla (FISEVI)
2019 Phase 4 EUCTR2019-000717-37-ES Spain;
AMGEVITA®
Fundación Publica Andaluza para la Gestión de Salud en Sevilla (FISEVI)
2019 Phase 4 EUCTR2019-000717-37-ES Spain;
AN100226
Elan Pharma Ltd.
2005 - EUCTR2004-003839-31-DK Denmark;
APD334
ARENA PHARMACEUTICALS, INC.
2021 Phase 2;Phase 3 EUCTR2020-004775-40-IT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-IT Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Arena Pharmaceuticals Inc.
2021 Phase 2;Phase 3 EUCTR2020-004775-40-PT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-NL Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-LT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-HU Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-HR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-ES Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-DK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-DE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-CZ Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-BG Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-SK Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-PT Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-NO Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-NL Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-LT Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-HU Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-GR Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-GB Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-FR Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-ES Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-CZ Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-BG Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Arena Pharmaceuticals, Inc.
2017 Phase 2 EUCTR2016-003797-40-DE Belgium;Germany;United States;
2017 Phase 2 EUCTR2016-003797-40-BE Belgium;Germany;United States;
APD371
Arena Pharmaceuticals
2017 Phase 2 NCT03155945 United States;
AR401959 L-arginine
ARENA PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-002895-14-IT Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Arena Pharmaceuticals Inc.
2021 Phase 2;Phase 3 EUCTR2020-004775-40-PT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-NL Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-LT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-HU Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-HR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-ES Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-DK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-DE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-CZ Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-BG Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-SK Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-PT Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-NO Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-NL Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-LT Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-HU Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-GR Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-GB Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-FR Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-ES Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-CZ Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-BG Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
ASCs: Adipose derived Stem Cells
CELLERIX S.A.
2009 - EUCTR2008-004286-25-DE Austria;Belgium;Czech Republic;Germany;Netherlands;Spain;
2009 - EUCTR2008-004286-25-BE Austria;Belgium;Czech Republic;Germany;Netherlands;Spain;
AST-120
Ocera Therapeutics, Inc.
2007 - EUCTR2005-005363-28-HU Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
2007 - EUCTR2005-005363-28-AT Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
2006 Phase 3 EUCTR2005-005363-28-GB Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
2006 - EUCTR2005-005363-28-DE Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
2006 - EUCTR2005-005363-28-CZ Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
2006 - EUCTR2005-005363-28-BE Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
ATG
Paul Szabolcs
2012 Phase 1/Phase 2 NCT00692939 United States;
AVB-114
Avobis Bio, LLC
2021 Phase 2 NCT04847739 United States;
AZA
Merck Sharp & Dohme Corp.
2003 Phase 3 NCT00796250 -
AZA capsules
Centre Hospitalier Universitaire, Amiens
2021 Phase 3 NCT05040464 France;
AZATHIOPRINE or METHOTREXATE
Prof. Arie Levine
2013 Phase 4 NCT01802593 Israel;
AZATIOPRINA ASPEN - 50 COMPRESSE
UMBERTO I - POLICLINICO DI ROMA
2017 Phase 4 EUCTR2016-000522-18-IT Belgium;Czech Republic;Czechia;France;Germany;Hungary;Italy;Netherlands;Poland;United Kingdom;
AZD9056
AstraZeneca AB
2006 - EUCTR2005-002319-26-HU Austria;Belgium;Germany;Hungary;
2006 - EUCTR2005-002319-26-AT Austria;Belgium;Germany;Hungary;
2005 - EUCTR2005-002319-26-DE Austria;Belgium;Germany;Hungary;
2005 - EUCTR2005-002319-26-BE Austria;Belgium;Germany;Hungary;
Abatacept
Bristol-Myers Squibb
2006 Phase 3 NCT00406653 Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;India;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;South Africa;Spain;Switzerland;United Kingdom;United States;
Bristol-Myers Squibb International Corporation
2008 Phase 3 EUCTR2006-003371-13-IE Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2008 - EUCTR2006-003371-13-PL Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2008 - EUCTR2006-003371-13-CZ Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 Phase 3 EUCTR2006-003371-13-FR Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-NL Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-IT Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-GB Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-DK Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-DE Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-BE Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
Abrilumab
Amgen
2012 Phase 2 NCT01696396 Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Netherlands;Switzerland;United Kingdom;United States;
Accelerated 1 hour-infusion
Asan Medical Center
2011 Phase 4 NCT01346826 Korea, Republic of;
Accelerated 30 minutes-infusion
Asan Medical Center
2011 Phase 4 NCT01346826 Korea, Republic of;
Acetaminophen
Cedars-Sinai Medical Center
2020 Phase 1/Phase 2 NCT04224558 United States;
Adalimumab
AbbVie
2016 - NCT02750800 Hungary;
2015 Phase 3 NCT02499783 China;
2014 Phase 4 NCT02148718 Spain;
2014 Phase 3 NCT02185014 Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Puerto Rico;Romania;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
2014 Phase 3 NCT02065570 Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Puerto Rico;Romania;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
2013 Phase 3 NCT01958827 Japan;
2013 Phase 2 NCT02015793 China;
2013 - NCT01768858 Austria;
AbbVie (prior sponsor, Abbott)
2011 Phase 3 NCT01235689 Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;
2008 Phase 3 NCT00686374 Belgium;Canada;Czech Republic;Czechia;France;Netherlands;Poland;United Kingdom;United States;
AbbVie Deutschland GmbH & Co. KG
2015 Phase 3 EUCTR2013-004034-15-IT Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
2015 Phase 3 EUCTR2013-004034-15-GB Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
2015 Phase 3 EUCTR2013-004034-15-FR Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
2015 Phase 3 EUCTR2013-004034-15-DK Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
2015 Phase 3 EUCTR2013-004034-15-DE Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
2015 Phase 3 EUCTR2013-004034-15-BE Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
2015 Phase 3 EUCTR2013-001746-33-FR Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2015 Phase 3 EUCTR2013-001746-33-BE Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2014 Phase 3 EUCTR2013-004034-15-SK Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004034-15-HU Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
2014 Phase 3 EUCTR2013-004034-15-ES Austria;Canada;Czech Republic;Denmark;European Union;France;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
2014 Phase 3 EUCTR2013-004034-15-AT Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
2014 Phase 3 EUCTR2013-001746-33-SK Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2014 Phase 3 EUCTR2013-001746-33-NL Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2014 Phase 3 EUCTR2013-001746-33-IT Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2014 Phase 3 EUCTR2013-001746-33-ES Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2014 Phase 3 EUCTR2013-001746-33-DK Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2014 Phase 3 EUCTR2013-001746-33-DE Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2014 Phase 3 EUCTR2013-001746-33-CZ Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Hungary;Israel;Netherlands;Slovakia;Spain;Switzerland;United States;
2014 Phase 3 EUCTR2013-001746-33-AT Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2014 - EUCTR2013-001746-33-HU Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Hungary;Israel;Netherlands;Slovakia;Spain;Switzerland;United States;
2009 Phase 3 EUCTR2007-006494-90-CZ Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
AbbVie GK
2013 Phase 3 JPRN-JapicCTI-142426 -
Abbott
2007 Phase 3 NCT00427921 United States;
2007 Phase 3 NCT00409682 Belgium;Canada;Czech Republic;France;Italy;Netherlands;Poland;United Kingdom;United States;
2007 Phase 2/Phase 3 NCT00445939 Japan;
2007 Phase 2/Phase 3 NCT00445432 Japan;
2006 Phase 3 NCT00409617 Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Norway;Portugal;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States;
2006 Phase 3 NCT00348283 Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Sweden;United States;
2006 Phase 3 NCT00338650 United States;
2004 Phase 3 NCT00195715 Australia;Belgium;Canada;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;South Africa;Spain;Sweden;United Kingdom;United States;
2004 Phase 3 NCT00105300 Belgium;Canada;France;United States;
2003 Phase 3 NCT00077779 United States;
Abbott GmBH Co KG
2005 - EUCTR2004-002163-24-IT Denmark;Germany;Hungary;Italy;Spain;United Kingdom;
Abbott GmBH & Co. KG
2010 Phase 3 EUCTR2010-020137-10-IT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
Abbott GmbH Co.KG
2006 - EUCTR2005-005291-32-IT Austria;Belgium;Germany;Italy;Netherlands;Sweden;
Abbott GmbH & Co. K.G.
2009 Phase 3 EUCTR2007-006494-90-GB Belgium;Czech Republic;United Kingdom;
- - EUCTR2007-006494-90-Outside-EU/EEA Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
Abbott GmbH & Co. KG
2009 - EUCTR2006-004814-41-GB Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
2008 - EUCTR2006-004814-41-NL Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
2008 - EUCTR2006-004814-41-IT Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
2008 - EUCTR2006-004814-41-CZ Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
2008 - EUCTR2006-004814-41-BE Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
2008 - EUCTR2004-002163-24-GB Denmark;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-004814-41-FR Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
2006 - EUCTR2005-005291-32-SE Austria;Belgium;Germany;Italy;Netherlands;Sweden;
2006 - EUCTR2005-005291-32-NL Austria;Belgium;Germany;Italy;Netherlands;Sweden;
2006 - EUCTR2005-005291-32-DE Austria;Belgium;Germany;Italy;Netherlands;Sweden;
2006 - EUCTR2005-005291-32-BE Austria;Belgium;Germany;Italy;Netherlands;Sweden;
2006 - EUCTR2005-005291-32-AT Austria;Belgium;Germany;Italy;Netherlands;Sweden;
2005 - EUCTR2004-002934-20-BE Belgium;
2005 - EUCTR2004-002163-24-DE Denmark;Germany;Hungary;Italy;Spain;United Kingdom;
2004 - EUCTR2004-002163-24-SE Denmark;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
2004 - EUCTR2004-002163-24-ES Denmark;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
2004 - EUCTR2004-002163-24-DK Denmark;Germany;Hungary;Italy;Spain;United Kingdom;
- - EUCTR2006-004814-41-Outside-EU/EEA -
Abbott GmbH & Co. KG (Abbott)
2006 - EUCTR2006-002078-23-NL Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
Abbott GmbH & co. KG
2004 - EUCTR2004-002163-24-BE Belgium;Denmark;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
Abbott Japan Co., Ltd.
2007 Phase 2-3 JPRN-JapicCTI-070367 -
2007 Phase 2-3 JPRN-JapicCTI-070366 -
Abbott Laboratories
2004 - EUCTR2004-002163-24-HU Belgium;Denmark;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
Abbvie Deutschland GmbH & Co. K.G.
2008 Phase 3 EUCTR2007-006494-90-BE Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
Academic Medical Center
2019 Phase 4 EUCTR2018-002064-15-NL Netherlands;
2013 Phase 4 EUCTR2013-002932-25-NL Netherlands;
Biogen
2019 - NCT04089514 Belgium;Germany;Ireland;Italy;Spain;United Kingdom;
2018 - NCT03662919 France;
Children's Hospital Medical Center, Cincinnati
2019 - NCT04131504 United States;
Department of Internal Medicine, School of Medicine, Keio University
2013 - JPRN-UMIN000009596 Japan;
2011 Phase 4 JPRN-UMIN000005146 Japan;
Department of Lower Gastroenterology, Hyogo College of Medicine
2012 Phase 4 JPRN-UMIN000006882 Japan;
Foundation for Liver Research
2008 Phase 3 NCT00736983 Netherlands;
Fukuoka University Chikushi Hospital
2016 - JPRN-UMIN000023871 Japan;
GETAID - Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives
2015 Phase 4 EUCTR2013-003199-11-BE Belgium;France;
GETECCU
2011 - EUCTR2011-000885-36-ES Spain;
Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
2012 Phase 3 NCT01564823 Spain;
Hospital Universitari Vall d'Hebron Research Institute
2014 - NCT02539849 Spain;
ISTITUTO CLINICO HUMANITAS
2009 - EUCTR2009-011763-37-IT Italy;
Innovaderm Research Inc.
2012 Phase 4 NCT01556672 Canada;
Iwate Medical UniversityKochi Medical School HospitalKeio University School of Medicine
2016 - JPRN-UMIN000019958 Japan;
Janssen Research & Development, LLC
2021 Phase 2 NCT04655807 Canada;France;Germany;Italy;Japan;Spain;Sweden;United States;
Kenji Watanabe
2010 - JPRN-UMIN000005762 Japan;
2010 - JPRN-UMIN000005761 Japan;
Landos Biopharma Inc.
2021 Phase 2 NCT05057273 -
Maastricht University Medical Center
2019 Phase 4 NCT03917303 Netherlands;
McMaster University
2018 Phase 4 NCT03059849 -
Mikami Yohei
2019 - JPRN-jRCT1031190056 Japan;
Nagoya University Gradeate School of MedicineDepartment of Gastroenterology
2012 Phase 2 JPRN-UMIN000007514 Japan;
Numaguchi Hirotaka
2021 Phase 2 JPRN-jRCT2031200406 Canada;France;Germany;Italy;Japan;Spain;United States Of America;
PIBD-Net
2017 Phase 4 NCT02852694 France;
Radboud University
2017 Phase 4 NCT03172377 Netherlands;
Royal Liverpool University Hospital
2012 - EUCTR2011-006084-22-GB United Kingdom;
Saitama Medical Center
2016 - JPRN-UMIN000022270 Japan;
Saitama Medical Center, Saitama Medical University
2016 - JPRN-UMIN000023735 Japan;
Sakura Medical Center,Toho university
2012 Phase 2 JPRN-UMIN000009284 Japan;
Sakura medical center, Toho university
2015 - JPRN-UMIN000032485 Japan;
Sara Varea
2014 Phase 3 NCT01986127 Spain;
Schneider Children's Medical Center, Israel
2015 Phase 4 NCT02256462 Israel;
Takeda
2017 Phase 4 NCT02764762 Canada;United States;
Tel-Aviv Sourasky Medical Center
2012 Phase 3 NCT01629628 Israel;
Toho University Medical Center Sakura Hospital
2016 - JPRN-UMIN000024566 Japan;
Tohoku University Graduate School of Medicine (Tohoku University Hospital)
2012 - JPRN-UMIN000007343 Japan;
UCB Biopharma SRL
2021 Phase 3 NCT04643483 -
Universitaire Ziekenhuizen Leuven
2012 - NCT02450513 Belgium;
University Hospital Southampton NHS Foundation Trust
2019 Phase 4 EUCTR2018-004967-30-GB United Kingdom;
University Medical Center Groningen
2021 Phase 4 NCT04646187 Belgium;Netherlands;Spain;
University of Alberta
2009 Phase 4 NCT00972218 Canada;
University of Western Ontario, Canada
2014 Phase 4 NCT01960426 United States;
Vanderbilt University Medical Center
2008 Phase 4 NCT00517296 United States;
Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine
2021 Phase 4 ChiCTR2000036845 China;
Yamaguchi University Graduate School of Medicine Department of Gastroenterology and Hepatology
2011 - JPRN-UMIN000007047 Japan;
waqqas.afif
2017 - NCT03261102 Canada;
Adalimumab (40 mg)
Janssen Scientific Affairs, LLC
2018 Phase 3 NCT03464136 Australia;Belgium;Brazil;Bulgaria;Canada;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
Adalimumab (D2E7)
Abbott
2002 Phase 2 NCT00055523 United States;
Adalimumab 40 mg eow or ew
Abbott
2002 Phase 3 NCT01070303 United States;
Adalimumab Injection
St Vincent's Hospital Melbourne
2017 Phase 4 NCT03220841 Australia;
Adalimumab PRN
Peter Higgins
2013 Phase 3 NCT01674413 United States;
Adalimumab and Infliximab
University Hospital, Ghent
2011 - NCT01338740 Belgium;
Adult human mesenchymal stem cells
Mesoblast, Inc.
2010 Phase 3 NCT01233960 Australia;New Zealand;United States;
Agri-King Synbiotic (AKSB)
Mayo Clinic
2006 Phase 1/Phase 2 NCT00587041 United States;
Albendazole (Eskazole)
academic medical centre
2018 Phase 4 EUCTR2017-001737-85-NL Netherlands;
Alemtuzumab
Northwestern University
2019 Phase 2 NCT04154735 United States;
Paul Szabolcs
2012 Phase 1/Phase 2 NCT00692939 United States;
Alequel
Hadassah Medical Organization
2008 Phase 1/Phase 2 NCT02185183 -
Alfacalcidol
Nagoya University Hospital
2017 - JPRN-UMIN000025961 Japan;
Nakamura Masanao
2017 Phase 2 JPRN-jRCTs041180126 Japan;
Alicaforsen
Isis Pharmaceuticals
2002 Phase 3 NCT00048295 Belgium;Czech Republic;Germany;Italy;Poland;Spain;
2001 Phase 3 NCT00048113 Canada;United States;
Alicalm (polymeric liquid formula)
University Hospital Birmingham
2008 Phase 4 NCT00609752 United Kingdom;
Allogeneic Bone Marrow Transplantation
Fred Hutchinson Cancer Research Center
2012 Phase 2 NCT01570348 United States;
Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs)
Joshua M Hare
2019 Phase 1 NCT02677350 United States;
Allogeneic Stem Cell Therapy
Northwestern University
2010 Phase 1/Phase 2 NCT01288053 United States;
Allogenic eASCs 5 milion cells/ml suspension for injection. Cx601
CELLERIX S.A.
2012 Phase 3 EUCTR2011-006064-43-IT Austria;Belgium;Germany;Israel;Italy;Netherlands;Spain;
Allogenic eASCs 5 million cells/ml suspension for injection CX601
TIGENIX S.A.U
2018 Phase 3 EUCTR2017-000725-12-IT Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
TiGenix, S.A.U.
2021 Phase 3 EUCTR2017-000725-12-SE Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2017-000725-12-DK Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2017-000725-12-GB Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2017-000725-12-DE Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-PL Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-HU Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-FR Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-CZ Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-BE Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
Allogenic eASCs 5 million cells/ml suspension for injection. CX601
TiGenix S.A.U.
2012 Phase 3 EUCTR2011-006064-43-DE Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;
TiGenix, S.A.U.
2012 Phase 3 EUCTR2011-006064-43-AT Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;
Allogenic eASCs 5 million/ml suspension for injection.
TiGenix, S.A. Unipersonal
2012 Phase 3 EUCTR2011-006064-43-BE Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;
2012 - EUCTR2011-006064-43-NL Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;
Allopurinol
SOIBD (The Swedish Organisation for the study of Inflammatory Bowel Diseases)
2018 Phase 4 EUCTR2016-004112-35-SE Sweden;
Allopurinol Sandoz 100 mg, tabletten
Meander Medical Center
2016 Phase 4 EUCTR2016-001638-84-NL Netherlands;
Alofisel
MILLENNIUM PHARMACEUTICALS, INC.
2019 Phase 4 EUCTR2019-000333-39-IT Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
Millennium Pharmaceuticals, Inc (MPI)
2020 Phase 4 EUCTR2019-000333-39-FR Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2020 Phase 4 EUCTR2017-002491-10-FR Austria;Czech Republic;France;Germany;Spain;United Kingdom;
2020 Phase 4 EUCTR2017-002491-10-ES Austria;Czech Republic;France;Germany;Spain;United Kingdom;
2020 Phase 4 EUCTR2017-002491-10-CZ Austria;Czech Republic;Czechia;France;Germany;Spain;United Kingdom;
2019 Phase 4 EUCTR2019-000333-39-CZ Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
Takeda Development Center Americas, Inc
2020 Phase 4 EUCTR2019-000333-39-BE Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
Takeda Development Center Americas, Inc.
2021 Phase 3 EUCTR2020-003193-48-NL Israel;Italy;Japan;Netherlands;Poland;Spain;
2020 Phase 4 EUCTR2017-002491-10-DE Austria;Czech Republic;Czechia;France;Germany;Israel;Spain;
2020 Phase 4 EUCTR2017-002491-10-AT Austria;Czech Republic;Czechia;France;Germany;Israel;Spain;
- Phase 3 EUCTR2020-003193-48-PL Israel;Japan;Netherlands;Poland;
TiGenix, S.A.U.
2021 Phase 3 EUCTR2017-000725-12-SE Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2017-000725-12-DK Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2017-000725-12-GB Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2017-000725-12-DE Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-PL Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-HU Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-CZ Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-BE Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
Also referred to as 'MEDI2070'
AstraZeneca AB
2021 Phase 2;Phase 3 EUCTR2018-004346-42-HU Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-004346-42-DE Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Also referred to as MED2070
ASTRAZENECA AB
2021 Phase 3 EUCTR2019-001866-14-IT Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
AstraZeneca AB
2021 Phase 3 EUCTR2019-001866-14-PL Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2019-001866-14-HU Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2019-001866-14-DE Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Also referred to as MEDI2070
ASTRAZENECA AB
2021 Phase 3 EUCTR2019-001866-14-IT Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
AstraZeneca AB
2021 Phase 3 EUCTR2019-001866-14-PL Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2019-001866-14-HU Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2019-001866-14-DE Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Amgevita
University Medical Center Groningen
2021 Phase 4 EUCTR2020-001811-26-BE Belgium;Netherlands;
2020 Phase 4 EUCTR2020-001811-26-NL Netherlands;
Amgevita 40 mg Injektionslösung im Fertigpen
Universitätsklinikum Erlangen
2019 Phase 4 EUCTR2019-003662-40-DE Germany;
Amgevita 40 mg Injektionslösung in einer Fertigspritze
Universitätsklinikum Erlangen
2019 Phase 4 EUCTR2019-003662-40-DE Germany;
Amgevita 40Mg Solution for Injection
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
2019 Phase 4 NCT04131322 Spain;
Amoxicillin
Ishikawa Dai
2017 - JPRN-jRCTs031180415 Japan;
Juntendo university school of medicineDepartment of gastroenterology
2017 - JPRN-UMIN000025846 Japan;
Andecaliximab
Gilead Sciences
2015 Phase 2 NCT02405442 Australia;Canada;Czech Republic;Czechia;France;Germany;Hungary;Iceland;Italy;New Zealand;Poland;South Africa;Spain;United Kingdom;United States;
AndoSan
Oslo University Hospital
2011 Phase 2/Phase 3 NCT01496053 Norway;
Anti TNF
University Hospital, Lille
2017 - NCT02872506 -
Anti TNF Alfa.
Carmel Medical Center
2014 - NCT01881464 Israel;
Anti TNF humanized antibody Fab fragment-PEG conjugate
UCB PHARMA S.A.
2008 - EUCTR2007-003239-21-FR France;
Anti TNF therapy including infliximab
Janssen Biotech, Inc.
2007 - NCT00606346 Canada;United States;
Anti-CD3 Monoclonal antibody
PDL BioPharma, Inc
2005 - EUCTR2004-004388-31-DE Germany;
PDL BioPharma, Inc.
2005 - EUCTR2004-004387-72-DE Germany;
Protein Design Labs, Inc.
2005 - EUCTR2004-004387-72-AT Austria;Germany;
Anti-IL-23 monoclonal antibody
Allergan Limited
2017 Phase 2 EUCTR2015-000609-38-GB Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2015-000609-38-HU Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2015-000609-38-DE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2015-000609-38-BG Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
AstraZeneca AB
2013 Phase 2 EUCTR2012-004098-26-HU Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United States;
2013 Phase 2 EUCTR2012-004098-26-FR Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United States;
2013 Phase 2 EUCTR2012-004098-26-ES Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United States;
2013 Phase 2 EUCTR2012-004098-26-DE Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United States;
2013 Phase 2 EUCTR2012-004098-26-CZ Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United States;
MedImmune Limited
2016 Phase 2 EUCTR2015-000609-38-CZ Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
MedImmune, Ltd, a wholly owned subsidiary of AstraZeneca UK
2016 Phase 2 EUCTR2015-000609-38-NL Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2015-000609-38-ES Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2015-000609-38-BE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
Anti-IL-6 mAb
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2012 - EUCTR2011-004763-72-IT Australia;Austria;Brazil;Canada;Czech Republic;European Union;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
Bristol-Myers Squibb International Corporation
2012 - EUCTR2011-004763-72-NL Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-004763-72-HU Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-004763-72-GB Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-004763-72-DE Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-004763-72-CZ Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-004763-72-AT Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
Anti-Interferon-gamma monoclonal antibody
Facet Biotech
2002 Phase 2 NCT00072943 Canada;United States;
Anti-Interleukin-23 Immunoglobulin G2 (IgG2) Huma
ALLERGAN LIMITED
2020 Phase 2;Phase 3 EUCTR2018-004346-42-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Anti-Interleukin-23 Immunoglobulin G2 (IgG2) Human Monoclonal Antibody
ALLERGAN LIMITED
2020 Phase 2;Phase 3 EUCTR2018-004346-42-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
ASTRAZENECA AB
2021 Phase 3 EUCTR2019-001866-14-IT Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Allergan Limited
2021 Phase 3 EUCTR2019-001866-14-ES Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Allergan Ltd.
2020 Phase 2;Phase 3 EUCTR2018-004346-42-RO Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2;Phase 3 EUCTR2018-004346-42-BG Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2;Phase 3 EUCTR2018-004346-42-BE Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-004346-42-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-004346-42-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
AstraZeneca AB
2021 Phase 3 EUCTR2019-001866-14-PL Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2019-001866-14-HU Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2019-001866-14-DE Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2018-004346-42-HU Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-004346-42-GB Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-004346-42-DE Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2019-001866-14-GB Australia;Austria;Belgium;Bulgaria;Canada;China;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2018-004346-42-PL Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Astrazeneca AB
2020 Phase 2;Phase 3 EUCTR2018-004346-42-AT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Anti-Interleukin-6 Monoclonal Antibody
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2012 - EUCTR2011-004763-72-IT Australia;Austria;Brazil;Canada;Czech Republic;European Union;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
Bristol-Myers Squibb International Corporation
2012 - EUCTR2011-004763-72-NL Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-004763-72-HU Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-004763-72-GB Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-004763-72-DE Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-004763-72-CZ Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-004763-72-AT Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
Anti-MAdCAM antibody
Pfizer Inc.
2013 - EUCTR2012-002030-37-BE Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Norway;Poland;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;United Kingdom;
SHIRE HUMAN GENETIC THERAPIES, INC
2019 Phase 3 EUCTR2017-000617-23-IT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
Shire Human Genetic Therapies, Inc.
2019 Phase 3 EUCTR2017-000617-23-GR Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-000576-29-GR Argentina;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Estonia;Greece;Hungary;Ireland;Japan;Korea, Republic of;Mexico;Portugal;Slovakia;Spain;Switzerland;Ukraine;United States;
2019 Phase 3 EUCTR2017-000574-11-GR Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000617-23-ES Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000576-29-HU Argentina;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Estonia;Greece;Hungary;Ireland;Japan;Korea, Republic of;Mexico;Portugal;Slovakia;Spain;Switzerland;Ukraine;United States;
2018 Phase 3 EUCTR2017-000576-29-ES Argentina;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Estonia;France;Greece;Hungary;Ireland;Japan;Korea, Republic of;Mexico;Portugal;Slovakia;Spain;Switzerland;Ukraine;United States;
2018 Phase 3 EUCTR2017-000576-29-BE Argentina;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Estonia;Greece;Hungary;Ireland;Japan;Korea, Republic of;Mexico;Portugal;Slovakia;Spain;Switzerland;Ukraine;United States;
- Phase 3 EUCTR2017-000617-23-CZ Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2017-000575-88-CZ Australia;Austria;Brazil;Croatia;Czech Republic;Germany;Israel;Italy;Japan;Lithuania;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;South Africa;United Kingdom;United States;
Anti-TNF
University of Maryland, Baltimore
2011 - NCT02619552 United States;
Anti-TNF Drug
Hospices Civils de Lyon
2021 - NCT03712826 France;
Schneider Children's Medical Center, Israel
2019 - NCT03681652 Israel;
Anti-TNF Therapy
Takeda
2017 - NCT03090139 Argentina;China;Colombia;Korea, Republic of;Mexico;Russian Federation;Saudi Arabia;Singapore;Taiwan;Turkey;
Anti-TNF discontinuation: Physiological saline solution
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
2017 Phase 4 NCT02994836 Spain;
Anti-TNF: Infliximab (Infusion)
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
2017 Phase 4 NCT02994836 Spain;
Anti-TNF:Adalimumab (Subcutaneus)
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
2017 Phase 4 NCT02994836 Spain;
Anti-thymocyte globulin (rabbit)
Cedars-Sinai Medical Center
2020 Phase 1/Phase 2 NCT04224558 United States;
Antibiotics
St Vincent's Hospital Melbourne
2021 Phase 2/Phase 3 NCT04970446 -
Anticorpo monoclonale anti IL-23
ASTRAZENECA
2013 Phase 2 EUCTR2012-004098-26-IT Canada;Czech Republic;France;Germany;Hungary;Italy;Spain;United States;
Anticorpo monoclonale anti-IL-23
MEDIMMUNE, LLC
2016 Phase 2 EUCTR2015-000609-38-IT Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
Anticorpo monoclonale umano anti-Interleuchina-23 Immunoglobulina G2 (IgG2)
ALLERGAN LIMITED
2020 Phase 2;Phase 3 EUCTR2018-004346-42-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Antithymocyte immunoglobulin (rabbit)
WOLFSON DIGESTIVE DISEASES CENTRE
2007 - EUCTR2005-003337-40-IT Italy;United Kingdom;
Apheresis catheter placement
Cedars-Sinai Medical Center
2020 Phase 1/Phase 2 NCT04224558 United States;
Apixaban 2.5 milligram
McMaster University
2021 Early Phase 1 NCT03935451 Canada;
Application of Adalimumab
Gerhard Rogler
2009 - NCT01012570 Switzerland;
Artesunate
Sanjay Gandhi Postgraduate Institute of Medical Sciences
2021 Phase 2 NCT04713631 India;
Atorvastatin
Region Skåne
2006 - EUCTR2005-000496-17-SE Sweden;
Skane University Hospital
2006 Phase 2 NCT00454545 Sweden;
Autologous ADIpose derived stromal vascular fraction
ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE
2019 Phase 2 EUCTR2019-001948-21-FR France;
Autologous CD34-selected peripheral blood stem cells transplant
Paul Szabolcs
2012 Phase 1/Phase 2 NCT00692939 United States;
Autologous Stem Cell Transplantation
Northwestern University
2005 Phase 2 NCT00271947 United States;
Autologous mesenchymal stromal cell
Emory University
2012 Phase 1 NCT01659762 United States;
Autologous ovalbumin-specific type 1 regulatory T lymphocytes expanded population
TxCell
2014 Phase 2 EUCTR2014-001295-65-IT Austria;Belgium;Germany;Italy;
2014 Phase 2 EUCTR2014-001295-65-DE Austria;Belgium;Germany;Italy;
2014 Phase 2 EUCTR2014-001295-65-BE Austria;Belgium;Germany;Italy;
2014 Phase 2 EUCTR2014-001295-65-AT Austria;Belgium;Germany;Italy;
Autologous stem cell transplant
Icahn School of Medicine at Mount Sinai
2017 Phase 2 NCT03219359 United States;
Azathioprin
PIBD-Net
2017 Phase 3 EUCTR2016-000522-18-DE Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
PIBDNet
2018 Phase 4 EUCTR2016-000522-18-CZ Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
Azathioprin-ratiopharm
Abbott GmBH & Co. KG
2010 Phase 3 EUCTR2010-020137-10-IT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
Azathioprin-ratiopharm 25mg Filmtabletten
AbbVie Deutschland GmbH & Co. KG
2015 Phase 3 EUCTR2010-020137-10-LT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2010-020137-10-HU Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2010-020137-10-BE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-SE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-NL Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2010-020137-10-GB Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-DE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-CZ Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-AT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
Abbott GmbH & Co. KG
2010 Phase 3 EUCTR2010-020137-10-FR Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2010-020137-10-ES Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
Azathioprin-ratiopharm 50 mg Filmtabletten
AbbVie Deutschland GmbH & Co. KG
2015 Phase 3 EUCTR2010-020137-10-LT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2010-020137-10-HU Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2010-020137-10-BE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-SE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-NL Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2010-020137-10-GB Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-DE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-CZ Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-AT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
Abbott GmbH & Co. KG
2010 Phase 3 EUCTR2010-020137-10-FR Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2010-020137-10-ES Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
Azathioprine
Dental University Gastroenterology
AbbVie (prior sponsor, Abbott)
2011 Phase 3 NCT01235689 Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;
Academic Medical Center, department of Gastroenterology and hepatology
2008 - EUCTR2008-001131-35-NL Netherlands;
Centocor B.V.
2005 Phase 3 EUCTR2004-002815-10-GB Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
2005 Phase 3 EUCTR2004-002815-10-ES Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-SE Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-DK Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-DE Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-AT Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
Department of Gastroenterology and Hepatology, Kyoto University Hospital
2011 - JPRN-UMIN000005689 Japan;
Department of Gastroenterology, Nanfang Hospital, Southern Medical University
2016 - ChiCTR1800020305 China;
Department of Internal Medicine, School of Medicine, Keio University
2013 - JPRN-UMIN000009596 Japan;
2011 Phase 4 JPRN-UMIN000005146 Japan;
Dr. Falk Pharma GmbH
2002 Phase 3 NCT00946946 Austria;Germany;
Erasmus Medical Center
2015 Phase 4 NCT02517684 Belgium;Denmark;Finland;Italy;Netherlands;Poland;
2013 Phase 4 NCT01880307 Italy;Netherlands;
GETAID
2018 Phase 4 EUCTR2014-002311-41-NL Belgium;France;Germany;Netherlands;Sweden;United Kingdom;
2015 Phase 4 EUCTR2014-002311-41-DE Australia;France;Germany;Netherlands;Sweden;United Kingdom;
2014 - EUCTR2014-002311-41-FR France;Sweden;United Kingdom;
Gastroenterology Research of America
2013 Phase 3 NCT01817972 United States;
Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
2012 Phase 3 NCT01564823 Spain;
Indiana University
2015 - NCT02413047 United States;
Jinling Hospital, China
2009 - NCT01015391 China;
Lower GI disease, Hyogo College of Medicine
2007 Phase 2,3 JPRN-UMIN000004427 Japan;
Massachusetts General Hospital
2005 Phase 3 NCT00098111 United States;
Novartis Pharma Services AG
2005 Phase 2 EUCTR2005-001148-22-SK Slovakia;
PIBD net
2018 Phase 4 EUCTR2016-000522-18-GB Belgium;Canada;Czech Republic;France;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
PIBDnet (Pediatric Inflammatory Bowel Disease Network)
- Phase 4 EUCTR2016-000522-18-PL Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
Region Örebro län
2021 Phase 4 EUCTR2019-002942-19-DK Denmark;
SOIBD (The Swedish Organisation for the study of Inflammatory Bowel Diseases)
2018 Phase 4 EUCTR2016-004112-35-SE Sweden;
Schneider Children's Medical Center, Israel
2019 - NCT03681652 Israel;
Shanghai Research Institute of Acupuncture and Meridian
2016 Phase 1 study ChiCTR-IIR-16007751 China;
Sixth Affiliated Hospital, Sun Yat-sen University
2021 - NCT04761952 -
2017 Phase 3 NCT03185611 China;
Tokyo Medical &
University of Edinburgh
2015 - EUCTR2014-002311-41-GB Belgium;France;Germany;Sweden;United Kingdom;
Zhu Weiming
2018 - NCT04160325 China;
Azathioprine (AZA) caps
Centocor Ortho Biotech Services, L.L.C.
2005 Phase 3 NCT00094458 Austria;Belgium;Canada;Denmark;France;Germany;Greece;Israel;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States;
Azathioprine (AZA) or 6-mercaptopurine (6-MP)
ZonMw: The Netherlands Organisation for Health Research and Development
2007 - NCT00521950 Netherlands;
Azathioprine - ratiopharm
Abbott GmBH & Co. KG
2010 Phase 3 EUCTR2010-020137-10-IT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
Azathioprine / 6 Mercaptopurine
PIBD-Net
2017 Phase 4 NCT02852694 France;
Azathioprine OR Mesalazine
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
2002 Phase 3 NCT00976690 France;
Azathioprine in case of endoscopic recurrence
Universitaire Ziekenhuizen Leuven
2005 Phase 2 NCT02247258 Belgium;Czech Republic;Greece;
Azathioprine individualised dose
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2005 Phase 2 NCT00113503 Canada;United States;
Azathioprine or 6-mercaptopurine
ZonMw: The Netherlands Organisation for Health Research and Development
2007 - NCT00521950 Netherlands;
Azathioprine or adalimumab and infliximab
Tokyo Medical and Dental University
2014 Phase 3 NCT02332356 Japan;
Azathioprine weight-based dose
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2005 Phase 2 NCT00113503 Canada;United States;
Azathioprine+enteral nutrition
Jinling Hospital, China
2012 - NCT01823042 China;
Azatioprina
GETECCU
2011 - EUCTR2011-000885-36-ES Spain;
Azithromycin
Erasmus MC
2014 - EUCTR2012-005226-29-PL Belgium;Canada;Israel;Netherlands;Poland;Portugal;United States;
University of North Carolina, Chapel Hill
2021 Phase 2 NCT04186247 Canada;Israel;Netherlands;United States;
Wolfson Medical Center
2013 - EUCTR2012-005226-29-BE Belgium;Canada;Israel;Netherlands;Poland;Portugal;United States;
- - EUCTR2012-005226-29-NL Canada;Israel;Netherlands;United States;
Azithromycin + Metronidazole
Prof. Arie Levine
2012 Phase 4 NCT01596894 Israel;
B. theta
4D Pharma
2015 Phase 1 EUCTR2014-005666-29-GB United Kingdom;
BFAHF-2
Icahn School of Medicine at Mount Sinai
2021 Phase 1 NCT03992469 United States;
BI 655066 10 mg/ml
AbbVie Deutschland GmbH & Co. KG
2015 Phase 2 EUCTR2015-001834-15-NL Belgium;Canada;Germany;Korea, Republic of;Netherlands;Spain;United States;
2015 Phase 2 EUCTR2015-001834-15-DE Belgium;Canada;Germany;Ireland;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 2 EUCTR2015-001834-15-BE Belgium;Canada;Germany;Korea, Republic of;Netherlands;Spain;United States;
Boehringer Ingelheim España, S.A.
2015 Phase 2 EUCTR2015-001834-15-ES Belgium;Canada;Germany;Korea, Republic of;Netherlands;Spain;United States;
2014 Phase 2 EUCTR2013-002902-29-ES Belgium;Canada;France;Ireland;Korea, Republic of;Netherlands;Spain;United Kingdom;United States;
Boehringer Ingelheim bv
2015 Phase 2 EUCTR2013-002902-29-NL Belgium;Canada;Germany;Ireland;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
SCS Boehringer Ingelheim Comm.V
2014 Phase 2 EUCTR2013-002902-29-BE Belgium;Canada;Germany;Ireland;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
BI 655066 90 mg/ml
AbbVie Deutschland GmbH & Co. KG
2015 Phase 2 EUCTR2015-001834-15-NL Belgium;Canada;Germany;Korea, Republic of;Netherlands;Spain;United States;
2015 Phase 2 EUCTR2015-001834-15-DE Belgium;Canada;Germany;Ireland;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
2015 Phase 2 EUCTR2015-001834-15-BE Belgium;Canada;Germany;Korea, Republic of;Netherlands;Spain;United States;
Boehringer Ingelheim España, S.A.
2015 Phase 2 EUCTR2015-001834-15-ES Belgium;Canada;Germany;Korea, Republic of;Netherlands;Spain;United States;
2014 Phase 2 EUCTR2013-002902-29-ES Belgium;Canada;France;Ireland;Korea, Republic of;Netherlands;Spain;United Kingdom;United States;
Boehringer Ingelheim bv
2015 Phase 2 EUCTR2013-002902-29-NL Belgium;Canada;Germany;Ireland;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
SCS Boehringer Ingelheim Comm.V
2014 Phase 2 EUCTR2013-002902-29-BE Belgium;Canada;Germany;Ireland;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
BI 655130
BOEHRINGER-INGELHEIM ITALIA S.P.A.
2021 Phase 2 EUCTR2020-005770-99-IT Aruba;Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Serbia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Boehringer Ingelheim
2021 Phase 2 EUCTR2020-005770-99-NL Australia;Austria;Belgium;Brazil;Canada;China;Denmark;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Serbia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2021 Phase 2 EUCTR2019-001673-93-BE Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
2020 Phase 2 EUCTR2019-001673-93-AT Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
Boehringer Ingelheim AB
2021 Phase 2 EUCTR2020-005770-99-SE Australia;Austria;Belgium;Brazil;Canada;China;Denmark;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Serbia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Boehringer Ingelheim B.V
2021 Phase 2 EUCTR2020-005770-99-DK Australia;Austria;Belgium;Brazil;Canada;China;Denmark;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Serbia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Boehringer Ingelheim BV
2020 Phase 2 EUCTR2017-003090-34-DK Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
Boehringer Ingelheim Ltd
2021 Phase 2 EUCTR2020-005770-99-IE Australia;Austria;Belgium;Brazil;Canada;China;Denmark;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Serbia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Boehringer Ingelheim Netherlands BV
2019 Phase 2 EUCTR2017-003090-34-NL Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
Boehringer Ingelheim Norway KS
2022 Phase 2 EUCTR2020-005770-99-NO Australia;Austria;Belgium;Brazil;Canada;China;Denmark;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Serbia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Boehringer Ingelheim Pharma GmbH & Co. KG
2020 Phase 2 EUCTR2019-001673-93-DE Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
2019 Phase 2 EUCTR2017-003090-34-DE Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
Boehringer Ingelheim RCV GmbH & Co KG
2020 Phase 2 EUCTR2019-001673-93-HU Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
2019 Phase 2 EUCTR2017-003090-34-HU Austria;Belgium;Germany;Hungary;Netherlands;
2019 Phase 2 EUCTR2017-003090-34-AT Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
Boehringer Ingelheim S.A.
2021 Phase 2 EUCTR2019-001673-93-ES Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
SCS Boehringer Ingelheim Comm.V
2018 Phase 2 EUCTR2017-003090-34-BE Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
BI 695501
Boehringer Ingelheim
2016 Phase 3 NCT02871635 Belarus;Bosnia and Herzegovina;Croatia;Czechia;Germany;Greece;Israel;Poland;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
Boehringer Ingelheim International GmbH
2017 Phase 3 EUCTR2016-000612-14-HR Belarus;Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000612-14-GR Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000612-14-GB Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000612-14-DE Belarus;Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000612-14-CZ Belarus;Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
BI 706321
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
2021 Phase 2 EUCTR2020-004527-16-IT Belgium;Czechia;France;Italy;Poland;Spain;United States;
Boehringer Ingelheim
2021 Phase 2 NCT04978493 Poland;United States;
BIBR 796 BS,
Boehringer Ingelheim
2001 Phase 2 NCT02209792 -
BLI-1300 high dose
Braintree Laboratories
2011 Phase 2 NCT01442363 United States;
BLI-1300 low dose
Braintree Laboratories
2011 Phase 2 NCT01442363 United States;
BMS-188667
Bristol-Myers Squibb International Corporation
2008 Phase 3 EUCTR2006-003371-13-IE Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2008 - EUCTR2006-003371-13-PL Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2008 - EUCTR2006-003371-13-CZ Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 Phase 3 EUCTR2006-003371-13-FR Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-NL Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-GB Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-DK Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-DE Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-BE Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
BMS-936557
Bristol-Myers Squibb International Corporation
2012 - EUCTR2011-002981-19-PL Belgium;France;Hungary;Poland;South Africa;United States;
2012 - EUCTR2011-002981-19-HU Belgium;France;Hungary;Poland;South Africa;United States;
2012 - EUCTR2011-002981-19-BE Belgium;France;Hungary;Poland;South Africa;United States;
BMS-936557 (Anti-IP-10 Antibody)
Bristol-Myers Squibb
2011 Phase 2 NCT01466374 Belgium;France;Hungary;Israel;Poland;Puerto Rico;South Africa;United States;
BMS-945429
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2012 - EUCTR2011-004763-72-IT Australia;Austria;Brazil;Canada;Czech Republic;European Union;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
Bristol-Myers Squibb International Corporation
2012 - EUCTR2011-004763-72-NL Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-004763-72-HU Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-004763-72-GB Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-004763-72-DE Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-004763-72-CZ Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-004763-72-AT Australia;Austria;Brazil;Canada;Czech Republic;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
CSL Behring
2012 Phase 2 NCT01545050 Australia;Austria;Brazil;Canada;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Singapore;Switzerland;Taiwan;United Kingdom;United States;
BMS-986165
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2021 Phase 2 EUCTR2020-004461-40-IT Australia;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 2 EUCTR2017-001976-48-IT Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Poland;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
Bristol-Myers Squibb
2021 Phase 2 NCT04877990 Australia;Brazil;China;Germany;Hungary;Italy;Japan;Poland;Romania;Russian Federation;United Kingdom;United States;
2018 Phase 2 NCT03599622 Australia;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
Bristol-Myers Squibb International Corporation
2021 Phase 2 EUCTR2020-004461-40-DE Australia;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
2021 Phase 2 EUCTR2017-001976-48-NL Australia;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
2021 Phase 2 EUCTR2017-001976-48-BE Australia;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 2 EUCTR2017-001976-48-DK Australia;Belgium;Bouvet Island;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Slovakia;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2017-001976-48-GB Australia;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
Bristol-Myers Squibb international Corporation
2020 Phase 2 EUCTR2017-001976-48-FR Australia;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 2 EUCTR2017-001976-48-PT Australia;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 2 EUCTR2017-001976-48-PL Australia;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 2 EUCTR2017-001976-48-HU Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Poland;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 2 EUCTR2017-001976-48-ES Australia;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States;
2018 Phase 2 EUCTR2017-001976-48-DE Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
BMS986165
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2018 Phase 2 EUCTR2017-001976-48-IT Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Poland;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
Bristol-Myers Squibb International Corporation
2021 Phase 2 EUCTR2020-004461-40-DE Australia;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
2021 Phase 2 EUCTR2017-001976-48-NL Australia;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 2 EUCTR2017-001976-48-DK Australia;Belgium;Bouvet Island;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Slovakia;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2017-001976-48-GB Australia;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
Bristol-Myers Squibb international Corporation
2020 Phase 2 EUCTR2017-001976-48-FR Australia;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
2019 Phase 2 EUCTR2017-001976-48-PT Australia;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 2 EUCTR2017-001976-48-PL Australia;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 2 EUCTR2017-001976-48-HU Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Poland;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
2018 Phase 2 EUCTR2017-001976-48-ES Australia;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Mexico;Poland;Romania;Spain;Taiwan;United Kingdom;United States;
2018 Phase 2 EUCTR2017-001976-48-DE Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States;
BT-11
Landos Biopharma Inc.
2021 Phase 2 EUCTR2019-000824-17-SK Albania;Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Georgia;North Macedonia;Poland;Serbia;Slovakia;Spain;Turkey;Ukraine;United States;
2021 Phase 2 EUCTR2019-000824-17-HR Albania;Austria;Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Czechia;Georgia;Moldova, Republic of;Netherlands;North Macedonia;Poland;Serbia;Slovakia;Spain;Turkey;Ukraine;United States;
2021 Phase 2 EUCTR2019-000824-17-BG Albania;Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Georgia;North Macedonia;Poland;Serbia;Slovakia;Spain;Turkey;Ukraine;United States;
2020 Phase 2 EUCTR2018-005086-39-BG Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Georgia;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
2019 Phase 2 EUCTR2018-005086-39-PL Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Georgia;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
2019 Phase 2 EUCTR2018-005086-39-HU Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Georgia;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
2019 Phase 2 EUCTR2018-005086-39-HR Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Georgia;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
BT-11 (Omilancor)
Landos Biopharma Inc.
2021 Phase 2 NCT05057273 -
BT-11 1,
Landos Biopharma Inc.
2021 Phase 2 NCT03870334 Bulgaria;Poland;United States;
BT-11 Active
Landos Biopharma Inc.
2018 Phase 1 NCT03860571 United States;
Bacteriophage preparation
Intralytix, Inc.
2019 Phase 1/Phase 2 NCT03808103 United States;
Bacteriotherapy
David Suskind
2012 Phase 1 NCT01757964 United States;
Beta carotene from Dunaliella algae
Bnai Zion Medical Center
2002 Phase 3 NCT00275418 Israel;
Betamethasone
The Sixth Affiliated Hospital of Sun Yat-sen University
2019 - ChiCTR1900023696 China;
Bezlotoxumab
David Binion, MD
2021 Phase 4 NCT04626947 United States;
Bif195 capsules
Hvidovre University Hospital
2021 - NCT04842149 Denmark;
Bifidobacterium infantis 35624
University College Cork
2002 Phase 2/Phase 3 NCT00510978 Ireland;
Biological samplings
Hospices Civils de Lyon
2011 - NCT02504255 France;
Biosimilar
McGill University Health Centre/Research Institute of the McGill University Health Centre
2018 - NCT03729674 Canada;
Biosimilar infliximab
Diakonhjemmet Hospital
2014 Phase 4 NCT02148640 Norway;
Bleomycin
The Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine
2020 Phase 0 ChiCTR2000031344 China;
Blood and stools samples
University Hospital, Lille
2015 - NCT02851134 France;
Blood sample
Centre Hospitalier Universitaire, Amiens
2021 Phase 3 NCT05040464 France;
Blood sampling
Centre Hospitalier Universitaire Dijon
2013 - NCT02859675 France;
Blood sampling from infant
UCB BIOSCIENCES, Inc.
2014 Phase 1 NCT02019602 France;Netherlands;Switzerland;United States;
Blood sampling from mother
UCB BIOSCIENCES, Inc.
2014 Phase 1 NCT02019602 France;Netherlands;Switzerland;United States;
Blood sampling from umbilical cord
UCB BIOSCIENCES, Inc.
2014 Phase 1 NCT02019602 France;Netherlands;Switzerland;United States;
Blue light photopheresis
University Hospital, Akershus
2019 Phase 1/Phase 2 NCT04164849 Norway;
Bone Marrow Derived Mesenchymal Stem cells (MSCs)
Leiden University Medical Center
2010 - EUCTR2009-015680-14-NL Netherlands;
Bone Marrow MSC Derived Extracellular Vesicle Isolate
Direct Biologics, LLC
2022 Phase 1 NCT05130983 -
Boulardii
University Clinic Dr Dragisa Misovic-Dedinje
2019 - NCT03941418 -
Brazikumab
ASTRAZENECA AB
2021 Phase 3 EUCTR2019-001866-14-IT Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Brazikumab IV Infusion
Allergan
2016 Phase 2 NCT02574637 Australia;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
Brazikumab Induction Dose
AstraZeneca
2020 Phase 3 NCT03961815 Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Brazikumab Maintenance Dose
AstraZeneca
2020 Phase 3 NCT03961815 Austria;Canada;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Brazikumab SC Injection
Allergan
2016 Phase 2 NCT02574637 Australia;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
Brazikumab high dose
AstraZeneca
2018 Phase 2/Phase 3 NCT03759288 Australia;Austria;Bulgaria;Canada;China;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Brazikumab low dose
AstraZeneca
2018 Phase 2/Phase 3 NCT03759288 Australia;Austria;Bulgaria;Canada;China;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Breast milk sampling
UCB BIOSCIENCES, Inc.
2014 Phase 1 NCT02154425 France;Netherlands;Switzerland;United States;
Brepocitinib
Pfizer Inc.
2018 Phase 2 EUCTR2017-003359-43-SK Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-CZ Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017
2018 Phase 2 EUCTR2017-003359-43-PL Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-HU Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-DE Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-BE Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-AT Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
Budenofalk
Dr. Falk Pharma GmbH
2007 - EUCTR2004-001213-34-GB Czech Republic;United Kingdom;
University Medical Center Utrecht
2009 - EUCTR2007-005455-42-NL Netherlands;
Budenofalk 3mg gastro-resistant capsules
Dr. Falk Pharma GmbH
2009 - EUCTR2008-006957-42-SK Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Slovakia;
2009 - EUCTR2008-006957-42-LV Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Slovakia;
2009 - EUCTR2008-006957-42-LT Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Romania;Russian Federation;Slovakia;Ukraine;
2009 - EUCTR2008-006957-42-HU Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Slovakia;
2009 - EUCTR2008-006957-42-DE Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Romania;Russian Federation;Slovakia;Ukraine;
2009 - EUCTR2008-006957-42-CZ Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Slovakia;
2009 - EUCTR2008-006957-42-BG Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Slovakia;
Budenofalk 9mg gastro-resistant granules
Dr. Falk Pharma GmbH
2009 - EUCTR2008-006957-42-SK Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Slovakia;
2009 - EUCTR2008-006957-42-LV Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Slovakia;
2009 - EUCTR2008-006957-42-LT Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Romania;Russian Federation;Slovakia;Ukraine;
2009 - EUCTR2008-006957-42-HU Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Slovakia;
2009 - EUCTR2008-006957-42-DE Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Romania;Russian Federation;Slovakia;Ukraine;
2009 - EUCTR2008-006957-42-CZ Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Slovakia;
2009 - EUCTR2008-006957-42-BG Bulgaria;Czech Republic;Germany;Hungary;Latvia;Lithuania;Slovakia;
Budesonide
AstraZeneca
- Phase 2 JPRN-JapicCTI-080566 -
AstraZeneca AB
- - EUCTR2011-003743-22-DE Canada;Germany;Italy;Poland;United States;
AstraZeneca K.K.
- Phase 3 EUCTR2014-004132-20-Outside-EU/EEA Japan;
Dr. Falk Pharma GmbH
2009 Phase 3 NCT01086553 Germany;
2007 - EUCTR2004-001213-34-GB Czech Republic;United Kingdom;
2004 Phase 3 NCT00300118 Germany;
2004 Phase 3 EUCTR2004-001213-34-SK Czech Republic;Slovakia;United Kingdom;
2004 - EUCTR2004-001213-34-CZ Czech Republic;United Kingdom;
Hillel Yaffe Medical Center
2020 - NCT04233463 Israel;
Osaka University Graduate School of MedicineDepartment of Gastroenterology and Hepatology
2018 - JPRN-UMIN000031839 Japan;
Royal Liverpool & Broadgreen University Hospitals Trust
2009 Phase 2 EUCTR2008-001137-99-GB United Kingdom;
Royal Liverpool University Hospital
2014 Phase 2 NCT01783106 United Kingdom;
Takehara Tetsuo
2018 Phase 2 JPRN-jRCT1051190043 Japan;
Tohoku University Hospital, Division of Gastroenterology
2018 - JPRN-UMIN000030884 Japan;
Budesonide ( Zentacort Capsules 3mg )
ZERIA Pharmaceutical Co., Ltd.
2017 - JPRN-JapicCTI-184152 -
Bupivacaine/epinephrine/dexamethasone
Cedars-Sinai Medical Center
2018 Phase 4 NCT03723447 United States;
By demand
Hospital Galdakao-Usansolo
2020 - NCT04188990 Spain;
C326, IL-6 Inhibitory Avimer protein
Avidia
2006 Phase 1 NCT00353756 Australia;
CC-5013
Celgene Corporation
2002 Phase 2 NCT00446433 France;Israel;United Kingdom;United States;
CCX282-B
ChemoCentryx
2006 Phase 2 NCT00306215 Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Netherlands;Poland;South Africa;Sweden;United Kingdom;
2004 Phase 2 NCT00102921 United States;
ChemoCentryx, Inc
2007 - EUCTR2005-003827-38-SE Austria;Belgium;Bulgaria;Czech Republic;Denmark;France;Hungary;Sweden;United Kingdom;
2007 - EUCTR2005-003827-38-HU Austria;Belgium;Bulgaria;Czech Republic;Denmark;France;Hungary;Sweden;United Kingdom;
2007 - EUCTR2005-003827-38-FR Austria;Belgium;Bulgaria;Czech Republic;Denmark;France;Hungary;Sweden;United Kingdom;
2007 - EUCTR2005-003827-38-DE Austria;Belgium;Bulgaria;Czech Republic;Denmark;France;Germany;Hungary;Sweden;United Kingdom;
2007 - EUCTR2005-003827-38-BG Austria;Belgium;Bulgaria;Czech Republic;Denmark;France;Hungary;Sweden;United Kingdom;
2007 - EUCTR2005-003827-38-BE Austria;Belgium;Bulgaria;Czech Republic;Denmark;France;Hungary;Sweden;United Kingdom;
2007 - EUCTR2005-003827-38-AT Austria;Belgium;Bulgaria;Czech Republic;Denmark;France;Hungary;Sweden;United Kingdom;
2006 Phase 2 EUCTR2005-003827-38-GB Austria;Belgium;Bulgaria;Czech Republic;Denmark;France;Germany;Hungary;Sweden;United Kingdom;
2006 - EUCTR2005-003827-38-DK Austria;Belgium;Bulgaria;Czech Republic;Denmark;France;Hungary;Sweden;United Kingdom;
2006 - EUCTR2005-003827-38-CZ Austria;Belgium;Bulgaria;Czech Republic;Denmark;France;Hungary;Sweden;United Kingdom;
CD
Fukuoka University Chikushi Hospital
2011 - JPRN-UMIN000005946 Japan;
Hyogo College of Medicine, Department of Inflammatory Bowel Disease, Division of Internal Medicine
2012 - JPRN-UMIN000013534 Japan;
Icahn School of Medicine at Mount Sinai
2019 - NCT03850600 United States;
NHS Greater Glasgow and Clyde
2020 - NCT04225689 United Kingdom;
Nanfang Hospital, Southern Medical University
2019 - ChiCTR1900027370 China;
Shikamura Mitsuhiro
2022 Phase 3 JPRN-jRCT2071210031 Australia;Belgium;Bosnia;China;Croatia;Czech Republic;Germany;Hungary;Israel;Italy;Japan;Lithuania;New Zealand;Poland;Romania;Russia;Slovakia;Spain;Ukraine;United Kingdom;United States;
The 7th Medical Center of the PLA General Hospital (Army general hospital)
2019 Phase 0 ChiCTR1900022728 China;
The First Hospital Affiliated to Sun Yat sen University
2020 - ChiCTR2000029543 China;
University of Glasgow
2014 - NCT02426567 United Kingdom;
University of Miami
2019 - NCT04213729 United States;
CD-C-Food
Second Affiliated Hospital, School of Medicine, Zhejiang University
2020 - NCT04976491 China;
CD7 CAR T-cells
Zhejiang University
2022 Early Phase 1 NCT05239702 China;
CDP6038
UCB BIOSCIENCES GmbH
2012 Phase 2 EUCTR2011-002517-11-BG Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Netherlands;Poland;Romania;Serbia;
2012 - EUCTR2011-002517-11-HU Czech Republic;Germany;Hungary;Serbia;
2012 - EUCTR2011-002517-11-DE Czech Republic;Germany;Hungary;Serbia;
2012 - EUCTR2011-002517-11-CZ Czech Republic;Germany;Hungary;Serbia;
CDP870
UCB AE
2006 - EUCTR2006-002027-16-GR Greece;
UCB Celletech
2008 - EUCTR2007-001913-41-IT Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
UCB Celltech
2008 - EUCTR2007-002716-26-IT Austria;Belgium;Czech Republic;Estonia;Finland;Hungary;Italy;Latvia;
2008 - EUCTR2007-002716-26-EE Austria;Belgium;Czech Republic;Estonia;Finland;Hungary;Italy;Latvia;
2008 - EUCTR2007-002716-26-CZ Austria;Belgium;Czech Republic;Estonia;Finland;Hungary;Italy;Latvia;
2008 - EUCTR2007-002716-26-BE Australia;Austria;Belgium;Brazil;Canada;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;New Zealand;Poland;Romania;Russian Federation;Ukraine;United States;
2008 - EUCTR2007-002716-26-AT Australia;Austria;Belgium;Brazil;Canada;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;New Zealand;Poland;Romania;Russian Federation;Ukraine;United States;
2008 - EUCTR2007-001913-41-EE Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
2008 - EUCTR2007-001913-41-DE Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
2008 - EUCTR2007-001913-41-CZ Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
2008 - EUCTR2007-001913-41-BE Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
2008 - EUCTR2007-001913-41-AT Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
2007 - EUCTR2007-002716-26-LV Austria;Belgium;Czech Republic;Estonia;Finland;Hungary;Italy;Latvia;
2007 - EUCTR2007-002716-26-HU Australia;Austria;Belgium;Brazil;Canada;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;New Zealand;Poland;Romania;Russian Federation;Ukraine;United States;
2007 - EUCTR2007-002716-26-FI Austria;Belgium;Czech Republic;Estonia;Finland;Hungary;Italy;Latvia;
2007 - EUCTR2007-001913-41-LV Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
2007 - EUCTR2007-001913-41-HU Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
2007 - EUCTR2007-001913-41-FI Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
- - EUCTR2014-004381-24-Outside-EU/EEA Australia;Canada;New Zealand;United States;
UCB Japan Co., Ltd.
- - EUCTR2014-004400-30-Outside-EU/EEA Japan;
- - EUCTR2014-004399-42-Outside-EU/EEA Japan;
- - EUCTR2014-004354-34-Outside-EU/EEA Japan;
UCB PHARMA
2007 - EUCTR2006-001729-24-IT Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
UCB PHARMA S.A.
2008 - EUCTR2007-003239-21-FR France;
UCB Pharma S.A
2007 - EUCTR2005-003977-25-DE Belgium;Germany;
UCB Pharma S.A.
2007 - EUCTR2006-003871-11-DE Germany;
2007 - EUCTR2006-001729-24-SE Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-003870-88-DE Germany;
2006 - EUCTR2005-004104-37-DE Austria;Belgium;Germany;Italy;Spain;Sweden;United Kingdom;
UCB Pharma SA
2007 - EUCTR2006-001729-24-DE Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
UCB S.A
2007 Phase 3 EUCTR2006-001729-24-GB Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-001729-24-AT Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2005-003977-25-BE Belgium;Germany;
UCB S.A.
2007 Phase 3 EUCTR2006-001729-24-FR Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-001729-24-NL Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-001729-24-ES Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2005-004104-37-GB Austria;Belgium;Denmark;Germany;Italy;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2005-004104-37-ES Austria;Belgium;Denmark;Germany;Italy;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-001729-24-BE Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004104-37-SE Austria;Belgium;Germany;Italy;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004104-37-DK Austria;Belgium;Denmark;Germany;Italy;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004104-37-BE Austria;Belgium;Germany;Italy;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004104-37-AT Austria;Belgium;Germany;Italy;Spain;Sweden;United Kingdom;
CHOLECALCIFEROL CONCENTRATE
Academic Medical Center
2013 Phase 3 EUCTR2013-002838-20-NL Belgium;Netherlands;
CHOLECALCIFEROL CONCENTRATE (WATER-DISPERSIBLE FORM)
Academic Medical Center
2014 Phase 3 EUCTR2013-002838-20-BE Belgium;Netherlands;
CNTO1275
JANSSEN CILAG INTERNATIONAL NV
2019 Phase 3 EUCTR2018-002629-51-IT Austria;Czech Republic;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004209-41-IT Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-IT Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002918-43-IT Belgium;Denmark;France;Germany;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2016 Phase 2 EUCTR2016-000634-21-IT Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
JANSSEN-CILAG INTERNATIONAL N.V.
2011 - EUCTR2010-022759-42-IT Australia;Brazil;Bulgaria;Canada;Croatia;Germany;Hungary;Iceland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-022758-18-IT Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;New Zealand;South Africa;Spain;United Kingdom;United States;
Janssen-Cilag International N.V.
2020 Phase 3 EUCTR2018-002629-51-GB Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002629-51-SE Austria;Czech Republic;Czechia;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002629-51-FR France;Germany;Netherlands;Spain;Sweden;United States;
2019 Phase 3 EUCTR2018-002629-51-AT Austria;France;Germany;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2018-002629-51-ES France;Germany;Netherlands;Spain;Sweden;United States;
2018 Phase 3 EUCTR2017-004209-41-PL Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004209-41-FR Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004209-41-ES Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004209-41-BG Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004209-41-BE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2016-002918-43-SK Belgium;Denmark;France;Germany;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2018 Phase 3 EUCTR2016-002918-43-DK Belgium;Denmark;France;Germany;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2017 Phase 3 EUCTR2016-002918-43-SE Belgium;Denmark;France;Germany;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2017 Phase 3 EUCTR2016-002918-43-PT Belgium;Denmark;France;Germany;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2017 Phase 3 EUCTR2016-002918-43-NL Belgium;Denmark;France;Germany;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2017 Phase 3 EUCTR2016-002918-43-GB Belgium;Germany;Netherlands;Portugal;Spain;United Kingdom;
2017 Phase 3 EUCTR2016-002918-43-FR Belgium;Denmark;France;Germany;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2017 Phase 3 EUCTR2016-002918-43-ES Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2017 Phase 3 EUCTR2016-002918-43-DE Belgium;Denmark;France;Germany;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2017 Phase 3 EUCTR2016-002918-43-BE Belgium;Denmark;France;Germany;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2017 Phase 1 EUCTR2016-001956-22-PL Belgium;Canada;France;Germany;Poland;United States;
2017 Phase 1 EUCTR2016-001956-22-DE Belgium;Canada;France;Germany;Poland;United States;
2017 Phase 1 EUCTR2016-001956-22-BE Belgium;Canada;France;Germany;Poland;United States;
2012 Phase 3 EUCTR2010-022760-12-NL Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
2012 Phase 3 EUCTR2010-022760-12-BE Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
2012 Phase 3 EUCTR2010-022758-18-BE Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;European Union;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;New Zealand;Serbia;South Africa;Spain;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022760-12-IT Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022760-12-IS Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022760-12-IE Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022760-12-HU Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022760-12-GB Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022760-12-FR Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022760-12-ES Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022760-12-DK Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022760-12-DE Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022760-12-CZ Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022760-12-BG Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;European Union;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022760-12-AT Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;France;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022759-42-GB Australia;Brazil;Bulgaria;Canada;Croatia;Germany;Hungary;Iceland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;South Africa;Spain;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022758-18-GB Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;New Zealand;Serbia;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-022759-42-NL Australia;Brazil;Bulgaria;Canada;Croatia;European Union;Germany;Hungary;Iceland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-022759-42-IS Australia;Brazil;Bulgaria;Canada;Croatia;European Union;Germany;Hungary;Iceland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-022759-42-HU Australia;Brazil;Bulgaria;Canada;Croatia;European Union;Germany;Hungary;Iceland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-022759-42-ES Australia;Brazil;Bulgaria;Canada;Croatia;European Union;Germany;Hungary;Iceland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-022759-42-DE Australia;Brazil;Bulgaria;Canada;Croatia;European Union;Germany;Hungary;Iceland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-022759-42-BG Australia;Brazil;Bulgaria;Canada;Croatia;European Union;Germany;Hungary;Iceland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-022758-18-IS Austria;Belgium;Czech Republic;Denmark;Germany;Hungary;Iceland;Ireland;Italy;Spain;United Kingdom;
2011 - EUCTR2010-022758-18-IE Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;New Zealand;Serbia;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-022758-18-HU Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;European Union;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;New Zealand;Serbia;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-022758-18-ES Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;European Union;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;New Zealand;Serbia;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-022758-18-DK Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;European Union;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;New Zealand;Serbia;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-022758-18-DE Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;European Union;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;New Zealand;Serbia;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-022758-18-CZ Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;European Union;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;New Zealand;Serbia;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-022758-18-AT Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Hungary;Iceland;Ireland;Israel;Italy;Japan;Korea, Republic of;New Zealand;Serbia;South Africa;Spain;United Kingdom;United States;
- Phase 1 EUCTR2016-001956-22-FR Belgium;Canada;France;Germany;Poland;United States;
Janssen-Cilag International NV
2021 Phase 3 EUCTR2020-004457-76-PL Argentina;France;Japan;Poland;Russian Federation;Turkey;United States;
2021 Phase 3 EUCTR2019-004225-24-HU Belgium;Germany;Hungary;Japan;Poland;Russian Federation;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004225-24-DE Belgium;Germany;Hungary;Japan;Poland;Russian Federation;United Kingdom;United States;
2021 Phase 3 EUCTR2019-004225-24-BE Belgium;Germany;Hungary;Japan;Poland;Russian Federation;United Kingdom;United States;
2021 Phase 3 EUCTR2018-002629-51-CZ Austria;Czech Republic;Czechia;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-002629-51-NL Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2017-002195-13-PT Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2017-002195-13-GB Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2016-000634-21-FR Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004209-41-NL Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004209-41-GB Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004209-41-DE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004209-41-CZ Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-PL Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-NL Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-LV Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-LT Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-HR Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-GR Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-ES Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-DE Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-CZ Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-BE Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-AT Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000634-21-PL Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2016-000634-21-HU Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2016-000634-21-GB Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2016-000634-21-DE Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2020-004457-76-FR Argentina;Belgium;France;Germany;Hungary;Italy;Japan;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2019-004225-24-PL Belgium;Germany;Hungary;Japan;Poland;Russian Federation;United Kingdom;United States;
- Phase 3 EUCTR2019-004225-24-Outside-EU/EEA Belgium;Germany;Hungary;Japan;Poland;Russian Federation;United Kingdom;United States;
- Phase 3 EUCTR2019-004225-24-GB Belgium;Germany;Hungary;Japan;Poland;Russian Federation;United Kingdom;United States;
CNTO1959
JANSSEN CILAG INTERNATIONAL NV
2018 Phase 2;Phase 3 EUCTR2017-002195-13-IT Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
Janssen-Cilag International NV
2019 Phase 2;Phase 3 EUCTR2017-002195-13-PT Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2017-002195-13-GB Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-SK Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-PL Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-NL Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-LV Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-LT Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-HR Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-GR Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-ES Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-DE Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-CZ Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-BE Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-002195-13-AT Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;China;Colombia;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
CP-461
Astellas Pharma Inc
2002 Phase 2 NCT00042055 United States;
CP-690,550
PFIZER
2008 - EUCTR2008-003571-45-IT Belgium;Czech Republic;France;Hungary;Italy;Netherlands;Spain;United Kingdom;
Pfizer
2012 Phase 2 NCT01470599 Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Ukraine;United States;
2012 Phase 2 NCT01393899 Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Ukraine;United States;
2011 Phase 2 NCT01393626 Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Romania;South Africa;Spain;Sweden;Ukraine;United States;
2008 Phase 2 NCT00615199 Belgium;Czech Republic;France;Hungary;Italy;Netherlands;Poland;Slovakia;South Africa;Spain;United Kingdom;United States;
Pfizer Limited, Ramsgate Road,Sandwich,Kent CT13 9NJ
2009 - EUCTR2008-003571-45-GB Belgium;Czech Republic;France;Hungary;Italy;Netherlands;Spain;United Kingdom;
Pfizer Ltd, Ramsgate Road,Sandwich,Kent CT13 9NJ
2009 - EUCTR2008-003571-45-CZ Belgium;Czech Republic;France;Hungary;Italy;Netherlands;Spain;United Kingdom;
2008 Phase 2 EUCTR2008-003571-45-SK Belgium;Czech Republic;France;Hungary;Italy;Netherlands;Slovakia;Spain;United Kingdom;
2008 Phase 2 EUCTR2008-003571-45-FR Belgium;Czech Republic;France;Hungary;Italy;Netherlands;Slovakia;Spain;United Kingdom;
2008 - EUCTR2008-003571-45-NL Belgium;Czech Republic;France;Hungary;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2008-003571-45-HU Belgium;Czech Republic;France;Hungary;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2008-003571-45-BE Belgium;Czech Republic;France;Hungary;Italy;Netherlands;Spain;United Kingdom;
Pfizer S.A
2008 Phase 2 EUCTR2008-003571-45-ES Belgium;Czech Republic;France;Hungary;Italy;Netherlands;Slovakia;Spain;United Kingdom;
CP-690,550-10
Pfizer Inc
2012 Phase 2 EUCTR2011-003622-27-CZ Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
Pfizer Inc, 235 East 42nd Street, New York, New York 10017
2013 Phase 2 EUCTR2011-003622-27-NL Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
2013 Phase 2 EUCTR2011-003622-27-HR Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Romania;South Africa;Spain;Sweden;Ukraine;United States;
2013 Phase 2 EUCTR2011-003622-27-AT Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Romania;South Africa;Spain;Sweden;Ukraine;United States;
2012 Phase 2 EUCTR2011-003622-27-HU Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
2012 Phase 2 EUCTR2011-003622-27-GR Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Netherlands;Norway;Romania;Slovakia;South Africa;Spain;Sweden;Ukraine;United States;
2012 Phase 2 EUCTR2011-003622-27-ES Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Netherlands;Norway;Romania;Slovakia;South Africa;Spain;Sweden;Ukraine;United States;
2012 Phase 2 EUCTR2011-003622-27-BG Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
2012 - EUCTR2011-003622-27-SE Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Netherlands;Norway;Romania;Slovakia;South Africa;Spain;Sweden;Ukraine;United States;
Pfizer Inc, 235 East 42nd Street, New York, New York 10017, USA
2012 Phase 2 EUCTR2011-003622-27-DE Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;Netherlands Antilles;South Africa;Spain;Sweden;Ukraine;United States;
Pfizer Inc.
2012 Phase 2 EUCTR2011-001754-28-CZ Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
2012 - EUCTR2011-001733-16-CZ Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
Pfizer Inc.235 East 42nd Street, New York, NY 10017
2013 Phase 2 EUCTR2011-001754-28-HR Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Romania;South Africa;Spain;Sweden;Ukraine;United States;
2013 - EUCTR2011-001733-16-HR Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Romania;South Africa;Spain;Sweden;Ukraine;United States;
2012 Phase 2 EUCTR2011-001754-28-BG Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
2012 - EUCTR2011-001754-28-NL Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
2012 - EUCTR2011-001754-28-HU Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
2012 - EUCTR2011-001754-28-GR Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Norway;Romania;Slovakia;South Africa;Spain;Sweden;Ukraine;United States;
2012 - EUCTR2011-001754-28-ES Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Norway;Romania;Slovakia;South Africa;Spain;Sweden;Ukraine;United States;
2012 - EUCTR2011-001754-28-AT Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Romania;South Africa;Spain;Sweden;Ukraine;United States;
2012 - EUCTR2011-001733-16-NL Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
2012 - EUCTR2011-001733-16-HU Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;Norway;Slovakia;South Africa;Spain;Sweden;Ukraine;United States;
2012 - EUCTR2011-001733-16-GR Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Norway;Romania;Slovakia;South Africa;Spain;Sweden;Ukraine;United States;
2012 - EUCTR2011-001733-16-BG Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
2012 - EUCTR2011-001733-16-AT Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Romania;South Africa;Spain;Sweden;Ukraine;United States;
2011 - EUCTR2011-001754-28-SE Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Norway;Romania;Slovakia;South Africa;Spain;Sweden;Ukraine;United States;
2011 - EUCTR2011-001733-16-SE Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Norway;Romania;Slovakia;South Africa;Spain;Sweden;Ukraine;United States;
2011 - EUCTR2011-001733-16-ES Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Japan;Korea, Republic of;Netherlands;Norway;Romania;Slovakia;South Africa;Spain;Sweden;Ukraine;United States;
Pfizer Inc.235 East 42nd Street, New York, NY 10017, USA
2012 Phase 2 EUCTR2011-001754-28-DE Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
2012 - EUCTR2011-001733-16-DE Australia;Austria;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Netherlands;South Africa;Spain;Sweden;Ukraine;United States;
CPSI-2364
Ferring Pharmaceuticals
2009 Phase 1 NCT00950105 United States;
CROWN
Prometheus Laboratories
2016 Phase 2 NCT02793778 United States;
CT-P13
CELLTRION INC.
2019 Phase 3 EUCTR2019-001087-30-IT Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
Celltrion
2016 Phase 1 NCT02883452 Korea, Republic of;
2014 Phase 3 NCT02096861 United States;
Celltrion, Inc
2019 Phase 3 EUCTR2019-001087-30-PL Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Czechia;Estonia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-LV Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-HU Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-HR Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-GR Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-FR Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-ES Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-DE Austria;Belarus;Bulgaria;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-CZ Austria;Belarus;Bulgaria;Chile;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-BG Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Czechia;Estonia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-AT Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
Celltrion, Inc.
2014 Phase 3 EUCTR2013-004497-10-RO Belgium;Brazil;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004497-10-NL Belgium;Brazil;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004497-10-IT Belgium;Brazil;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004497-10-HU Belgium;Brazil;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004497-10-GB Belgium;Brazil;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004497-10-ES Belgium;Brazil;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004497-10-DK Belgium;Brazil;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004497-10-BE Belgium;Brazil;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Pfizer
2015 - NCT02539368 Belgium;Czech Republic;Czechia;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
CT-P13 SC (Infliximab)
Celltrion
2019 Phase 3 NCT03945019 Poland;United States;
CTLA4Ig
Bristol-Myers Squibb International Corporation
2008 Phase 3 EUCTR2006-003371-13-IE Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2008 - EUCTR2006-003371-13-PL Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2008 - EUCTR2006-003371-13-CZ Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 Phase 3 EUCTR2006-003371-13-FR Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-NL Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-GB Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-DK Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-DE Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-BE Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
CURCUMA LONGA RHIZOMA
CHU de Clermont-Ferrand
2014 Phase 3 EUCTR2014-000261-51-FR France;
Caffeine
Janssen Research & Development, LLC
2018 Phase 1 NCT03358706 Austria;Belgium;Denmark;Germany;Sweden;United Kingdom;United States;
Takeda
2016 Phase 4 NCT02760615 United States;
Calcitonin nasal spray (salmon)
Children's Hospital Boston
2004 - NCT00114803 United States;
Calcitriol
Atlanta VA Medical Center
2007 - NCT00427804 United States;
Caltrate Pill
Second Affiliated Hospital of Wenzhou Medical University
2020 Early Phase 1 NCT04276636 China;
2014 - NCT04606017 China;
Cannabidiol
Meir Medical Center
2010 Phase 1/Phase 2 NCT01037322 Israel;
University of Illinois at Chicago
2018 Phase 2/Phase 3 NCT03467620 -
Cannabidiol , synthetic form
Stero Biotechs Ltd.
2019 Phase 2 NCT04056442 Israel;
Cannabis, Medical
OMNI Medical Services, LLC
2018 Phase 2 NCT03944447 United States;
Capsule endoscopy
Innovaderm Research Inc.
2012 Phase 4 NCT01556672 Canada;
Capsule fecal microbiota material (cap-FMT)
University of Minnesota
2022 Phase 1 NCT05248191 United States;
Celebrex
University of Pittsburgh
2003 Phase 4 NCT00177866 United States;
Cellulose
Ciim Plus, d.o.o.
2018 - NCT04370535 Slovenia;
Certican
Novartis Pharma Services AG
2005 Phase 2 EUCTR2005-001148-22-SK Slovakia;
Certolizumab
Baylor College of Medicine
2011 - NCT01582568 United States;
Certolizumab Pegol (CDP870)
UCB Pharma
2004 Phase 3 NCT00152425 -
2003 Phase 3 NCT00152490 -
UCB Pharma SA
2004 Phase 3 NCT00160706 Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;New Zealand;Norway;Poland;Russian Federation;Serbia;Singapore;Slovenia;South Africa;Spain;Ukraine;United States;
2004 Phase 3 NCT00160524 Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Estonia;Georgia;Germany;Hong Kong;Hungary;Israel;Italy;Latvia;Lithuania;New Zealand;Norway;Poland;Russian Federation;Serbia;Singapore;Slovenia;South Africa;Spain;Sweden;Tunisia;Ukraine;United States;
Certolizumab Pegol /Cimzia
UCB Celltech
- - EUCTR2014-004381-24-Outside-EU/EEA Australia;Canada;New Zealand;United States;
UCB Japan Co., Ltd.
- - EUCTR2014-004400-30-Outside-EU/EEA Japan;
- - EUCTR2014-004399-42-Outside-EU/EEA Japan;
- - EUCTR2014-004354-34-Outside-EU/EEA Japan;
Certolizumab pegol
Atlanta Gastroenterology Associates
2009 Phase 4 NCT01024647 United States;
Gastroenterology Research of America
2013 Phase 3 NCT01817972 United States;
Shafran Gastroenterology Center
2010 - NCT01053559 United States;
UCB AE
2006 - EUCTR2006-002027-16-GR Greece;
UCB Biopharma SRL
2021 Phase 3 NCT04643483 -
UCB Celletech
2008 - EUCTR2007-001913-41-IT Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
UCB Celltech
2008 - EUCTR2007-002716-26-IT Austria;Belgium;Czech Republic;Estonia;Finland;Hungary;Italy;Latvia;
2008 - EUCTR2007-002716-26-EE Austria;Belgium;Czech Republic;Estonia;Finland;Hungary;Italy;Latvia;
2008 - EUCTR2007-002716-26-CZ Austria;Belgium;Czech Republic;Estonia;Finland;Hungary;Italy;Latvia;
2008 - EUCTR2007-002716-26-BE Australia;Austria;Belgium;Brazil;Canada;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;New Zealand;Poland;Romania;Russian Federation;Ukraine;United States;
2008 - EUCTR2007-002716-26-AT Australia;Austria;Belgium;Brazil;Canada;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;New Zealand;Poland;Romania;Russian Federation;Ukraine;United States;
2008 - EUCTR2007-001913-41-EE Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
2008 - EUCTR2007-001913-41-DE Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
2008 - EUCTR2007-001913-41-CZ Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
2008 - EUCTR2007-001913-41-BE Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
2008 - EUCTR2007-001913-41-AT Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
2007 - EUCTR2007-002716-26-LV Austria;Belgium;Czech Republic;Estonia;Finland;Hungary;Italy;Latvia;
2007 - EUCTR2007-002716-26-HU Australia;Austria;Belgium;Brazil;Canada;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;New Zealand;Poland;Romania;Russian Federation;Ukraine;United States;
2007 - EUCTR2007-002716-26-FI Austria;Belgium;Czech Republic;Estonia;Finland;Hungary;Italy;Latvia;
2007 - EUCTR2007-001913-41-LV Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
2007 - EUCTR2007-001913-41-HU Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
2007 - EUCTR2007-001913-41-FI Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;
UCB PHARMA
2007 - EUCTR2006-001729-24-IT Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
UCB Pharma
2010 Phase 2 NCT01190410 Australia;Canada;United States;
2007 Phase 3 NCT00358683 -
2007 Phase 3 NCT00356408 Canada;Germany;United States;
2007 Phase 3 NCT00354367 -
2007 Phase 3 NCT00307931 Greece;
2006 Phase 3 NCT00349752 Belgium;Canada;Germany;United States;
2006 Phase 3 NCT00308581 Austria;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;United Kingdom;United States;
2006 Phase 3 NCT00297648 Belgium;France;Germany;
2006 Phase 2 NCT00329420 Japan;
UCB Pharma S.A
2007 - EUCTR2005-003977-25-DE Belgium;Germany;
UCB Pharma S.A.
2007 - EUCTR2006-003871-11-DE Germany;
2007 - EUCTR2006-001729-24-SE Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-003870-88-DE Germany;
2006 - EUCTR2005-004104-37-DE Austria;Belgium;Germany;Italy;Spain;Sweden;United Kingdom;
UCB Pharma SA
2007 - EUCTR2006-001729-24-DE Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
UCB S.A
2007 Phase 3 EUCTR2006-001729-24-GB Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-001729-24-AT Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2005-003977-25-BE Belgium;Germany;
UCB S.A.
2007 Phase 3 EUCTR2006-001729-24-FR Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-001729-24-NL Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-001729-24-ES Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2005-004104-37-GB Austria;Belgium;Denmark;Germany;Italy;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2005-004104-37-ES Austria;Belgium;Denmark;Germany;Italy;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-001729-24-BE Austria;Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004104-37-SE Austria;Belgium;Germany;Italy;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004104-37-DK Austria;Belgium;Denmark;Germany;Italy;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004104-37-BE Austria;Belgium;Germany;Italy;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004104-37-AT Austria;Belgium;Germany;Italy;Spain;Sweden;United Kingdom;
Certolizumab pegol (CDP870)
UCB Pharma
2006 Phase 3 NCT00333788 Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
Certolizumab pegol (CDP870, CZP)
UCB Pharma
2008 Phase 3 NCT00552058 Australia;Austria;Belgium;Brazil;Canada;Chile;Czech Republic;Czechia;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;New Zealand;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
Certolizumab pegol (CZP)
UCB Japan Co. Ltd.
2006 Phase 2 NCT00329550 Japan;
Certolizumab pegol (rINN)
UCB PHARMA S.A.
2008 - EUCTR2007-003239-21-FR France;
ChAdOx2 HAV
University of Oxford
2017 Phase 1 NCT03027193 United Kingdom;
Chenodiol
University Medical Center Utrecht
2009 - EUCTR2009-013348-35-NL Netherlands;
Chenofalk
University Medical Center Utrecht
2009 - EUCTR2009-013348-35-NL Netherlands;
Chimeric IgG1 monoclonal antibody
Centocor B.V.
2005 Phase 3 EUCTR2004-002815-10-GB Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-SE Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-DK Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-DE Denmark;Germany;Spain;Sweden;United Kingdom;
Cholecalciferol
Boston Children’s Hospital
2008 - NCT00621257 United States;
University Hospital Birmingham NHS Foundation Trust
2019 Phase 4 NCT03718182 United Kingdom;
University of California, Los Angeles
2010 Phase 1 NCT01046773 United States;
Cholecalciferol 10,000 IU
University of Michigan
2015 Phase 4 NCT02208310 United States;
Cholecalciferol 400 IU
University of Michigan
2015 Phase 4 NCT02208310 United States;
Cholestagel
LMU München, Campus Großhadern
2011 - EUCTR2009-010727-91-DE Germany;
University College London
2009 Phase 2 EUCTR2009-010163-16-GB United Kingdom;
Chondroitin sulfate
University Hospital Case Medical Center
2011 Phase 1/Phase 2 NCT01245088 United States;
Cimzia
Milton S. Hershey Medical Center
2013 Phase 4 NCT01696942 United States;
UCB BIOSCIENCES GmbH
2008 Phase 3 NCT00552344 Australia;Austria;Belgium;Brazil;Canada;Chile;Czech Republic;Czechia;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;New Zealand;Poland;Romania;Russian Federation;Ukraine;United States;
UCB Pharma
2009 - NCT00844285 United States;
Cimzia 200 mg solution for injection
Ghent University Hospital
2012 Phase 3 EUCTR2009-017998-37-BE Belgium;
Ciprofloxacin
Assistance Publique - Hôpitaux de Paris
2015 Phase 2 NCT02620007 France;
Children's Hospital of Philadelphia
2018 Phase 2 NCT03476317 United States;
European Group for Blood and Marrow Transplantation (EMBT)
2006 - EUCTR2005-003337-40-GB United Kingdom;
Foundation for Liver Research
2008 Phase 3 NCT00736983 Netherlands;
Mount Sinai Hospital, Canada
2006 Phase 2 NCT00257699 Canada;
Royal Liverpool University Hospital
2014 Phase 2 NCT01783106 United Kingdom;
University of North Carolina, Chapel Hill
2008 Phase 2 NCT00609973 United States;
University of Pennsylvania
2016 Phase 2 NCT02765256 United States;
Ciprofloxacin hydrochloride
Royal Liverpool & Broadgreen University Hospitals Trust
2009 Phase 2 EUCTR2008-001137-99-GB United Kingdom;
Clarithromycin
Royal Liverpool University Hospital
2000 Phase 3 NCT00269386 United Kingdom;
Clofarabine
Jonsson Comprehensive Cancer Center
2016 Early Phase 1 NCT02925351 United States;
Coffee
University Hospital Heidelberg
2010 - NCT01231217 Germany;
Colecalciferol
Academic Medical Center
2013 Phase 3 EUCTR2013-002838-20-NL Belgium;Netherlands;
Colecalciferol D3 (Vigantol Oil)
Imperial College London
2008 Phase 4 NCT00672763 United Kingdom;
Colesevelam
Florian Beigel
2010 Phase 4 NCT01203254 Germany;
LMU München, Campus Großhadern
2011 - EUCTR2009-010727-91-DE Germany;
ColoVit capsule
University Medical Center Groningen
2021 - NCT04913467 Netherlands;
Colonoscopic fecal microbiota material (colo-FMT)
University of Minnesota
2022 Phase 1 NCT05248191 United States;
Colony-purified Bacteroides thetaiotaomicron (B.theta)
4D Pharma
2015 Phase 1 EUCTR2014-005666-29-GB United Kingdom;
Companion diagnostic (CDx)
Prometheus Biosciences, Inc.
2021 Phase 2 NCT05013905 United States;
Computed Tomography
Jonsson Comprehensive Cancer Center
2016 Early Phase 1 NCT02925351 United States;
Continuous Mononuclear Cell Collection (CMNC)
University Hospital, Akershus
2019 Phase 1/Phase 2 NCT04164849 Norway;
Contrast Enhanced Ultrasound
University of Michigan
2015 Phase 1/Phase 2 NCT02061163 United States;
Contrast enhanced ultrasound
Yonsei University
2020 Phase 4 NCT04660136 Korea, Republic of;
Cortecosteroid
Children's Hospital Medical Center, Cincinnati
2005 Phase 2 NCT00109473 United States;
Corticosteroid
Jinling Hospital, China
2014 Phase 4 NCT02056418 China;
Yale University
2015 Phase 4 NCT02392286 United States;
CosmoFer 50mg/ml solution for infusion or injection
Barts Health NHS Trust
2011 Phase 4 EUCTR2010-023797-39-GB United Kingdom;
Crohn's Disease
Ferring Pharmaceuticals
2005 Phase 4 NCT00225810 Czech Republic;
Crohn's disease exclusion diet
Hospital Italiano de Buenos Aires
2021 - NCT05034458 Argentina;
Crohn's disease exclusion diet (CDED)
Assistance Publique - Hôpitaux de Paris
2022 Phase 2/Phase 3 NCT05284136 France;Netherlands;
Crohns Disease Exclusion Diet + PEN
Prof. Arie Levine
2016 - NCT02231814 Israel;
Curcumin
Hamamatsu South Hospital, Centre for Gastroenterology and Inflammatory Bowel Disease Research
2014 - JPRN-UMIN000015770 Japan;
Sanjay Gandhi Postgraduate Institute of Medical Sciences
2021 Phase 2 NCT04713631 India;
Seattle Children's Hospital
2009 Phase 1 NCT00889161 United States;
University Hospital, Clermont-Ferrand
2014 Phase 3 NCT02255370 France;
Cx401
CELLERIX S.A.
2009 - EUCTR2008-004286-25-DE Austria;Belgium;Czech Republic;Germany;Netherlands;Spain;
2009 - EUCTR2008-004286-25-BE Austria;Belgium;Czech Republic;Germany;Netherlands;Spain;
Cx601
MILLENNIUM PHARMACEUTICALS, INC.
2019 Phase 4 EUCTR2019-000333-39-IT Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
Millennium Pharmaceuticals, Inc (MPI)
2020 Phase 4 EUCTR2019-000333-39-FR Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2020 Phase 4 EUCTR2017-002491-10-FR Austria;Czech Republic;France;Germany;Spain;United Kingdom;
2020 Phase 4 EUCTR2017-002491-10-ES Austria;Czech Republic;France;Germany;Spain;United Kingdom;
2020 Phase 4 EUCTR2017-002491-10-CZ Austria;Czech Republic;Czechia;France;Germany;Spain;United Kingdom;
2019 Phase 4 EUCTR2019-000333-39-CZ Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
Takeda Development Center Americas, Inc
2020 Phase 4 EUCTR2019-000333-39-BE Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
Takeda Development Center Americas, Inc.
2021 Phase 3 EUCTR2020-003193-48-NL Israel;Italy;Japan;Netherlands;Poland;Spain;
2020 Phase 4 EUCTR2017-002491-10-DE Austria;Czech Republic;Czechia;France;Germany;Israel;Spain;
2020 Phase 4 EUCTR2017-002491-10-AT Austria;Czech Republic;Czechia;France;Germany;Israel;Spain;
- Phase 3 EUCTR2020-003193-48-PL Israel;Japan;Netherlands;Poland;
TiGenix, S.A. Unipersonal
2012 Phase 3 EUCTR2011-006064-43-BE Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;
2012 - EUCTR2011-006064-43-NL Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;
TiGenix, S.A.U.
2017 Phase 3 EUCTR2017-000725-12-ES Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
Tigenix S.A.U.
2017 Phase 3 NCT03279081 Belgium;Canada;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Puerto Rico;Spain;Sweden;United Kingdom;United States;
2009 Phase 1/Phase 2 NCT01372969 Spain;
Cyclophosphamide
Cedars-Sinai Medical Center
2020 Phase 1/Phase 2 NCT04224558 United States;
European Group for Blood and Marrow Transplantation (EMBT)
2006 - EUCTR2005-003337-40-GB United Kingdom;
Fred Hutchinson Cancer Research Center
2012 Phase 2 NCT01570348 United States;
Icahn School of Medicine at Mount Sinai
2017 Phase 2 NCT03219359 United States;
Northwestern University
2019 Phase 2 NCT04154735 United States;
Paul Szabolcs
2012 Phase 1/Phase 2 NCT00692939 United States;
WOLFSON DIGESTIVE DISEASES CENTRE
2007 - EUCTR2005-003337-40-IT Italy;United Kingdom;
Cyclophosphamide monohydrate
Barts Health NHS Trust
2017 Phase 3 EUCTR2017-002545-30-GB United Kingdom;
Cyltezo
Boehringer Ingelheim International GmbH
2017 Phase 3 EUCTR2016-000612-14-HR Belarus;Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000612-14-DE Belarus;Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000612-14-CZ Belarus;Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
Cytochrome P450 (CYP) Substrates
AbbVie
2020 Phase 1 NCT04254783 Germany;Israel;United States;
Cytoxan
Cedars-Sinai Medical Center
2020 Phase 1/Phase 2 NCT04224558 United States;
D9421-C
AstraZeneca
- Phase 3 JPRN-JapicCTI-121765 -
AstraZeneca K.K.
- Phase 3 EUCTR2014-004132-20-Outside-EU/EEA Japan;
D9421-C capsule
AstraZeneca
2012 Phase 3 NCT01514240 Japan;
D9421-C,
AstraZeneca
2006 Phase 2 NCT00573469 Japan;
DB adalimumab 40 mg eow
Abbott
2002 Phase 3 NCT00055497 United States;
DB adalimumab 40 mg ew
Abbott
2002 Phase 3 NCT00055497 United States;
DEXA scan
University of Texas Southwestern Medical Center
2006 - NCT00286689 United States;
DLX105
Delenex Therapeutics AG
2012 Phase 2 NCT01624376 Switzerland;
DOXYCYCLINE HYCLATE
Royal Liverpool & Broadgreen University Hospitals Trust
2009 Phase 2 EUCTR2008-001137-99-GB United Kingdom;
DR-6MP
Teva GTC
2011 Phase 2 NCT01433432 Israel;
Darvadstrocel
MILLENNIUM PHARMACEUTICALS, INC.
2019 Phase 4 EUCTR2019-000333-39-IT Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
Millennium Pharmaceuticals, Inc (MPI)
2020 Phase 4 EUCTR2017-002491-10-FR Austria;Czech Republic;France;Germany;Spain;United Kingdom;
2020 Phase 4 EUCTR2017-002491-10-ES Austria;Czech Republic;France;Germany;Spain;United Kingdom;
2020 Phase 4 EUCTR2017-002491-10-CZ Austria;Czech Republic;Czechia;France;Germany;Spain;United Kingdom;
Millennium Pharmaceuticals, Inc.
2019 Phase 3 NCT04075825 Belgium;Czechia;France;Hungary;Israel;Italy;Poland;Spain;United States;
Shikamura Mitsuhiro
2021 Phase 3 JPRN-jRCT2033200314 Israel;Italy;Japan;Netherlands;Poland;Spain;
Takeda
2021 Phase 3 NCT04701411 Israel;Japan;Netherlands;Poland;Spain;
2021 - NCT05113095 Japan;
2020 Phase 4 NCT04118088 Austria;Czechia;France;Germany;Israel;Spain;
2019 Phase 3 NCT03706456 Japan;
Takeda Development Center Americas, Inc.
2021 Phase 3 EUCTR2020-003193-48-NL Israel;Italy;Japan;Netherlands;Poland;Spain;
2020 Phase 4 EUCTR2017-002491-10-DE Austria;Czech Republic;Czechia;France;Germany;Israel;Spain;
2020 Phase 4 EUCTR2017-002491-10-AT Austria;Czech Republic;Czechia;France;Germany;Israel;Spain;
- Phase 3 EUCTR2020-003193-48-PL Israel;Japan;Netherlands;Poland;
Takeda Pharmaceutical Company Limited
2019 Phase 3 JPRN-JapicCTI-184145 Japan;
TiGenix, S.A.U.
2021 Phase 3 EUCTR2017-000725-12-DK Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
Decortin
AbbVie Deutschland GmbH & Co. KG
2015 Phase 3 EUCTR2010-020137-10-LT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2010-020137-10-HU Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2010-020137-10-BE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-SE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-NL Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2010-020137-10-GB Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-DE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-CZ Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-AT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
Abbott GmBH & Co. KG
2010 Phase 3 EUCTR2010-020137-10-IT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
Abbott GmbH & Co. KG
2010 Phase 3 EUCTR2010-020137-10-FR Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2010-020137-10-ES Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
Dehydroepiandrosterone [DHEA]
Inflabloc Pharmaceuticals
2005 Phase 2 NCT00106314 Canada;United States;
Dekristol 20.000 ie
Jørgen Agnholt
2013 Phase 3 EUCTR2013-000971-34-DK Denmark;
Delayed Release 6 mercaptopurine
Teva GTC
2010 Phase 1/Phase 2 NCT01094613 Israel;
2008 Phase 1 NCT00774982 Israel;
Delayed Release 6MP or Calcitriol vs. Purinethol
Teva GTC
2006 Phase 1/Phase 2 NCT00287170 Israel;
Denosumab
University of Manitoba
2015 Phase 1/Phase 2 NCT02321280 Canada;
Deucravacitinib
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2021 Phase 2 EUCTR2020-004461-40-IT Australia;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
Bristol-Myers Squibb International Corporation
2021 Phase 2 EUCTR2020-004461-40-DE Australia;Belgium;Brazil;Canada;China;Czechia;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom;United States;
Dexamethasone
Erydel
2009 Phase 3 NCT01277289 Italy;Romania;Spain;
Dexamethasone sodium phosphate 250 mg/ 10 ml
ERYDEL S.P.A.
2009 - EUCTR2008-007329-38-IT Italy;Spain;
2009 - EUCTR2008-007329-38-ES Italy;Spain;
Dextromethorphan
Janssen Research & Development, LLC
2018 Phase 1 NCT03358706 Austria;Belgium;Denmark;Germany;Sweden;United Kingdom;United States;
Takeda
2016 Phase 4 NCT02760615 United States;
Diet 1
University of Washington
2017 - NCT03012542 United States;
Diet 2
University of Washington
2017 - NCT03012542 United States;
Dietary therapy
Rush University Medical Center
2006 Phase 1/Phase 2 NCT00343642 United States;
Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphtalen-2-ylmethyl]-ammonium chloride mon
Italfarmaco S.p.A.
2005 Phase 2 EUCTR2004-004854-19-SK Slovakia;
Dietician designed diet
St Vincent's Hospital Melbourne
2021 Phase 2/Phase 3 NCT04970446 -
Diflucan
Cliniques Universitaires Saint Luc
2008 - EUCTR2008-003167-39-BE Belgium;
Diphenhydramine
Cedars-Sinai Medical Center
2020 Phase 1/Phase 2 NCT04224558 United States;
Dipyridamole
Guangzhou Women and Children's Medical Center
2021 Phase 0 ChiCTR2100048717 China;
Doxycycline
Royal Liverpool University Hospital
2014 Phase 2 NCT01783106 United Kingdom;
E-Device
UCB Biopharma S.P.R.L.
2017 Phase 3 NCT03357471 United States;
E6011
EA Pharma Co., Ltd.
2019 Phase 2 NCT03733314 Czechia;Hungary;Japan;Poland;Russian Federation;
2019 Phase 2 EUCTR2018-002109-70-HU Czech Republic;Hungary;Japan;Poland;
2019 Phase 2 EUCTR2018-002109-70-CZ Czech Republic;Czechia;Hungary;Japan;Poland;Russian Federation;
2014 Phase 1/Phase 2 NCT02039063 Japan;
Eisai Inc.
2014 Phase 1 NCT02249078 -
EB8018
Millennium Pharmaceuticals, Inc (a wholly owned subsidiary
2020 Phase 2 EUCTR2019-000886-19-FR France;Germany;United Kingdom;United States;
2019 Phase 2 EUCTR2019-000886-19-GB Austria;France;Germany;Netherlands;United Kingdom;United States;
Millennium Pharmaceuticals, Inc (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited)
2020 Phase 2 EUCTR2019-000886-19-NL Austria;France;Germany;Netherlands;United Kingdom;United States;
2020 Phase 2 EUCTR2019-000886-19-AT Austria;France;Germany;Netherlands;United Kingdom;United States;
Takeda Development Center Americas,Inc.
2019 Phase 2 EUCTR2019-000886-19-DE Austria;France;Germany;Netherlands;United Kingdom;United States;
EB8018 (First-in-class FimH blocker)
Enterome
2018 Phase 1 NCT03709628 Austria;France;Germany;Italy;
EEN
Sun Yat-sen University
2013 - NCT02887287 China;
The Second Hospital of Nanjing Medical University
2016 - NCT02897661 China;
EEN (Nestle Modulen®)
Duzce University
2021 Phase 3 NCT04921033 Turkey;
EEN intervention group
Shaare Zedek Medical Center
2020 - NCT04239248 Israel;
EGG WHITE PROTEIN
Lument AB
2019 Phase 2 EUCTR2019-002093-32-SE Sweden;
EMEA/H/C/000240
Santeon
2015 Phase 4 EUCTR2015-001954-14-NL Netherlands;
EMEA/H/C/002576
Amsterdam UMC location AMC
2021 Phase 3;Phase 4 EUCTR2021-000469-33-NL Netherlands;
EMEA/H/C/002778
Department of medical gastroenterology, Herlev Hospital
2016 Phase 4 EUCTR2012-002702-51-NO Denmark;Finland;Norway;Sweden;
ENDOXAN BAXTER
WOLFSON DIGESTIVE DISEASES CENTRE
2007 - EUCTR2005-003337-40-IT Italy;United Kingdom;
ENTYVIO - 300 MG - POLVERE PE RCONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) (20ML) - 1 FLACONCINO
FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
2016 Phase 4 EUCTR2015-003270-32-IT Italy;
TAKEDA DEVELOPMENT CENTER AMERICAS INC.
2021 Phase 3 EUCTR2020-004301-31-IT Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;China;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Lithuania;New Zealand;Poland;Romania;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
ERB-041
Wyeth is now a wholly owned subsidiary of Pfizer
2004 Phase 1 NCT00245947 -
ERY-DEX
ERYDEL S.P.A.
2009 - EUCTR2008-007329-38-IT Italy;Spain;
2009 - EUCTR2008-007329-38-ES Italy;Spain;
EU/1/03/268/002
LMU München, Campus Großhadern
2011 - EUCTR2009-010727-91-DE Germany;
EU/1/99/116/003
Academic Medical Center, department of Gastroenterology and hepatology
2008 - EUCTR2008-001131-35-NL Netherlands;
EUA with seton placement if necessary
Vanderbilt University Medical Center
2008 Phase 4 NCT00517296 United States;
EUS
Vanderbilt University Medical Center
2008 Phase 4 NCT00517296 United States;
Early immunosuppressants (azathioprine, methotrexate)
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
2005 Phase 4 NCT00546546 France;
Ebetrex 15 mg = 0,75 ml, oplossing voor injectie in voorgevulde injectiespuit 20 mg/ml
Amsterdam UMC location AMC
2021 Phase 3;Phase 4 EUCTR2021-000469-33-NL Netherlands;
Efmarodocokin alfa
Genentech, Inc.
2018 Phase 2 EUCTR2017-004997-32-IE Bulgaria;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
Egg Albumen Powder
Lument AB
2019 Phase 2 EUCTR2019-002093-32-SE Sweden;
Eicosapentaenoic acid
Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi
2014 - NCT02179372 Italy;
Empagliflozin
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 1 NCT05078879 United States;
Endopath from Itamar medical - FDA approved device.
Carmel Medical Center
2014 - NCT01881464 Israel;
Endoscopic balloon dilatation
St Vincent's Hospital Melbourne
2017 Phase 4 NCT03220841 Australia;
Entecavir
Saitama Medical University
2016 - JPRN-UMIN000020029 Japan;
Enteral nutrition
Jinling Hospital, China
2014 Phase 4 NCT02056418 China;
Zhu Weiming
2012 - NCT01820247 China;
Enteral nutrition.
Jinling Hospital, China
2012 - NCT01823029 China;
Entocort
ASTRAZENECA
2011 Phase 3 EUCTR2011-003743-22-IT Canada;Germany;Italy;United States;
AstraZeneca K.K.
- Phase 3 EUCTR2014-004132-20-Outside-EU/EEA Japan;
Padagis LLC
2011 Phase 3 NCT01453946 Canada;Germany;Italy;Poland;United States;
2011 Phase 3 NCT01444092 Canada;Germany;Italy;Poland;United States;
Entocort CR
Royal Liverpool & Broadgreen University Hospitals Trust
2009 Phase 2 EUCTR2008-001137-99-GB United Kingdom;
Entocort® Kapseln
AstraZeneca AB
- - EUCTR2011-003743-22-DE Canada;Germany;Italy;Poland;United States;
- - EUCTR2011-003742-40-DE Canada;Germany;Italy;Poland;United States;
Entyvio
AMC MEDICAL RESEARCH B.V.
2017 Phase 3 EUCTR2015-000555-24-IT France;Italy;Netherlands;Spain;
Academic Medical Center Amsterdam
2016 Phase 4 EUCTR2015-000555-24-NL Netherlands;
2016 Phase 4 EUCTR2015-000555-24-FR France;Netherlands;Spain;
2016 Phase 4 EUCTR2015-000555-24-ES Netherlands;Spain;
Academic Medical Center, Gastroenterology
2017 Phase 4 EUCTR2014-005376-29-HU Belgium;Hungary;Netherlands;
2015 Phase 4 EUCTR2014-005376-29-BE Belgium;Netherlands;
2015 - EUCTR2014-005376-29-NL Netherlands;
TAKEDA DEVELOPMENT CENTRE EUROPE LTD
2016 Phase 3 EUCTR2015-000481-58-IT Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Takeda Development Centre Europe Limited
2017 Phase 4 EUCTR2016-000678-40-BG Australia;Bulgaria;Czech Republic;Estonia;Hungary;India;Italy;Korea, Republic of;Latvia;Malaysia;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Turkey;Ukraine;
2016 Phase 4 EUCTR2016-000678-40-LV Australia;Bulgaria;Czech Republic;Estonia;Hungary;India;Italy;Korea, Republic of;Latvia;Malaysia;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Turkey;Ukraine;
2016 Phase 4 EUCTR2016-000678-40-HU Australia;Bulgaria;Czech Republic;Czechia;Estonia;Hungary;India;Italy;Korea, Republic of;Latvia;Malaysia;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Turkey;Ukraine;
2016 Phase 4 EUCTR2016-000678-40-EE Australia;Bulgaria;Czech Republic;Estonia;Hungary;India;Italy;Korea, Republic of;Latvia;Malaysia;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Turkey;Ukraine;
2016 Phase 4 EUCTR2016-000678-40-CZ Australia;Bulgaria;Czech Republic;Estonia;Hungary;India;Italy;Korea, Republic of;Latvia;Malaysia;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Turkey;Ukraine;
Takeda Development Centre Europe, Ltd.
2018 Phase 2 EUCTR2017-002231-41-PL Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002231-41-NL Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002231-41-BE Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002182-21-PL Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002182-21-NL Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002182-21-BE Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2017 Phase 4 EUCTR2015-000852-12-BE Belgium;Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2017-002231-41-HU Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2017-002231-41-GB Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2017-002231-41-DE Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2017-002182-21-HU Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2017-002182-21-GB Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2017-002182-21-FR Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2017-002182-21-DE Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2016 Phase 4 EUCTR2015-000852-12-NL Belgium;Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
2016 Phase 4 EUCTR2015-000852-12-GB Belgium;Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
2016 Phase 4 EUCTR2015-000852-12-FR Belgium;Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
2016 Phase 4 EUCTR2015-000852-12-ES Belgium;Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000482-31-NL Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000482-31-HR Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-SK Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-SE Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-NL Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-LT Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-HU Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-GB Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-ES Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-DK Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-DE Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-CZ Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-BG Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-BE Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
- Phase 2 EUCTR2017-002231-41-FR Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
Epanova
Tillotts Pharma AG
2003 Phase 3 NCT00613197 Belgium;
Epanova™ (Omega-3 Free Fatty Acids)
Tillotts Pharma AG
2002 Phase 3 NCT00074542 Canada;United States;
Epaxal Berna (virosomal hepatitis A vaccine)
Asan Medical Center
2011 Phase 4 NCT01341808 Korea, Republic of;
Ergocalciferol
Boston Children’s Hospital
2008 - NCT00621257 United States;
Erythropoietin
Jinling Hospital, China
2012 - NCT01823029 China;
Etiprednol dicloacetate
Teva Branded Pharmaceutical Products R&D, Inc.
2002 Phase 2 NCT00035503 Canada;United States;
Etrasimod
Arena Pharmaceuticals
2020 Phase 2/Phase 3 NCT04173273 Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United States;
Samia Hassan El-Shishtawy
2021 Phase 2/Phase 3 NCT05033340 -
Etrasimod L-arginine
ARENA PHARMACEUTICALS, INC.
2021 Phase 2;Phase 3 EUCTR2020-004775-40-IT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-IT Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Arena Pharmaceuticals Inc.
2021 Phase 2;Phase 3 EUCTR2020-004775-40-PT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-NL Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-LT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-HU Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-HR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-ES Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-DK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-DE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-CZ Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2;Phase 3 EUCTR2020-004775-40-BG Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Malaysia;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-SK Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-PT Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-NO Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-NL Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-LT Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-HU Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-GR Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-GB Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-FR Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-ES Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-CZ Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002895-14-BG Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Egypt;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lebanon;Lithuania;Mexico;Moldova, Republic of;Norway;Peru;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Etrolizumab
F. HOFFMANN - LA ROCHE LTD.
2016 Phase 3 EUCTR2014-003855-76-IT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003824-36-IT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;Italy;Korea, Democratic People's Republic of;Latvia;Lithuania;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
Hoffmann-La Roche
2018 Phase 1 NCT03478956 Belgium;Germany;Poland;Spain;United Kingdom;United States;
2015 Phase 3 NCT02403323 Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Luxembourg;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2015 Phase 3 NCT02394028 Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Luxembourg;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
Evaluation of biological predictive factors of clinical response to ustekinumab
Hospices Civils de Lyon
2018 - NCT03351647 France;
Everolimus
Novartis Pharma Services AG
2005 Phase 2 EUCTR2005-001148-22-SK Slovakia;
Exclusive Enteral Nutrition
Children's Hospital of Fudan University
2022 Phase 4 NCT04530877 -
2017 - NCT03755583 China;
McMaster University
2018 Phase 4 NCT03833596 Canada;
Tel-Aviv Sourasky Medical Center
2020 Phase 3 NCT04398836 Israel;
Exclusive Enteral Nutrition Therapy
Jinling Hospital, China
2013 - NCT02233062 China;
Expanded allogenic adipose-derived adult stem cells
Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz
2009 Phase 1/Phase 2 NCT00999115 Spain;
Expanded autologous adipose-derived adult stem cells (eASCs)
Tigenix S.A.U.
2008 Phase 3 NCT01378390 Austria;Netherlands;Spain;
Expanded human allogenic mesemchymal adult stem cells extracted from adipose tissue (eASCs)
TiGenix, S.A. Unipersonal
2012 - EUCTR2011-006064-43-NL Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;
Expanded human allogenic mesenchymal adult stem cells extractd from adipose tissue (eASCs)
CELLERIX S.A.
2012 Phase 3 EUCTR2011-006064-43-IT Austria;Belgium;Germany;Israel;Italy;Netherlands;Spain;
Expanded human allogenic mesenchymal adult stem cells extracted from adipose
MILLENNIUM PHARMACEUTICALS, INC.
2019 Phase 4 EUCTR2019-000333-39-IT Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
Expanded human allogenic mesenchymal adult stem cells extracted from adipose tissue (eASCs
Millennium Pharmaceuticals, Inc (MPI)
2020 Phase 4 EUCTR2017-002491-10-FR Austria;Czech Republic;France;Germany;Spain;United Kingdom;
2020 Phase 4 EUCTR2017-002491-10-ES Austria;Czech Republic;France;Germany;Spain;United Kingdom;
2020 Phase 4 EUCTR2017-002491-10-CZ Austria;Czech Republic;Czechia;France;Germany;Spain;United Kingdom;
Takeda Development Center Americas, Inc.
2020 Phase 4 EUCTR2017-002491-10-DE Austria;Czech Republic;Czechia;France;Germany;Israel;Spain;
2020 Phase 4 EUCTR2017-002491-10-AT Austria;Czech Republic;Czechia;France;Germany;Israel;Spain;
Expanded human allogenic mesenchymal adult stem cells extracted from adipose tissue (eASCs)
Millennium Pharmaceuticals, Inc (MPI)
2020 Phase 4 EUCTR2019-000333-39-FR Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 4 EUCTR2019-000333-39-CZ Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
Takeda Development Center Americas, Inc
2020 Phase 4 EUCTR2019-000333-39-BE Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
Takeda Development Center Americas, Inc.
2021 Phase 3 EUCTR2020-003193-48-NL Israel;Italy;Japan;Netherlands;Poland;Spain;
- Phase 3 EUCTR2020-003193-48-PL Israel;Japan;Netherlands;Poland;
TiGenix S.A.U.
2012 Phase 3 EUCTR2011-006064-43-DE Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;
TiGenix, S.A. Unipersonal
2012 Phase 3 EUCTR2011-006064-43-BE Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;
TiGenix, S.A.U.
2021 Phase 3 EUCTR2017-000725-12-SE Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2017-000725-12-DK Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2017-000725-12-GB Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2017-000725-12-DE Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-PL Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-HU Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-FR Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-ES Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-CZ Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-BE Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-006064-43-AT Austria;Belgium;France;Germany;Israel;Italy;Netherlands;Spain;
Extracorporeal Photopheresis
Mallinckrodt
2004 Phase 2 NCT00221026 Austria;Belgium;Germany;United States;
FE 999301
University Hospital Schleswig-Holstein (UKSH)
2016 Phase 2 EUCTR2016-000205-36-DE Germany;
FFP104
Fast Forward Pharmaceuticals
2016 Phase 1/Phase 2 NCT02465944 Belgium;Netherlands;
Fast Forward Pharmaceuticals, B.V.
2016 Phase 2 EUCTR2015-001678-17-NL Belgium;Netherlands;
2015 Phase 2 EUCTR2015-001678-17-BE Belgium;Netherlands;
FITC-Adalimumab
University of Erlangen-Nürnberg Medical School
2011 Phase 1/Phase 2 NCT01275508 Germany;
FMT
Children's Hospital Los Angeles
2017 Phase 1/Phase 2 NCT03194529 United States;
St Vincent's Hospital Melbourne
2021 Phase 2/Phase 3 NCT04970446 -
Yanling Wei
2015 Phase 2 NCT02335281 China;
FOS
Hospital Universitari Vall d'Hebron Research Institute
2014 - NCT02539849 Spain;
Faecal Microbiota Transplantation
St Vincent's Hospital Melbourne
2018 - NCT03477032 Australia;
Faecal microbiota transplantation
Torkell Ellingsen
2022 Phase 2 NCT04924270 -
Fecal Microbial Transplantation
Beth Israel Deaconess Medical Center
2013 Phase 1 NCT01847170 United States;
Stony Brook University
2017 Early Phase 1 NCT03267238 United States;
Fecal Microbial transplant
Seattle Children's Hospital
2015 Phase 1/Phase 2 NCT02272868 United States;
Fecal Microbiota Transplant
Children's Hospital of Philadelphia
2015 - NCT02636517 United States;
Stacy A. Kahn
2017 Phase 1/Phase 2 NCT02330211 United States;
University of Alberta
2014 Phase 1/Phase 2 NCT02199561 Canada;
Fecal Microbiota Transplant (FMT)
Boston Medical Center
2015 Phase 2 NCT02417974 United States;
Stacy A. Kahn
2015 Phase 1/Phase 2 NCT02330653 United States;
University of Alberta
2017 Phase 2 NCT03078803 Canada;
Fecal Microbiota Transplantation
Stanford University
2022 Phase 1 NCT03747718 United States;
Fecal Microbiota Transplantation (FMT)
Assistance Publique - Hôpitaux de Paris
2021 Phase 3 NCT04997733 France;
Children's Mercy Hospital Kansas City
2014 Phase 1 NCT02108821 United States;
Fecal microbiota
ASSISTANCE PUBLIQUE -HOPITAUX DE PARIS (AP-HP)
2019 Phase 3 EUCTR2019-003816-29-FR France;
Fecal microbiota transplantation
Gulhane Military Medical Academy
2015 Phase 3 NCT02575040 Turkey;
Ferric Carboxy Maltose
Shield Therapeutics
2016 Phase 3 NCT02680756 Belgium;France;Germany;Hungary;Spain;United States;
Ferric carboxymaltose
Vifor Inc.
2008 Phase 3 NCT00810030 Austria;Russian Federation;
Ferrous sulphate
Barts Health NHS Trust
2011 Phase 4 EUCTR2010-023797-39-GB United Kingdom;
Queen Mary University of London
2011 Phase 4 NCT01991314 United Kingdom;
Fibrin glue injection in fistula
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
2003 Phase 3 NCT00723047 Belgium;France;
Filgotinib
GILEAD SCIENCES INCORPORATED
2018 Phase 3 EUCTR2016-002763-34-IT Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001367-36-IT Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
Gilead Sciences
2018 Phase 1 NCT03417778 Germany;New Zealand;United States;
2017 Phase 3 NCT02914600 Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 2 NCT03077412 Austria;Belgium;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 2 NCT03046056 Austria;Belgium;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Spain;Ukraine;United Kingdom;United States;
2016 Phase 3 NCT02914561 Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
Filgrastim
Barts Health NHS Trust
2017 Phase 3 EUCTR2017-002545-30-GB United Kingdom;
Cedars-Sinai Medical Center
2020 Phase 1/Phase 2 NCT04224558 United States;
European Group for Blood and Marrow Transplantation (EMBT)
2006 - EUCTR2005-003337-40-GB United Kingdom;
Fish oil
The First Affiliated Hospital of Sun Yat-sen University
2011 - ChiCTR-TRC-11001321 China;
Flagyl
GETECCU
2011 - EUCTR2011-000885-36-ES Spain;
Flixabi
University Medical Center Groningen
2021 Phase 4 EUCTR2020-001811-26-BE Belgium;Netherlands;
2020 Phase 4 EUCTR2020-001811-26-NL Netherlands;
University Southampton Hospital NHS Foundation Trust
2018 Phase 4 EUCTR2018-001546-33-GB United Kingdom;
Fluconazole
Children's Hospital of Philadelphia
2018 Phase 2 NCT03476317 United States;
University Hospital, Lille
2008 Phase 2 NCT02997059 France;
University of Pennsylvania
2016 Phase 2 NCT02765256 United States;
Fludarabine
Cedars-Sinai Medical Center
2020 Phase 1/Phase 2 NCT04224558 United States;
Northwestern University
2019 Phase 2 NCT04154735 United States;
Fludarabine Phosphate
Fred Hutchinson Cancer Research Center
2012 Phase 2 NCT01570348 United States;
Fludarabine phosphate
Barts Health NHS Trust
2017 Phase 3 EUCTR2017-002545-30-GB United Kingdom;
Fluorescence endoscopy and spectroscopy
University Medical Center Groningen
2020 Phase 1 NCT04112212 Netherlands;
FolateScan (Technetium Tc 99mEC20)
Mayo Clinic
2006 Phase 2 NCT00588393 United States;
Foralumab
Tiziana Life Sciences, PLC
2021 Phase 1 NCT05028946 -
Fosfato sodico de dexametasona
ERYDEL S.P.A.
2009 - EUCTR2008-007329-38-ES Italy;Spain;
Fosfomycin
Ishikawa Dai
2017 - JPRN-jRCTs031180415 Japan;
Fully humanised, recombinant monoclonal antibody (IgG1)
University of Birmingham
2018 Phase 1 EUCTR2018-002001-65-GB United Kingdom;
G-CSF
National Institute of Allergy and Infectious Diseases (NIAID)
2001 Phase 1 NCT00025805 United States;
Northwestern University
2019 Phase 2 NCT04154735 United States;
Paul Szabolcs
2012 Phase 1/Phase 2 NCT00692939 United States;
G321605
Galapagos NV
2014 - EUCTR2014-001892-30-HU Belgium;Czech Republic;France;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;United Kingdom;
2014 - EUCTR2014-001892-30-BE Belgium;Czech Republic;France;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;United Kingdom;
GED-0301
CELGENE CORPORATION
2017 Phase 3 EUCTR2015-001924-40-IT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-IT Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2015-001693-18-IT Italy;
Celgene
2017 Phase 3 NCT02974322 Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 NCT02641392 Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 2 NCT02685683 Italy;
2015 Phase 3 NCT02596893 Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;Former Serbia and Montenegro;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2015 Phase 1 NCT02367183 Australia;Canada;Hungary;Slovakia;United States;
Celgene Corporation
2017 Phase 3 EUCTR2015-001963-37-FI Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001925-18-FI Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-SK Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-PT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-NL Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-LV Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-HU Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-HR Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-GR Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-GB Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-FR Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-FI Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-ES Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-DK Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-DE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-CZ Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-BE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-AT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-SK Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-SE Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-PT Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-LV Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-HU Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-HR Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-GR Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-GB Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Oman;Pakistan;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-ES Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-DK Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-DE Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-CZ Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-BG Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-BE Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-AT Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-SK Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-SE Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-PT Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-LV Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-HU Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-HR Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-GR Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-GB Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-ES Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-DK Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-DE Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-CZ Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-BG Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-BE Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-AT Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2015 Phase 3 EUCTR2015-001963-37-EE Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2015 Phase 3 EUCTR2015-001925-18-EE Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2015-001925-18-NO Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2015-001924-40-PL Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
GIULIANI
2013 - EUCTR2011-002640-27-DE Germany;Italy;
2012 - EUCTR2011-005678-47-IT Italy;
2011 - EUCTR2011-002640-27-IT Germany;Italy;
GLPG0634
Galapagos NV
2014 Phase 2 NCT02048618 Belgium;Czech Republic;France;Germany;Hungary;Poland;Romania;Russian Federation;United Kingdom;
2014 Phase 2 EUCTR2013-002857-32-GB Belgium;Czech Republic;France;Germany;Hungary;Poland;Romania;Russian Federation;United Kingdom;
2014 Phase 2 EUCTR2013-002857-32-DE Belgium;Czech Republic;France;Germany;Hungary;Poland;Romania;Russian Federation;United Kingdom;
2014 Phase 2 EUCTR2013-002857-32-CZ Belgium;Czech Republic;France;Germany;Hungary;Poland;Romania;Russian Federation;United Kingdom;
2014 - EUCTR2013-002857-32-PL Belgium;Czech Republic;France;Germany;Hungary;Poland;Romania;Russian Federation;United Kingdom;
2014 - EUCTR2013-002857-32-HU Belgium;Czech Republic;France;Germany;Hungary;Poland;Romania;Russian Federation;United Kingdom;
2014 - EUCTR2013-002857-32-BE Belgium;Czech Republic;France;Germany;Hungary;Poland;Romania;Russian Federation;United Kingdom;
GLPG1205
Galapagos NV
2014 - EUCTR2014-001892-30-HU Belgium;Czech Republic;France;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;United Kingdom;
2014 - EUCTR2014-001892-30-BE Belgium;Czech Republic;France;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;United Kingdom;
GS-5745
GILEAD SCIENCES INCORPORATED
2015 Phase 2 EUCTR2015-001249-10-IT Australia;Canada;Czech Republic;Germany;Hungary;Iceland;Italy;South Africa;Spain;United Kingdom;United States;
Gilead Sciences, Inc
2016 Phase 2 EUCTR2015-001249-10-IS Australia;Canada;Czech Republic;Germany;Hungary;Iceland;New Zealand;South Africa;Spain;United Kingdom;United States;
2015 Phase 2 EUCTR2015-001249-10-HU Australia;Canada;Czech Republic;Germany;Hungary;Iceland;New Zealand;South Africa;Spain;United Kingdom;United States;
2015 Phase 2 EUCTR2015-001249-10-GB Australia;Canada;Czech Republic;Germany;Hungary;Iceland;Italy;New Zealand;South Africa;Spain;United Kingdom;United States;
2015 Phase 2 EUCTR2015-001249-10-ES Australia;Canada;Czech Republic;Germany;Hungary;Iceland;New Zealand;South Africa;Spain;United Kingdom;United States;
2015 Phase 2 EUCTR2015-001249-10-DE Australia;Canada;Czech Republic;Germany;Hungary;Iceland;New Zealand;South Africa;Spain;United Kingdom;United States;
2015 Phase 2 EUCTR2015-001249-10-CZ Australia;Canada;Czech Republic;Germany;Hungary;Iceland;New Zealand;South Africa;Spain;United Kingdom;United States;
GS-6034
GILEAD SCIENCES INCORPORATED
2018 Phase 3 EUCTR2016-002763-34-IT Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2016-001367-36-IT Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003179-23-IT Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003153-15-IT Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States;
Galapagos NV
2017 Phase 3 EUCTR2016-002763-34-SK Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002763-34-SE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002763-34-HU Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002763-34-DE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002763-34-BG Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001367-36-SK Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001367-36-DE Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001367-36-BG Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
Gilead Sciences, Inc.
2018 Phase 2 EUCTR2016-003179-23-BE Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2016-003179-23-AT Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2016-003153-15-BE Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2018 Phase 2 EUCTR2016-003153-15-AT Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002763-34-PT Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002763-34-NL Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002763-34-IS Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002763-34-HR Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002763-34-GR Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002763-34-GB Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002763-34-ES Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002763-34-CZ Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002763-34-BE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002763-34-AT Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001367-36-SE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001367-36-PT Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001367-36-NO Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001367-36-NL Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001367-36-IS Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001367-36-HU Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001367-36-HR Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001367-36-GR Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001367-36-GB Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001367-36-ES Argentina;Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001367-36-CZ Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001367-36-BE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-001367-36-AT Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sri Lanka;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003179-23-PL Austria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003179-23-HU Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003179-23-GB Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003179-23-FR Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003179-23-ES Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003179-23-DE Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003179-23-CZ Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003153-15-PL Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003153-15-HU Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003153-15-GB Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003153-15-ES Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003153-15-DE Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003153-15-CZ Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States;
GSK1070806
University of Birmingham
2019 Phase 1/Phase 2 NCT03681067 United Kingdom;
2018 Phase 1 EUCTR2018-002001-65-GB United Kingdom;
GSK1605786
GlaxoSmithKline
2011 Phase 1 NCT01489943 United States;
2010 Phase 1 NCT01611805 Australia;
GSK1605786 ChemoCentryx: formulation A
GlaxoSmithKline
2010 Phase 1 NCT01114607 United States;
GSK1605786 GSK direct-fill: formulation C
GlaxoSmithKline
2010 Phase 1 NCT01114607 United States;
GSK1605786 GSK modified-process: formulation D
GlaxoSmithKline
2010 Phase 1 NCT01114607 United States;
GSK1605786 GSK tablet: formulation E
GlaxoSmithKline
2010 Phase 1 NCT01114607 United States;
GSK1605786 GSK: formulation B
GlaxoSmithKline
2010 Phase 1 NCT01114607 United States;
GSK1605786 capsule
GlaxoSmithKline
2013 Phase 1 NCT01827631 China;
GSK1605786A
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
2012 - EUCTR2010-022384-35-IT Argentina;Australia;Austria;Brazil;Bulgaria;Canada;China;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;New Zealand;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2010-022383-12-IT Argentina;Australia;Austria;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Estonia;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2010-022382-10-IT Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;South Africa;Spain;Sweden;United Kingdom;United States;
GlaxoSmithKline
2011 Phase 3 NCT01536418 Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 NCT01318993 Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;New Zealand;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 3 NCT01316939 Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2010 Phase 3 NCT01277666 Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
GlaxoSmithKline Research & Development Limited
2013 - EUCTR2010-022383-12-BG Argentina;Austria;Brazil;Bulgaria;Chile;Czech Republic;Denmark;Estonia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2012 Phase 3 EUCTR2010-022382-10-ES Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2010-022383-12-SK Argentina;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Denmark;Estonia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022383-12-PT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2010-022383-12-GR Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2010-022383-12-ES Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2010-022383-12-EE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022383-12-AT Argentina;Australia;Austria;Brazil;Bulgaria;Chile;Czech Republic;Denmark;Estonia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022382-10-SK Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2010-022382-10-AT Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022383-12-SE Argentina;Austria;Brazil;Bulgaria;Chile;Czech Republic;Denmark;Estonia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-022383-12-NL Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2011 - EUCTR2010-022383-12-DK Argentina;Austria;Brazil;Bulgaria;Chile;Czech Republic;Denmark;Estonia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
GlaxoSmithKline Research & Development Ltd
2013 - EUCTR2010-022384-35-BG Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2012 Phase 3 EUCTR2010-022384-35-EE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022384-35-SK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022384-35-PT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2010-022384-35-PL Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2010-022384-35-GR Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2010-022384-35-ES Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2010-022384-35-AT Argentina;Austria;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2010-022383-12-PL Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022384-35-GB Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022384-35-DK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022384-35-BE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022383-12-NO Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;Germany;Greece;Hungary;Italy;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2011 Phase 3 EUCTR2010-022383-12-GB Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;Germany;Greece;Hungary;Italy;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2011 Phase 3 EUCTR2010-022383-12-BE Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022382-10-GB Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022382-10-BE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022384-35-SE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-022384-35-HU Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022384-35-DE Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022384-35-CZ Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022383-12-HU Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022383-12-CZ Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022382-10-SE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022382-10-NL Austria;Belgium;Czech Republic;Denmark;Germany;Hungary;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
2011 - EUCTR2010-022382-10-HU Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022382-10-DK Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022382-10-DE Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
2010 - EUCTR2010-022382-10-CZ Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2010-022382-10-NO Austria;Belgium;Czech Republic;Denmark;Germany;Hungary;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
- - EUCTR2010-022383-12-DE Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Italy;Japan;Netherlands;Norway;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
GlaxoSmithKline Research and Development Limited
2013 - EUCTR2011-002817-12-NL Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2013 - EUCTR2011-002817-12-DE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2013 - EUCTR2011-002817-12-CZ Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2013 - EUCTR2011-002817-12-BG Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2012 Phase 3 EUCTR2011-002817-12-DK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-002817-12-SK Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-002817-12-PT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-002817-12-HU Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-002817-12-GR Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-002817-12-ES Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2012 - EUCTR2011-002817-12-EE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-002817-12-AT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
GSK2330811
GlaxoSmithKline
2021 Phase 2 NCT04151225 -
Glatiramer acetate
Tel-Aviv Sourasky Medical Center
2008 Phase 2 NCT00731172 Israel;
Glucose
The First Affiliated Hospital of Sun Yat-sen University
2011 - ChiCTR-TRC-11001321 China;
Glutamine
All India Institute of Medical Sciences, New Delhi
2005 Phase 1 NCT00838149 India;
Gold
The 7th Medical Center of the PLA General Hospital (Army general hospital)
2019 Phase 0 ChiCTR1900022728 China;
The First Affiliated Hospital of Anhui Medical University
2020 Phase 0 ChiCTR2000037094 China;
The First Hospital Affiliated to Sun Yat sen University
2020 - ChiCTR2000029543 China;
West China Hospital, Sichuan University
2013 - ChiCTR-DDT-14004999 China;
Golimumab
Janssen Research & Development, LLC
2022 Phase 2 NCT05242471 Italy;
Janssen Scientific Affairs, LLC
2013 Phase 4 NCT01804166 United States;
Green Tea
University Hospital Heidelberg
2010 - NCT01231217 Germany;
Group 2 ustekinumab
Janssen Research & Development, LLC
2011 Phase 3 NCT01369342 Australia;Belgium;Brazil;Bulgaria;Canada;Croatia;France;Germany;Hungary;Iceland;Ireland;Israel;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
2011 Phase 3 NCT01369329 Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Hungary;Iceland;Ireland;Israel;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Serbia;South Africa;Spain;United Kingdom;United States;
Group 3: ustekinumab approximately
Janssen Research & Development, LLC
2011 Phase 3 NCT01369342 Australia;Belgium;Brazil;Bulgaria;Canada;Croatia;France;Germany;Hungary;Iceland;Ireland;Israel;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Russian Federation;Serbia;South Africa;Spain;United Kingdom;United States;
2011 Phase 3 NCT01369329 Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Hungary;Iceland;Ireland;Israel;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Serbia;South Africa;Spain;United Kingdom;United States;
Growth hormone
Children's Hospital Medical Center, Cincinnati
2005 Phase 2 NCT00109473 United States;
Guselkumab
Janssen Pharmaceutical K.K.
2020 Phase 3 NCT04397263 Japan;
2020 Phase 3 JPRN-JapicCTI-205298 Japan;
2018 Phase 2-3 JPRN-JapicCTI-183950 Japan, North America;
Janssen Research & Development, LLC
2022 Phase 2 NCT05242471 Italy;
University of California, San Diego
2013 - NCT02103361 United States;
Guselkumab Dose 1
Janssen Research & Development, LLC
2022 Phase 3 NCT05197049 Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;China;Croatia;Czechia;France;Germany;Hungary;Italy;Japan;Jordan;Korea, Republic of;Lithuania;Netherlands;New Zealand;Poland;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2/Phase 3 NCT03466411 Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Colombia;Croatia;Czechia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, The Former Yugoslav Republic of;Malaysia;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Puerto Rico;Russian Federation;Saudi Arabia;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
Guselkumab Dose 2
Janssen Research & Development, LLC
2022 Phase 3 NCT05197049 Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;China;Croatia;Czechia;France;Germany;Hungary;Italy;Japan;Jordan;Korea, Republic of;Lithuania;Netherlands;New Zealand;Poland;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2/Phase 3 NCT03466411 Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Colombia;Croatia;Czechia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, The Former Yugoslav Republic of;Malaysia;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Puerto Rico;Russian Federation;Saudi Arabia;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
Guselkumab Dose 3
Janssen Research & Development, LLC
2022 Phase 3 NCT05197049 Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;China;Croatia;Czechia;France;Germany;Hungary;Italy;Japan;Jordan;Korea, Republic of;Lithuania;Netherlands;New Zealand;Poland;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2/Phase 3 NCT03466411 Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Colombia;Croatia;Czechia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, The Former Yugoslav Republic of;Malaysia;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Puerto Rico;Russian Federation;Saudi Arabia;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
Guselkumab Dose 4
Janssen Research & Development, LLC
2018 Phase 2/Phase 3 NCT03466411 Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Colombia;Croatia;Czechia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, The Former Yugoslav Republic of;Malaysia;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Puerto Rico;Russian Federation;Saudi Arabia;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
Guselkumab Dose 5
Janssen Research & Development, LLC
2018 Phase 2/Phase 3 NCT03466411 Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Colombia;Croatia;Czechia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, The Former Yugoslav Republic of;Malaysia;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Puerto Rico;Russian Federation;Saudi Arabia;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Tunisia;Turkey;Ukraine;United Kingdom;United States;
HM201
Syneos Health
2021 Early Phase 1 NCT05088369 -
HMPL-004
Hutchison Medipharma Limited
2006 Phase 2 NCT00655733 United States;
HMPL004-6599
Nutrition Science Partners Limited
2018 Phase 1 NCT03597971 Australia;
HUMAN ALBUMIN AS MACROAGGREGATES
ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE
2019 Phase 2 EUCTR2019-001948-21-FR France;
HUMAN PLASMA FOR FRACTIONATION
Fundación FISEVI
2012 - EUCTR2011-006127-38-ES Spain;
2012 - EUCTR2011-004820-37-ES Spain;
HUMIRA
Abbott GmbH & Co. KG
2008 - EUCTR2006-004814-41-IT Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
Abbott GmbH & Co. KG (Abbott)
- Phase 3 EUCTR2006-002078-23-SK Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
Boehringer Ingelheim
2016 Phase 3 NCT02871635 Belarus;Bosnia and Herzegovina;Croatia;Czechia;Germany;Greece;Israel;Poland;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
GETAID
2014 Phase 4 EUCTR2013-003199-11-FR Belgium;France;
University of Leuven, Division of Gastroenterology
2007 Phase 4 EUCTR2006-006632-22-BE Belgium;
HUMIRA (adalimumab)
Boehringer Ingelheim International GmbH
2017 Phase 3 EUCTR2016-000612-14-HR Belarus;Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000612-14-GR Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000612-14-GB Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000612-14-DE Belarus;Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000612-14-CZ Belarus;Bosnia and Herzegovina;Croatia;Czech Republic;European Union;Germany;Greece;Israel;Russian Federation;Serbia;Turkey;Ukraine;United Kingdom;United States;
HUMIRA - 40MG/0.8ML SOLUZ. INIETTABILE- USO SOTTOCUTANEO-FLACONCINO(VETRO) 0.8ML 2 ASTUCCI:1 FLACONCINO+1SIRINGA+1AGO+1ADATT.STERILE-2TAMPONI IMBEVUTI ALCOOL
UMBERTO I - POLICLINICO DI ROMA
2017 Phase 4 EUCTR2016-000522-18-IT Belgium;Czech Republic;Czechia;France;Germany;Hungary;Italy;Netherlands;Poland;United Kingdom;
HUMIRA 40 mg solución inyectable en jeringa precargada
Abbott GmbH & Co. KG
2010 Phase 3 EUCTR2010-020137-10-ES Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
HUMIRA 40Mg Solution for Injection
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
2019 Phase 4 NCT04131322 Spain;
HUMIRA ®
Fundación Publica Andaluza para la Gestión de Salud en Sevilla (FISEVI)
2019 Phase 4 EUCTR2019-000717-37-ES Spain;
HUMIRA*SC 2SIR+F 40MG 0,8ML+2T
Abbott GmBH Co KG
2005 - EUCTR2004-002163-24-IT Denmark;Germany;Hungary;Italy;Spain;United Kingdom;
Abbott GmBH & Co. KG
2010 Phase 3 EUCTR2010-020137-10-IT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
Abbott GmbH Co.KG
2006 - EUCTR2005-005291-32-IT Austria;Belgium;Germany;Italy;Netherlands;Sweden;
HYDROXYCHLOROQUINE SULPHATE
Royal Liverpool & Broadgreen University Hospitals Trust
2009 Phase 2 EUCTR2008-001137-99-GB United Kingdom;
Hematopoietic stem cell transplantation
University of California, Los Angeles
2014 Phase 0 NCT01932658 United States;
Herpes Zoster Vaccine
University of Alabama at Birmingham
2016 Phase 2 NCT02538341 United States;
2013 Phase 2 NCT02538757 United States;
Hextend
Spectrum Health Hospitals
2007 Phase 3 NCT00467922 United States;
High Oligosaccharide Group
University of British Columbia
2015 - NCT02193750 Australia;Canada;
High dose TSO
Dr. Falk Pharma GmbH
2010 Phase 2 NCT01279577 Germany;
High serine diet
University of Michigan
2021 - NCT04795960 United States;
High-dose Cyclophosphamide
Johns Hopkins University
2015 Phase 1/Phase 2 NCT01836289 United States;
HuM291
PDL BioPharma, Inc
2005 - EUCTR2004-004388-31-DE Germany;
PDL BioPharma, Inc.
2005 - EUCTR2004-004387-72-DE Germany;
Protein Design Labs, Inc.
2005 - EUCTR2004-004387-72-AT Austria;Germany;
Hulio
University Medical Center Groningen
2021 Phase 4 EUCTR2020-001811-26-BE Belgium;Netherlands;
2020 Phase 4 EUCTR2020-001811-26-NL Netherlands;
Human Anti-IL-12 Antibody
Centocor BV
2009 Phase 2 EUCTR2008-000649-77-FR Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
2009 Phase 2 EUCTR2008-000649-77-ES Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-000649-77-NL Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-000649-77-GB Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-000649-77-DE Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-000649-77-BE Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
2008 - EUCTR2008-000649-77-AT Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
Human Monoclonal Antibody (CNTO 1275) to Interleukin 12p-40
Centocor BV
2009 Phase 2 EUCTR2008-000649-77-FR Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
2009 Phase 2 EUCTR2008-000649-77-ES Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-000649-77-NL Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-000649-77-GB Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-000649-77-DE Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-000649-77-BE Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
2008 - EUCTR2008-000649-77-AT Austria;Belgium;France;Germany;Netherlands;Spain;United Kingdom;
Human Placenta-Derived Cells PDA001 Intravenous Infusion
Celularity Incorporated
2010 Phase 2 NCT01155362 United States;
Human Umbilical Cord Mesenchymal Stem Cells
Shanghai East Hospital
2022 - NCT05262829 China;
Human anti-IP10 monoclonal antibody
Bristol-Myers Squibb International Corporation
2012 - EUCTR2011-002981-19-PL Belgium;France;Hungary;Poland;South Africa;United States;
2012 - EUCTR2011-002981-19-HU Belgium;France;Hungary;Poland;South Africa;United States;
2012 - EUCTR2011-002981-19-BE Belgium;France;Hungary;Poland;South Africa;United States;
Human umbilical cord mesenchymal stem cells (UC-MSCs)
CryoCord Sdn Bhd
2022 Phase 1 NCT05039411 Malaysia;
Humira
Abbott GmbH & Co. KG
2008 - EUCTR2006-004814-41-NL Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
2008 - EUCTR2006-004814-41-CZ Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
2008 - EUCTR2006-004814-41-BE Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
2008 - EUCTR2004-002163-24-GB Denmark;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-004814-41-FR Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
2006 - EUCTR2005-005291-32-SE Austria;Belgium;Germany;Italy;Netherlands;Sweden;
2006 - EUCTR2005-005291-32-NL Austria;Belgium;Germany;Italy;Netherlands;Sweden;
2006 - EUCTR2005-005291-32-DE Austria;Belgium;Germany;Italy;Netherlands;Sweden;
2006 - EUCTR2005-005291-32-BE Austria;Belgium;Germany;Italy;Netherlands;Sweden;
2006 - EUCTR2005-005291-32-AT Austria;Belgium;Germany;Italy;Netherlands;Sweden;
2005 - EUCTR2004-002934-20-BE Belgium;
2005 - EUCTR2004-002163-24-DE Denmark;Germany;Hungary;Italy;Spain;United Kingdom;
2004 - EUCTR2004-002163-24-SE Denmark;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
2004 - EUCTR2004-002163-24-ES Denmark;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
2004 - EUCTR2004-002163-24-DK Denmark;Germany;Hungary;Italy;Spain;United Kingdom;
- - EUCTR2006-004814-41-Outside-EU/EEA -
Abbott GmbH & co. KG
2004 - EUCTR2004-002163-24-BE Belgium;Denmark;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
Abbott Laboratories
2004 - EUCTR2004-002163-24-HU Belgium;Denmark;Germany;Hungary;Italy;Spain;Sweden;United Kingdom;
Academic Medical Center
2019 Phase 4 EUCTR2018-002064-15-NL Netherlands;
2013 Phase 4 EUCTR2013-002932-25-NL Netherlands;
Department of medical gastroenterology, Herlev Hospital
2009 Phase 4 EUCTR2009-009926-94-DK Denmark;
Fundació Clínic per a la Recerca Biomèdica
2013 Phase 3 EUCTR2012-001723-12-ES Spain;
GETAID - Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives
2015 Phase 4 EUCTR2013-003199-11-BE Belgium;France;
GETECCU
2011 - EUCTR2011-000885-36-ES Spain;
Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU)
2012 - EUCTR2011-003966-34-ES Spain;
2011 Phase 3 EUCTR2011-003966-34-BE Belgium;Spain;
IBD Center LMU Munich
2008 - EUCTR2008-004926-18-DE Germany;
PIBD-Net
2017 Phase 3 EUCTR2016-000522-18-DE Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
PIBDNet
2018 Phase 4 EUCTR2016-000522-18-BE Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
2017 Phase 4 EUCTR2016-000522-18-NL Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
- Phase 4 EUCTR2016-000522-18-FR Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
Region Örebro län
2021 Phase 4 EUCTR2019-002942-19-DK Denmark;
Robarts Clinical Trials
2015 Phase 4 EUCTR2014-001050-41-DE Canada;Germany;United Kingdom;United States;
Royal Liverpool University Hospital
2012 - EUCTR2011-006084-22-GB United Kingdom;
University Hospital Southampton NHS Foundation Trust
2019 Phase 4 EUCTR2018-004967-30-GB United Kingdom;
University Maastricht
2019 Phase 4 EUCTR2017-004588-11-NL Netherlands;
University Medical Center Groningen
2021 Phase 4 EUCTR2020-001811-26-BE Belgium;Netherlands;
2020 Phase 4 EUCTR2020-001811-26-NL Netherlands;
Humira (adalimumab original)
Fundación Publica Andaluza para la Gestión de Salud en Sevilla (FISEVI)
2019 Phase 4 EUCTR2019-000717-37-ES Spain;
Humira (adalimumab)
Radboud University Medical Centre
2017 Phase 4 EUCTR2016-003321-42-NL Netherlands;
Humira 20 mg solution for injection in pre-filled syringe
AbbVie Deutschland GmbH & Co. KG
2009 Phase 3 EUCTR2007-006494-90-CZ Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
Abbott GmbH & Co. K.G.
- - EUCTR2007-006494-90-Outside-EU/EEA Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
Abbvie Deutschland GmbH & Co. K.G.
2008 Phase 3 EUCTR2007-006494-90-BE Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
Humira 40 mg injekcní roztok v predplnené injekcní stríkacce
PIBDNet
2018 Phase 4 EUCTR2016-000522-18-CZ Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
Humira 40 mg solution for injection in pre-filled pen
Abbott GmbH & Co. KG
2009 - EUCTR2006-004814-41-GB Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
Humira 40 mg solution for injection in pre-filled syringe
AbbVie Deutschland GmbH & Co. KG
2015 Phase 3 EUCTR2013-004034-15-IT Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
2015 Phase 3 EUCTR2013-004034-15-GB Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
2015 Phase 3 EUCTR2013-004034-15-FR Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
2015 Phase 3 EUCTR2013-004034-15-DK Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
2015 Phase 3 EUCTR2013-004034-15-DE Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
2015 Phase 3 EUCTR2013-004034-15-BE Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
2015 Phase 3 EUCTR2013-001746-33-FR Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2015 Phase 3 EUCTR2013-001746-33-BE Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2015 Phase 3 EUCTR2010-020137-10-LT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004034-15-SK Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004034-15-HU Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
2014 Phase 3 EUCTR2013-004034-15-ES Austria;Canada;Czech Republic;Denmark;European Union;France;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
2014 Phase 3 EUCTR2013-004034-15-AT Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Slovakia;Spain;Switzerland;Ukraine;United States;
2014 Phase 3 EUCTR2013-001746-33-SK Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2014 Phase 3 EUCTR2013-001746-33-NL Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2014 Phase 3 EUCTR2013-001746-33-IT Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2014 Phase 3 EUCTR2013-001746-33-ES Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2014 Phase 3 EUCTR2013-001746-33-DK Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2014 Phase 3 EUCTR2013-001746-33-DE Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2014 Phase 3 EUCTR2013-001746-33-CZ Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Hungary;Israel;Netherlands;Slovakia;Spain;Switzerland;United States;
2014 Phase 3 EUCTR2013-001746-33-AT Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Netherlands;Slovakia;Spain;Switzerland;United States;
2014 - EUCTR2013-001746-33-HU Austria;Belgium;Canada;Czech Republic;Denmark;European Union;France;Hungary;Israel;Netherlands;Slovakia;Spain;Switzerland;United States;
2012 Phase 3 EUCTR2010-020137-10-HU Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 Phase 3 EUCTR2010-020137-10-BE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-SE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-NL Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
2010 Phase 3 EUCTR2010-020137-10-GB Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-DE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-CZ Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020137-10-AT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;United States;
2009 Phase 3 EUCTR2007-006494-90-CZ Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
AbbVie Farmacéutica S.L.U.
2014 Phase 4 EUCTR2013-004781-34-ES Spain;
Abbott GmbH & Co. K.G.
2009 Phase 3 EUCTR2007-006494-90-GB Belgium;Czech Republic;United Kingdom;
- - EUCTR2007-006494-90-Outside-EU/EEA Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
Abbott GmbH & Co. KG
2010 Phase 3 EUCTR2010-020137-10-FR Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2006-004814-41-GB Belgium;Czech Republic;France;Italy;Netherlands;United Kingdom;
Abbvie Deutschland GmbH & Co. K.G.
2008 Phase 3 EUCTR2007-006494-90-BE Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
Humira 40 mg/0.8 ml solution for injection
AbbVie GK
- - EUCTR2015-004121-13-Outside-EU/EEA Japan;
Abbott Deutschland GmbH & Co. KG
- - EUCTR2014-004560-38-Outside-EU/EEA Japan;
- - EUCTR2014-004531-39-Outside-EU/EEA Japan;
Humira 40mg/0.4ml pre-filled syringe
PIBD net
2018 Phase 4 EUCTR2016-000522-18-GB Belgium;Canada;Czech Republic;France;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
Humira 40mg/0.8ml solution for injection for paediatric use
AbbVie Deutschland GmbH & Co. KG
2009 Phase 3 EUCTR2007-006494-90-CZ Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
Abbott GmbH & Co. K.G.
- - EUCTR2007-006494-90-Outside-EU/EEA Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
Abbvie Deutschland GmbH & Co. K.G.
2008 Phase 3 EUCTR2007-006494-90-BE Belgium;Canada;Czech Republic;Poland;United Kingdom;United States;
Humira pre-filled PEN
Abbott GmbH & Co. KG
2007 - EUCTR2006-002078-23-SE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
2007 - EUCTR2006-002078-23-PT Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
2007 - EUCTR2006-002078-23-GR Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-002078-23-FI Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
2006 - EUCTR2006-002078-23-ES Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002078-23-DK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
Abbott GmbH & Co. KG (Abbott)
2010 - EUCTR2006-002078-23-IE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
2007 - EUCTR2006-002078-23-GB Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Slovakia;Sweden;United Kingdom;
2006 Phase 3 EUCTR2006-002078-23-FR Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002078-23-NO Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002078-23-NL Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002078-23-DE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
2006 - EUCTR2006-002078-23-CZ Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
2006 - EUCTR2006-002078-23-BE Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-002078-23-AT Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
Humira®
ALLERGAN LIMITED
2020 Phase 2;Phase 3 EUCTR2018-004346-42-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Allergan Ltd.
2020 Phase 2;Phase 3 EUCTR2018-004346-42-RO Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2;Phase 3 EUCTR2018-004346-42-BG Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2;Phase 3 EUCTR2018-004346-42-BE Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-004346-42-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-004346-42-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
AstraZeneca
2018 Phase 2/Phase 3 NCT03759288 Australia;Austria;Bulgaria;Canada;China;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
AstraZeneca AB
2021 Phase 2;Phase 3 EUCTR2018-004346-42-HU Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2020 Phase 2;Phase 3 EUCTR2018-004346-42-CZ Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-004346-42-GB Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-004346-42-DE Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2018-004346-42-PL Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Astrazeneca AB
2020 Phase 2;Phase 3 EUCTR2018-004346-42-AT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
JANSSEN CILAG INTERNATIONAL NV
2018 Phase 3 EUCTR2017-004209-41-IT Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
Janssen-Cilag International N.V.
2018 Phase 3 EUCTR2017-004209-41-PL Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004209-41-FR Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004209-41-ES Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004209-41-BG Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004209-41-BE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
Janssen-Cilag International NV
2018 Phase 3 EUCTR2017-004209-41-NL Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004209-41-GB Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004209-41-DE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004209-41-CZ Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
Samsung Bioepis Co., Ltd.
2014 Phase 3 EUCTR2013-005013-13-BG Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
2014 - EUCTR2013-005013-13-PL Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
2014 - EUCTR2013-005013-13-LT Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
2014 - EUCTR2013-005013-13-CZ Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
Hydroxychloroquine
Royal Liverpool University Hospital
2014 Phase 2 NCT01783106 United Kingdom;
ICG-guided bowel perfusion assessment
Leiden University Medical Center
2020 Phase 3 NCT04712032 Netherlands;
IGG2 ANTIBODIES
EA Pharma Co., Ltd.
2019 Phase 2 EUCTR2018-002109-70-HU Czech Republic;Hungary;Japan;Poland;
2019 Phase 2 EUCTR2018-002109-70-CZ Czech Republic;Czechia;Hungary;Japan;Poland;Russian Federation;
IM90838
Immunic AG
2019 Phase 2 EUCTR2018-001895-39-NL Bulgaria;Croatia;Czech Republic;Germany;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001895-39-HR Bulgaria;Croatia;Czech Republic;Germany;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001895-39-CZ Bulgaria;Croatia;Czech Republic;Germany;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001895-39-BG Bulgaria;Croatia;Czech Republic;Germany;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Ukraine;United Kingdom;United States;
IMP will be labeled as ''PF-04236921 106mg/vial, Clonal SC lyophilized form''.
PFIZER INC.
2011 - EUCTR2010-023034-23-IT Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Hungary;Israel;Italy;New Zealand;Sweden;Switzerland;United Kingdom;United States;
IMP will be labeled as PF-04236921 106mg/vial, Clonal SC lyophilized form
PFIZER INC.
2012 - EUCTR2011-000722-30-IT Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Greece;Hungary;Ireland;Israel;Italy;New Zealand;Sweden;Switzerland;United Kingdom;United States;
IMU-838
Immunic AG
2019 Phase 2 EUCTR2018-001895-39-NL Bulgaria;Croatia;Czech Republic;Germany;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001895-39-HR Bulgaria;Croatia;Czech Republic;Germany;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001895-39-CZ Bulgaria;Croatia;Czech Republic;Germany;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2 EUCTR2018-001895-39-BG Bulgaria;Croatia;Czech Republic;Germany;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Ukraine;United Kingdom;United States;
ITF 2357
ITALFARMACO
2008 - EUCTR2007-000189-19-IT Belgium;Italy;Netherlands;
ITF2357
Italfarmaco
2007 Phase 1/Phase 2 NCT00792740 Belgium;
Italfarmaco S.p.A.
2007 - EUCTR2007-000189-19-NL Belgium;Italy;Netherlands;
2007 - EUCTR2007-000189-19-BE Belgium;Italy;Netherlands;
2005 Phase 2 EUCTR2004-004854-19-SK Slovakia;
Ileocecal resection
University Hospital, Lille
2017 - NCT02872506 -
Ileocolonoscopy
Universitaire Ziekenhuizen Leuven
2005 Phase 2 NCT02247258 Belgium;Czech Republic;Greece;
Immune Ablation and Hematopoietic Stem Cell Support
Richard Burt, MD
2001 Phase 1 NCT00278577 United States;
Immunonutrition
Istituto Clinico Humanitas
2020 - NCT04014517 -
Immunosuppressor/TNFalpha
University Hospital, Grenoble
2018 - NCT03623932 France;
Immunosuppressors (Thiopurines or Methotrexate)
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
2021 Phase 4 NCT05072782 -
Impact
Lawson Health Research Institute
2016 - NCT02742597 Canada;
NHS Greater Glasgow and Clyde
2020 - NCT04273399 United Kingdom;
Imraldi
University Hospital Southampton NHS Foundation Trust
2019 Phase 4 EUCTR2018-004967-30-GB United Kingdom;
Imuran
Academic Medical Center, department of Gastroenterology and hepatology
2008 - EUCTR2008-001131-35-NL Netherlands;
Amsterdam UMC location AMC
2021 Phase 3;Phase 4 EUCTR2021-000469-33-NL Netherlands;
Centocor B.V.
2005 Phase 3 EUCTR2004-002815-10-GB Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
2005 Phase 3 EUCTR2004-002815-10-ES Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-SE Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-DK Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-DE Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-AT Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
Novartis Pharma Services AG
2005 Phase 2 EUCTR2005-001148-22-SK Slovakia;
PIBDNet
2017 Phase 4 EUCTR2016-000522-18-NL Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
University of Edinburgh
2015 - EUCTR2014-002311-41-GB Belgium;France;Germany;Sweden;United Kingdom;
Imurel
GETAID
2015 Phase 4 EUCTR2014-002311-41-SE France;Germany;Netherlands;Sweden;United Kingdom;
GETECCU
2011 - EUCTR2011-000885-36-ES Spain;
Marianne Kiszka-Kanowitz
2013 Phase 3 EUCTR2013-001503-37-DK Denmark;
PIBDNet
2018 Phase 4 EUCTR2016-000522-18-BE Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
- Phase 4 EUCTR2016-000522-18-FR Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
Region Örebro län
2021 Phase 4 EUCTR2019-002942-19-DK Denmark;
SOIBD (The Swedish Organisation for the study of Inflammatory Bowel Diseases)
2018 Phase 4 EUCTR2016-004112-35-SE Sweden;
InVita D3
Academic Medical Center
2013 Phase 3 EUCTR2013-002838-20-NL Belgium;Netherlands;
Increlex 10mg/ml solution for injection
Greater Glasgow & Clyde NHS
2011 Phase 2 EUCTR2010-022215-19-GB United Kingdom;
Queen Mary, University of London
2008 - EUCTR2007-004269-16-GB United Kingdom;
Indocyanine green
Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
2017 - ChiCTR-INR-17012532 China;
Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine
2020 Phase 0 ChiCTR2000035737 China;
Inflectra
CELLTRION INC.
2019 Phase 3 EUCTR2019-001087-30-IT Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
CUB- Hopital Erasme
2016 Phase 4 EUCTR2015-004618-10-BE Belgium;
Celltrion, Inc
2019 Phase 3 EUCTR2019-001087-30-PL Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Czechia;Estonia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-LV Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-HU Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-HR Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-GR Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-FR Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-ES Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-DE Austria;Belarus;Bulgaria;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-CZ Austria;Belarus;Bulgaria;Chile;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-BG Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Czechia;Estonia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-AT Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
Department of medical gastroenterology, Herlev Hospital
2016 Phase 4 EUCTR2012-002702-51-NO Denmark;Finland;Norway;Sweden;
Erasmus Medical Center
2015 Phase 4 EUCTR2014-005702-37-NL Netherlands;
Pfizer
2018 - NCT03801928 Canada;United States;
University Medical Center Groningen
2021 Phase 4 EUCTR2020-001811-26-BE Belgium;Netherlands;
2020 Phase 4 EUCTR2020-001811-26-NL Netherlands;
Inflectra 100 mg powder for concentrate for solution for infusion
Santeon
2015 Phase 4 EUCTR2015-001954-14-NL Netherlands;
Infliximab
Academic Medical Center
2019 Phase 4 EUCTR2018-002064-15-NL Netherlands;
2014 - EUCTR2013-001029-17-NL Netherlands;
2013 Phase 4 EUCTR2013-002932-25-NL Netherlands;
Academic Medical Center, department of Gastroenterology and hepatology
2008 - EUCTR2008-001131-35-NL Netherlands;
Beth Israel Deaconess Medical Center
2021 Phase 4 NCT04835506 United States;
Biogen
2018 - NCT03662919 France;
CHRU de Lille
2008 - EUCTR2006-004784-58-FR Belgium;France;Germany;United Kingdom;
Centocor B.V.
2005 Phase 3 EUCTR2004-002815-10-GB Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
2005 Phase 3 EUCTR2004-002815-10-ES Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-SE Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-DK Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-DE Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-AT Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
Centocor, Inc.
2003 Phase 3 NCT00207675 -
2000 Phase 3 NCT00207766 -
2000 Phase 3 NCT00207662 -
1996 Phase 3 NCT00269841 -
1995 Phase 2/Phase 3 NCT00269854 -
Chiba University Hospital
2012 Phase 2 JPRN-UMIN000015297 Japan;
2012 Phase 2 JPRN-UMIN000007806 Japan;
Children's Hospital Medical Center, Cincinnati
2019 - NCT04131504 United States;
Children's Hospital of Fudan University
2022 Phase 4 NCT04530877 -
Clinical Research Group of inflammatory bowel disease in Japan
2009 Phase 4 JPRN-UMIN000002604 Japan;
Copenhagen University Hospital at Herlev
2013 Phase 4 NCT01817426 Denmark;Finland;Norway;Sweden;
Daping Hospital, Army Medical University (Third Military Medical University)
2018 - ChiCTR1800019958 China;
Department of Gastroenterology and Hepatology, Kyoto University Hospital
2011 - JPRN-UMIN000005689 Japan;
Department of Gastroenterology, Nanfang Hospital, Southern Medical University
2016 - ChiCTR1800020305 China;
Department of Lower Gastroenterology, Hyogo College of Medicine
2012 Phase 4 JPRN-UMIN000006889 Japan;
Erasmus Medical Center
2015 Phase 4 NCT02517684 Belgium;Denmark;Finland;Italy;Netherlands;Poland;
2013 Phase 4 NCT01880307 Italy;Netherlands;
Ernest Seidman
2014 - NCT02453607 Canada;
Fukuoka University Chikushi Hospital
2021 - JPRN-UMIN000043165 Japan;
Graduate School of Medical Sciences, Kyushu University
2009 - JPRN-UMIN000010293 Japan;
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
2012 Phase 4 NCT01442025 France;
2005 Phase 3 NCT00571337 Belgium;France;
Hikma Pharmaceuticals LLC
2018 - NCT03452501 Saudi Arabia;
Hvidovre University Hospital
2014 - NCT02060318 Denmark;
IBD Center, Sapporo Kosei General Hospital
2014 - JPRN-UMIN000014006 Japan;
IRCCS Burlo Garofolo
2018 Phase 3 NCT03221166 Italy;
Ishida Tetsuya
2020 Phase 3 JPRN-jRCT2031200117 Austria;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Japan;Latvia;Poland;Spain;US;
Janssen Biotech, Inc.
2010 Phase 3 NCT01190839 Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Netherlands;New Zealand;Poland;Spain;United Kingdom;United States;
Janssen Korea, Ltd., Korea
2007 - NCT00724529 Korea, Republic of;
Janssen Scientific Affairs, LLC
2013 Phase 4 NCT01804166 United States;
Johnson & Johnson (China) Investment Ltd.
2020 - NCT04312659 China;
Klinikum Westbrandenburg GmbH
2015 - NCT02522169 -
Lower GI disease, Hyogo College of Medicine
2007 Phase 2,3 JPRN-UMIN000004427 Japan;
Massachusetts General Hospital
2019 - NCT04655729 United States;
Merck Sharp & Dohme Corp.
2012 - NCT01349920 Moldova, Republic of;United Kingdom;
2010 - NCT00988832 United Kingdom;
2006 - NCT00727298 Germany;
2005 - NCT00705471 -
2004 - NCT00724958 Austria;
2003 Phase 3 NCT00796250 -
Mikami Yohei
2019 - JPRN-jRCT1031190056 Japan;
Nanfang Hospital of Southern Medical University
2014 - NCT02088944 -
Novartis Pharmaceuticals
2011 Phase 2 NCT01355614 Germany;Switzerland;
Oregon Health and Science University
2010 - NCT01266785 United States;
Renji Hospital, School of Medicine, Shanghai Jiaotong University
2020 Phase 0 ChiCTR2000029323 China;
Royal Liverpool University Hospital
2012 - EUCTR2011-006084-22-GB United Kingdom;
Saitama Medical University
2011 - JPRN-UMIN000006232 Japan;
Saitama Medical center
2014 - JPRN-UMIN000012790 Japan;
Samsung Medical Center
2009 Phase 3 NCT01661257 Korea, Republic of;
Second Affiliated Hospital of Wenzhou Medical University
2017 - NCT04272788 China;
Sheba Medical Center
2005 - NCT00252369 Israel;
Sixth Affiliated Hospital, Sun Yat-sen University
2021 - NCT04761952 -
The First Affiliated Hospital of Sun Yat-sen University
2019 - ChiCTR1900026091 China;
The Jikei University School of MedicineDivision of Gastroenterology and Hepatology
2012 Phase 4 JPRN-UMIN000008043 Japan;
Tohoku University Graduate School of Medicine (Tohoku University Hospital)
2012 - JPRN-UMIN000007343 Japan;
University Hospitals Cleveland Medical Center
2008 - NCT00791557 United States;
University Medical Center Groningen
2021 Phase 4 NCT04646187 Belgium;Netherlands;Spain;
University Southampton Hospital NHS Foundation Trust
2018 Phase 4 EUCTR2018-001546-33-GB United Kingdom;
University of Alberta
2015 - NCT02847884 Canada;
University of Leuven Hospitals
2009 Phase 4 EUCTR2006-004784-58-GB Belgium;France;Germany;United Kingdom;
University of Pittsburgh
2005 Phase 4 NCT00688636 United States;
University of Rochester
2007 Phase 4 NCT00462072 United States;
University of Toyama
2017 - JPRN-UMIN000026330 Japan;
University of Western Ontario, Canada
2014 Phase 4 NCT01960426 United States;
Vanderbilt-Ingram Cancer Center
2006 - NCT00897312 -
Infliximab (IFX alone)
Children's Memorial Health Institute, Poland
2008 Phase 3 NCT01559142 Poland;
Infliximab (Remicade)
Centocor, Inc.
2002 - NCT00261976 Argentina;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Hungary;Ireland;Israel;Netherlands;Norway;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
Infliximab (Remicade): 100 mg of lyophilized infliximab
First Department of Medicine, University of Szeged
2014 - EUCTR2013-005629-21-HU Hungary;
Infliximab 5 mg/kg body weight infused over 2 hours
Janssen Inc.
2012 Phase 4 NCT01181765 Canada;
Infliximab 5 mg/kg every 6 weeks
Merck Sharp & Dohme Corp.
2008 Phase 4 NCT00752622 Canada;
Infliximab 7 mg/kg every 8 weeks
Merck Sharp & Dohme Corp.
2008 Phase 4 NCT00752622 Canada;
Infliximab CT-P13
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
2021 Phase 4 NCT05072782 -
Infliximab [infliximab biosimilar 3]
Pfizer
2019 - NCT03884439 Japan;
Infliximab and adalimumab
Regionshospitalet Viborg, Skive
2009 - NCT02322008 -
Infliximab and azathioprine combination at week 0
Sixth Affiliated Hospital, Sun Yat-sen University
2017 - NCT03393247 China;
Infliximab and azathioprine combination at week 14
Sixth Affiliated Hospital, Sun Yat-sen University
2017 - NCT03393247 China;
Infliximab and immunosuppressives
Children's Hospital of Fudan University
2022 Phase 4 NCT05043870 -
Infliximab infusion
Centocor Ortho Biotech Services, L.L.C.
2005 Phase 3 NCT00094458 Austria;Belgium;Canada;Denmark;France;Germany;Greece;Israel;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States;
Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
2019 Phase 4 NCT03885713 Spain;
Infliximab therapeutic drug monitoring
Imelda GI Clinical Research Center
2018 Phase 4 NCT04775732 Belgium;
Infliximab with azathioprine (IIFX + AZA)
Children's Memorial Health Institute, Poland
2008 Phase 3 NCT01559142 Poland;
Infliximab+azathioprine
Belgian IBD Research Group
2001 Phase 4 NCT00554710 Belgium;
Infliximab, adalimumab, certolizumab pegol
Oslo University Hospital
2013 - NCT02073526 Norway;
Infliximab, azathioprine
Sixth Affiliated Hospital, Sun Yat-sen University
2016 - NCT02998827 -
Infliximab-Biosimilar
Onze Lieve Vrouwe Gasthuis
2015 Phase 4 NCT02452151 -
Infliximab-Innovator
Onze Lieve Vrouwe Gasthuis
2015 Phase 4 NCT02452151 -
Injection of iron
Jinling Hospital, China
2012 - NCT01823029 China;
Innovator infliximab
Diakonhjemmet Hospital
2014 Phase 4 NCT02148640 Norway;
Inositol
National Cancer Institute (NCI)
2010 Phase 1/Phase 2 NCT01111292 United States;
Instillation of fibrin glue
Sheba Medical Center
2005 - NCT00252369 Israel;
Interferon beta-1a
EMD Serono
2001 Phase 2 NCT00304252 Germany;Italy;Sweden;Switzerland;United Kingdom;
Interleukin-2 (aldesleukin).
Boston Children's Hospital
2021 Phase 1/Phase 2 NCT04263831 United States;
Intestinal surgery for Crohn's Disease
Sir Run Run Shaw Hospital
2019 Phase 4 NCT03901937 China;
Intralipid
Mayo Clinic
2018 - NCT03773237 United States;
Radboud University
2014 Phase 4 NCT02349594 Netherlands;
Iron sulphate 200mg coated tablets
Barts Health NHS Trust
2011 Phase 4 EUCTR2010-023797-39-GB United Kingdom;
Iron supplement 300-600 mg/day
University Health Network, Toronto
2002 Phase 2 NCT00152841 Canada;
Iron(III)- hydroxide dextran complex
Barts Health NHS Trust
2011 Phase 4 EUCTR2010-023797-39-GB United Kingdom;
Itraconazole 400 mg/day and terbinafine 500 mg/day administered orally.
Montreal Heart Institute
2022 Phase 2 NCT05049525 -
J695
National Institute of Allergy and Infectious Diseases (NIAID)
2000 Phase 1 NCT00007163 United States;
J695, BSF 415977 (formerly LU415977), WAY-165772, A-796874.0
Abbott
2009 - EUCTR2008-004919-36-SE Austria;Denmark;Sweden;
2009 - EUCTR2008-004919-36-DK Austria;Denmark;Sweden;
2009 - EUCTR2008-004919-36-BE Austria;Belgium;Denmark;Sweden;
2009 - EUCTR2008-004919-36-AT Austria;Denmark;Sweden;
JNJ-40346527-AAC
Provention Bio, Inc.
2018 Phase 2 EUCTR2017-003017-25-PL Austria;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
2018 Phase 2 EUCTR2017-003017-25-HU Austria;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
2018 Phase 2 EUCTR2017-003017-25-ES Austria;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
2018 Phase 2 EUCTR2017-003017-25-DE Austria;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
2018 Phase 2 EUCTR2017-003017-25-AT Austria;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
JNJ-64304500
JANSSEN CILAG INTERNATIONAL NV
2021 Phase 2 EUCTR2020-002701-26-IT Canada;France;Germany;Italy;Japan;Spain;Sweden;United States;
Janssen Research & Development, LLC
2021 Phase 2 NCT04655807 Canada;France;Germany;Italy;Japan;Spain;Sweden;United States;
2016 Phase 2 NCT02877134 Belgium;Bulgaria;Canada;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Serbia;Ukraine;United Kingdom;United States;
JNJ-64304500-AAA
JANSSEN CILAG INTERNATIONAL NV
2016 Phase 2 EUCTR2016-000634-21-IT Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
Janssen-Cilag International NV
2019 Phase 2 EUCTR2016-000634-21-FR Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-000634-21-PL Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2016-000634-21-HU Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2016-000634-21-GB Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2016-000634-21-DE Belgium;Bulgaria;Canada;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine;United Kingdom;United States;
JNJ-67864238
JANSSEN CILAG INTERNATIONAL NV
2019 Phase 2 EUCTR2019-003335-37-IT Argentina;Germany;Italy;Poland;Russian Federation;United States;
Janssen Research & Development, LLC
2019 Phase 2 NCT04102111 Argentina;France;Germany;Italy;Poland;Russian Federation;Ukraine;United States;
Janssen-Cilag International NV
2020 Phase 2 EUCTR2019-003335-37-DE Argentina;Germany;Italy;Poland;Russian Federation;United States;
JNJ-78934804
Janssen Research & Development, LLC
2022 Phase 2 NCT05242471 Italy;
Kanamycin
Hyogo college of medicine
2014 Phase 2 JPRN-UMIN000013369 Japan;
Kenacort
University Medical Center Utrecht
2009 - EUCTR2007-005455-42-NL Netherlands;
Kremezin®, Spherical Adsorptive Carbon
Ocera Therapeutics, Inc.
2007 - EUCTR2005-005363-28-HU Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
2007 - EUCTR2005-005363-28-AT Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
2006 Phase 3 EUCTR2005-005363-28-GB Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
2006 - EUCTR2005-005363-28-DE Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
2006 - EUCTR2005-005363-28-CZ Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
2006 - EUCTR2005-005363-28-BE Austria;Belgium;Czech Republic;Germany;Hungary;United Kingdom;
L 44
Lument AB
2019 Phase 2 EUCTR2019-002093-32-SE Sweden;
L01BA
PIBDNet
2017 Phase 4 EUCTR2016-000522-18-NL Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
LDP-02
Millennium Pharmaceuticals, Inc.
2000 Phase 2 NCT00655135 -
LY3074828
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2021 Phase 3 EUCTR2019-002687-27-IT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004614-18-IT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Eli Lilly and Company
2022 Phase 3 EUCTR2019-002687-27-HR Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2019-002687-27-SK Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2019-002687-27-LV Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2019-002687-27-LT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2019-002687-27-FR Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2019-002687-27-DE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002687-27-NL Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-002687-27-HU Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004614-18-LV Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004614-18-LT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004614-18-HR Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004614-18-DK Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004614-18-PL Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004614-18-NL Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004614-18-HU Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004614-18-GB Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004614-18-FR Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004614-18-DE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004614-18-AT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-002204-84-PL Australia;Austria;Belgium;Canada;Czech Republic;France;Hungary;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Switzerland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-002204-84-NL Australia;Austria;Belgium;Canada;Czech Republic;France;Hungary;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Switzerland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-002204-84-HU Australia;Austria;Belgium;Canada;Czech Republic;France;Hungary;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Switzerland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-002204-84-GB Australia;Austria;Belgium;Canada;Czech Republic;France;Hungary;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Switzerland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-002204-84-CZ Australia;Austria;Belgium;Canada;Czech Republic;France;Hungary;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Switzerland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-002204-84-BE Australia;Austria;Belgium;Canada;Czech Republic;France;Hungary;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Switzerland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-002204-84-AT Australia;Austria;Belgium;Canada;Czech Republic;France;Hungary;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Switzerland;Ukraine;United Kingdom;United States;
Lilly S.A.
2019 Phase 3 EUCTR2018-004614-18-ES Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Lactated Ringers
Spectrum Health Hospitals
2007 Phase 3 NCT00467922 United States;
Lactobacillus salivarius UCC118
University College Cork
2002 Phase 2/Phase 3 NCT00510978 Ireland;
Lactulose/Rhamnose solution
MediBeacon
2019 Early Phase 1 NCT03962998 United States;
Lap TAP Bupivacaine/Epinephrine
Cedars-Sinai Medical Center
2015 - NCT02538679 -
Laquinimod
Teva Pharmaceutical Industries
2010 Phase 2 NCT00737932 Belgium;France;Israel;Italy;Netherlands;Poland;South Africa;Spain;United Kingdom;
Teva Pharmaceutical Industries Ltd.
2008 - EUCTR2008-004276-49-IT Belgium;France;Italy;Netherlands;Spain;United Kingdom;
Laquinimod Capsules
Teva Pharmaceutical Industries Ltd.
2008 Phase 2 EUCTR2008-004276-49-GB Belgium;France;Italy;Netherlands;Spain;United Kingdom;
2008 Phase 2 EUCTR2008-004276-49-FR Belgium;France;Italy;Netherlands;Spain;United Kingdom;
2008 Phase 2 EUCTR2008-004276-49-BE Belgium;France;Italy;Netherlands;Spain;United Kingdom;
2008 - EUCTR2008-004276-49-NL Belgium;France;Italy;Netherlands;Spain;United Kingdom;
Laquinimod Cápsulas
Teva Pharmaceutical Industries Ltd.
2008 Phase 2 EUCTR2008-004276-49-ES Belgium;France;Italy;Netherlands;Spain;United Kingdom;
Leucine
Showa Inan General Hospital
2020 - NCT04535882 Japan;
Leukapheresis
Cedars-Sinai Medical Center
2020 Phase 1/Phase 2 NCT04224558 United States;
Lipitor
University College London
2009 Phase 2 EUCTR2009-010163-16-GB United Kingdom;
Liposomal bupivacaine
Cedars-Sinai Medical Center
2018 Phase 4 NCT03723447 United States;
Losartan
Takeda
2016 Phase 4 NCT02760615 United States;
Low dose TSO
Dr. Falk Pharma GmbH
2010 Phase 2 NCT01279577 Germany;
Low dose naltrexone
Santa Barbara Cottage Hospital
2013 Phase 2 NCT01810185 United States;
Low serine diet
University of Michigan
2021 - NCT04795960 United States;
Low-dose IL-2 administration
Nationwide Children's Hospital
2013 Phase 2 NCT02676622 -
Lumbar puncture
Shire
2012 Phase 1 NCT01387594 Austria;Belgium;France;Germany;Netherlands;
Lumentin 44
Lument AB
2019 Phase 2 EUCTR2019-002093-32-SE Sweden;
Lymphocyte immune globulin
Cedars-Sinai Medical Center
2020 Phase 1/Phase 2 NCT04224558 United States;
MB-102
MediBeacon
2019 Early Phase 1 NCT03962998 United States;
MDGN-002
Aevi Genomic Medicine, LLC, a Cerecor company
2017 Phase 1 NCT03169894 United States;
MDX-1100
Bristol-Myers Squibb International Corporation
2012 - EUCTR2011-002981-19-PL Belgium;France;Hungary;Poland;South Africa;United States;
2012 - EUCTR2011-002981-19-HU Belgium;France;Hungary;Poland;South Africa;United States;
2012 - EUCTR2011-002981-19-BE Belgium;France;Hungary;Poland;South Africa;United States;
MEDI2070
ASTRAZENECA
2013 Phase 2 EUCTR2012-004098-26-IT Canada;Czech Republic;France;Germany;Hungary;Italy;Spain;United States;
Allergan
2013 Phase 2 NCT01714726 Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Spain;United States;
Allergan Limited
2017 Phase 2 EUCTR2015-000609-38-GB Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2015-000609-38-HU Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2015-000609-38-DE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2015-000609-38-BG Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
AstraZeneca AB
2020 Phase 2;Phase 3 EUCTR2018-004346-42-CZ Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2013 Phase 2 EUCTR2012-004098-26-HU Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United States;
2013 Phase 2 EUCTR2012-004098-26-FR Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United States;
2013 Phase 2 EUCTR2012-004098-26-ES Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United States;
2013 Phase 2 EUCTR2012-004098-26-DE Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United States;
2013 Phase 2 EUCTR2012-004098-26-CZ Canada;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United States;
MEDIMMUNE, LLC
2016 Phase 2 EUCTR2015-000609-38-IT Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
MedImmune Limited
2016 Phase 2 EUCTR2015-000609-38-CZ Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
MedImmune, Ltd, a wholly owned subsidiary of AstraZeneca UK
2016 Phase 2 EUCTR2015-000609-38-NL Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2015-000609-38-ES Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2015-000609-38-BE Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Slovenia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
METHOTREXATE - 20 MG/0.8 ML SOLUZIONE INIETTABILE 4 SIRINGHE PRERIEMPITE MONOUSO DA 1.25 ML
UMBERTO I - POLICLINICO DI ROMA
2017 Phase 4 EUCTR2016-000522-18-IT Belgium;Czech Republic;Czechia;France;Germany;Hungary;Italy;Netherlands;Poland;United Kingdom;
METHOTREXATE DISODIUM
GETAID
2015 Phase 4 EUCTR2014-002311-41-SE France;Germany;Netherlands;Sweden;United Kingdom;
MICROBIOTA
McMaster Children's Hospital
2018 Phase 1 NCT03378167 Canada;
MLN0002
AMC MEDICAL RESEARCH B.V.
2017 Phase 3 EUCTR2015-000555-24-IT France;Italy;Netherlands;Spain;
Academic Medical Center Amsterdam
2016 Phase 4 EUCTR2015-000555-24-NL Netherlands;
2016 Phase 4 EUCTR2015-000555-24-FR France;Netherlands;Spain;
2016 Phase 4 EUCTR2015-000555-24-ES Netherlands;Spain;
Academic Medical Center, Gastroenterology
2015 Phase 4 EUCTR2014-005376-29-BE Belgium;Netherlands;
MILLENNIUM PHARMACEUTICALS, INC.
2011 - EUCTR2009-016488-12-IT Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Netherlands;
2009 - EUCTR2008-002783-33-IT Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
Millennium Pharmaceuticals, Inc.
2011 Phase 3 EUCTR2009-016488-12-SK Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Netherlands;Slovakia;
2011 Phase 3 EUCTR2009-016488-12-BE Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Netherlands;Slovakia;
2011 - EUCTR2009-016488-12-NL Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Netherlands;
2011 - EUCTR2009-016488-12-DE Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Poland;Slovakia;South Africa;Turkey;United States;
2011 - EUCTR2009-016488-12-CZ Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Netherlands;Slovakia;
2011 - EUCTR2009-016488-12-AT Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Poland;Slovakia;South Africa;Turkey;United States;
2010 - EUCTR2009-016488-12-HU Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Netherlands;
2009 Phase 3 EUCTR2008-002784-14-PT Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-002784-14-IE Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2009 Phase 3 EUCTR2008-002784-14-GR Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-002784-14-FR Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-002784-14-EE Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2009 Phase 3 EUCTR2008-002783-33-IS Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-002783-33-GB Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-002783-33-FR Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-002783-33-BE Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-002784-14-MT Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-002783-33-SK Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-002783-33-SE Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-002783-33-PT Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-002783-33-NL Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-002783-33-MT Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-002783-33-IE Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-002783-33-HU Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-002783-33-GR Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-002783-33-EE Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-002783-33-DE Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;
2009 - EUCTR2008-002783-33-CZ Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-002783-33-BG Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-002783-33-AT Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;
2008 - EUCTR2008-002783-33-LV Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2008 - EUCTR2008-002783-33-DK Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
TAKEDA DEVELOPMENT CENTER AMERICAS INC.
2021 Phase 3 EUCTR2020-004301-31-IT Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;China;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Lithuania;New Zealand;Poland;Romania;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
Takeda Development Center Americas, Inc.
2021 Phase 3 EUCTR2020-004301-31-SK Australia;Belgium;Canada;China;Croatia;Czech Republic;Czechia;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004301-31-LT Australia;Belgium;Canada;China;Croatia;Czech Republic;Czechia;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004301-31-HU Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;China;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Lithuania;New Zealand;Poland;Romania;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004301-31-HR Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;China;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Lithuania;New Zealand;Poland;Romania;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004301-31-ES Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;China;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Lithuania;New Zealand;Poland;Romania;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2020-004301-31-PL Australia;Belgium;Canada;China;Croatia;Czech Republic;Czechia;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2020-004301-31-CZ Australia;Belgium;Canada;China;Croatia;Czech Republic;Czechia;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2020-004301-31-BE Australia;Belgium;Canada;China;Croatia;Czech Republic;Czechia;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States;
Takeda Development Centre Europe Ltd
2015 Phase 3 EUCTR2014-003509-13-PL Belgium;Canada;Czech Republic;Hungary;Poland;United States;
2015 Phase 3 EUCTR2014-003509-13-HU Belgium;Canada;Czech Republic;Hungary;Poland;United States;
2015 Phase 3 EUCTR2014-003509-13-CZ Belgium;Canada;Czech Republic;Hungary;Poland;United States;
2015 Phase 3 EUCTR2014-003509-13-BE Belgium;Canada;Czech Republic;Hungary;Poland;United States;
2009 Phase 3 EUCTR2008-002784-14-IS Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Greece;Hungary;Iceland;Ireland;Italy;Latvia;Malta;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
Takeda Development Centre Europe Ltd.
2010 Phase 3 EUCTR2008-002784-14-SE Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2010 Phase 3 EUCTR2008-002784-14-GB Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-002784-14-SK Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2009 Phase 3 EUCTR2008-002784-14-NL Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2009 Phase 3 EUCTR2008-002784-14-DE Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2009 Phase 3 EUCTR2008-002784-14-CZ Australia;Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;
2009 Phase 3 EUCTR2008-002784-14-BG Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2009 Phase 3 EUCTR2008-002784-14-BE Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2009 Phase 3 EUCTR2008-002784-14-AT Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2008 Phase 3 EUCTR2008-002784-14-LV Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Takeda Development Centre Europe ltd.
2009 Phase 3 EUCTR2008-002784-14-HU Australia;Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Greece;Hong Kong;Hungary;Iceland;India;Ireland;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Malta;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Takeda Development Centre Europe, Ltd.
2018 Phase 2 EUCTR2017-002231-41-PL Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002231-41-NL Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002231-41-BE Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002182-21-PL Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002182-21-NL Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2017-002182-21-BE Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2017-002231-41-HU Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2017-002231-41-GB Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2017-002231-41-DE Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2017-002182-21-HU Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2017-002182-21-GB Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2017-002182-21-FR Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2017-002182-21-DE Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
- Phase 2 EUCTR2017-002231-41-FR Belgium;Canada;France;Germany;Hungary;Israel;Netherlands;Poland;Ukraine;United Kingdom;United States;
MLN0002 (Vedolizumab)
Takeda Pharmaceutical Company Limited
2014 Phase 3 JPRN-JapicCTI-142402 Japan;
MLN0002 SC
TAKEDA DEVELOPMENT CENTRE EUROPE LTD
2016 Phase 3 EUCTR2015-000482-31-IT Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Montenegro;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-IT Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Takeda Development Centre Europe, Ltd.
2016 Phase 3 EUCTR2015-000482-31-SK Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000482-31-SE Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000482-31-NL Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000482-31-LT Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000482-31-HU Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000482-31-HR Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000482-31-GB Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000482-31-ES Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000482-31-DK Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000482-31-DE Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000482-31-CZ Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000482-31-BG Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000482-31-BE Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-SK Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-SE Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-NL Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-LT Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-HU Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-GB Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-ES Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-DK Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-DE Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-CZ Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-BG Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-000481-58-BE Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
MLN002
Takeda Development Centre Europe Limited
2016 Phase 4 EUCTR2016-000678-40-CZ Australia;Bulgaria;Czech Republic;Estonia;Hungary;India;Italy;Korea, Republic of;Latvia;Malaysia;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Turkey;Ukraine;
MODULEN IBD
Assistance Publique - Hôpitaux de Paris
2014 - NCT02201693 France;
MODULEN IBD (R) (specific Enteral Nutrition)
Hôpital Necker-Enfants Malades
2005 Phase 4 NCT00265772 France;
MONOCLONAL ANTIBODY ANTI-IGG1
Boehringer Ingelheim
2021 Phase 2 EUCTR2019-001673-93-BE Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
2020 Phase 2 EUCTR2019-001673-93-AT Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
Boehringer Ingelheim BV
2020 Phase 2 EUCTR2017-003090-34-DK Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
Boehringer Ingelheim Netherlands BV
2019 Phase 2 EUCTR2017-003090-34-NL Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
Boehringer Ingelheim Pharma GmbH & Co. KG
2020 Phase 2 EUCTR2019-001673-93-DE Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
2019 Phase 2 EUCTR2017-003090-34-DE Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
Boehringer Ingelheim RCV GmbH & Co KG
2020 Phase 2 EUCTR2019-001673-93-HU Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
2019 Phase 2 EUCTR2017-003090-34-HU Austria;Belgium;Germany;Hungary;Netherlands;
2019 Phase 2 EUCTR2017-003090-34-AT Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
Boehringer Ingelheim S.A.
2021 Phase 2 EUCTR2019-001673-93-ES Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
SCS Boehringer Ingelheim Comm.V
2018 Phase 2 EUCTR2017-003090-34-BE Austria;Belgium;Denmark;Germany;Hungary;Korea, Republic of;Netherlands;Spain;
MSB11022
Fresenius Kabi SwissBioSim GmbH
2019 Phase 1 NCT04018599 United States;
MSC
CHU-ULg
2012 - EUCTR2011-005966-39-BE Belgium;
MSC injection 01
Sixth Affiliated Hospital, Sun Yat-sen University
2017 Phase 2/Phase 3 NCT03056664 -
MSC injection 02
Sixth Affiliated Hospital, Sun Yat-sen University
2017 Phase 2/Phase 3 NCT03056664 -
MSC treatment 01
Sixth Affiliated Hospital, Sun Yat-sen University
2016 Phase 2/Phase 3 NCT02532738 -
MSC treatment 02
Sixth Affiliated Hospital, Sun Yat-sen University
2016 Phase 2/Phase 3 NCT02532738 -
MSC-AFP
Mayo Clinic
2018 Phase 1 NCT03449069 United States;
2017 Phase 1 NCT03220243 United States;
William A. Faubion, M.D.
2013 Phase 1 NCT01915927 United States;
MT-1303
Mitsubishi Tanabe Pharma Corporation
2015 Phase 2 NCT02389790 Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;Ukraine;
2015 Phase 2 NCT02378688 Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;Ukraine;
2014 Phase 1 NCT02148185 Japan;
Mitsubishi Tanabe Pharma Corporation (MTPC)
2015 Phase 2 EUCTR2014-002557-19-SK Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;
2015 Phase 2 EUCTR2014-002557-19-PL Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;Ukraine;
2015 Phase 2 EUCTR2014-002557-19-NL Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;Ukraine;
2015 Phase 2 EUCTR2014-002557-19-IT Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;
2015 Phase 2 EUCTR2014-002556-77-SK Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;Ukraine;
2015 Phase 2 EUCTR2014-002556-77-PL Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;Ukraine;
2015 Phase 2 EUCTR2014-002556-77-NL Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;Ukraine;
2015 Phase 2 EUCTR2014-002556-77-IT Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;
2014 Phase 2 EUCTR2014-002557-19-HU Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;
2014 Phase 2 EUCTR2014-002557-19-CZ Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;Ukraine;
2014 Phase 2 EUCTR2014-002556-77-HU Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;
2014 Phase 2 EUCTR2014-002556-77-CZ Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Slovakia;Ukraine;
MTX
Centre Hospitalier Universitaire, Amiens
2021 Phase 3 NCT05040464 France;
Peking Union Medical College Hospital
2016 - ChiCTR-OPC-16008655 China;
MVA HAV
University of Oxford
2017 Phase 1 NCT03027193 United Kingdom;
Magnetic Resonance Enterography (MRE)
Mayo Clinic
2017 Phase 4 NCT03235180 United States;
Maltodextrin
Katholieke Universiteit Leuven
2008 - NCT01487759 Belgium;
University of Alberta
2021 - NCT04804046 Canada;
2020 - NCT03950336 Canada;
Mango polyphenolics
Texas A&M University
2014 - NCT02227602 United States;
Mannitol
Sanming First Affiliated Hospital of Fujian Medical University
2014 Phase 4 study ChiCTR-DDT-14004402 China;
Mare´s milk
University of Jena
2000 - NCT00940576 Germany;
Masitinib mesylate
AB Science
2015 Phase 2;Phase 3 EUCTR2012-004222-25-GR Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;India;Italy;Morocco;Poland;Romania;Russian Federation;Slovakia;Spain;Tunisia;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-004222-25-SK Belgium;Czech Republic;France;Greece;India;Morocco;Slovakia;Spain;Tunisia;
2013 Phase 3 EUCTR2012-004222-25-BE Belgium;Canada;Central African Republic;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Romania;Slovakia;South Africa;Spain;Switzerland;Tunisia;United Kingdom;United States;
Measurement of serum infliximab and anti-infliximab antibodies
Copenhagen University Hospital at Herlev
2009 Phase 4 NCT00851565 Denmark;
Mecasermin [rDNA Origin] 10mg/ml solution
Greater Glasgow & Clyde NHS
2011 Phase 2 EUCTR2010-022215-19-GB United Kingdom;
Medium chain triglycerides
Imperial College London
2008 Phase 4 NCT00672763 United Kingdom;
Medium dose TSO
Dr. Falk Pharma GmbH
2010 Phase 2 NCT01279577 Germany;
Melphalan
Paul Szabolcs
2012 Phase 1/Phase 2 NCT00692939 United States;
Mensa
European Group for Blood and Marrow Transplantation (EMBT)
2006 - EUCTR2005-003337-40-GB United Kingdom;
Mercaptopurine
Lower GI disease, Hyogo College of Medicine
2007 Phase 2,3 JPRN-UMIN000004427 Japan;
University of Edinburgh
2015 - EUCTR2014-002311-41-GB Belgium;France;Germany;Sweden;United Kingdom;
Mesalamine
Milton S. Hershey Medical Center
2013 Phase 4 NCT01696942 United States;
Mesalamine, 5-aminosalicylic acid
Ferring Pharmaceuticals A/S
2009 Phase 3 EUCTR2008-002100-26-FR Belgium;Denmark;France;Germany;Sweden;United Kingdom;
2009 - EUCTR2008-002100-26-GB Belgium;Denmark;France;Germany;Sweden;United Kingdom;
2009 - EUCTR2008-002100-26-BE Belgium;Denmark;France;Germany;Sweden;United Kingdom;
2008 - EUCTR2008-002100-26-SE Belgium;Denmark;France;Germany;Sweden;United Kingdom;
2008 - EUCTR2008-002100-26-DK Belgium;Denmark;France;Germany;Sweden;United Kingdom;
2008 - EUCTR2008-002100-26-DE Belgium;Denmark;France;Germany;Sweden;United Kingdom;
Mesalazine
AstraZeneca
- Phase 3 JPRN-JapicCTI-121765 -
AstraZeneca K.K.
- Phase 3 EUCTR2014-004132-20-Outside-EU/EEA Japan;
Dr. Falk Pharma GmbH
2007 - EUCTR2004-001213-34-GB Czech Republic;United Kingdom;
2004 Phase 3 NCT00300118 Germany;
2004 Phase 3 EUCTR2004-001213-34-SK Czech Republic;Slovakia;United Kingdom;
2004 - EUCTR2004-001213-34-CZ Czech Republic;United Kingdom;
2002 Phase 3 NCT00946946 Austria;Germany;
Ferring Laegemidler A/S
2005 - EUCTR2005-002472-15-SE Sweden;
University Medical Center Utrecht
2009 - EUCTR2009-011220-62-NL Netherlands;
Yanling Wei
2015 Phase 2 NCT02335281 China;
Zeria Pharmaceutical Co., Ltd.
- Phase 2 JPRN-JapicCTI-111460 -
Zeria Pharmaceutical Co.,LTD
2005 Phase 3 JPRN-C000000300 Japan;
Zeria Pharmaceutical Co.,LTD.
2005 Phase 2,3 JPRN-C000000301 Japan;
Mesalazine (Mesalamine)
Ferring Pharmaceuticals
2009 Phase 3 NCT00245505 Sweden;
Mesalazine EC
Disphar International B.V.
2005 Phase 3 EUCTR2004-004083-77-SK Czech Republic;Slovakia;
2004 - EUCTR2004-004083-77-CZ Czech Republic;
Mesalazine Sustained-Release Tablets
Xijing Hospital of Digestive Diseases
2016 Phase 3 NCT02769494 China;
Mesalazine tablets
AstraZeneca
2012 Phase 3 NCT01514240 Japan;
Mesalazine, Tripterygium glycosides
Zhu Weiming
2014 Phase 2/Phase 3 NCT02044952 China;
Mesenchymal Stem Cells
Amy Lightner
2020 Phase 1/Phase 2 NCT04519697 United States;
2020 Phase 1/Phase 2 NCT04519671 United States;
Mesenchymal Stem Cells (MSC)
University of Liege
2013 Phase 1/Phase 2 NCT01540292 Belgium;
Mesenchymal Stromal Cells
University of Liege
2018 Phase 1/Phase 2 NCT03901235 Belgium;
Mesenchymal cell and fibroblast injection
Royan Institute
2013 Phase 1 NCT01874015 Iran, Islamic Republic of;
Mesenchymal cell transplantation
Royan Institute
2013 Phase 1 NCT01874015 Iran, Islamic Republic of;
Mesenchymal stem cells
Amy Lightner
2021 Phase 1 NCT04791878 United States;
2020 Phase 1/Phase 2 NCT04519684 United States;
CHU-ULg
2012 - EUCTR2011-005966-39-BE Belgium;
Mesenchymal stem cells (MSCs)
The Cleveland Clinic
2021 Phase 1 NCT04073472 United States;
Mesenchymal stromal cells (MSC) for infusion
R.P.Herrmann
2010 Phase 2 NCT01090817 Australia;
Mesna
Cedars-Sinai Medical Center
2020 Phase 1/Phase 2 NCT04224558 United States;
European Group for Blood and Marrow Transplantation (EMBT)
2006 - EUCTR2005-003337-40-GB United Kingdom;
Northwestern University
2019 Phase 2 NCT04154735 United States;
Paul Szabolcs
2012 Phase 1/Phase 2 NCT00692939 United States;
Methacholine
Rambam Health Care Campus
2008 - NCT01297907 Israel;
Methotrexat
PIBD-Net
2017 Phase 3 EUCTR2016-000522-18-DE Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
Methotrexate
Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University
2011 - JPRN-UMIN000005251 Japan;
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
2015 Phase 4 NCT02177071 Australia;Belgium;France;
Indiana University
2015 - NCT02413047 United States;
PIBD net
2018 Phase 4 EUCTR2016-000522-18-GB Belgium;Canada;Czech Republic;France;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
PIBD-Net
2017 Phase 4 NCT02852694 France;
PIBDNet
2018 Phase 4 EUCTR2016-000522-18-BE Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
- Phase 4 EUCTR2016-000522-18-FR Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;United Kingdom;
Takeda
2017 Phase 4 NCT02764762 Canada;United States;
University of Edinburgh
2015 - EUCTR2014-002311-41-GB Belgium;France;Germany;Sweden;United Kingdom;
University of North Carolina, Chapel Hill
2016 Phase 3 NCT02772965 United States;
University of Western Ontario, Canada
2005 Phase 3 NCT00132899 Canada;
Methotrexate injection
Amsterdam UMC location AMC
2019 Phase 4 EUCTR2018-003594-95-NL Netherlands;
Methoxsalen
Therakos
2005 - EUCTR2004-002693-37-DE Germany;
2004 - EUCTR2004-002693-37-AT Austria;Germany;
Methoxsalen +ECP
Mallinckrodt
2004 Phase 2 NCT00221026 Austria;Belgium;Germany;United States;
Methyl prednisolone
European Group for Blood and Marrow Transplantation (EMBT)
2006 - EUCTR2005-003337-40-GB United Kingdom;
Methylprednisolone
Cedars-Sinai Medical Center
2020 Phase 1/Phase 2 NCT04224558 United States;
Icahn School of Medicine at Mount Sinai
2017 Phase 2 NCT03219359 United States;
Methylprednisolone or budesonide
Belgian IBD Research Group
2001 Phase 4 NCT00554710 Belgium;
Metoject
GETAID
2015 Phase 4 EUCTR2014-002311-41-SE France;Germany;Netherlands;Sweden;United Kingdom;
Metotrexat
GETAID
2015 Phase 4 EUCTR2014-002311-41-SE France;Germany;Netherlands;Sweden;United Kingdom;
Metronidazol
GETECCU
2011 - EUCTR2011-000885-36-ES Spain;
Metronidazole
Erasmus MC
2014 - EUCTR2012-005226-29-PL Belgium;Canada;Israel;Netherlands;Poland;Portugal;United States;
Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
2012 Phase 3 NCT01564823 Spain;
Hyogo college of medicine
2014 Phase 2 JPRN-UMIN000013369 Japan;
Ishikawa Dai
2017 - JPRN-jRCTs031180415 Japan;
Juntendo university school of medicineDepartment of gastroenterology
2017 - JPRN-UMIN000025846 Japan;
Mount Sinai Hospital, Canada
2006 Phase 2 NCT00257699 Canada;
S.L.A. Pharma AG
2007 Phase 1 NCT00774969 United Kingdom;
University of North Carolina, Chapel Hill
2021 Phase 2 NCT04186247 Canada;Israel;Netherlands;United States;
Wolfson Medical Center
2013 - EUCTR2012-005226-29-BE Belgium;Canada;Israel;Netherlands;Poland;Portugal;United States;
- - EUCTR2012-005226-29-NL Canada;Israel;Netherlands;United States;
Metronidazole Ointment
S.L.A. Pharma AG
2005 Phase 3 NCT00509639 United Kingdom;United States;
Metronidazole Oral
University of Louisville
2021 Phase 4 NCT04682522 United States;
Midazolam
GlaxoSmithKline
2011 Phase 1 NCT01489943 United States;
Janssen Research & Development, LLC
2018 Phase 1 NCT03358706 Austria;Belgium;Denmark;Germany;Sweden;United Kingdom;United States;
Takeda
2016 Phase 4 NCT02760615 United States;
Mirikizumab
Eli Lilly and Company
2021 Phase 3 NCT04844606 Israel;Japan;Korea, Republic of;United States;
2020 Phase 3 NCT04232553 Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 NCT03926130 Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czechia;Denmark;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 2 NCT02891226 Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Hungary;Japan;Netherlands;Poland;Romania;Russian Federation;Switzerland;Ukraine;United Kingdom;United States;
Yoshimoto Yusuke
2021 Phase 3 JPRN-jRCT2031210210 Japan;United States;
Mobilization of stem cells to prepare for Leukapheresis
Nationwide Children's Hospital
2013 Phase 2 NCT02676622 -
Moderate Oligosaccharide Group
University of British Columbia
2015 - NCT02193750 Australia;Canada;
Modulen
Hillel Yaffe Medical Center
2020 - NCT04233463 Israel;
Mongersen
CELGENE CORPORATION
2017 Phase 3 EUCTR2015-001924-40-IT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-IT Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2015-001693-18-IT Italy;
Celgene Corporation
2017 Phase 3 EUCTR2015-001963-37-FI Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001925-18-FI Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-SK Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-PT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-NL Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-LV Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-HU Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-HR Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-GR Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-GB Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-FR Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-FI Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-ES Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-DK Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-DE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-CZ Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-BE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2015-001924-40-AT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-SK Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-SE Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-PT Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-LV Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-HU Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-HR Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-GR Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-GB Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Oman;Pakistan;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-ES Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-DK Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-DE Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-CZ Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-BG Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-BE Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001963-37-AT Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-SK Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-SE Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-PT Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-LV Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-HU Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-HR Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-GR Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-GB Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-ES Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-DK Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-DE Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-CZ Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-BG Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-BE Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001925-18-AT Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2015 Phase 3 EUCTR2015-001963-37-EE Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2015 Phase 3 EUCTR2015-001925-18-EE Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2015-001925-18-NO Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2015-001924-40-PL Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Monoclonal antibodies
MILLENNIUM PHARMACEUTICALS, INC.
2011 - EUCTR2009-016488-12-IT Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Netherlands;
Monoclonal antibody cA2
FDA Office of Orphan Products Development
1996 Phase 3 NCT00004941 -
Mosapride
Department of Gastroenterology, Graduate School of Medicine, Osaka City University
2012 - JPRN-UMIN000008199 Japan;
Movprep
Lument AB
2019 Phase 2 EUCTR2019-002093-32-SE Sweden;
Mycodigest supplement
Tel-Aviv Sourasky Medical Center
2018 - NCT04329481 Israel;
N-3 Polyunsaturated Fatty Acids
Sixth Affiliated Hospital, Sun Yat-sen University
2021 - NCT04761952 -
N-{4-Chloro-2-[(1-oxido-4-pyridinyl)carbonyl]phenyl}-4-(1,1-dimethylethyl)benzenesulfonamide, sodium
GlaxoSmithKline Research & Development Ltd
2011 - EUCTR2010-022382-10-NL Austria;Belgium;Czech Republic;Denmark;Germany;Hungary;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
- Phase 3 EUCTR2010-022382-10-NO Austria;Belgium;Czech Republic;Denmark;Germany;Hungary;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
N-{4-Chloro-2-[(1-oxido-4-pyridinyl)carbonyl]phenyl}-4-(1,1-dimethylethyl)benzenesulfonamidesodium
GlaxoSmithKline Research & Development Ltd
2011 Phase 3 EUCTR2010-022383-12-NO Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;Germany;Greece;Hungary;Italy;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2011 Phase 3 EUCTR2010-022383-12-GB Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;Germany;Greece;Hungary;Italy;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;
NI-0401 (anti-CD3 mAB)
NovImmune SA
2006 Phase 1/Phase 2 NCT00630643 -
NNC 0142-0000-0002
Janssen Research & Development, LLC
2011 Phase 2 NCT01203631 Belgium;Canada;France;Hungary;Israel;Poland;Russian Federation;United States;
NNC0114-0006
Novo Nordisk A/S
2013 Phase 2 NCT01751152 Bulgaria;Czech Republic;Poland;Russian Federation;Serbia;Slovakia;Spain;United States;
NNC0142-0000-0002
Novo Nordisk A/S
2011 Phase 2 EUCTR2010-020836-21-BE Belgium;Canada;European Union;Hungary;Israel;Poland;Russian Federation;United States;
2011 - EUCTR2010-020836-21-PL Belgium;Canada;European Union;Hungary;Israel;Poland;Russian Federation;United States;
2010 - EUCTR2010-020836-21-HU Belgium;Hungary;Poland;
NNC142-0002
Novo Nordisk A/S
2011 Phase 2 EUCTR2010-020836-21-BE Belgium;Canada;European Union;Hungary;Israel;Poland;Russian Federation;United States;
2011 - EUCTR2010-020836-21-PL Belgium;Canada;European Union;Hungary;Israel;Poland;Russian Federation;United States;
2010 - EUCTR2010-020836-21-HU Belgium;Hungary;Poland;
NO
Rambam Health Care Campus
2008 - NCT01297907 Israel;
University of Texas at Austin
2021 - NCT04898530 United States;
2021 - NCT04617184 United States;
NORMIX*AD 12CPR RIV
ALFA WASSERMANN
2007 - EUCTR2007-001014-17-IT France;Germany;Hungary;Italy;
NSP001
Provexis Plc
2009 Phase 2 EUCTR2006-005526-23-GB United Kingdom;
Naltrexone
Milton S. Hershey Medical Center
2008 Phase 2 NCT00715117 United States;
Naltrexone hydrochloride
ErasmusMC
2020 Phase 2 EUCTR2019-000852-32-NL Netherlands;
Naltrexone-HCl
Milton S. Hershey Medical Center
2006 Phase 2 NCT00663117 United States;
Nap
TiGenix, S.A.U.
2021 Phase 3 EUCTR2017-000725-12-SE Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2017-000725-12-GB Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2017-000725-12-DE Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-PL Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-HU Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-FR Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-CZ Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000725-12-BE Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;United States;
Natalizumab
Biogen
2008 Phase 4 NCT00801125 -
2008 - NCT00707512 Puerto Rico;United States;
2004 Phase 3 NCT00078611 Canada;United States;
2002 Phase 4 NCT00280956 United States;
2002 Phase 3 NCT00032786 -
2002 Phase 2 NCT00055536 United States;
2002 Phase 2 NCT00055367 United Kingdom;United States;
2001 Phase 3 NCT00032799 United States;
Elan Pharma Ltd.
2005 - EUCTR2004-003839-31-DK Denmark;
Neomycin
Children's Hospital of Philadelphia
2018 Phase 2 NCT03476317 United States;
University of Pennsylvania
2016 Phase 2 NCT02765256 United States;
Nessuno
GILEAD SCIENCES INCORPORATED
2015 Phase 2 EUCTR2015-001249-10-IT Australia;Canada;Czech Republic;Germany;Hungary;Iceland;Italy;South Africa;Spain;United Kingdom;United States;
Nitazoxanide
Romark Laboratories L.C.
2005 Phase 2 NCT00130390 United States;
Nivolumab
Alliance Foundation Trials, LLC.
2019 Phase 1 NCT03656627 United States;
National Cancer Institute (NCI)
2019 Phase 1 NCT03816345 Canada;United States;
None
Abbott
2009 - EUCTR2008-004919-36-SE Austria;Denmark;Sweden;
2009 - EUCTR2008-004919-36-DK Austria;Denmark;Sweden;
2009 - EUCTR2008-004919-36-BE Austria;Belgium;Denmark;Sweden;
Novartis Pharma Services AG
2009 - EUCTR2009-011621-14-AT Austria;Germany;
None at this time
Millennium Pharmaceuticals, Inc (a wholly owned subsidiary
2020 Phase 2 EUCTR2019-000886-19-FR France;Germany;United Kingdom;United States;
Normal Saline
Seattle Children's Hospital
2015 Phase 1/Phase 2 NCT02272868 United States;
Nutraceutical Combination
Columbia University
2012 Phase 2 NCT01647412 United States;
Nutrition treat
Jinling Hospital, China
2011 - NCT01540942 China;
Nutritional dietary intervention
Hospital Galdakao-Usansolo
2020 - NCT04188990 Spain;
NutropinAq 10mg/2ml solution for injection
Greater Glasgow & Clyde NHS
2011 Phase 2 EUCTR2010-022215-19-GB United Kingdom;
NutropinAq®
Greater Glasgow & Clyde NHS
2011 Phase 2 EUCTR2010-022215-19-GB United Kingdom;
OL adalimumab
Abbott
2002 Phase 3 NCT00055497 United States;
OPC-6535
Otsuka Pharmaceutical Co., Ltd.
2009 Phase 2/Phase 3 NCT00989573 Japan;Korea, Republic of;
OPC-6535(Tetomilast)
Otsuka Pharmaceutical Co., Ltd.
2006 Phase 2 NCT00317369 Japan;
OPS-2071
Otsuka Pharmaceutical Development & Commercialization, Inc.
2020 Phase 2 NCT03850509 Poland;United States;
2020 Phase 2 EUCTR2019-000176-41-PL Belgium;Canada;Germany;Italy;Poland;United States;
2020 Phase 2 EUCTR2019-000176-41-HU Canada;Germany;Hungary;Italy;Poland;Russian Federation;Ukraine;United States;
- Phase 2 EUCTR2019-000176-41-DE Canada;Germany;Hungary;Italy;Poland;Russian Federation;Ukraine;United States;
Otsuka Pharmaceutical Development and Commercialization, Inc
2020 Phase 2 EUCTR2019-000176-41-IT Belgium;Canada;Germany;Hungary;Italy;Poland;United States;
Oligofructose enriched inulin
Katholieke Universiteit Leuven
2008 - NCT01487759 Belgium;
Olokizumab
UCB BIOSCIENCES GmbH
2012 Phase 2 EUCTR2011-002517-11-BG Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Netherlands;Poland;Romania;Serbia;
2012 - EUCTR2011-002517-11-HU Czech Republic;Germany;Hungary;Serbia;
2012 - EUCTR2011-002517-11-DE Czech Republic;Germany;Hungary;Serbia;
2012 - EUCTR2011-002517-11-CZ Czech Republic;Germany;Hungary;Serbia;
Olokizumab (OKZ)
UCB BIOSCIENCES GmbH
2012 Phase 2 NCT01635621 Bulgaria;Czech Republic;Germany;Hungary;Poland;
Omegaven
Radboud University
2014 Phase 4 NCT02349594 Netherlands;
Omeprazole
GlaxoSmithKline
2011 Phase 1 NCT01489943 United States;
Janssen Research & Development, LLC
2018 Phase 1 NCT03358706 Austria;Belgium;Denmark;Germany;Sweden;United Kingdom;United States;
Takeda
2016 Phase 4 NCT02760615 United States;
Only 1 arm: treatment with MSC-AFP
William A. Faubion, M.D.
2017 Phase 1 NCT03014219 United States;
Ontamalimab
SHIRE HUMAN GENETIC THERAPIES, INC
2018 Phase 3 EUCTR2017-000574-11-IT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
Shire
2019 Phase 3 NCT03627091 Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 NCT03566823 Argentina;Belgium;Bosnia and Herzegovina;Bulgaria;Colombia;Estonia;Greece;Hungary;Ireland;Japan;Korea, Republic of;Lebanon;Mexico;New Zealand;Portugal;Slovakia;Spain;Turkey;Ukraine;United States;
2018 Phase 3 NCT03559517 Australia;Austria;Croatia;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;South Africa;United Kingdom;United States;
2018 Phase 3 NCT03283085 Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Croatia;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
Shire Human Genetic Therapies, Inc.
2019 Phase 3 EUCTR2017-000617-23-HR Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-000617-23-GB Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-000575-88-HR Australia;Austria;Brazil;Croatia;Czech Republic;Czechia;Germany;Israel;Italy;Japan;Lithuania;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;South Africa;United Kingdom;United States;
2019 Phase 3 EUCTR2017-000575-88-GB Australia;Austria;Brazil;Croatia;Czech Republic;Germany;Israel;Italy;Japan;Lithuania;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;South Africa;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000617-23-SK Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000617-23-PT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000617-23-NL Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000617-23-LT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000617-23-HU Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000617-23-EE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000617-23-DE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000617-23-BG Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000617-23-BE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000617-23-AT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000576-29-SK Argentina;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Estonia;Greece;Hungary;Ireland;Japan;Korea, Republic of;Lebanon;Mexico;Portugal;Slovakia;Spain;Switzerland;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-000576-29-PT Argentina;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Estonia;Greece;Hungary;Ireland;Japan;Korea, Republic of;Lebanon;Mexico;Portugal;Slovakia;Spain;Switzerland;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-000576-29-EE Argentina;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Estonia;Greece;Hungary;Ireland;Japan;Korea, Republic of;Mexico;Portugal;Slovakia;Spain;Switzerland;Ukraine;United States;
2018 Phase 3 EUCTR2017-000576-29-BG Argentina;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Estonia;Greece;Hungary;Ireland;Japan;Korea, Republic of;Lebanon;Mexico;Portugal;Slovakia;Spain;Switzerland;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-000575-88-NL Australia;Austria;Brazil;Croatia;Czech Republic;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;South Africa;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000575-88-LT Australia;Austria;Brazil;Croatia;Czech Republic;Czechia;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;South Africa;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000575-88-DE Australia;Austria;Brazil;Croatia;Czech Republic;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;South Africa;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000575-88-AT Australia;Austria;Brazil;Croatia;Czech Republic;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;South Africa;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000574-11-PT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000574-11-NL Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000574-11-LT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000574-11-IE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000574-11-HU Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000574-11-HR Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000574-11-GB Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000574-11-EE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000574-11-DE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000574-11-BG Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000574-11-BE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000574-11-SK Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000574-11-AT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2017-000617-23-PL Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2017-000617-23-IE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2017-000576-29-IE Argentina;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Estonia;Greece;Hungary;Ireland;Japan;Korea, Republic of;Lebanon;Mexico;Portugal;Slovakia;Spain;Switzerland;Turkey;Ukraine;United States;
- Phase 3 EUCTR2017-000575-88-PL Australia;Austria;Brazil;Croatia;Czech Republic;Czechia;Germany;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;South Africa;United Kingdom;United States;
- Phase 3 EUCTR2017-000574-11-PL Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2017-000574-11-CZ Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lebanon;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
Optison
University of Michigan
2015 Phase 1/Phase 2 NCT02061163 United States;
Oral prednisolone
Assistance Publique - Hôpitaux de Paris
2022 Phase 2/Phase 3 NCT05284136 France;Netherlands;
Orencia
Bristol-Myers Squibb International Corporation
2008 - EUCTR2006-003371-13-PL Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2008 - EUCTR2006-003371-13-CZ Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-DK Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-DE Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
2007 - EUCTR2006-003371-13-BE Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;United Kingdom;
Originator (legacy) drug
McGill University Health Centre/Research Institute of the McGill University Health Centre
2018 - NCT03729674 Canada;
Ossium vBM-MSC
Amy Lightner
2022 Phase 1/Phase 2 NCT05075811 United States;
Other Biologic Therapies
Janssen Scientific Affairs, LLC
2021 - NCT04372108 United States;
Other Biological Agent
Takeda
2015 - NCT02678052 Canada;United States;
Ova-Treg
TxCell
2014 Phase 2 EUCTR2014-001295-65-IT Austria;Belgium;Germany;Italy;
2014 Phase 2 EUCTR2014-001295-65-DE Austria;Belgium;Germany;Italy;
2014 Phase 2 EUCTR2014-001295-65-BE Austria;Belgium;Germany;Italy;
2014 Phase 2 EUCTR2014-001295-65-AT Austria;Belgium;Germany;Italy;
Ovasave
TxCell
2014 Phase 2 NCT02327221 Austria;Belgium;France;Germany;Italy;United Kingdom;
2014 Phase 2 EUCTR2014-001295-65-IT Austria;Belgium;Germany;Italy;
2014 Phase 2 EUCTR2014-001295-65-DE Austria;Belgium;Germany;Italy;
2014 Phase 2 EUCTR2014-001295-65-BE Austria;Belgium;Germany;Italy;
2014 Phase 2 EUCTR2014-001295-65-AT Austria;Belgium;Germany;Italy;
Oxadrop
Mayo Clinic
2006 Phase 1/Phase 2 NCT00587041 United States;
Oxygen
Assaf-Harofeh Medical Center
2013 - NCT01828190 Israel;
Daping Hospital, Army Medical University (Third Military Medical University)
2018 - ChiCTR1800019958 China;
Ozanimod
CELGENE INTERNATIONAL II SàRL
2018 Phase 3 EUCTR2017-004292-31-IT Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2015-002025-19-IT Canada;Hungary;Italy;Poland;Ukraine;United States;
Celgene
2018 Phase 3 NCT03467958 Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 NCT03464097 Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 NCT03440385 Australia;Austria;Brazil;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Korea, Republic of;Lithuania;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
2018 Phase 3 NCT03440372 Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;Moldova, Republic of;Norway;Poland;Romania;Russian Federation;Saudi Arabia;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Celgene International II Sarl (CISII) awholly owned subsidiary of Celgene Corporation
2015 Phase 2 EUCTR2015-002025-19-HU Canada;Hungary;Italy;Poland;Ukraine;United States;
Celgene International II Sàrl (CIS II), a wholly owned subsidiary of Celgene Corporation
2016 Phase 2 EUCTR2015-002025-19-PL Canada;Hungary;Poland;Ukraine;United States;
Ozanimod hydrochloride
CELGENE INTERNATIONAL II SàRL
2018 Phase 3 EUCTR2017-004294-14-IT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Celgene International II Sàrl
2016 Phase 1 EUCTR2016-003073-18-GB United Kingdom;
P28GST
University Hospital, Lille
2014 Phase 2 NCT02281916 France;
PDA001
Celularity Incorporated
2013 Phase 1 NCT01769755 United States;
PENTASA Sachet
Ferring Pharmaceuticals A/S
2009 Phase 3 EUCTR2008-002100-26-FR Belgium;Denmark;France;Germany;Sweden;United Kingdom;
2009 - EUCTR2008-002100-26-GB Belgium;Denmark;France;Germany;Sweden;United Kingdom;
2009 - EUCTR2008-002100-26-BE Belgium;Denmark;France;Germany;Sweden;United Kingdom;
2008 - EUCTR2008-002100-26-SE Belgium;Denmark;France;Germany;Sweden;United Kingdom;
2008 - EUCTR2008-002100-26-DK Belgium;Denmark;France;Germany;Sweden;United Kingdom;
2008 - EUCTR2008-002100-26-DE Belgium;Denmark;France;Germany;Sweden;United Kingdom;
PF-00547659
PFIZER SLU
2011 - EUCTR2010-023437-30-ES Austria;Belgium;Bulgaria;Germany;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;
PFIZER, S.L.U.
2011 - EUCTR2010-024638-48-ES Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
Pfizer Inc.
2013 - EUCTR2012-002030-37-BE Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Norway;Poland;Serbia;Slovakia;South Africa;Spain;Sweden;Switzerland;United Kingdom;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017
2012 Phase 2 EUCTR2010-024638-48-NO Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;United States;
2012 Phase 2 EUCTR2010-024638-48-DE Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
2012 Phase 2 EUCTR2010-024638-48-BG Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
2012 Phase 2 EUCTR2010-024638-48-BE Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
2012 Phase 2 EUCTR2010-023437-30-BG Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;South Africa;Spain;Sweden;United States;
2012 - EUCTR2010-023437-30-PL Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;South Africa;Spain;Sweden;United States;
2011 Phase 2 EUCTR2010-024638-48-SK Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
2011 Phase 2 EUCTR2010-024638-48-SE Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
2011 Phase 2 EUCTR2010-024638-48-NL Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Romania;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
2011 Phase 2 EUCTR2010-024638-48-AT Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
2011 Phase 2 EUCTR2010-023437-30-SE Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
2011 Phase 2 EUCTR2010-023437-30-PT Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;South Africa;Spain;Sweden;United States;
2011 Phase 2 EUCTR2010-023437-30-NO Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
2011 - EUCTR2010-024638-48-PT Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
2011 - EUCTR2010-023437-30-SK Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;South Africa;Spain;Sweden;United States;
2011 - EUCTR2010-023437-30-NL Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;South Africa;Spain;Sweden;United States;
2011 - EUCTR2010-023437-30-DE Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;South Africa;Spain;Sweden;United States;
2011 - EUCTR2010-023437-30-BE Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;South Africa;Spain;Sweden;United States;
2011 - EUCTR2010-023437-30-AT Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;South Africa;Spain;Sweden;United States;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017, United States
2012 Phase 2 EUCTR2010-024638-48-PL Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;Slovenia;South Africa;Spain;Sweden;United States;
Shire
2011 Phase 2 NCT01298492 Austria;Belgium;Bulgaria;Canada;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
PF-00547659 SC injection
Shire
2011 Phase 2 NCT01276509 Austria;Belgium;Bulgaria;Canada;Croatia;France;Germany;Japan;Korea, Republic of;Netherlands;Norway;Poland;Portugal;Serbia;Slovakia;South Africa;Spain;Sweden;United States;
PF-04236921
Pfizer
2011 Phase 2 NCT01345318 Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;New Zealand;Switzerland;United Kingdom;United States;
PF-04236921 SC injection
Pfizer
2011 Phase 2 NCT01287897 Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;New Zealand;Romania;Sweden;Switzerland;United Kingdom;United States;
PF-06651600
Pfizer
2018 Phase 2 NCT03395184 Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
PF-06651600-15
PFIZER INC
2018 Phase 2 EUCTR2017-003359-43-IT Austria;Belgium;Croatia;Czech Republic;Germany;Hungary;Italy;Lithuania;Poland;Slovakia;Spain;United States;
Pfizer Inc.
2018 Phase 2 EUCTR2017-003359-43-SK Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-CZ Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017
2018 Phase 2 EUCTR2017-003359-43-PL Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-LT Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-HU Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-HR Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-ES Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Georgia;Germany;Hungary;Israel;Italy;Korea, Republic of;Lebanon;Lithuania;New Zealand;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-DE Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-BE Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-AT Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
PF-06700841
Pfizer
2018 Phase 2 NCT03395184 Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
PF-06700841-15
PFIZER INC
2018 Phase 2 EUCTR2017-003359-43-IT Austria;Belgium;Croatia;Czech Republic;Germany;Hungary;Italy;Lithuania;Poland;Slovakia;Spain;United States;
Pfizer Inc.
2018 Phase 2 EUCTR2017-003359-43-SK Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-CZ Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017
2018 Phase 2 EUCTR2017-003359-43-PL Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-LT Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-HU Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-HR Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-ES Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Georgia;Germany;Hungary;Israel;Italy;Korea, Republic of;Lebanon;Lithuania;New Zealand;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-DE Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-BE Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-AT Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
PL 17901/0122
Royal Liverpool & Broadgreen University Hospitals Trust
2009 Phase 2 EUCTR2008-001137-99-GB United Kingdom;
PL 20532/0012
Royal Liverpool & Broadgreen University Hospitals Trust
2009 Phase 2 EUCTR2008-001137-99-GB United Kingdom;
PLAQUENIL
Royal Liverpool & Broadgreen University Hospitals Trust
2009 Phase 2 EUCTR2008-001137-99-GB United Kingdom;
PMA-zeolite
Ciim Plus, d.o.o.
2018 - NCT04370535 Slovenia;
PRA023
Prometheus Biosciences, Inc.
2021 Phase 2 EUCTR2021-000092-37-PL Australia;Belarus;Belgium;Canada;Czech Republic;Czechia;France;Georgia;Israel;Poland;Russian Federation;Ukraine;United States;
2021 Phase 2 EUCTR2021-000092-37-CZ Australia;Belgium;Canada;Czech Republic;Czechia;France;Georgia;Poland;Russian Federation;Ukraine;United States;
PRA023 IV
Prometheus Biosciences, Inc.
2021 Phase 2 NCT05013905 United States;
PROCHYMAL (remestemcel-L)
Mesoblast, Inc.
2010 - NCT01510431 United States;
PROCHYMAL adult human mesenchymal stem cells
Mesoblast, Inc.
2007 Phase 3 NCT00543374 Canada;United States;
PRV-6527
Provention Bio, Inc.
2018 Phase 2 NCT03854305 Austria;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
PRV-6527 (JNJ-40346527)
Provention Bio, Inc.
2018 Phase 2 EUCTR2017-003017-25-PL Austria;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
2018 Phase 2 EUCTR2017-003017-25-ES Austria;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
2018 Phase 2 EUCTR2017-003017-25-DE Austria;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
2018 Phase 2 EUCTR2017-003017-25-AT Austria;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
PRV-6527(JNJ-40346527)
Provention Bio, Inc.
2018 Phase 2 EUCTR2017-003017-25-HU Austria;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
PTG-200
Janssen-Cilag International NV
2020 Phase 2 EUCTR2019-003335-37-DE Argentina;Germany;Italy;Poland;Russian Federation;United States;
PURINETHOL - 50 MG COMPRESSE25 COMPRESSE
UMBERTO I - POLICLINICO DI ROMA
2017 Phase 4 EUCTR2016-000522-18-IT Belgium;Czech Republic;Czechia;France;Germany;Hungary;Italy;Netherlands;Poland;United Kingdom;
Partial Enteral Nutrition
NHS Greater Glasgow and Clyde
2021 - NCT04859088 United Kingdom;
Pectin
Jinling Hospital, China
2014 Phase 2 NCT02164877 China;
Pegylated interferon alfa
Vanderbilt-Ingram Cancer Center
2006 - NCT00897312 -
Pending
Reistone Biopharma Company Limited
2019 Phase 2 EUCTR2018-003303-19-PL China;Poland;Ukraine;United States;
Pentasa
AstraZeneca K.K.
- Phase 3 EUCTR2014-004132-20-Outside-EU/EEA Japan;
Ferring Pharmaceuticals
2009 Phase 3 NCT00862121 Belgium;Denmark;France;Germany;Spain;Sweden;United Kingdom;United States;
Pentasa Sachet 1 g prolonged release granules
Ferring Laegemidler A/S
2005 - EUCTR2005-002472-15-SE Sweden;
Pentoxifylline
University of Miami
2017 Early Phase 1 NCT02953275 United States;
Peptidic+Probiotic
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
2020 - NCT04305535 Spain;
Peripheral Blood Stem Cell Infusion
Cedars-Sinai Medical Center
2020 Phase 1/Phase 2 NCT04224558 United States;
Pharmacokinetics of certolizumab pegol
UCB Biopharma S.P.R.L.
2020 Phase 1 NCT04163016 Canada;France;Germany;Netherlands;Spain;Switzerland;United States;
Phase1 : CDED/Modulen™IBD® + Maintenance therapy
Assistance Publique - Hôpitaux de Paris
2022 Phase 3 NCT04777656 France;
Phase2 and 3 :
Assistance Publique - Hôpitaux de Paris
2022 Phase 3 NCT04777656 France;
Phylloquinone (vitamin K1)
University College Cork
2008 Phase 4 NCT01235325 Ireland;
Physician standard-of-care
Merck Sharp & Dohme Corp.
2011 - NCT01218360 Greece;
Pioglitazone
GlaxoSmithKline
2011 Phase 1 NCT01489943 United States;
Placebo
Abbott Japan Co., Ltd.
2007 Phase 2-3 JPRN-JapicCTI-070367 -
2007 Phase 2-3 JPRN-JapicCTI-070366 -
Janssen Pharmaceutical K.K.
2018 Phase 2-3 JPRN-JapicCTI-183950 Japan, North America;
Takeda Pharmaceutical Company Limited
2016 Phase 3 JPRN-JapicCTI-163386 Japan, Refer to Othersection;
2014 Phase 3 JPRN-JapicCTI-142402 Japan;
Plantain NSP
Provexis Plc
2009 Phase 2 EUCTR2006-005526-23-GB United Kingdom;
Plasma rico en plaquetas y coagulo de fibrina procesados mediante la tecnología PRGF-System (BTI)
Fundación FISEVI
2012 - EUCTR2011-006127-38-ES Spain;
2012 - EUCTR2011-004820-37-ES Spain;
Pnemovax
Statens Serum Institut
2013 - EUCTR2012-002867-86-DK Denmark;
Pneumovax
Statens Serum Institut
2013 Phase 4 NCT01947010 Denmark;
2013 - EUCTR2012-002867-86-DK Denmark;
Polaprezinc
Kawasaki Medical School
2011 - JPRN-UMIN000005970 Japan;
Polyethylene Glycol 3350
Children's Hospital of Philadelphia
2018 Phase 2 NCT03476317 United States;
University of Pennsylvania
2016 Phase 2 NCT02765256 United States;
Pomegranate
IRCCS Azienda Ospedaliero-Universitaria di Bologna
2017 - NCT03000101 Italy;
Posaconazole Delayed Release Oral Tablet
Cedars-Sinai Medical Center
2022 Phase 4 NCT04966585 United States;
Positron Emission Tomography
Jonsson Comprehensive Cancer Center
2016 Early Phase 1 NCT02925351 United States;
Postoperative 3-month exclusive enteral nutrition
Zhu Weiming
2018 - NCT04160325 China;
Pravastatin
University of Virginia
2004 - NCT00599625 United States;
Prebiotics
University of Alberta
2020 - NCT03950336 Canada;
Precedentemente denominato MEDI2070 e AMG 139
ALLERGAN LIMITED
2020 Phase 2;Phase 3 EUCTR2018-004346-42-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Prednisolon
Erasmus Medical Center
2013 Phase 4 NCT01880307 Italy;Netherlands;
Hôpital Necker-Enfants Malades
2005 Phase 4 NCT00265772 France;
Prednisolon Jenapharm
4SC AG
2010 - EUCTR2008-005903-25-BG Bulgaria;Germany;
2009 - EUCTR2008-005903-25-DE Bulgaria;Germany;
Prednisolone
Central Manchester University Hospitals Foundation Trust
2011 Phase 2 EUCTR2010-022017-26-GB United Kingdom;
Erasmus Medical Center
2015 Phase 4 NCT02517684 Belgium;Denmark;Finland;Italy;Netherlands;Poland;
Merck Sharp & Dohme Corp.
2003 Phase 3 NCT00796250 -
University Hospital Birmingham
2008 Phase 4 NCT00609752 United Kingdom;
Prednisone
AbbVie (prior sponsor, Abbott)
2011 Phase 3 NCT01235689 Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Lithuania;Netherlands;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;
Abbott GmBH & Co. KG
2010 Phase 3 EUCTR2010-020137-10-IT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
Icahn School of Medicine at Mount Sinai
2016 Phase 4 NCT02324699 United States;
McMaster University
2018 Phase 4 NCT03833596 Canada;
Shanghai Research Institute of Acupuncture and Meridian
2016 Phase 1 study ChiCTR-IIR-16007751 China;
Preparative regimen 4-6 weeks after Leukapheresis
Nationwide Children's Hospital
2013 Phase 2 NCT02676622 -
Prevenar 13
Statens Serum Institut
2013 Phase 4 NCT01947010 Denmark;
2013 - EUCTR2012-002867-86-DK Denmark;
Previously referred to as MEDI2070 and AMG 139, AGN-151-598
ALLERGAN LIMITED
2020 Phase 2;Phase 3 EUCTR2018-004346-42-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Allergan Limited
2021 Phase 3 EUCTR2019-001866-14-ES Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Allergan Ltd.
2020 Phase 2;Phase 3 EUCTR2018-004346-42-RO Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2;Phase 3 EUCTR2018-004346-42-BG Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2;Phase 3 EUCTR2018-004346-42-BE Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-004346-42-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2018-004346-42-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
AstraZeneca AB
2019 Phase 2;Phase 3 EUCTR2018-004346-42-GB Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2019-001866-14-GB Australia;Austria;Belgium;Bulgaria;Canada;China;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2018-004346-42-PL Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Astrazeneca AB
2020 Phase 2;Phase 3 EUCTR2018-004346-42-AT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Probiotic
The Baruch Padeh Medical Center, Poriya
2013 Phase 4 NCT01765998 Israel;
Probiotic - VSL#3
University of Alberta
2003 Phase 3 NCT00175292 Canada;
Probiotic Mixture
Massachusetts General Hospital
2017 - NCT03266484 United States;
Probiotics
The Baruch Padeh Medical Center, Poriya
2012 Phase 4 NCT01078935 -
Prochymal®
Mesoblast, Inc.
2007 Phase 3 NCT00482092 Australia;Canada;New Zealand;United States;
Prochymal™ adult human mesenchymal stem cells
Mesoblast, Inc.
2006 Phase 2 NCT00294112 United States;
Promethazine
University of Pennsylvania
2016 Phase 2 NCT02765256 United States;
Prucalopride
University of British Columbia
2016 Phase 4 NCT02806206 Canada;
Puri Nethol
Amsterdam UMC location AMC
2021 Phase 3;Phase 4 EUCTR2021-000469-33-NL Netherlands;
Puri-Nethol
GETAID
2015 Phase 4 EUCTR2014-002311-41-SE France;Germany;Netherlands;Sweden;United Kingdom;
Puri-nethol
Region Örebro län
2021 Phase 4 EUCTR2019-002942-19-DK Denmark;
QAX567
Gerhard Rogler
2011 Phase 2 NCT01316601 Switzerland;
QAX576
Novartis Pharma AG
2011 - EUCTR2010-019973-13-DE Germany;Switzerland;
Novartis Pharmaceuticals
2011 Phase 2 NCT01355614 Germany;Switzerland;
QBECO
Qu Biologics Inc.
2013 Phase 1/Phase 2 NCT01809275 Canada;
QBECO-SSI
Qu Biologics Inc.
2018 Phase 2 NCT03472690 Canada;
RAD001
Novartis Pharma Services AG
2005 Phase 2 EUCTR2005-001148-22-SK Slovakia;
RCTB-401
SBL Vaccin AB
2005 - EUCTR2005-002048-25-SE Sweden;
REMSIMA - 100 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLANCONCINO (VETRO) - 1 FLACONCINO
UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
2016 Phase 4 EUCTR2016-002061-54-IT Italy;
REMSINA
Celltrion, Inc
2019 Phase 3 EUCTR2019-001087-30-CZ Austria;Belarus;Bulgaria;Chile;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
RHB-104
RedHill Biopharma Limited
2017 Phase 3 NCT03009396 Canada;Czechia;Israel;New Zealand;Poland;Serbia;United States;
2013 Phase 3 NCT01951326 Australia;Bulgaria;Canada;Czech Republic;Czechia;Israel;New Zealand;Poland;Serbia;Slovakia;United States;
RedHill Biopharma Ltd.
2019 Phase 3 EUCTR2016-005199-90-SK Australia;Canada;Czech Republic;Israel;New Zealand;Poland;Serbia;Slovakia;United States;
2017 Phase 3 EUCTR2015-001179-36-SK Australia;Bulgaria;Canada;Czech Republic;Israel;New Zealand;Poland;Romania;Serbia;Slovakia;United States;
2017 Phase 3 EUCTR2015-001179-36-CZ Australia;Bulgaria;Canada;Czech Republic;Israel;New Zealand;Poland;Romania;Serbia;Slovakia;United States;
2017 Phase 3 EUCTR2015-001179-36-BG Australia;Bulgaria;Canada;Czech Republic;Israel;New Zealand;Poland;Romania;Serbia;Slovakia;United States;
2015 Phase 3 EUCTR2015-001179-36-PL Australia;Bulgaria;Canada;Czech Republic;Israel;New Zealand;Poland;Romania;Serbia;Slovakia;United States;
2015 Phase 3 EUCTR2014-004108-31-HU Belgium;Czech Republic;Germany;Hungary;Ireland;Netherlands;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;
2015 Phase 3 EUCTR2014-004108-31-CZ Czech Republic;Hungary;Ireland;Russian Federation;Ukraine;United Kingdom;
RPC0163
CELGENE INTERNATIONAL II SàRL
2016 Phase 2 EUCTR2015-002025-19-IT Canada;Hungary;Italy;Poland;Ukraine;United States;
RPC1063
CELGENE INTERNATIONAL II SàRL
2018 Phase 3 EUCTR2017-004292-31-IT Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2015-002025-19-IT Canada;Hungary;Italy;Poland;Ukraine;United States;
Celgene
2015 Phase 2 NCT02531113 Canada;Hungary;Italy;Poland;Ukraine;United States;
Celgene International II Sàrl (CIS II), a wholly owned subsidiary of Celgene Corporation
2016 Phase 2 EUCTR2015-002025-19-PL Canada;Hungary;Poland;Ukraine;United States;
RPC1063 (equivalent to ozanimod HCl)
Celgene International II Sàrl
2019 Phase 3 EUCTR2017-004295-55-PT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-004295-55-FR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-004294-14-FR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2017-004293-33-FR Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2017-004292-31-FR Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-SK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-SI Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-SE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-PL Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-NL Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-LV Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-LT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-IE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-HU Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-HR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-GR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-GB Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-FI Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-ES Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-DK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-DE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-BG Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-BE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004295-55-AT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-SK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-SI Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-SE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-PT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-PL Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-NL Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-LV Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-LT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-IE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-HU Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-HR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-GR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-GB Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-FI Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-ES Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-DK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-DE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-CZ Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-BG Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-BE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004294-14-AT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004293-33-SK Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-004293-33-SI Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-004293-33-SE Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-004293-33-PT Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-004293-33-PL Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-004293-33-NL Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-004293-33-LT Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-004293-33-HU Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-004293-33-GR Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-004293-33-FI Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-004293-33-ES Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-004293-33-BG Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-004293-33-AT Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
2018 Phase 3 EUCTR2017-004292-31-PL Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004292-31-LV Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004292-31-IE Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004292-31-HR Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004292-31-GB Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004292-31-ES Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004292-31-DK Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004292-31-DE Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004292-31-CZ Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004292-31-BG Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2017-004292-31-BE Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Moldova, Republic of;New Zealand;Norway;Poland;Puerto Rico;Romania;Russian Federation;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2017-004295-55-CZ Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2017-004293-33-DE Australia;Austria;Bulgaria;Canada;China;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Israel;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
RPC1063 equiv to ozanimod HCI
CELGENE INTERNATIONAL II SàRL
2018 Phase 3 EUCTR2017-004295-55-IT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
RPC1063 equiv. to ozanimod HCI
CELGENE INTERNATIONAL II SàRL
2018 Phase 3 EUCTR2017-004294-14-IT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
RR110 (Tamibarotene)
R&R Inc.
2006 Phase 2 NCT00417391 Japan;
RVG 05565
Academic Medical Center, department of Gastroenterology and hepatology
2008 - EUCTR2008-001131-35-NL Netherlands;
RVG 07151
University Medical Center Utrecht
2009 - EUCTR2009-013348-35-NL Netherlands;
RVG 114681
Amsterdam UMC location AMC
2021 Phase 3;Phase 4 EUCTR2021-000469-33-NL Netherlands;
RVG 116648
Amsterdam UMC location AMC
2021 Phase 3;Phase 4 EUCTR2021-000469-33-NL Netherlands;
RVG00859
Amsterdam UMC location AMC
2021 Phase 3;Phase 4 EUCTR2021-000469-33-NL Netherlands;
RYAH-Medtech Inhaler
OMNI Medical Services, LLC
2018 Phase 2 NCT03944447 United States;
Rabbit anti-human thymocyte immunoglobulin
Barts Health NHS Trust
2017 Phase 3 EUCTR2017-002545-30-GB United Kingdom;
Rabbit antithymocyte globulin
European Group for Blood and Marrow Transplantation (EMBT)
2006 - EUCTR2005-003337-40-GB United Kingdom;
Racol
Graduate School of Medical Sciences, Kyushu University
2009 - JPRN-UMIN000010293 Japan;
Ranolazine
Vanderbilt University Medical Center
2022 Phase 2 NCT04456517 United States;
Rapamycin
The Second Hospital of Nanjing Medical University
2015 - NCT02675153 China;
Raptiva 100 mg/ml powder and solvent for solution for injection
Merck Serono International S.A.
2009 - EUCTR2007-001377-28-PT Austria;France;Germany;Netherlands;Portugal;
2008 - EUCTR2007-001377-28-NL Austria;France;Germany;Netherlands;Portugal;
2008 - EUCTR2007-001377-28-FR Austria;France;Germany;Netherlands;Portugal;
2008 - EUCTR2007-001377-28-DE Austria;France;Germany;Netherlands;Portugal;
2008 - EUCTR2007-001377-28-AT Austria;France;Germany;Netherlands;Portugal;
RbATG
European Group for Blood and Marrow Transplantation (EMBT)
2006 - EUCTR2005-003337-40-GB United Kingdom;
Received hormone maintenance therapy
Fuzhou General Hospital
2012 Phase 1/Phase 2 NCT02445547 China;
Recombinant Human Interleukin-11 (rhIL-11)
Wyeth is now a wholly owned subsidiary of Pfizer
2002 Phase 2 NCT00040521 United States;
Recombinant growth hormone
Greater Glasgow & Clyde NHS
2011 Phase 2 EUCTR2010-022215-19-GB United Kingdom;
Recombinant human Insulin-like Growth Factor
Greater Glasgow & Clyde NHS
2011 Phase 2 EUCTR2010-022215-19-GB United Kingdom;
Red light photopheresis
University Hospital, Akershus
2019 Phase 1/Phase 2 NCT04164849 Norway;
Remicade
Academic Medical Center
2019 Phase 4 EUCTR2018-002064-15-NL Netherlands;
2014 - EUCTR2013-001029-17-NL Netherlands;
2013 Phase 4 EUCTR2013-002932-25-NL Netherlands;
Academic Medical Center, department of Gastroenterology and hepatology
2008 - EUCTR2008-001131-35-NL Netherlands;
CHRU de Lille
2008 - EUCTR2006-004784-58-FR Belgium;France;Germany;United Kingdom;
CUB- Hopital Erasme
2016 Phase 4 EUCTR2015-004618-10-BE Belgium;
Celltrion
2014 Phase 3 NCT02096861 United States;
Centocor B.V.
2005 Phase 3 EUCTR2004-002815-10-GB Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
2005 Phase 3 EUCTR2004-002815-10-ES Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-SE Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-DK Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-DE Denmark;Germany;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-002815-10-AT Austria;Denmark;Germany;Spain;Sweden;United Kingdom;
Department of medical gastroenterology S, Odense University Hospital
2015 Phase 4 EUCTR2012-002702-51-SE Denmark;Finland;Norway;Sweden;
2012 Phase 4 EUCTR2012-002702-51-DK Denmark;Finland;Norway;Sweden;
Department of medical gastroenterology, Herlev Hospital
2016 Phase 4 EUCTR2012-002702-51-NO Denmark;Finland;Norway;Sweden;
2015 Phase 4 EUCTR2012-002702-51-FI Denmark;Finland;Norway;Sweden;
2009 Phase 4 EUCTR2009-009926-94-DK Denmark;
ErasmusMC
2013 - EUCTR2012-000645-13-BE Belgium;Netherlands;
2012 - EUCTR2012-000645-13-NL Belgium;Italy;Netherlands;
GETAID
2015 Phase 4 EUCTR2014-002311-41-SE France;Germany;Netherlands;Sweden;United Kingdom;
IBD Center LMU Munich
2008 - EUCTR2008-004926-18-DE Germany;
Janssen Biologics B.V.
2009 - EUCTR2008-005237-30-NL Canada;Netherlands;Sweden;United States;
Janssen Biologics BV
2011 - EUCTR2008-005237-30-SE Belgium;France;Germany;Hungary;Italy;Netherlands;Sweden;United Kingdom;United States;
Jørgen Agnholt
2013 Phase 3 EUCTR2013-000971-34-DK Denmark;
Katholieke Universiteit Leuven
2011 Phase 4 EUCTR2011-002061-38-BE Belgium;
Merck Sharp & Dohme Corp.
2003 - NCT00705614 -
Novartis Pharma AG
2011 - EUCTR2010-019973-13-DE Germany;Switzerland;
Pfizer
2015 - NCT02539368 Belgium;Czech Republic;Czechia;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
Region Örebro län
2021 Phase 4 EUCTR2019-002942-19-DK Denmark;
Royal Liverpool University Hospital
2012 - EUCTR2011-006084-22-GB United Kingdom;
Shradha Agarwal
2011 - NCT01438151 United States;
Univeristy Hospital Na Bulovce
2009 Phase 3 EUCTR2008-005688-32-CZ Czech Republic;
University Medical Center Groningen
2021 Phase 4 EUCTR2020-001811-26-BE Belgium;Netherlands;
2020 Phase 4 EUCTR2020-001811-26-NL Netherlands;
University of Edinburgh
2015 - EUCTR2014-002311-41-GB Belgium;France;Germany;Sweden;United Kingdom;
University of Leuven
2008 - EUCTR2006-004784-58-DE Belgium;France;Germany;United Kingdom;
2007 - EUCTR2006-004784-58-BE Belgium;France;Germany;United Kingdom;
University of Leuven Hospitals
2009 Phase 4 EUCTR2006-004784-58-GB Belgium;France;Germany;United Kingdom;
University of Leuven Hospitals, Division of Gastroenterology
2009 - EUCTR2008-007519-34-SE Sweden;
Universitätsklinik für Innere Medizin III, Klinische Abteilung für Gastroenterologie und Hepatologie
2013 - EUCTR2011-001332-29-AT Austria;
Remicade (infliximab)
Merck Sharp & Dohme Corp.
2002 - NCT00818272 Germany;
Zon MW
2014 Phase 4 EUCTR2013-002651-15-NL Netherlands;
Remicade 100 mg powder for concentrate for solution for infusion.
Santeon
2015 Phase 4 EUCTR2015-001954-14-NL Netherlands;
Remicade 100 mg pulver til konsentrat til infusjonsvæske, oppløsning
Diakonhjemmet Hospital AS
2014 - EUCTR2014-002056-40-NO Norway;
Remisma
CELLTRION INC.
2019 Phase 3 EUCTR2019-001087-30-IT Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
Remsima
Amsterdam UMC location AMC
2021 Phase 3;Phase 4 EUCTR2021-000469-33-NL Netherlands;
CUB- Hopital Erasme
2016 Phase 4 EUCTR2015-004618-10-BE Belgium;
Celltrion, Inc
2019 Phase 3 EUCTR2019-001087-30-PL Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Czechia;Estonia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-DE Austria;Belarus;Bulgaria;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2019 Phase 3 EUCTR2019-001087-30-BG Austria;Belarus;Brazil;Bulgaria;Chile;Croatia;Czech Republic;Czechia;Estonia;France;Georgia;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
Department of medical gastroenterology S, Odense University Hospital
2015 Phase 4 EUCTR2012-002702-51-SE Denmark;Finland;Norway;Sweden;
2012 Phase 4 EUCTR2012-002702-51-DK Denmark;Finland;Norway;Sweden;
Department of medical gastroenterology, Herlev Hospital
2016 Phase 4 EUCTR2012-002702-51-NO Denmark;Finland;Norway;Sweden;
2015 Phase 4 EUCTR2012-002702-51-FI Denmark;Finland;Norway;Sweden;
GETAID
2015 Phase 4 EUCTR2014-002311-41-SE France;Germany;Netherlands;Sweden;United Kingdom;
Jørgen Agnholt
2013 Phase 3 EUCTR2013-000971-34-DK Denmark;
Taina Sipponen
2016 Phase 4 EUCTR2016-001278-13-FI Finland;
University Medical Center Groningen
2021 Phase 4 EUCTR2020-001811-26-BE Belgium;Netherlands;
2020 Phase 4 EUCTR2020-001811-26-NL Netherlands;
Remsima (infliximab)
Mundipharma Pharmaceuticals B.V.
2016 Phase 4 EUCTR2014-004904-31-BE Belgium;Netherlands;
2015 Phase 4 EUCTR2014-004904-31-NL Netherlands;
Remsima 100 mg pulver til konsentrat til infusjonsvæske, oppløsning
Diakonhjemmet Hospital AS
2014 - EUCTR2014-002056-40-NO Norway;
Remsima and Inflectra
Janssen Biologics B.V.
2009 - EUCTR2008-005237-30-NL Canada;Netherlands;Sweden;United States;
RhIGF (Increlex)
Nationwide Children's Hospital
2008 Phase 2/Phase 3 NCT00764699 United States;
RhumAb to Il-17A (IgG1-k-class)
Novartis Pharma Services AG
2009 - EUCTR2008-008359-40-DE Austria;Germany;Poland;
RhumAb to Il-17A (IgG1-k-class) rhumAb to Il-17A (IgG1-k-class)
Novartis Pharma Services AG
2009 - EUCTR2008-008359-40-PL Austria;Germany;Poland;
Ribavirin
Vanderbilt-Ingram Cancer Center
2006 - NCT00897312 -
Riboflavin Sodium Phosphate Injection
Xijing Hospital of Digestive Diseases
2016 Phase 3 NCT02769494 China;
Riboflavin supplementation
University Medical Center Groningen
2016 - NCT02538354 Netherlands;
Rifabutin, Clarithromycin, and Clofazimine
Medstar Health Research Institute
2007 Phase 4 NCT00513552 United States;
Rifaximin
ALFA WASSERMANN
2007 - EUCTR2007-001014-17-IT France;Germany;Hungary;Italy;
Assistance Publique - Hôpitaux de Paris
2015 Phase 2 NCT02620007 France;
Mayo Clinic
2019 Phase 2 NCT04254549 United States;
Northwestern University
2019 Phase 2 NCT04154735 United States;
Scott Lee
2008 Phase 2 NCT00603616 United States;
Sixth Affiliated Hospital, Sun Yat-sen University
2017 Phase 3 NCT03185624 China;
2017 Phase 3 NCT03185611 China;
Rifaximin Delayed Release (DR)
Salix Pharmaceuticals, Inc subsidiary of Valeant Pharmaceuticals International Inc
2015 Phase 3 EUCTR2014-001645-24-CZ Canada;Czech Republic;France;Germany;Hungary;Israel;Poland;Russian Federation;United States;
Salix Pharmaceuticals, Inc.
2015 Phase 3 EUCTR2014-001645-24-PL Canada;Czech Republic;France;Germany;Hungary;Israel;Poland;Russian Federation;United States;
2015 Phase 3 EUCTR2014-001645-24-DE Canada;Czech Republic;France;Germany;Hungary;Israel;Poland;Russian Federation;United States;
2015 Phase 3 EUCTR2014-001644-38-PL Canada;Czech Republic;France;Germany;Hungary;Israel;Poland;Russian Federation;United States;
2015 Phase 3 EUCTR2014-001644-38-DE Canada;Czech Republic;France;Germany;Hungary;Israel;Poland;Russian Federation;United States;
2014 Phase 3 EUCTR2014-001645-24-HU Canada;Czech Republic;France;Germany;Hungary;Israel;Poland;Russian Federation;United States;
2014 Phase 3 EUCTR2014-001645-24-FR Canada;Czech Republic;France;Germany;Hungary;Israel;Poland;Russian Federation;United States;
2014 Phase 3 EUCTR2014-001644-38-HU Canada;Czech Republic;France;Germany;Hungary;Israel;Poland;Russian Federation;United States;
2014 Phase 3 EUCTR2014-001644-38-FR Canada;Czech Republic;France;Germany;Hungary;Israel;Poland;Russian Federation;United States;
Salix Pharmaceuticals, Inc. subsidiary of Valeant Pharmaceuticals International In
2015 Phase 3 EUCTR2014-001644-38-CZ Canada;Czech Republic;France;Germany;Hungary;Israel;Poland;Russian Federation;United States;
Rifaximin EIR
Bausch Health Americas, Inc.
2014 Phase 3 NCT02240121 United States;
2014 Phase 3 NCT02240108 United States;
Rifaximin delayed release 400 mg film coated tablet
ALFASIGMA S.P.A.
2018 Phase 2 EUCTR2017-002258-36-NL Belgium;Germany;Italy;Netherlands;Spain;
2018 Phase 2 EUCTR2017-002258-36-BE Belgium;Germany;Netherlands;Spain;
2017 Phase 2 EUCTR2017-002258-36-ES Germany;Spain;
2017 Phase 2 EUCTR2017-002258-36-DE Belgium;Germany;Netherlands;Spain;
Rifaximin delayed release tablets
Alfasigma S.p.A.
2017 Phase 2 NCT03537157 Italy;
Rifaximin+omeprazole+miralax
Seattle Children's Hospital
2015 Phase 1/Phase 2 NCT02272868 United States;
Rifaximin-EIR
ALFA WASSERMANN
2011 - EUCTR2011-002821-24-IT Italy;
ALFASIGMA S.P.A.
2018 Phase 2 EUCTR2017-002258-36-NL Belgium;Germany;Italy;Netherlands;Spain;
2018 Phase 2 EUCTR2017-002258-36-BE Belgium;Germany;Netherlands;Spain;
2017 Phase 2 EUCTR2017-002258-36-ES Germany;Spain;
2017 Phase 2 EUCTR2017-002258-36-DE Belgium;Germany;Netherlands;Spain;
Alfa Wassermann S.p.A.
2008 - EUCTR2007-001014-17-DE France;Germany;Hungary;Italy;
2007 Phase 2 NCT00528073 France;Germany;Hungary;Israel;Italy;Poland;Russian Federation;
2007 Phase 2 EUCTR2007-001014-17-HU France;Germany;Hungary;Italy;
2007 Phase 2 EUCTR2007-001014-17-FR France;Germany;Hungary;Italy;
Risankizumab
AbbVie
2020 Phase 3 NCT04524611 Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 1 NCT04254783 Germany;Israel;United States;
2019 - NCT03914261 Belgium;Israel;Spain;Switzerland;United States;
AbbVie Deutschland GmbH & Co. KG
2015 Phase 2 EUCTR2015-001834-15-DE Belgium;Canada;Germany;Ireland;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
Risankizumab 10 mg/ml
Boehringer Ingelheim Pharma GmbH & Co. KG
2014 Phase 2 EUCTR2013-002902-29-DE Belgium;Canada;Germany;Ireland;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
Risankizumab 180 mg SC
AbbVie
2015 Phase 2 NCT02513459 Belgium;Canada;Germany;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
Risankizumab 600 mg IV
AbbVie
2015 Phase 2 NCT02513459 Belgium;Canada;Germany;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
Risankizumab 90 mg/ml
Boehringer Ingelheim Pharma GmbH & Co. KG
2014 Phase 2 EUCTR2013-002902-29-DE Belgium;Canada;Germany;Ireland;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
Risankizumab IV
AbbVie
2018 Phase 3 NCT03105102 American Samoa;Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 NCT03105128 Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 NCT03104413 American Samoa;Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2014 Phase 2 NCT02031276 Belgium;Canada;France;Germany;Ireland;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
Risankizumab On-Body Injector (OBI)
AbbVie
2018 Phase 3 NCT03105102 American Samoa;Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Risankizumab SC
AbbVie
2018 Phase 3 NCT03105102 American Samoa;Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 NCT03105128 Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
2017 Phase 3 NCT03104413 American Samoa;Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Denmark;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2014 Phase 2 NCT02031276 Belgium;Canada;France;Germany;Ireland;Korea, Republic of;Netherlands;Poland;Spain;United Kingdom;United States;
Risedronate
University of Alberta
2010 Phase 4 NCT01215890 Canada;
Ritlecitinib
Pfizer Inc.
2018 Phase 2 EUCTR2017-003359-43-SK Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-CZ Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017
2018 Phase 2 EUCTR2017-003359-43-PL Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-HU Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-DE Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-BE Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
2018 Phase 2 EUCTR2017-003359-43-AT Australia;Austria;Belgium;Bosnia and Herzegovina;Canada;Croatia;Czech Republic;Czechia;Georgia;Germany;Hungary;Italy;Korea, Republic of;Lebanon;Lithuania;Poland;Russian Federation;Saudi Arabia;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Turkey;Ukraine;United Arab Emirates;United States;
Rituximab
Paul Szabolcs
2012 Phase 1/Phase 2 NCT00692939 United States;
Rizankisumab
AbbVie Deutschland GmbH & Co. KG
2017 Phase 3 EUCTR2016-003190-17-SK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;It